"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 Earnings Conference Call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",39,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 Earnings Conference Call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. Thanks for taking the time to join us for Eli Lilly Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chief Fi",1707,"Good morning. Thanks for taking the time to join us for Eli Lilly Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chief Financial officer, Derica Rice, our President of Lilly Research Laboratories, Dr. Jan Limburg; and Ronika Pletcher; and Gail from Investor Relations.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Form 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
We accomplished a great deal in 2010 while rapidly adapting to significant external and internal challenges. Here are some highlights.  For the full year, we again delivered strong financial performance, generating 6% revenue growth and we were able to leverage the 6% revenue growth into 8% non-GAAP net income growth as we made substantial progress reducing headcount and containing costs.
Our strong operating performance, along with prudent management of working capital generated nearly $7 billion of operating cash flow, easily covering capital expenditures of about $700 million, and our dividend of roughly $2.2 billion.
During the year, we did experience pipeline disappointments and to. However, our scientists remain focused on speeding innovation to patients, making significant pipeline progress. Advancing 16 new molecules into Phase I testing, nine molecules into Phase II testing, and two molecules into Phase III testing.
We also concluded a number of business development with a biased towards those that provide current or potential near-term revenues.
Our strong financial performance, focus on speeding innovation to patients and targeted use of business development all support our goal of successfully navigating our upcoming patent explorations and emerging with an even greater strength and capacity to drive future growth.
Since our last earnings call, we've made significant progress on a number of fronts. In clinical news, we began Phase III trials of our antibac antibody for both rheumatoid arthritis and lupus. Based on an interim review of long-term safety data, and after complication with the FDA, we made the decision to begin Phase III trials later this year of md three monotherapy treatment for schizophrenia. And along with our partner Insights Pharmaceuticals we disclosed promising Phase IIa data in rheumatoid arthritis for our jack one jack two inhibitor.
In regulatory news, we received FDA approval of Cymbalta for the management of chronic musculoskeletal pain. Based on its clinical trials in patients with chronic back pain and chronic pain due to osteoarthritis. And we'll begin active promotion for this syndication next week.
We also received FDA approval for Ask as replacement therapy e-mails for conditions so see with a deficiency or absence of endogenous testosterone. And we expect to launch the product midyear after building sufficient launch quantities.
Health Canada approved Ada to improve glycemic control in patients with type two diabetes and we also submitted SMDAs for by Ada used in combination with basal insulin and for sial us for benign prostatic hyperplasia.
On the legal front, the U.S. Mr. Corporate mold ruled that judgment will be in Lily's favor to do something patent challenge. Including our recently updated six-month pediatric exclusivity, this patent provides protection for lift until January 17. In the Court of Appeals for the Federal Circuit heard our appeal for the U.S. District Court's ruling in validating our Strattera method of use patent. As argued at the appeal hearing, we feel there is a strong basis for the CAFC to overturn the district court ruling. We are awaiting a decision by the CAFC and in the meantime an injunction from the CAFC provides generics from launching.
Finally in business development news, we announced and completed the acquisition of Abbott Radiopharmaceuticals. Abbott's lead asset for the. Was assigned for priority review by the FDA and just last week an FDA advisory committee recommended approval of the beta amyloid imaging agent if certain conditions are met related to physician training and re-reading of existing brain scans.
Along with Boehringer Ingelheim, we draw strategic alliance with commercial alliance two oral diabetes compounds from DBI and to basal analogue insulins from Lily. As we've done in previous calls, we'll focus our comments on the non-GAAP results, which we believe brought insights to some underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges.
On Slide 7, you can see the revenue grew 4% in Q4 to nearly $6.2 billion. As I'll show more detail in a minute, volume continued to be the major driver of our revenue growth. Gross margin as a percent of revenue increased 4.2 percentage points from 75.9% to 80.1%. Roughly 2/3 of this increase was due to the favorable effect of changes in foreign currency exchange rates on international inventory sold. Specifically, changes in the foreign currency value of the U.S. dollar substantially increased cost of sales in Q4 2009 but slightly decreased cost of sales in Q4 2010. The remaining improvement in gross margin as a percent of revenue was due to lower manufacturing costs, a tangible result of our ongoing productivity improvement efforts.
This quarter's total operating expense defined as the sum of R&D and SG&A grew 8%. Within operating expense, marketing, selling and administrative expenses grew only 2% as higher marketing and selling expenses outside the U.S. were partially offset by lower administrative expenses and a company-wide cost containment efforts. R&D expense on the other hand grew 18%. Approximately 2/3 of this increase was due to higher than normal charges related to business development committees and terminations determination of clinical trials. Other income and deductions improved due to primarily to lower miscellaneous other expense and to a lesser extent, lower net interest expense. In addition, our tax rate fell by four percentage points largely due to the recognition in Q4 of the full year impact of the extension of the R&D tax credit. Net income and earnings per share increased 24% in 22% respectively.
For the year, you can see that we generated leverage between revenue and net income as revenue grew 6% while net income grew 8%. We achieved this leverage between revenue and net income despite foreign exchange being a drag on our gross margin percent for the full year, higher than normal charges flowing through R&D in 2010 and a 1.6 percentage point increase in the full year tax rate largely due to the $85 million tax charge taken in Q1, 2010 as a result of U.S. healthcare reform.
Slide 8 shows our reported income statement while Slide 9 provides a reconciliation between reported in non-GAAP earnings per share. Additional details about our reported earnings are available in today's earnings press release.
As you can see on Slide 10, for both the fourth quarter and the full year, foreign exchange had little effect on revenue growth as a weaker euro was offset by strength in other foreign currencies including the Japanese yen.
Consequently, performance growth and total revenue of 5% for both the quarter and the year was driven by 3% volume growth and a favorable 2% impact from price. In both periods, we saw robust double-digit volume growth in our Japanese chemo Pharmaceutical business and our global animal health business. Now, let's look at the rest of the income statement.
Slide 11 shows the year on year growth of select line items of our non-GAAP income statement with and without the effective changes of foreign exchange rate. The numbers in the first column by the same as those you saw earlier on our non-GAAP income statement. If you look at the top of the second column of numbers, you'll see the 5% performance growth in revenue I mentioned previously. Below that, you'll see the cost of sales actually decreased 2% excluding the effect of foreign exchange. As a result, gross margin grew 7%. Operating expenses grew faster than revenue this quarter. The larger than normal R&D charge is mentioned earlier drove the majority of the 9% performance growth in operating expenses. As a result of this increase in operating expenses, our 5% performance growth in revenue translated into 3% performance growth in operating income while the lower tax rate this quarter boosted growth in EPS to 10%.
Finally, you'll see that in the last column and for the year, we've leveraged 5% performance growth in revenue to 7% and 8% growth in operating income and earnings per share respectively. We achieved this leverage due primarily to lower manufacturing costs. For your information, Slide 12, we provided the year on year growth of select line items of our reported income statement with and without the effect of foreign exchange rates. 
Next, I'll briefly cover some highlights from our quarterly pipeline update.
Slide 13 shows our pipeline as of January 24, and highlights changes since our last earnings call on her October 21. Movement of molecules to the next phase of development are shown by green arrows of additions from business development additions are shown by green stars. They both demonstrate our focus on addressing our upcoming patent expirations through innovation both that coming from our own lives as well as those from outside our walls. You can see that we added two compounds under regulatory review, that beta amyloid imaging agent from Abbott and litigate the oral DPP for an inhibitor for diabetes from PI. The BI alliance also brought a Phase III compound BI 10773 and oral SGL to inhibitor. We also saw significant movement in the pipeline as sarong was approved. We began Phase III testing of our antibac antibody for both rheumatoid arthritis and lupus. For molecules began Phase II testing. Three new molecules began Phase I testing and we terminated development of five molecules and sold one molecule to a third-party. 
Now, I'll turn the call over to Derica to cover some of the key events we anticipate in 2011 and a detailed discussion of our 2011 financial guidance. Derica?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals including Bydureon in the EU a",2533,"Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals including Bydureon in the EU and a number pending here in the U.S. Linagliptin for type 2 diabetes in collaboration with BI; the liprotamase our recombinant pancreatic enzyme replacement therapy, Cialis for BPH and Byetta in combination with basal insulin.
Expected regulatory submissions include our response to the FDA complete response letter from Bydureon and sBLAs for Erbitux, a first-line colorectal cancer, head and neck cancer, and non-small cell lung cancer. In terms of Phase III trials, we'll complete the DURATION 6-trial comparing Bydureon to Victoza. We also expect the present initial results from the Phase III trials  and advance non small cell lung cancer of Alimta induction followed by Alimta maintenance therapy. Following the initiation of Phase III trials late last year for both and depression and our antibac and antibody RA and lupus, Phase III trials are slated to begin this year for mGlu2/3 in schizophrenia, our novel basal insulin analog and our new insulin glargine product and potentially for our anti-IL 17 antibody in RA.
Now as I move on to guidance, I'm going to take a bit more time today and I have in the past to walk you through it. As I want to make sure you understand how we expect some of the more substantial drivers to effect our results in 2011. Now clearly, more sales of the parks in a Gemzar outside of Japan due primarily to global patent expiration as well as the incremental impact of U.S. healthcare reform will have a significant negative impact on our 2011 results. In addition, we'll face some near-term earnings dilution from our strategic diabetes alliance with Boehringer Ingelheim. At the same time, we expect continued strong performance in the rest of our business in 2011 including the counter cyclical growth engines we've discussed for some time. Japan, emerging markets and animal health, as well as in a number of our patent-protected products in the U.S. and in Europe.
In addition, we expect to see continued benefit from our cost reduction and productivity efforts. I want to make sure you have good visibility into this growth within our business. 
I'll start with a discussion of our bottom-line EPS expectations and then review our individual line item guidance. As you've seen in our press release, we expect 2011 non-GAAP earnings per share between $4.15 and $4.30. Our 2011 reported EPS guidance range is $0.23 lower due to the estimated IP R&D charge from the BI alliance. On a non-GAAP basis, this represents a decline of between 9% and 12% when compared to 2010. So how does this 9% to 12% EPS decline break out between the negative EPS impact of the items I mentioned earlier and the continued growth in the rest of our business? I'll start with the latter. The underlying EPS growth we expect to see from our business before factoring in expected sales decline in the parks in a Gemzar outside Japan due primarily to patent expirations and U.S. healthcare and the BI Alliance. Now as we've discussed before, we've been making targeted investments in Japan, our emerging markets and animal health and more broadly in our remaining patent protected products. And also we've been aggressively reducing headcount and controlling expenses as we re-base the size of our business. We've seen these efforts pay off in 2010 and expect to see the same in 2011 and beyond. In fact, our 2011 non-GAAP EPS guidance of $4.15 to $4.30 implies a growth contribution of roughly 15% from these parts of our business.
In Japan, our sales growth has been outstanding in recent years fueled by the launch of products and indications that we're launching more earlier in the U.S. and Europe. On a local currency basis, sales in Japan grew 15% in 2009 and 25% in 2010. As reported by IMS, currently we are far away the fastest-growing major pharmaceutical company in this major market and we or seeing strong growth from a host of products in Japan. Please note that going forward, I'll be citing local currency growth for certain products in Japan as well as in Europe. The effect of foreign exchange for any individual product is similar to that shown on Slide 10 for that relevant something.
Now Zyprexa, our largest-selling product grew 8% on a local currency basis for 2010 and we expect continued growth. In Q4 last year, Zyprexa became the first a typical antipsychotic approved in Japan for bipolar mania. And later this year, we plan to submit for approval in bipolar depression. The remember, we maintain exclusivity in Japan for Zyprexa until September of 2016 and we expect Japan to help drive what we hope will be a significant sail of the Zyprexa sales post in 2011.
Alimta was approved for non-small cell lung cancer in Japan in Q2 of 2009 and achieved the best share of market uptick in the first line non-squamous segment of any market in the world. It is now our second-largest product in Japan and we see continued growth room for growth as we believe more patients with non-squamous cell histology can benefit from treatment with Alimta. 
We've also been driving increased market share with Humalog. This product has been growing at roughly twice the insulin market growth rate and registered 14% growth in local currency in 2010. We are focused on continuing the strong momentum. And we expect to see significant growth contributions from Cymbalta which was launched in Q2 of last year; and for state Byetta both launched this past quarter.
Now turning to emerging markets. Revenue grew 10% in 2010 on a local currency basis. As we've shared with you in the past, we've been making targeted investments in six markets: China, Russia, Turkey, Korea, Brazil and Mexico. In these investments are paying off. Volume growth has accelerated in each of these markets with the exception of Brazil. From 2009 to 2010, volume growth accelerated from 18% to 21% in China from a minus 7% to a positive 21% in Russia, from 4% to 20% in Turkey and from a minus 2% to a positive 19% in Korea, and from 1% to 7% in Mexico.
More broadly, for the 12 months ending September 2010, IMS showed that Lily ranked first in sales growth at 12% among the 10 leading multinational countries across five emerging markets: China, Turkey, Korea, Brazil and Mexico.
We remain focused on driving profitable growth in emerging markets. We see significant opportunities to do so with our core assets, including Cymbalta, Cialis, Humalog and Alimta. While the majority of our efforts will be concentrated on maximizing opportunities from our core assets, we will continue to look to supplement this organic growth with targeted business development. 
On a local currency basis, our ALICO animal health business grew 12% in 2009 and 14% in 2010 significantly outpacing overall industry growth. This solid growth was driven by our food animal business and by come for this, our oral flea control products for controlling pain in animals which is a strong update here in the United States.
Going forward, we expect Animal Health revenue growth to benefit from international launches of comport to including in the EU this quarter.
In addition, our information has built a robust innovation pipeline and is poised to maintain double-digit growth in the coming years would launch is expected for multiple products targeting high-value markets such as livestock immune enhancement, control of parasites in companion animals and pain control. This quarter in the U.S., we'll launch Assurity, a couple seek treatment for cats and Trizec this, an oral flea and heartworm treatment for dogs. We've also build a substantial development capability in animal health vaccine and have demonstrated willingness to drive the growth in this business via business development. Apart from continued strength in these three countercyclical growth engines, we also see opportunities for growth in the number of patent protected product outside of the emerging markets in Japan.
Now let me cite a few examples. On a local currency basis, Cymbalta grew 15% in Europe last year. Here in the U.S., Cymbalta continues to fare well existing mood and pain indications in a market dominated by generics. And we'll begin active promotional efforts next week for Cymbalta's latest FDA-approved indication, management of chronic musculoskeletal pain.
2010 local currency growth of Alimta was 20% in Europe and 17% in the U.S. This year, we anticipate submitting the results of our S1 2/4 study the FDA for approval of Alimta-induction treatment followed by Alimta maintenance treatment in patients with advanced non-squamous non-small cell lung cancer.
In our diabetes business, Humalog registered solid 6% local currency growth in Europe in 2010. Now while sales in the U.S. were essentially flat, in the second half of the year, we saw sustained growth in our new prescription share of rapid and middle realtime analog market for the first time in years. We've also improved Humalog access which should reinforce the positive sharemarket trend as we began in 2011.
Now for Cialis, in Europe we have continue to extend our leading DOT and can sharemarket. While in the U.S., Cialis continued to gain market share and a declining the market.
At the end of last year, we've submitted Cialis for the treatment of benign hyperplasia for the FDA and could have an action before the end of this year. Finally, we continue to see consistent growth and sheriff market for F. yet in the U.S. and in Europe. 2010 sales totaled 150 million and sales in the fourth quarter were $47 million. We remain committed to this product and based on the clinical data we've generated along with we believe FDA has an important role to play in the treatment of patients undergoing PCI.
In addition to maximizing opportunities to drive topline revenue growth for the company, we've also been focused on driving greater productivity. Through deliberate and determine actions, we are tracking to achieve the headcount and cost containment goals we laid out in September of 2009. As of December 312010, excluding strategic headcount additions in key emerging markets in Japan and business development, we have reduced headcount by 3,450 or nearly 2/3 of our goal of 5,500. And we're on track to meet or exceed our goal of reducing our project 2011 cost by $1 billion. We saw some of those benefits of these efforts in the leverage we've generated in 2010 between revenue growth in net income growth, and we expect to see an even greater benefit in 2011. Now hopefully, the information I've shared blisters the opportunities we see for many areas of our company to generate future top line growth and to deliver on our productivity improvement goal. It is through these opportunities and efforts that we expect to generate mid-teens earnings per share growth excluding the impact of the Zyprexa and Gemzar sales reductions outside of Japan. U.S. healthcare U.S. healthcare and the BL Alliance.
Now let me turn to those other items. Outside of Japan, we estimate that Zyprexa and Gemzar sales will decline significantly in 2011 compared to 2010 driven by patent explorations. In total, we anticipate this for EPS growth by approximately 15 to 17 percentage points. We are already seeing rapid erosion of Gemzar to see some continued erosion on interaction international sales where we long patent protection in many markets in early 2009. We also Zyprexa sales to decline rapidly post patent expiration which occurs in April for some International Markets and September for most major European countries, and in October and the United States.
Compared to 2010, U.S. by healthcare reform by an incremental $170 to $270 million and add an additional $150 million to $250 million in non-tax-deductible operating commitments through the Pharmaceutical industry fee. Combined, we estimate this could reduce 2011 EPS growth by approximately 4.5 to 5.5 percentage points.
Finally, we expect our strategic diabetes alliance with Boehringer Ingelheim to reduce 2011 non-GAAP ATSG to increase SG&A and R&D expenses. Specifically, we expect this alliance to reduce 2011 non-GAAP EPS growth by approximately 4.5% to 5.5 percentage points. However, we view this near-term earnings dilution very differently than that from patent expirations or governmental actions. Clearly, we've anticipated that the near-term earnings dilution is a precursor to longer term EPS accretion and that this alliance adds economic value to Lily and its shareholders and is thus a good investment for the business.
So while we face major headwinds in 2011, we've taken a number of actions designed to significantly mitigate this negative impact and position the company to continue to invest in our long-term growth potential, while funding our dividends, capital expenditures and targeted business development. 
Now, I'll provide some color commentary for our guidance. In terms of the top line, we anticipate 2011 revenue will be flat to slightly increasing compared to 2010. Excluding the anticipated decline of that Zyprexa and Gemzar sales outside of Japan and the incremental impact of U.S. healthcare reform, we expect 2011 revenue to grow in the mid- to high-single-digits. We expect gross margin as a percent of revenue to decline approximately two percentage points due to the negative effect of patent losses, the Puerto Rican export tax, and the anticipated negative effect of foreign exchange on international inventory sold.
Marketing, selling and administrative expenses are projected to grow in the low- to mid- single-digits. Now it is important to note that the new pharmaceutical industry fee will be booked in this line item of our income statement. In addition, we expect to have substantial additional marketing and selling expenses as a result of the lines for BI. Excluding anticipated expenses from the pharmaceutical industry fee and the BI Alliance, we would anticipate marketing, selling and administrative expenses to be essentially flat. Research and development expenses are expected to be relatively flat. This growth rate is affected by the higher than normal charges in 2010 that flowed through R&D. Excluding these charges from the base period, R&D expenses would be expected to grow in the mid-single-digits with much of this growth driven by our portion of the anticipated clinical trials spent for BI's DPP4 and SGL2 inhibitors.
For the year, other income and deductions are expected to be a net expense of between $50 million and $150 million driven largely by net interest expense. The tax rate is anticipated to be approximately 21.5% for the year while the IRS has not provided a final ruling on U.S. tax treatment of the Puerto Rican export tax, for the purposes of our guidance, we have assumed that this export tax will be creditable in the U.S.
Finally, we expect operating cash flow to be more than sufficient to fund capital expenditures of $800 to $900 million as well as the dividend and continued business development.
Slide 19 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our 2011 guidance. 
This concludes our prepared remarks. And now, we'll take questions. Operator, first caller please."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out of the Phase III is positive sign and in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if",139,"I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out of the Phase III is positive sign and in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seizures were not an issue and the data says that you felt comfortable moving forward and when we'll be able to see a Phase II data if the profile similar to what was hypothesized in the nature of the article that was published in the compound back in time? And then just one other question I like to ask you which is about by Bydureon, I'm wondering if the FDA is come back to you with any more questions on the QT front us the FDA decision was handed?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One thing for Katherine in mGlu trials these Oregon have a number of occurrences of these seizure-type events. I believe the total number was 80. Well actually I think this longer-term data that we're generating only having had to admit events to date aga",114,"One thing for Katherine in mGlu trials these Oregon have a number of occurrences of these seizure-type events. I believe the total number was 80. Well actually I think this longer-term data that we're generating only having had to admit events to date again one prior to mend randomization and the other oncoming at this continued for lack of the efficacy and typical gives us hope that this actually will not be particular issue for the drug. Again patient something extremely important a lot of it's going forward we've extended that to go out 12 months. Look forward to presenting six-month data in April but the 12 month data subsequently when that's matured."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Tony Butler with Barclays Capital.",13,"We have a question from the line of Tony Butler with Barclays Capital."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. I'll take both your questions. First of all, will be watching Cymbalta for chronic pain next year. Here in the U.S., we feel well prepared for that launch and we feel like we've got the right salesforce coverage for the right positions",327,"Tony, this is John. I'll take both your questions. First of all, will be watching Cymbalta for chronic pain next year. Here in the U.S., we feel well prepared for that launch and we feel like we've got the right salesforce coverage for the right positions to make sure that the appropriate message is getting out there. I'm not -- right now at liberty to discuss the range of tactics, et cetera. But it's obviously a very important new indication for -- as you know from molecule that now has five or six approved indications in different countries around the world. It's going to be Cymbalta's, as Derica point out going to be an important growth driver for us in this beginning of something period. With respect insulins, I think it really remains to be seen how big of a threat so-called generic versions of insulins will be. We're not blind to this year? Or keeping a careful eye on it, as you know, insulins are a different kind of biologic product. Their production outputs are in the thousands of kilos as supposed to molecule like APO and others. The capital investments required, the complexity of the technology around insulins, I think, serve as more of a barrier to entry perhaps for would be competitors and is going to be the case and other therapeutic categories. But obviously, we're going to stay very plugged into this. I think it's very important to keep in mind that we believe the world can benefit from new and improved insulins which is why we're excited about our two insulin analogues that we disclosed. We were now partnering with BI to bring to the market. In addition, delivery technology has moved a considerable ways since the era of the violent syringe and the something going to continue to pioneer more and more new and innovative ways to administer insulin as part of our value proposition for all those products going forward."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of work you slip from BMO Capital Markets.",15,"Our next question comes from the line of work you slip from BMO Capital Markets."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","Just declare there is an asset when you're seeing in the months. So it's a matter of months. We don't really have a specific time line obviously where work into the judiciously with the FDA its something we think we'll be able to address here in the relat",52,"Just declare there is an asset when you're seeing in the months. So it's a matter of months. We don't really have a specific time line obviously where work into the judiciously with the FDA its something we think we'll be able to address here in the relative we near term."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Bernstein.",12,"Our next question comes from the line of Tim Anderson with Bernstein."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up to and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then sec",92,"On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up to and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then second question on 2014 guidance that you've given before, I got on the call late but I'm not sure if you've talked about 2014 or not. Is that still on track? And then third question, a quick one, just emerging market revenue growth in fourth quarter?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations, with the tracks the engines or the mix affect of that creep upward pressure on our tax rate. Also, t",131,"Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations, with the tracks the engines or the mix affect of that creep upward pressure on our tax rate. Also, the second factor affecting our tax rate which also creates upward pressure is the pharmaceutical industry fee which is non-tax-deductible. What's creating a lowering pressure in our effective tax rate is the assumption that we'll be able to credit Puerto Rico excise tax. So that's how we get the tax rate that you saw. In regards to the 2014 guidance, we did not discuss that on the call today and we still forward to updating you on that argument Jun analyst meeting in New York."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of John Boris from City.",12,"Our next question comes from the line of John Boris from City."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second",123,"First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second question on your diabetes portfolio, in particular, if you look at the Canadian label, it does increase a small increase in QTC that you highlighted in that label. Can you just help us understand that and also maybe what any implications are on the U.S. label for by. And then last, is it possible just to get an update on where you are at their own fleet-humanized GOP-1 program going forward? Any update on enrollment involvement on timing reviews of results there?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","We'll probably go ahead and tag team this, John let me start by how we characterize our international sales. Stopped doing today, little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Sl",203,"We'll probably go ahead and tag team this, John let me start by how we characterize our international sales. Stopped doing today, little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10 time, you'll see from the PR E. if you could just the total here year, what is really driving our overall revenue growth so a new reps for the year, we had 3% volume growth. In Japan, we had 26% volume growth. And the rest of the world in those markets outside the U.S., we had 6% of volume growth. And when you break that down, you really saw even in Europe where we are already in some why you see Gemzar, we were still able to drive good erosion in growth volume growth. So we look forward, we really see the Smart it's the emerging markets in Japan really acting in a counter cyclical manner compared to what they're going to see in the U.S. in 2011 as well as in Europe major markets in 2011 with the Zyprexa effect. So this is where we anticipate their writing the future growth."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Real quick in term's of sales numbers on that Slide GEN. 10 which is the effective tax rate on volume and revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, we can com",194,"Real quick in term's of sales numbers on that Slide GEN. 10 which is the effective tax rate on volume and revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, we can comment during the prepared remarks over 10%, essentially roughly 10% of our sales or coming from emerging markets. I don't have the exact percentages for you broken out by the international, but I think hopefully those two numbers will allow you to make that calculation. And then fourth John for the candied up item? John, we're very pleased by Itaipu approved in Canada and about the labeling in front of me but my recollection is not an counter indication warning. The fact is that the FDA is asking some questions for Bydureon on QT and whether that's connected with questions that Canadians might have. Something that I can't speculate on but we are obviously well along with meeting with we understand to be at these requirements so that we can refile Bydureon in the second half of this year and ultimately hopefully gain approval for that."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger with Morgan Stanley.",13,"Our next question comes from the line of David Risinger with Morgan Stanley."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. First, maybe you can just help us understand the something demand interim look for 2011? What are the scenarios for that interim look, typically Phase III trial have to run to completion. Is it a DSMB interim look or what exactly is",99,"A couple of questions. First, maybe you can just help us understand the something demand interim look for 2011? What are the scenarios for that interim look, typically Phase III trial have to run to completion. Is it a DSMB interim look or what exactly is the interim look? That's the first question. Second, in terms of other key late stage pipeline to watch in 2011, what a few that are most important but gets done in terms of Phase III results? And then third, can you just update us on the Strattera and Cymbalta patent litigation outlooks please?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Dave. I'll take a shot at your first two questions and then ask running at the answer the last one. So on something demand looked at tracking exactly directly that for efficacy, these trials need to run all the way to completion to be able to in thi",263,"Sure, Dave. I'll take a shot at your first two questions and then ask running at the answer the last one. So on something demand looked at tracking exactly directly that for efficacy, these trials need to run all the way to completion to be able to in this particular case statistical powering to be the show the slowing of progression of the disease. So this will be a look that's a safety look, so these trials can only be stopped early for either safety issues or for very something signals the way the primary endpoint can be that they cannot be stopped early for efficacy. In terms of the Phase III data, a couple of the major ones that were mentioned on the call are private ones that would highlight to you as well which would be the DURATION-6 data head-to-head with Bydureon versus the Cosa. I believe much becoming you're probably in the first half of the year. Expectation would be the much something you have in the past you probably have the top line results press release with subsequent presentation at a medical meeting time and medical meeting is difficult to know, that might be ADA or UASD. And then obviously with Alimta, we continue to build out that franchise hopefully be up to do so that's a 24 something that the recount mentioned that this linagliptin induction followed by a lipid maintenance therapy. Never call it the current maintenance indication that we have to be used but look at setting followed by a first line treatment with platinum agents."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","I just want to mention that we've got FDA action dates for data peer which receives a priority review status through something abbot beta amyloid imaging agent. For Linagliptin in this is the FBI the beauty four and also for liprotamase the molecule that",49,"I just want to mention that we've got FDA action dates for data peer which receives a priority review status through something abbot beta amyloid imaging agent. For Linagliptin in this is the FBI the beauty four and also for liprotamase the molecule that we acquired with Alnara."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our last question comes from the line of with Chris Schott with JPMorgan.",13,"Our last question comes from the line of with Chris Schott with JPMorgan."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","31st some gross margin two percentage point decline can you give us a little more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales and gross margin relative to some of the factors you mentioned?",129,"31st some gross margin two percentage point decline can you give us a little more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales and gross margin relative to some of the factors you mentioned? I guess he said those two products are much of the impact or some of the things like Puerto Rico play a bigger role? And then second question was on SG&A expense. You mentioned flat SG&A at healthcare reform and the BI announcement. With the restructuring initiatives that you've announced, I guess it would've anticipated a bit more of a decline in 2011. Can you just help us a little bit a little better what pushes the pole going into SG&A in 2011?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Chris, this is Derica. Let me try to address both of your questions. In response to gross margin, we will see a downward pressure on our gross margin driven by the mix of that due to the loss of the metrics by the Zyprexa and Gemzar patent. And so that's",254,"Chris, this is Derica. Let me try to address both of your questions. In response to gross margin, we will see a downward pressure on our gross margin driven by the mix of that due to the loss of the metrics by the Zyprexa and Gemzar patent. And so that's going to create a negative pressure. You're also going to see negative pressure on gross margins attributable to the Puerto Rico excise tax. Because it's an excise tax, it will actually flowed through comps or manufacturing costs, thus reducing our gross margin. And then obviously it's offset or credit it through the tax rate in the line item below that. And those are the two factors that's are driving the decline our gross margin by approximately two percentage points in aggregate. I'm not prepared to break those out into pieces. In regards to the SG&A and being flat, if you exclude the Pharmaceutical industry fee as well as the BI Alliance aligns expenses. What you see is kind of a mix of in the U.S. and our European markets, you are seeing a dramatic decline in our overall operating expense base in terms of SG&A. But as I highlighted on the call, we are making strategic investments in some of our key emerging markets like China as well as in markets like Japan where we are expected to drive significant counter cyclical growth as we go through this period of wisely. So that's what's driving the overall effect of SG&A being essentially flat. John?"
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Well I want to thank everyone for taking time for taking time morning for this update on Eli Lilly & Co. As always, we appreciate your continued interest in our company. We thought, and for the most part, overcame significant headwinds to post strong fina",495,"Well I want to thank everyone for taking time for taking time morning for this update on Eli Lilly & Co. As always, we appreciate your continued interest in our company. We thought, and for the most part, overcame significant headwinds to post strong financial performance in 2010. This was highlighted by volume driven revenue growth. On a performance basis, we delivered increasing gross margin as a percent of revenue. We gain leverage between revenue and operating income growth and posted a robust 8% net income growth. We prudently manage working capital and capital expenditures. And once again generated strong operating cash flow. We're pleased with our performance and our progress in 2010. We're excited about the opportunities before us in 2011.
As Derica discussed, we entered this year with a keen wariness of the challenges posed by the patent expirations since we face in the YZ period ahead. But we have a focused strategy vote centered on innovation that we're aggressively pursuing. Over the last year, we advanced 16 new molecules into Phase I clinical testing, nine molecules into Phase II testing; and two molecules nearing depression and hour and feedback antibac antibody for rheumatoid arthritis and lupus was into Phase III testing. We concluded the number of business development deals with a bias towards those that provide current or potential near-term revenues. We acquired forbid up here with our acquisition of Abbot radiopharmaceuticals. And just last week on FDA advisory committee recommended approval of the beta amyloid imaging agent if we provide appropriate physician training and successfully reread existing brain scans. And our strategic alliance with Boehringer Ingelheim includes the development and commercialization of two oral diabetes compounds from BI including Linagliptin which could be approved this year and two basal analogue insulins from Lilly. 
In addition, we are prepared to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency and have a number of potential regulatory approvals including Bydureon in the EU and several pending here in the U.S. At the same time, we expect continued strong performance in the rest of our business in 2011, including the three countercyclical growth engines we've discussed for some time. Lily is, today, the fastest-growing pharma company in Japan and the fastest-growing among the top 10 multinational companies in key emerging markets.
While Alinco animal health is outpacing its industries growth as well. We'll continue to take advantage of this counter cyclical growth as well as the growth in the number of our patent protected products in the U.S. and Europe. Our strong financial performance, our focus on speeding innovations to patients, and targeted use of business development all support our goal of successfully traversing years YZ. and emerging with even greater strength and the capacity to drive future growth. We'll continue to act with urgency and purpose to overcome the challenges we face. And as always, we will keep you informed of our progress. Thanks again for joining us. Have a great day."
285467,97242168,95858,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011 at midnight. You may access the AT&T executive playback service by dialing 1-800 number 1-800 475-6701 and entering access code 186408. I",73,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011 at midnight. You may access the AT&T executive playback service by dialing 1-800 number 1-800 475-6701 and entering access code 186408. International participants may dial area (320)365-3844. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation using AT&T executive teleconference service. You may now disconnect. Have great day."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",39,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chie",1696,"Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chief Financial officer, Derica Rice, our President of Lilly Research Laboratories, Dr. Jan Lundberg; and Ronika Pletcher; and Jill Thoren from Investor Relations.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
We accomplished a great deal in 2010, while rapidly adapting to significant external and internal challenges. Here are some highlights.  For the full year, we again delivered strong financial performance, generating 6% revenue growth, and we were able to leverage this 6% revenue growth into 8% non-GAAP net income growth, as we made substantial progress reducing headcount and containing costs.
Our strong operating performance, along with prudent management of working capital generated nearly $7 billion of operating cash flow, easily covering capital expenditures of about $700 million, and our dividend of roughly $2.2 billion.
During the year, we did experience pipeline disappointments with  [ph] teplizumab and tasisulam. However, our scientists remain focused on speeding innovation to patients, making significant pipeline progress. Advancing 16 new molecules into Phase I testing, nine molecules into Phase II testing, and two molecules into Phase III testing.
We also concluded a number of business development deals with a bias towards those that provide current or potential near-term revenues.
Our strong financial performance, focus on speeding innovation to patients and targeted use of business development all support our goal of successfully navigating our upcoming patent explorations and emerging with an even greater strength and capacity to drive future growth.
Since our last earnings call, we've made significant progress on a number of fronts. In clinical news, we began Phase III trials of our antibac antibody for both rheumatoid arthritis and lupus. Based on an interim review of long-term safety data, and after complication with the FDA, we made the decision to begin Phase III trials later this year of mGlu2/3 of monotherapy treatment for schizophrenia. And along with our partner, Incyte Pharmaceuticals, we disclosed promising Phase IIa data in rheumatoid arthritis for our JACK1/JACK2 inhibitor.
In regulatory news, we received FDA approval of Cymbalta for the management of chronic musculoskeletal pain based on clinical trials in patients with chronic low back pain and chronic pain due to osteoarthritis. And we'll begin active promotion for this indication next week.
We also received FDA approval for Axiron as replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. And we expect to launch the product midyear after building sufficient launch quantities.
Health Canada approved Byetta to improve glycemic control in patients with type 2 diabetes. And we also submitted sNDAs for Byetta used in combination with basal insulin and for Cialis for benign prostatic hyperplasia.
On the legal front, the U.S. District Court ruled that judgment will be entered in Lilly's favor in the Alimta compound patent challenge. Including a recently obtained six-month pediatric exclusivity, this patent provides protection for Alimta until January 17. And the Court of Appeals for the Federal Circuit heard our appeal of the U.S. District Court's ruling invalidating our Strattera method-of-use patent. As argued at the appeal hearing, we feel there is a strong basis for the CAFC to overturn the district court ruling. We are awaiting a decision by the CAFC. And in the meantime, an injunction from the CAFC prevents generics from launching.
Finally in business development news, we announced and completed the acquisition of Avid Radiopharmaceuticals. Avid's lead asset, florbetapir, was assigned a priority review by the FDA. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if certain conditions are met related to physician training and re-reading of existing brain scans.
Along with Boehringer Ingelheim, we announced a broad strategic alliance to develop and commercialize two oral diabetes compounds from BI and two basal analog insulins from Lily. As we've done in previous calls, we'll focus our comments on the non-GAAP results, which we believe brought insights in some underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges.
On Slide 7, you can see the revenue grew 4% in Q4 to nearly $6.2 billion. As I'll show more detail in a minute, volume continue to be the major driver of our revenue growth. Gross margin as a percent of revenue increased 4.2 percentage points from 75.9% to 80.1%. Roughly 2/3 of this increase was due to the favorable effect of changes in foreign currency exchange rates on international inventory sold. Specifically, changes in the foreign currency value of the U.S. dollar substantially increased cost of sales in Q4 2009 but slightly decreased cost of sales in Q4 2010. The remaining improvement in gross margin as a percent of revenue was due to lower manufacturing costs, a tangible result of our ongoing productivity improvement efforts.
This quarter's total operating expense, defined as the sum of R&D and SG&A, grew 8%. Within operating expense, marketing, selling and administrative expenses grew only 2% as higher marketing and selling expenses outside the U.S. were partially offset by lower administrative expenses and a company-wide cost containment efforts. R&D expense, on the other hand, grew 18%. Approximately 2/3 of this increase was due to higher than normal charges related to business development activities and termination of clinical trials. Other income and deductions improved due to primarily to lower miscellaneous other expense and, to a lesser extent, lower net interest expense. In addition, our tax rate fell by four percentage points largely due to the recognition in Q4 of the full year impact of the extension of the R&D tax credit. Net income and earnings per share increased 24% and 22% respectively.
For the year, you can see that we generated leverage between revenue and net income, as revenue grew 6% while net income grew 8%. We achieved this leverage between revenue and net income despite foreign exchange being a drag on our gross margin percent for the full year, higher than normal charges flowing through R&D in 2010 and a 1.6 percentage point increase in the full year tax rate, largely due to the $85 million tax charge taken in Q1 2010 as a result of U.S. healthcare reform.
Slide 8 shows our reported income statement, while Slide 9 provides a reconciliation between reported and non-GAAP earnings per share. Additional details about our reported earnings are available in today's earnings press release.
As you can see on Slide 10, for both the fourth quarter and the full year, foreign exchange had little effect on revenue growth as a weaker euro was offset by strength in other foreign currencies, including the Japanese yen.
Consequently, performance growth and total revenue of 5% for both the quarter and the year was driven by 3% volume growth and a favorable 2% impact from price. In both periods, we saw robust, double-digit volume growth in our Japanese Human Pharmaceutical business and our Global Animal Health business. Now let's look at the rest of the income statement.
Slide 11 shows the year-on-year growth of select line items of our non-GAAP income statement with and without the effective changes in foreign exchange rates. The numbers in the first column are the same as those you saw earlier on our non-GAAP income statement. If you look at the top of the second column of numbers, you'll see the 5% performance growth in revenue I mentioned previously. Below that, you'll see the cost of sales actually decreased 2% excluding the effect of foreign exchange. As a result, gross margin grew 7%. Operating expenses grew faster than revenue this quarter. The larger than normal R&D charge, as mentioned earlier, drove the majority of the 9% performance growth in operating expenses. As a result of this increase in operating expenses, our 5% performance growth in revenue translated into 3% performance growth in operating income, while the lower tax rate this quarter boosted growth in EPS to 10%.
Finally, you'll see in the last column that for the year, we've leveraged 5% performance growth in revenue into 7% and 8% growth in operating income and earnings per share, respectively. We achieved this leverage due primarily to lower manufacturing costs. For your information, on Slide 12, we provided the year-on-year growth of select line items of our reported income statement with and without the effect of foreign exchange rates. 
Next, I'll briefly cover some highlights from our quarterly pipeline update.
Slide 13 shows our pipeline as of January 24 and highlights changes since our last earnings call on October 21. Movement of molecules to the next phase of development are shown by green arrows and additions from business development are shown by green stars. They both demonstrate our focus on addressing our upcoming patent expirations through innovation, both that coming from our own labs, as well as from outside our walls. You can see that we added two compounds under regulatory review: florbetapir, the beta-amyloid imaging agent from Avid and linagliptin, the oral DPP-4 inhibitor for diabetes from BI. The BI alliance also brought a Phase III compound, BI 10773, an oral SGLT-2 inhibitor. We also saw significant movement in the pipeline as Axiron was approved. We began Phase III testing of our antibac antibody for both rheumatoid arthritis and lupus. Four molecules began Phase II testing, three new molecules began Phase I testing, and we terminated development of five molecules and sold one molecule to a third-party. 
Now, I'll turn the call over to Derica to cover some of the key events we anticipate in 2011 and a detailed discussion of our 2011 financial guidance. Derica?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU",2548,"Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU and a number pending here in the U.S.; linagliptin for type 2 diabetes in collaboration with BI; liprotamase, our recombinant pancreatic enzyme replacement therapy, and florbetapir, Cialis for BPH and Byetta in combination with basal insulin.
Expected regulatory submissions include our response to the FDA complete response letter for Bydureon and sBLAs for Erbitux, a first-line metastatic colorectal cancer, head and neck cancer, and non-small cell lung cancer. In terms of Phase III trials, we'll complete the DURATION 6 trial comparing Bydureon to Victoza. We also expect to present initial results from the Phase III trial and advanced nonsquamous, non-small cell lung cancer of Alimta induction followed by Alimta maintenance therapy. Following the initiation of Phase III trials late last year for both NERI and depression and our antibac antibody in RA and lupus, Phase III trials are slated to begin this year for mGlu2/3 in schizophrenia, our novel basal insulin analog and our new insulin glargine product and potentially for our anti-IL 17 antibody in RA.
Now as I move on to guidance, I'm going to take a bit more time today than I have in the past to walk you through it, as I want to make sure you understand how we expect some of the more substantial drivers to effect our results in 2011. Now clearly, more sales of Zyprexa and Gemzar outside of Japan due primarily to global patent expiration as well as the incremental impact of U.S. healthcare reform will have a significant negative impact on our 2011 results. In addition, we'll face some near-term earnings dilution from our strategic diabetes alliance with Boehringer Ingelheim. At the same time, we expect continued strong performance in the rest of our business in 2011 including the three countercyclical growth engines we've discussed for some time, Japan, Emerging Markets and Animal Health, as well as and a number of our patent-protected products in the U.S. and in Europe.
In addition, we expect to see continued benefit from our cost reduction and productivity efforts. I want to make sure you have good visibility into this growth within our business. 
I'll start with a discussion of our bottom line EPS expectations and then review our individual line item guidance. As you've seen in our press release, we expect 2011 non-GAAP earnings per share between $4.15 and $4.30. Our 2011 reported EPS guidance range is $0.23 lower due to the estimated IP R&D charge from the BI alliance. On a non-GAAP basis, this represents a decline of between 9% and 12% when compared to 2010. So how does this 9% to 12% EPS decline break out between the negative EPS impact of the items I mentioned earlier and the continued growth in the rest of our business? I'll start with the latter. The underlying EPS growth we expect to see from our business before factoring in expected sales decline in Zyprexa and Gemzar outside of Japan due primarily to patent expirations and U.S. healthcare reform and the BI Alliance. Now as we've discussed before, we've been making targeted investments in Japan, our Emerging Markets and Animal Health and more broadly in our remaining patent protected products. And also, we've been aggressively reducing headcount and controlling expenses as we re-base the size of our business. We've seen these efforts pay off in 2010 and expect to see the same in 2011 and beyond. In fact, our 2011 non-GAAP EPS guidance of $4.15 to $4.30 implies a growth contribution of roughly 15% from these parts of our business.
In Japan, our sales growth has been outstanding at recent years fueled by the launch of products and indications that we're launching more earlier in the U.S. and Europe. On a local currency basis, sales in Japan grew 15% in 2009 and 25% in 2010. As reported by IMS, currently we are far and away  [ph] the fastest-growing major pharmaceutical company in this important market. And we're seeing strong growth from a host of products in Japan. Please note that, going forward, I'll be citing local currency growth for certain products in Japan, as well as in Europe. The effect of foreign exchange for any individual product is similar to that shown on Slide 10 for that relevant geography.
Now Zyprexa, our largest-selling product, grew 8% on a local currency basis in 2010, and we expect continued growth. In Q4 last year, Zyprexa became the first atypical antipsychotic approved in Japan for bipolar mania. And later this year, we plan to submit for approval in bipolar depression. Now remember, we maintain exclusivity in Japan for Zyprexa until December of 2015, and we expect Japan to help drive what we hope will be a significant tail of Zyprexa sales post 2011.
Alimta was approved for non-small cell lung cancer in Japan in Q2 of 2009 and achieved the best share of market uptick in the first line nonsquamous segment of any market in the world. It is now our second-largest product in Japan, and we see continued room for growth, as we believe more patients with nonsquamous cell histology can benefit from the treatment with Alimta. 
We've also been driving increased market share with Humalog. This product has been growing at roughly twice the insulin market growth rate and registered 14% growth in local currency in 2010. We are focused on continuing the strong momentum. And we expect to see significant growth contributions from Cymbalta, which was launched in Q2 of last year, and Forteo and Byetta, both launched this past quarter.
Now turning to emerging markets. Revenue grew 10% in 2010 on a local currency basis. As we've shared with you in the past, we've been making targeted investments in six markets: China, Russia, Turkey, Korea, Brazil and Mexico. And these investments are paying off. Volume growth has accelerated in each of these markets with the exception of Brazil. From 2009 to 2010, volume growth accelerated from 18% to 21% in China, from a minus 7% to a positive 21% in Russia, from 4% to 20% in Turkey and from a minus 2% to a positive 19% in Korea, and from 1% to 7% in Mexico.
More broadly, for the 12 months ending September 2010, IMS showed that Lily ranked first in sales growth at 12% among the 10 leading multinational countries across five emerging markets: China, Turkey, Korea, Brazil and Mexico.
We remain focused on driving profitable growth in emerging markets. We see significant opportunities to do so with our core assets, including Cymbalta, Cialis, Humalog and Alimta. While the majority of our efforts will be concentrated on maximizing opportunities from our core assets, we will continue to look to supplement this organic growth with targeted business development. 
On a local currency basis, our Elanco Animal Health business grew 12% in 2009 and 14% in 2010, significantly outpacing overall industry growth. This solid growth was driven by our Food Animal business and by Comfortis, our oral flea control products for companion animals, which has had a strong uptake here in the United States.
Going forward, we expect Animal Health revenue growth to benefit from international launches of Comfortis, including in the EU this quarter.
In addition, Elanco has built a robust innovation pipeline and is poised to maintain double-digit growth in the coming years with launched expected for multiple products targeting high-value markets, such as livestock immune enhancement, control of parasites in companion animals and pain control. This quarter in the U.S., we'll launch Assurity, a topical flea treatment for cats, and Trifexis, an oral flea and heartworm treatment for dogs. We've also built a substantial development capability in animal health vaccine and have demonstrated a willingness to drive the growth to this business via business development. Apart from continued strength in these three countercyclical growth engines, we also see opportunities for growth in a number of patent-protected product outside of the emerging markets in Japan.
Now let me cite a few examples. On a local currency basis, Cymbalta grew 15% in Europe last year. Here in the U.S., Cymbalta continues to fare well in its existing mood and pain indications in a market dominated by generics. And we'll begin active promotional efforts next week for Cymbalta's latest FDA-approved indication, management of chronic musculoskeletal pain.
2010 local currency growth of Alimta was 20% in Europe and 17% in the U.S. This year, we anticipate submitting the results of our S1 2/4 study to the FDA for approval of Alimta induction treatment followed by Alimta maintenance treatment in patients with advanced nonsquamous, non-small cell lung cancer.
In our Diabetes business, Humalog registered solid 6% local currency growth in Europe in 2010. Now while sales in the U.S. were essentially flat, in the second half of the year, we saw sustained growth in our new prescription share of rapid and middle time analog market for the first time in years. We've also improved Humalog access, which should reinforce the positive sharemarket trend as we begin 2011.
Now for Cialis, in Europe we have continued to extend our leading DOT and cash share market. While in the U.S., Cialis has continued to gain market share in a declining ED market.
At the end of last year, we've submitted Cialis for the treatment of benign prostatic hyperplasia to the FDA and could have an action before the end of this year. Finally, we continue to see consistent growth in shared market for Effient in the U.S. and in Europe. 2010 sales total $115 million, and sales in the fourth quarter were $47 million. We remain committed to this product, and based on the clinical data we've generated along with Daichi Sankyo, we believe Effient has an important role to play in the treatment of ACS patients undergoing PCI.
In addition to maximizing opportunities to drive top line revenue growth for the company, we've also been focused on driving greater productivity. Through deliberate and determined actions, we're tracking to achieve the headcount and cost containment goals we laid out in September of 2009. As of December 31, 2010, excluding strategic headcount additions in key emerging markets in Japan and business development, We had reduced headcount by 3,450 or nearly 2/3 of our goal of 5,500. And we're on track to meet or exceed our goal of reducing our projected 2011 cost by $1 billion. We saw some of those benefits of these efforts in the leverage we generated in 2010 between revenue growth and net income growth, and we expect to see an even greater benefit in 2011. Now hopefully, the information I've shared illustrates the opportunities we see for many areas of our company to generate future top line growth and to deliver on our productivity improvement goal. It is through these opportunities and efforts that we expect to generate mid-teens earnings per share growth, excluding the impact of the Zyprexa and Gemzar sales reductions outside of Japan, U.S. healthcare reform and the BI alliance.
Now let me turn to those other items. Outside of Japan, we estimate that Zyprexa and Gemzar sales will decline significantly in 2011 compared to 2010 driven by patent expirations. In total, we anticipate this will lower EPS growth by approximately 15 to 17 percentage points. We are already seeing rapid erosion of Gemzar sales in the US and expect to see some continued erosion in international sales where we lost patent protection in many markets in early 2009. We also anticipate Zyprexa sales to decline rapidly post patent expiration, which occurs in April for some International Markets and September for most major European countries, and in October, in the United States.
Compared to 2010, U.S. healthcare reform could lower 2011 revenue by an incremental $170 to $270 million and add an additional $150 million to $200 million in non-tax-deductible operating commitments through the pharmaceutical industry fee. Combined, we estimate this could reduce 2011 EPS growth by approximately 4.5 to 5.5 percentage points.
Finally, we expect our strategic diabetes alliance with Boehringer Ingelheim to reduce 2011 non-GAAP EPS to increase SG&A and R&D expenses. Specifically, we expect this alliance to reduce 2011 non-GAAP EPS growth by approximately 4.5 to 5.5 percentage points. However, we view this near-term earnings dilution very differently than that from patent expirations or governmental actions. Clearly, we've anticipated that the near-term earnings dilution is a precursor to longer term EPS accretion. And that this alliance adds economic value to Lily and its shareholders and is thus a good investment for the business.
So while we face major headwinds in 2011, we've taken a number of actions designed to significantly mitigate this negative impact and position the company to continue to invest in our long-term growth potential, while funding our dividends, capital expenditures and targeted business development. 
Now I'll provide some color commentary on our [ph] guidance. In terms of the top line, we anticipate 2011 revenue will be flat to slightly increasing compared to 2010. Excluding the anticipated decline in Zyprexa and Gemzar sales outside of Japan and the incremental impact of U.S. healthcare reform, we would expect 2011 revenue to grow in the mid- to high-single-digits. We expect gross margin as a percent of revenue to decline approximately two percentage points due to the negative effect of patent losses, the Puerto Rican export tax and the anticipated negative effect of foreign exchange on international inventories sold.
Marketing, selling and administrative expenses are projected to grow in the low- to mid- single-digits. Now it is important to note that the new pharmaceutical industry fee will be booked in this line item of our income statement. In addition, we expect to have substantial additional marketing and selling expenses as a result of the alliance with BI. Excluding anticipated expenses from the pharmaceutical industry fee and the BI alliance, we would anticipate marketing, selling and administrative expenses to be essentially flat. Research and development expenses are expected to be relatively flat. This growth rate is affected by the higher than normal charges in 2010 that flowed through R&D. Excluding these charges from the base period, R&D expenses would be expected to grow in the mid-single-digits with much of this growth driven by our portion of the anticipated clinical trials spent for BI's DPP-4 and SGLT-2 inhibitors.
For the year, other income and deductions are expected to be a net expense of between $50 million and $150 million driven largely by net interest expense. The tax rate is anticipated to be approximately 21.5% for the year, while the IRS has not provided a final ruling on U.S. tax treatment of the Puerto Rican export tax. For the purposes of our guidance, we have assumed that this export tax will be creditable in the U.S.
Finally, we expect operating cash flow to be more than sufficient to fund capital expenditures of approximately $800 to $900 million, as well as the dividend and continued business development.
Slide 19 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our 2011 guidance. 
This concludes our prepared remarks. And now, we'll take your questions. Operator, first caller, please."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seiz",137,"I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seizures were not an issue in the data such that you felt comfortable moving forward. And when we'll be able to see a Phase II data if the profile similar to what was sort of hypothesized in the nature article that was published on the compound back in time? And then just one other question I'd like to ask you which is about Bydureon. I'm wondering if the MEA has come back to you with any more questions on the QT front since the FDA decision was handed?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU.",26,"Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","But you might remember back in 2009, we started a safety and tolerability study for mGlu 2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That s",180,"But you might remember back in 2009, we started a safety and tolerability study for mGlu 2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That study, we now have six-month data on that study, which we plan to actually disclose at a European event in April. That study actually did have two additional seizures in that study. Of those two, one of the patients had the seizure actually before they were randomized the drug. And the second patient actually had their seizure after they came off of the study drug and before initiating the typical. So we are now getting that additional information to help us understand. But we feel confident in the data that we have so far on that six-month study to now go ahead and move ahead with our Phase III program. And that's also in combination with our prior Phase II, or Phase II studies that were presented and published back in 2007 and 2009."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?",36,"Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by t",55,"We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by the EU regulators."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that",135,"One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that we're generating only having had two events to date, again, one prior to randomization and the other one coming after the patient has discontinued for lack of efficacy and started up the typical -- gives us hope that this is actually something that will not be a particular issue for the drug. Again patient's age is extremely important to monitor, going forward. We've extended that to go out 12 months. I look forward to presenting our six-month data in April, but the 12 month data subsequently when that's matured."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Tony Butler with Barclays Capital.",13,"We have a question from the line of Tony Butler with Barclays Capital."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction,",162,"Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction, and what would that message be distant its use as an antidepressant? And then second, staying with you, John, if possible. I'm just curious how you think or if you could provide some color around a couple of institutions, principally in India and Korea, have made comments or seem to be gearing up for the introduction in Europe, possibly generic insulins or generic alternatives. And while generic insulin may not necessarily be a focus proper to really -- I guess, it could be over into Humalog. And I'm just curious about how you think those potential generic biologic entries into the European market over the next couple of years? And if you think that's really a possibility?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right posit",326,"Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right positions to make sure that the appropriate message is getting out there. I'm not, right now, at liberty to discuss the range of tactics, et cetera. But it's obviously a very important new indication for, as you know, for a molecule that now has five or six approved indications in different countries around the world. It's going to be Cymbalta, as Derica pointed out. It's going to be an important growth driver for us in this beginning of this Y-Z period. With respect to insulins, I think it really remains to be seen how big of a threat so-called generic versions of insulins will be. We're not blind to this? We're keeping a careful eye on it, as you know. Insulins are a different kind of biologic product. Their production outputs are in the thousands of kilos, as opposed to molecules like EPO and others. The capital investments required, the complexity of the technology around insulins, I think, serve as more of a barrier to entry perhaps for would-be competitors, then it's going to be the case in other therapeutic categories. But obviously, we're going to stay very plugged in to this. I think it's very important to keep in mind that we believe the world can benefit from new and improved insulins, which is why we're excited about our two insulin analogs that we disclosed. We were now partnering with BI to bring to the market. In addition, delivery technology has moved a considerable ways since the era of the violent syringe. And Lilly going to continue to pioneer new and more convenient ways to administer insulin as part of our value proposition for all those products going forward."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Our next question comes from the line of Bert Hazlett with BMO Capital Markets."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-r",76,"I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-read of the Phase II studies for Amyvid? And is that the gating item for resubmission? And then when is the next interim safety look for solanezumab, the A beta Alzheimer compound?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","If you want, I'll tale initial shot and then Derica on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's going",137,"If you want, I'll tale initial shot and then Derica on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's going to be a ramp up in that business. So I wouldn't take some of the initial data necessarily being the run rate for growth going forward. But clearly, it's a very important deal that we struck with Wal-Mart. We're very pleased with the initial results. I'd also say that in general, it seems that globally, we're having a very good run growth of Humulin, which for very strategic reasons, I believe that [ph] been taking as the market is opening itself up a bit to our Humulin. So, Jan, for the pipeline?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to the -- solanezumab, as you know, most of the Phase III studies have now been",82,"Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to the -- solanezumab, as you know, most of the Phase III studies have now been enrolled, and the duration is 18 months. And we will have an interim readout. I don't want to comment on exactly when, but we are following, I think, on track to deliver this molecule."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able",57,"And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able to address here in the relatively near term."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Bernstein.",12,"Our next question comes from the line of Tim Anderson with Bernstein."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then",92,"On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then second question on 2014 guidance that you've given before. I got on the call late, but I'm not sure if you've talked about 2014 or not. Is that still on track? And then third question, a quick one, just Emerging Market revenue growth in fourth quarter?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the sec",131,"Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the second factor affecting our tax rate, which also creates upward pressure, is the pharmaceutical industry fee, which is non-tax-deductible. What's creating a lowering pressure on our effective tax rate is the assumption that we'll be able to credit the Puerto Rico excise tax. So that's how we get to the tax rate that you saw. In regards to the 2014 guidance, Tim, we did not discuss that on the call today. And we still forward to update that at our June Analyst Meeting in New York."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage poi",221,"One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage points. That will not be recurring in our 2011 or going forward numbers. And then in terms of the emerging market, as we've said in the call, the full year growth rate was 14% total. Well, actually it's 10% performance, a very robust growth. We did have a spike in Q3 that came down a little bit in Q4 due to timing of orders. Specifically in Q4, we had about percent total growth, nearly all of which was from performance despite -- we have references that compares to 18% growth in Q3, 16% of which was performance. Some of the things that we saw, for example, Tim, to give some color. There would've been some Zyprexa orders, for example, in Brazil but would have expected to come through in Q4. They did not come through in Q4. They did come through early this Q1. So again, we think, by looking at that full-year number gives you a better trend for how the emerging markets are growing. And again that's 10% performance."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Next question comes from the line of John Boris with Citi.",11,"Next question comes from the line of John Boris with Citi."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second",130,"First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second question on your Diabetes portfolio, Byetta in particular. If you look at the Canadian label, it does increase a small increase in QTC that they've highlighted in that label. Can you just help us understand that and also walk through what the implications are on that for the U.S. label and for Bydureon? And then last, is it possible just to get an update on where you are at with your own fully humanized GLP-1 program going forward? Any update on enrollment and timing of release of results there?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you loo",194,"John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you look at just the total year here what was really driving our overall revenue growth. So in Europe for the year, we had 3% volume growth. In Japan, we had 26% volume growth. And the rest of the world, so in those markets outside the U.S., we had 6% of volume growth. And when you break that down, you really saw even in Europe where we are already in some YZ aspect in terms of Gemzar erosion, we still were able to drive good volume growth. And so when we look forward, we really see those markets, like the emerging market in Japan, really acting in a countercyclical manner compared to what we're going to see in the U.S. in 2011, as well as in Europe major markets in 2011 with the Zyprexa effect. So this is where we anticipate driving the future growth."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Real quick in term's of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as",103,"Real quick in term's of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as we commented during the prepared remarks, over 10%, essentially roughly 10% of our sales now are coming from emerging markets. I don't have the exact percentages for you broken out by the international, but I think hopefully those two numbers will allow you to make that calculation. And then for John for the Canada Byetta."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own qu",105,"Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own questions for Bydureon on QT. And whether that's connected with questions that Canadians might have. It's something I can't speculate on, but we're obviously well along with meeting what we understand to be FDA's requirements, so that we can refile Bydureon in the second half of this year, and ultimately hopefully gain approval for that."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. We had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably start a CD s",66,"Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. We had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably start a CD study. So we're pretty pleased with the progress of that program and look forward to sharing some data in early '12."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger with Morgan Stanley.",13,"Our next question comes from the line of David Risinger with Morgan Stanley."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. First, maybe you could just help us the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly is the inter",101,"A couple of questions. First, maybe you could just help us the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly is the interim look? That's the first question. Second, in terms of other key late stage pipeline results to watch in 2011, what are the few that are most important that you're focused on in terms of Phase III results? And then third, could you just update us on the Strattera and Cymbalta patent litigation outlooks, please?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to c",277,"Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to completion to be able to have in this particular case statistical powering to be able to show the slowing of progression of the disease. So this will be a look that's a safety look. So these trials can only be stopped early for either safety issues or for very curious signals that there's no way the primary endpoint could be met. They cannot be stopped early for efficacy. In terms of the Phase III data, a couple of the major ones that were mentioned on the call are private ones, I would highlight to you, as well, which would be the DURATION-6 data head-to-head with Bydureon versus Victoza. I believe that should be becoming here probably in the first half of the year. Expectation would be much like we have the past. You probably have the top line results press release with subsequent presentation at a medical meeting. Timing of that medical meeting is difficult to know if that might be ADA or EASD. And then obviously with Alimta, we continue to build out that franchise and are very hopeful that we'll be able to do so with the S124 study that Derica mentioned that is Alimta induction, followed by Alimta maintenance therapy. You may recall that the current maintenance indication that we have is for Alimta used in the maintenance setting followed by a first line treatment with platinum agents."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or a",68,"Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or at least a co-administrative study with the alpha blocker and develop with BPH. That's another set of Phase III data."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with A",44,"I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with Alnara."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've iss",74,"So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've issued for 2011. Cymbalta, last update we had, we remain on track for a trial to start here in the U.S. District Court for Southern Indiana on June 6 of this year."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our last question comes from the line of Chris Schott with JPMorgan.",12,"Our last question comes from the line of Chris Schott with JPMorgan."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the",135,"My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the factors you mentioned? I guess you said those two products had much of the impact or some of the things like Puerto Rico play a bigger role? And then the second question was on SG&A expense. You mentioned flat SG&A x healthcare reform and the BI announcement. With the restructuring initiatives you've announced, I guess I would've anticipated a bit more of a decline in 2011. Can you just help us a little bit better the pushes and pulls that are going into SG&A in 2011?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a",247,"Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a negative pressure. You're also going to see negative pressure on gross margins attributable to the Puerto Rico excise tax. Because it's an excise tax, it will actually flow through comps or manufacturing costs, thus reducing our gross margin. And then obviously it's offset or credited through the tax rate in the line item below that. And those are the two factors that's driving the decline in our gross margin by approximately two percentage points in aggregate. I'm not prepared to break those out into pieces. In regards to the SG&A and being flat, if you exclude the Pharmaceutical industry fee as well as the BI alliance aligns expenses, what you see is kind of a mix-up in the U.S. and our European markets. You are seeing a dramatic decline in our overall operating expense base in terms of SG&A. But as I highlighted on the call, we are making strategic investments in some of our key emerging markets, like China, as well as in markets like Japan, where we are expecting to drive significant countercyclical growth as we go through this period of YZ. So that's what's driving the overall effect of SG&A being essentially flat. John?"
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post",489,"Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post strong financial performance in 2010. This was highlighted by volume-driven revenue growth. On a performance basis, we delivered increasing gross margin as a percent of revenue. We gained leverage between revenue and operating income growth and posted a robust 8% net income growth. We prudently managed working capital and capital expenditures, and once again generated strong operating cash flow. We're pleased with our performance and our progress in 2010. We're excited about the opportunities before us in 2011.
As Derica discussed, we entered this year with a keen awareness of the challenges posed by the patent expirations since we faced in the YZ period ahead. But we have a focused strategy centered on innovation that we're aggressively pursuing. Over the last year, we advanced 16 new molecules into Phase I clinical testing, nine molecules into Phase II testing, and two molecules ready for depression and our antibac antibody for rheumatoid arthritis and lupus into Phase III testing. We concluded a number of business development deals with a bias toward those that provide current or potential near-term revenues. We acquired florbetapir with our acquisition of Avid Radiopharmaceuticals. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if we provide appropriate physician training and successfully re-read existing brain scans. And our strategic alliance with Boehringer Ingelheim includes the development and commercialization of two oral diabetes compounds from BI, including linagliptin, which could be approved this year and two basal analog insulins from Lilly. 
In addition, we are preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency and have a number of potential regulatory approvals, including Bydureon in the EU and several pending here in the U.S. At the same time, we expect continued strong performance in the rest of our business in 2011, including the three countercyclical growth engines we've discussed for some time. Lily is, today, the fastest-growing pharma company in Japan and the fastest-growing among the top 10 multinational companies in key emerging markets, while Elanco Animal Health is outpacing its industries growth, as well. We'll continue to take advantage of this countercyclical growth, as well as the growth in the number of our patent protected products in the U.S. and Europe. Our strong financial performance, our focus on speeding innovations to patients and targeted use of business development all support our goal of successfully traversing Years YZ and emerging with even greater strength and the capacity to drive future growth. We'll continue to act with urgency and purpose to overcome the challenges we face. And as always, we will keep you informed of our progress. Thanks again for joining us. Have a great day."
285467,97242168,96215,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International",70,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International participants may dial area (320)365-3844. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation using AT&T Executive TeleConference Service. You may now disconnect. Have great day."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",39,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chie",1697,"Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chief Financial officer, Derica Rice, our President of Lilly Research Laboratories, Dr. Jan Lundberg; and Ronika Pletcher; and Jill Thoren from Investor Relations.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
We accomplished a great deal in 2010, while rapidly adapting to significant external and internal challenges. Here are some highlights.  For the full year, we again delivered strong financial performance, generating 6% revenue growth, and we were able to leverage this 6% revenue growth into 8% non-GAAP net income growth, as we made substantial progress reducing headcount and containing costs.
Our strong operating performance, along with prudent management of working capital generated nearly $7 billion of operating cash flow, easily covering capital expenditures of about $700 million, and our dividend of roughly $2.2 billion.
During the year, we did experience pipeline disappointments with semagacestat, teplizumab and tasisulam. However, our scientists remain focused on speeding innovation to patients, making significant pipeline progress. Advancing 16 new molecules into Phase I testing, nine molecules into Phase II testing, and two molecules into Phase III testing.
We also concluded a number of business development deals with a bias towards those that provide current or potential near-term revenues.
Our strong financial performance, focus on speeding innovation to patients and targeted use of business development all support our goal of successfully navigating our upcoming patent explorations and emerging with an even greater strength and capacity to drive future growth.
Since our last earnings call, we've made significant progress on a number of fronts. In clinical news, we began Phase III trials of our antibac antibody for both rheumatoid arthritis and lupus. Based on an interim review of long-term safety data, and after complication with the FDA, we made the decision to begin Phase III trials later this year of mGlu2/3 of monotherapy treatment for schizophrenia. And along with our partner, Incyte Pharmaceuticals, we disclosed promising Phase IIa data in rheumatoid arthritis for our JAK-1/JAK-2 inhibitor.
In regulatory news, we received FDA approval of Cymbalta for the management of chronic musculoskeletal pain based on clinical trials in patients with chronic low back pain and chronic pain due to osteoarthritis. And we'll begin active promotion for this indication next week.
We also received FDA approval for Axiron as replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. And we expect to launch the product midyear after building sufficient launch quantities.
Health Canada approved Byetta to improve glycemic control in patients with type 2 diabetes. And we also submitted sNDAs for Byetta used in combination with basal insulin and for Cialis for benign prostatic hyperplasia.
On the legal front, the U.S. District Court ruled that judgment would be entered in Lilly's favor in the Alimta compound patent challenge. Including a recently obtained six-month pediatric exclusivity, this patent provides protection for Alimta until January 2017. And the Court of Appeals for the Federal Circuit heard our appeal of the U.S. District Court's ruling invalidating our Strattera method-of-use patent. As argued at the appeal hearing, we feel there is a strong basis for the CAFC to overturn the district court ruling. We are awaiting a decision by the CAFC. And in the meantime, an injunction from the CAFC prevents generics from launching.
Finally in business development news, we announced and completed the acquisition of Avid Radiopharmaceuticals. Avid's lead asset, florbetapir, was assigned a priority review by the FDA. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if certain conditions are met related to physician training and re-reading of existing brain scans.
Along with Boehringer Ingelheim, we announced a broad strategic alliance to develop and commercialize two oral diabetes compounds from BI and two basal analog insulins from Lilly. As we've done in previous calls, we'll focus our comments on the non-GAAP results, which we believe brought insights in some underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges.
On Slide 7, you can see the revenue grew 4% in Q4 to nearly $6.2 billion. As I'll show more detail in a minute, volume continue to be the major driver of our revenue growth. Gross margin as a percent of revenue increased 4.2 percentage points from 75.9% to 80.1%. Roughly 2/3 of this increase was due to the favorable effect of changes in foreign currency exchange rates on international inventory sold. Specifically, changes in the foreign currency value of the U.S. dollar substantially increased cost of sales in Q4 2009 but slightly decreased cost of sales in Q4 2010. The remaining improvement in gross margin as a percent of revenue was due to lower manufacturing costs, a tangible result of our ongoing productivity improvement efforts.
This quarter's total operating expense, defined as the sum of R&D and SG&A, grew 8%. Within operating expense, marketing, selling and administrative expenses grew only 2% as higher marketing and selling expenses outside the U.S. were partially offset by lower administrative expenses and a company-wide cost containment efforts. R&D expense, on the other hand, grew 18%. Approximately 2/3 of this increase was due to higher than normal charges related to business development activities and termination of clinical trials. Other income and deductions improved due to primarily to lower miscellaneous other expense and, to a lesser extent, lower net interest expense. In addition, our tax rate fell by four percentage points largely due to the recognition in Q4 2010 of the full year impact of the extension of the R&D tax credit. Net income and earnings per share increased 24% and 22% respectively.
For the year, you can see that we generated leverage between revenue and net income, as revenue grew 6% while net income grew 8%. We achieved this leverage between revenue and net income despite foreign exchange being a drag on our gross margin percent for the full year, higher than normal charges flowing through R&D in 2010 and a 1.6 percentage point increase in the full year tax rate, largely due to the $85 million tax charge taken in Q1 2010 as a result of U.S. healthcare reform.
Slide 8 shows our reported income statement, while Slide 9 provides a reconciliation between reported and non-GAAP earnings per share. Additional details about our reported earnings are available in today's earnings press release.
As you can see on Slide 10, for both the fourth quarter and the full year, foreign exchange had little effect on revenue growth as a weaker euro was offset by strength in other foreign currencies, including the Japanese Yen.
Consequently, performance growth and total revenue of 5% for both the quarter and the year was driven by 3% volume growth and a favorable 2% impact from price. In both periods, we saw robust, double-digit volume growth in our Japanese Human Pharmaceutical business and our Global Animal Health business. Now let's look at the rest of the income statement.
Slide 11 shows the year-on-year growth of select line items of our non-GAAP income statement with and without the effective changes in foreign exchange rates. The numbers in the first column are the same as those you saw earlier on our non-GAAP income statement. If you look at the top of the second column of numbers, you'll see the 5% performance growth in revenue I mentioned previously. Below that, you'll see the cost of sales actually decreased 2% excluding the effect of foreign exchange. As a result, gross margin grew 7%. Operating expenses grew faster than revenue this quarter. The larger than normal R&D charge, as mentioned earlier, drove the majority of the 9% performance growth in operating expenses. As a result of this increase in operating expenses, our 5% performance growth in revenue translated into 3% performance growth in operating income, while the lower tax rate this quarter boosted growth in EPS to 10%.
Finally, you'll see in the last column that for the year, we've leveraged 5% performance growth in revenue into 7% and 8% growth in operating income and earnings per share, respectively. We achieved this leverage due primarily to lower manufacturing costs. For your information, on Slide 12, we provided the year-on-year growth of select line items of our reported income statement with and without the effect of foreign exchange rates. 
Next, I'll briefly cover some highlights from our quarterly pipeline update.
Slide 13 shows our pipeline as of January 24 and highlights changes since our last earnings call on October 21. Movement of molecules to the next phase of development are shown by green arrows and additions from business development are shown by green stars. They both demonstrate our focus on addressing our upcoming patent expirations through innovation, both that coming from our own labs, as well as from outside our walls. You can see that we added two compounds under regulatory review: florbetapir, the beta-amyloid imaging agent from Avid and linagliptin, the oral DPP-4 inhibitor for diabetes from BI. The BI alliance also brought a Phase III compound, BI 10773, an oral SGLT-2 inhibitor. We also saw significant movement in the pipeline as Axiron was approved. We began Phase III testing of our antibac antibody for both rheumatoid arthritis and lupus. Four molecules began Phase II testing, three new molecules began Phase I testing, and we terminated development of five molecules and sold one molecule to a third-party. 
Now, I'll turn the call over to Derica to cover some of the key events we anticipate in 2011 and a detailed discussion of our 2011 financial guidance. Derica?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU",2549,"Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU and a number pending here in the U.S.; linagliptin for type 2 diabetes in collaboration with BI; liprotamase, our recombinant pancreatic enzyme replacement therapy, and florbetapir, Cialis for BPH and Byetta in combination with basal insulin.
Expected regulatory submissions include our response to the FDA complete response letter for Bydureon and sBLAs for Erbitux, a first-line metastatic colorectal cancer, head and neck cancer, and non-small cell lung cancer. In terms of Phase III trials, we'll complete the DURATION 6 trial comparing Bydureon to Victoza. We also expect to present initial results from the Phase III trial and advanced nonsquamous, non-small cell lung cancer of Alimta induction followed by Alimta maintenance therapy. Following the initiation of Phase III trials late last year for both NERI and depression and our antibac antibody in RA and lupus, Phase III trials are slated to begin this year for mGlu2/3 in schizophrenia, our novel basal insulin analog and our new insulin glargine product and potentially for our anti-IL 17 antibody in RA.
Now as I move on to guidance, I'm going to take a bit more time today than I have in the past to walk you through it, as I want to make sure you understand how we expect some of the more substantial drivers to affect our results in 2011. Now clearly, more sales of Zyprexa and Gemzar outside of Japan due primarily to global patent expiration as well as the incremental impact of U.S. healthcare reform will have a significant negative impact on our 2011 results. In addition, we'll face some near-term earnings dilution from our strategic diabetes alliance with Boehringer Ingelheim. At the same time, we expect continued strong performance in the rest of our business in 2011 including the three countercyclical growth engines we've discussed for some time, Japan, Emerging Markets and Animal Health, as well as and a number of our patent-protected products in the U.S. and in Europe.
In addition, we expect to see continued benefit from our cost reduction and productivity efforts. I want to make sure you have good visibility into this growth within our business. 
I'll start with a discussion of our bottom line EPS expectations and then review our individual line item guidance. As you've seen in our press release, we expect 2011 non-GAAP earnings per share between $4.15 and $4.30. Our 2011 reported EPS guidance range is $0.23 lower due to the estimated IP R&D charge from the BI alliance. On a non-GAAP basis, this represents a decline of between 9% and 12% when compared to 2010. So how does this 9% to 12% EPS decline break out between the negative EPS impact of the items I mentioned earlier and the continued growth in the rest of our business? I'll start with the latter. The underlying EPS growth we expect to see from our business before factoring in expected sales decline in Zyprexa and Gemzar outside of Japan due primarily to patent expirations and U.S. healthcare reform and the BI Alliance. Now as we've discussed before, we've been making targeted investments in Japan, our Emerging Markets and Animal Health and more broadly in our remaining patent protected products. And also, we've been aggressively reducing headcount and controlling expenses as we re-base the size of our business. We've seen these efforts pay off in 2010 and expect to see the same in 2011 and beyond. In fact, our 2011 non-GAAP EPS guidance of $4.15 to $4.30 implies a growth contribution of roughly 15% from these parts of our business.
In Japan, our sales growth has been outstanding at recent years fueled by the launch of products and indications that we're launch more earlier in the U.S. and Europe. On a local currency basis, sales in Japan grew 15% in 2009 and 25% in 2010. As reported by IMS, currently we are far and away the fastest-growing major pharmaceutical company in this important market. And we're seeing strong growth from a host of products in Japan. Please note that, going forward, I'll be citing local currency growth for certain products in Japan, as well as in Europe. The effect of foreign exchange for any individual product is similar to that shown on Slide 10 for that relevant geography.
Now Zyprexa, our largest-selling product, grew 8% on a local currency basis in 2010, and we expect continued growth. In Q4 last year, Zyprexa became the first atypical antipsychotic approved in Japan for bipolar mania. And later this year, we plan to submit for approval in bipolar depression. Now remember, we maintain exclusivity in Japan for Zyprexa until December of 2015, and we expect Japan to help drive what we hope will be a significant tail of Zyprexa sales post 2011.
Alimta was approved for non-small cell lung cancer in Japan in Q2 of 2009 and achieved the best share of market uptake in the first line nonsquamous segment of any market in the world. It is now our second-largest product in Japan, and we see continued room for growth, as we believe more patients with nonsquamous cell histology can benefit from the treatment with Alimta. 
We've also been driving increased share of market with Humalog. This product has been growing at roughly twice the insulin market growth rate and registered 14% growth in local currency in 2010. We are focused on continuing the strong momentum. And we expect to seek significant growth contributions from Cymbalta, which was launched in Q2 of last year, and FORTEO and Byetta, both launched this past quarter.
Now turning to emerging markets. Revenue grew 10% in 2010 on a local currency basis. As we've shared with you in the past, we've been making targeted investments in six markets: China, Russia, Turkey, Korea, Brazil and Mexico. And these investments are paying off. Volume growth has accelerated in each of these markets with the exception of Brazil. From 2009 to 2010, volume growth accelerated from 18% to 21% in China, from a minus 7% to a positive 21% in Russia, from 4% to 20% in Turkey and from a minus 2% to a positive 19% in Korea, and from 1% to 7% in Mexico.
More broadly, for the 12 months ending September 2010, IMS showed that Lilly ranked first in sales growth at 12% among the 10 leading multinational companies across five emerging markets: China, Turkey, Korea, Brazil and Mexico.
We remain focused on driving profitable growth in emerging markets. We see significant opportunities to do so with our core assets, including Cymbalta, Cialis, Humalog and Alimta. While the majority of our efforts will be concentrated on maximizing opportunities from our core assets, we will continue to look to supplement this organic growth with targeted business development. 
On a local currency basis, our Elanco Animal Health business grew 12% in 2009 and 14% in 2010, significantly outpacing overall industry growth. This solid growth was driven by our Food Animal business and by Comfortis, our oral flea control products for companion animals, which has had a strong uptake here in the United States.
Going forward, we expect Animal Health revenue growth to benefit from international launches of Comfortis, including in the EU this quarter.
In addition, Elanco has built a robust innovation pipeline and is poised to maintain double-digit growth in the coming years with launch as expected for multiple products targeting high-value markets, such as livestock immune enhancement, control of parasites in companion animals and pain control. This quarter in the U.S., we'll launch Assurity, a topical flea treatment for cats, and Trifexis, an oral flea and heartworm treatment for dogs. We've also built a substantial development capability in animal health vaccine and have demonstrated a willingness to drive the growth to this business via business development. Apart from continued strength in these three countercyclical growth engines, we also see opportunities for growth in a number of patent-protected product outside of the emerging markets in Japan.
Now let me cite a few examples. On a local currency basis, Cymbalta grew 15% in Europe last year. Here in the U.S., Cymbalta continues to fare well in its existing mood and pain indications in a market dominated by generics. And we'll begin active promotional efforts next week for Cymbalta's latest FDA-approved indication, management of chronic musculoskeletal pain.
2010 local currency growth of Alimta was 20% in Europe and 17% in the U.S. This year, we anticipate submitting the results of our S124 study to the FDA for approval of Alimta induction treatment followed by Alimta maintenance treatment in patients with advanced nonsquamous, non-small cell lung cancer.
In our Diabetes business, Humalog registered solid 6% local currency growth in Europe in 2010. Now while sales in the U.S. were essentially flat, in the second half of the year, we saw sustained growth in our new prescription share of rapid and middle time analog market for the first time in years. We've also improved Humalog access, which should reinforce the positive sharemarket trend as we begin 2011.
Now for Cialis, in Europe we have continued to extend our leading DOT and cash share market. While in the U.S., Cialis has continued to gain market share in a declining ED market.
At the end of last year, we've submitted Cialis for the treatment of benign prostatic hyperplasia to the FDA and could have an action before the end of this year. Finally, we continue to seek consistent growth in shared market for Effient in the U.S. and in Europe. 2010 sales total $115 million, and sales in the fourth quarter were $47 million. We remain committed to this product, and based on the clinical data we've generated along with Daichi Sankyo, we believe Effient has an important role to play in the treatment of ACS patients undergoing PCI.
In addition to maximizing opportunities to drive top line revenue growth for the company, we've also been focused on driving greater productivity. Through deliberate and determined actions, we're tracking to achieve the headcount and cost containment goals we laid out in September of 2009. As of December 31, 2010, excluding strategic headcount additions in key emerging markets in Japan and business development, we had reduced headcount by 3,450 or nearly 2/3 of our goal of 5,500. And we're on track to meet or exceed our goal of reducing our projected 2011 cost by $1 billion. We saw some of those benefits of these efforts in the leverage we generated in 2010 between revenue growth and net income growth, and we expect to see an even greater benefit in 2011. Now hopefully, the information I've shared illustrates the opportunities we see for many areas of our company to generate future top line growth and to deliver on our productivity improvement goal. It is through these opportunities and efforts that we expect to generate mid-teens earnings per share growth, excluding the impact of the Zyprexa and Gemzar sales reductions outside of Japan, U.S. healthcare reform and the BI alliance.
Now let me turn to those other items. Outside of Japan, we estimate that Zyprexa and Gemzar sales will decline significantly in 2011 compared to 2010 driven by patent expirations. In total, we anticipate this will lower EPS growth by approximately 15 to 17 percentage points. We are already seeing rapid erosion of Gemzar sales in the US and expect to see some continued erosion in international sales where we lost patent protection in many markets in early 2009. We also anticipate Zyprexa sales to decline rapidly post patent expiration, which occurs in April for some international markets and September for most major European countries, and in October, in the United States.
Compared to 2010, U.S. healthcare reform could lower 2011 revenue by an incremental $170 to $270 million and add an additional $150 million to $200 million in non-tax-deductible operating commitments through the pharmaceutical industry fee. Combined, we estimate this could reduce 2011 EPS growth by approximately 4.5 to 5.5 percentage points.
Finally, we expect our strategic diabetes alliance with Boehringer Ingelheim to reduce 2011 non-GAAP EPS to increase SG&A and R&D expenses. Specifically, we expect this alliance to reduce 2011 non-GAAP EPS growth by approximately 4.5 to 5.5 percentage points. However, we view this near-term earnings dilution very differently than that from patent expirations or governmental actions. Clearly, we've anticipated that the near-term earnings dilution is a precursor to longer term EPS accretion. And that this alliance adds economic value to Lilly and its shareholders and is thus a good investment for the business.
So while we face major headwinds in 2011, we've taken a number of actions designed to significantly mitigate this negative impact and position the company to continue to invest in our long-term growth potential, while funding our dividends, capital expenditures and targeted business development. 
Now I'll provide some color commentary on our [ph] guidance. In terms of the top line, we anticipate 2011 revenue will be flat to slightly increasing compared to 2010. Excluding the anticipated decline in Zyprexa and Gemzar sales outside of Japan and the incremental impact of U.S. healthcare reform, we would expect 2011 revenue to grow in the mid- to high-single-digits. We expect gross margin as a percent of revenue to decline approximately two percentage points due to the negative effect of patent losses, the Puerto Rican export tax and the anticipated negative effect of foreign exchange on international inventories sold.
Marketing, selling and administrative expenses are projected to grow in the low- to mid- single-digits. Now it is important to note that the new pharmaceutical industry fee will be booked in this line item of our income statement. In addition, we expect to have substantial additional marketing and selling expenses as a result of the alliance with BI. Excluding anticipated expenses from the pharmaceutical industry fee and the BI alliance, we would anticipate marketing, selling and administrative expenses to be essentially flat. Research and development expenses are expected to be relatively flat. This growth rate is affected by the higher than normal charges in 2010 that flowed through R&D. Excluding these charges from the base period, R&D expenses would be expected to grow in the mid-single-digits with much of this growth driven by our portion of the anticipated clinical trials spent for BI's DPP-4 and SGLT-2 inhibitors.
For the year, other income and deductions are expected to be a net expense of between $50 million and $150 million driven largely by net interest expense. The tax rate is anticipated to be approximately 21.5% for the year, while the IRS has not provided a final ruling on U.S. tax treatment of the Puerto Rican export tax. For the purposes of our guidance, we have assumed that this export tax will be creditable in the U.S.
Finally, we expect operating cash flow to be more than sufficient to fund capital expenditures of approximately $800 million to $900 million, as well as the dividend and continued business development.
Slide 19 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our 2011 guidance. 
This concludes our prepared remarks. And now, we'll take your questions. Operator, first caller, please."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seiz",137,"I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seizures were not an issue in the data such that you felt comfortable moving forward. And when we'll be able to see a Phase II data? If the profile similar to what was sort of hypothesized in the nature article that was published on the compound back in time? And then just one other question I'd like to ask you which is about Bydureon. I'm wondering if the MEA has come back to you with any more questions on the QT front since the FDA decision was handed?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU.",26,"Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","But you might remember back in 2009, we started a safety and tolerability study for mGlu2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That st",179,"But you might remember back in 2009, we started a safety and tolerability study for mGlu2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That study, we now have six-month data on that study, which we plan to actually disclose at a European event in April. That study actually did have two additional seizures in that study. Of those two, one of the patients had the seizure actually before they were randomized the drug. And the second patient actually had their seizure after they came off of the study drug and before initiating the typical. So we are now getting that additional information to help us understand. But we feel confident in the data that we have so far on that six-month study to now go ahead and move ahead with our Phase III program. And that's also in combination with our prior Phase II, or Phase II studies that were presented and published back in 2007 and 2009."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?",36,"Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by t",55,"We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by the EU regulators."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that",135,"One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that we're generating only having had two events to date, again, one prior to randomization and the other one coming after the patient has discontinued for lack of efficacy and started up the typical -- gives us hope that this is actually something that will not be a particular issue for the drug. Again patient's age is extremely important to monitor, going forward. We've extended that to go out 12 months. I look forward to presenting our six-month data in April, but the 12 month data subsequently when that's matured."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Tony Butler with Barclays Capital.",13,"We have a question from the line of Tony Butler with Barclays Capital."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction,",164,"Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction, and what would that message be distant from its use as an antidepressant? And then second, again, staying with you, John, if possible. I'm just curious how you think or if you could provide some color around a couple of institutions, principally in India and Korea, have made comments or seem to be gearing up for the introduction in Europe, possibly generic insulins or generic alternatives. And while generic insulin may not necessarily be a focus proper to Lilly -- I guess, it could be over into Humalog. And I'm just curious about how you think those potential generic biologic entries into the European market over the next couple of years? And if you think that's really a possibility?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right physi",326,"Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right physicians to make sure that the appropriate message is getting out there. I'm not, right now, at liberty to discuss the range of tactics, et cetera. But it's obviously a very important new indication for, as you know, for a molecule that now has five or six approved indications in different countries around the world. It's going to be Cymbalta, as Derica pointed out. It's going to be an important growth driver for us in this beginning of this YZ period. With respect to insulins, I think it really remains to be seen how big of a threat so-called generic versions of insulins will be. We're not blind to this. We're keeping a careful eye on it, as you know. Insulins are a different kind of biologic product. Their production outputs are in the thousands of kilos, as opposed to molecules like EPO and others. The capital investments required, the complexity of the technology around insulins, I think, serve as more of a barrier to entry perhaps for would-be competitors, then it's going to be the case in other therapeutic categories. But obviously, we're going to stay very plugged in to this. I think it's very important to keep in mind that we believe the world can benefit from new and improved insulins, which is why we're excited about our two insulin analogs that we disclosed. We were now partnering with BI to bring to the market. In addition, delivery technology has moved a considerable ways since the era of the violent syringe. And Lilly going to continue to pioneer new and more convenient ways to administer insulin as part of our value proposition for all those products going forward."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Our next question comes from the line of Bert Hazlett with BMO Capital Markets."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-r",77,"I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-read of the Phase II studies for Amyvid? And is that the gating item for resubmission? And then when is the next interim safety look for solanezumab, [ph] the A beta Alzheimer compound?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","If you want, I'll take initial shot and then Derica [ph] on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's",138,"If you want, I'll take initial shot and then Derica [ph] on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's going to be a ramp up in that business. So I wouldn't take some of the initial data necessarily being the run rate for growth going forward. But clearly, it's a very important deal that we struck with Wal-Mart. We're very pleased with the initial results. I'd also say that in general, it seems that globally, we're having a very good run growth of Humulin, which for very strategic reasons, I believe that [ph] been taking as the market is opening itself up a bit to our Humulin. So, Jan, for the pipeline?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to -- solanezumab, as you know, most of the Phase III studies have now been enro",81,"Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to -- solanezumab, as you know, most of the Phase III studies have now been enrolled, and the duration is 18 months. And we will have an interim readout. I don't want to comment on exactly when, but we are following, I think, on track to deliver this molecule."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able",57,"And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able to address here in the relatively near term."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Bernstein.",12,"Our next question comes from the line of Tim Anderson with Bernstein."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then",92,"On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then second question on 2014 guidance that you've given before. I got on the call late, but I'm not sure if you've talked about 2014 or not. Is that still on track? And then third question, a quick one, just Emerging Market revenue growth in fourth quarter?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the sec",132,"Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the second factor affecting our tax rate, which also creates upward pressure, is the pharmaceutical industry fee, which is non-tax-deductible. What's creating a lowering pressure on our effective tax rate is the assumption that we'll be able to credit the Puerto Rico excise tax. So that's how we get to the tax rate that you saw. In regards to the 2014 guidance, Tim, we did not discuss that on the call today. And we still look forward to update that at our June Analyst Meeting in New York."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage poi",221,"One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage points. That will not be recurring in our 2011 or going forward numbers. And then in terms of the emerging market, as we've said in the call, the full year growth rate was 14% total. Well, actually it's 10% performance, a very robust growth. We did have a spike in Q3 that came down a little bit in Q4 due to timing of orders. Specifically in Q4, we had about 6% total growth, nearly all of which was from performance despite -- we have references that compares to 18% growth in Q3, 16% of which was performance. Some of the things that we saw, for example, Tim, to give some color. There would've been some Zyprexa orders, for example, in Brazil but would have expected to come through in Q4. They did not come through in Q4. They did come through early this Q1. So again, we think, by looking at that full-year number gives you a better trend for how the emerging markets are growing. And again that's 10% performance."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Next question comes from the line of John Boris with Citi.",11,"Next question comes from the line of John Boris with Citi."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second",131,"First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second question on your Diabetes portfolio, Byetta in particular. If you look at the Canadian label, it does increase a small increase in QTC that they've highlighted in that label. Can you just help us understand that and also maybe walk through what the implications are on that for the U.S. label and for Bydureon? And then last, is it possible just to get an update on where you are at with your own fully humanized GLP-1 program going forward? Any update on enrollment and timing of release of results there?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you loo",194,"John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you look at just the total year here what was really driving our overall revenue growth. So in Europe for the year, we had 3% volume growth. In Japan, we had 26% volume growth. And the rest of the world, so in those markets outside the U.S., we had 6% of volume growth. And when you break that down, you really saw even in Europe where we are already in some YZ aspect in terms of Gemzar erosion, we still were able to drive good volume growth. And so when we look forward, we really see those markets, like the emerging market in Japan, really acting in a countercyclical manner compared to what we're going to see in the U.S. in 2011, as well as in Europe major markets in 2011 with the Zyprexa effect. So this is where we anticipate driving the future growth."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Real quick in terms of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as",102,"Real quick in terms of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as we commented during the prepared remarks, over 10%, essentially roughly 10% of our sales now are coming from emerging markets. I don't have the exact percentages for you broken out by the international, but I think hopefully those two numbers will allow you to make that calculation. And then for John for the Canada Byetta."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own qu",107,"Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own questions for Bydureon on QT. And whether or not that's connected with questions that Canadians might have. It's something I can't speculate on, but we're obviously well along with meeting what we understand to be FDA's requirements, so that we can refile Bydureon in the second half of this year, and ultimately hopefully gain approval for that."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. As well as, we had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably",69,"Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. As well as, we had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably start a CD study. So we're pretty pleased with the progress of that program and look forward to sharing some data in early '12."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger with Morgan Stanley.",13,"Our next question comes from the line of David Risinger with Morgan Stanley."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. First, maybe you could just help us understand the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly i",102,"A couple of questions. First, maybe you could just help us understand the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly is the interim look? That's the first question. Second, in terms of other key late stage pipeline results to watch in 2011, what are the few that are most important that you're focused on in terms of Phase III results? And then third, could you just update us on the Strattera and Cymbalta patent litigation outlooks, please?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to c",277,"Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to completion to be able to have in this particular case statistical powering to be able to show the slowing of progression of the disease. So this will be a look that's a safety look. So these trials can only be stopped early for either safety issues or for very curious signals that there's no way the primary endpoint could be met. They cannot be stopped early for efficacy. In terms of the Phase III data, a couple of the major ones that were mentioned on the call are private ones, I would highlight to you, as well, which would be the DURATION-6 data head-to-head with Bydureon versus Victoza. I believe that should be becoming here probably in the first half of the year. Expectation would be much like we have the past. You probably have the top line results press release with subsequent presentation at a medical meeting. Timing of that medical meeting is difficult to know if that might be ADA or EASD. And then obviously with Alimta, we continue to build out that franchise and are very hopeful that we'll be able to do so with the S124 study that Derica mentioned that is Alimta induction, followed by Alimta maintenance therapy. You may recall that the current maintenance indication that we have is for Alimta used in the maintenance setting followed by a first line treatment with platinum agents."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or a",69,"Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or at least a co-administrative study with the alpha blockers and develop with BPH. Those are another set of Phase III data."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with A",44,"I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with Alnara."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've iss",74,"So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've issued for 2011. Cymbalta, last update we had, we remain on track for a trial to start here in the U.S. District Court for Southern Indiana on June 6 of this year."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our last question comes from the line of Chris Schott with JPMorgan.",12,"Our last question comes from the line of Chris Schott with JPMorgan."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the",135,"My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the factors you mentioned? I guess you said those two products had much of the impact or some of the things like Puerto Rico play a bigger role? And then the second question was on SG&A expense. You mentioned flat SG&A x healthcare reform and the BI announcement. With the restructuring initiatives you've announced, I guess I would've anticipated a bit more of a decline in 2011. Can you just help us a little bit better the pushes and pulls that are going into SG&A in 2011?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a",247,"Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a negative pressure. You're also going to see negative pressure on gross margins attributable to the Puerto Rico excise tax. Because it's an excise tax, it will actually flow through comps or manufacturing costs, thus reducing our gross margins. And then obviously it's offset or credited through the tax rate in the line item below that. And those are the two factors that's driving the decline in our gross margin by approximately two percentage points in aggregate. I'm not prepared to break those out into pieces. In regards to the SG&A and being flat, if you exclude the Pharmaceutical industry fee as well as the BI alliance aligns expenses, what you see is kind of a mix-up in the U.S. and our European markets. You are seeing a dramatic decline in our overall operating expense base in terms of SG&A. But as I highlighted on the call, we are making strategic investments in some of our key emerging markets, like China, as well as in markets like Japan, where we are expecting to drive significant countercyclical growth as we go through this period of YZ. So that's what's driving the overall effect of SG&A being essentially flat. John?"
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post",486,"Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post strong financial performance in 2010. This was highlighted by volume-driven revenue growth. On a performance basis, we delivered increasing gross margin as a percent of revenue. We gained leverage between revenue and operating income growth and posted a robust 8% net income growth. We prudently managed working capital and capital expenditures, and once again generated strong operating cash flow. We're pleased with our performance and our progress in 2010. We're excited about the opportunities before us in 2011.
As Derica discussed, we entered this year with a keen awareness of the challenges posed by the patent expirations we faced in the YZ period ahead. But we have a focused strategy centered on innovation that we're aggressively pursuing. Over the last year, we advanced 16 new molecules into Phase I clinical testing, nine molecules into Phase II testing, and two molecules NERI for depression and our antibac antibody for rheumatoid arthritis and lupus into Phase III testing. We concluded a number of business development deals with a bias toward those that provide current or potential near-term revenues. We acquired florbetapir with our acquisition of Avid Radiopharmaceuticals. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if we provide appropriate physician training and successfully re-read existing brain scans. And our strategic alliance with Boehringer Ingelheim includes the development and commercialization of two oral diabetes compounds from BI, including linagliptin, which could be approved this year and two basal analog insulins from Lilly. 
In addition, we are preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency and have a number of potential regulatory approvals, including Bydureon in the EU and several pending here in the U.S. At the same time, we expect continued strong performance in the rest of our business in 2011, including the three countercyclical growth engines we've discussed for some time. Lilly is, today, the fastest-growing pharma company in Japan and the fastest-growing among the top 10 multinational companies in key emerging markets, while Elanco Animal Health is outpacing its industries growth, as well. We'll continue to take advantage of this countercyclical growth, as well as the growth in a number of our patent protected products in the U.S. and Europe. Our strong financial performance, our focus on speeding innovations to patients and targeted use of business development all support our goal of successfully traversing   and emerging with even greater strength and the capacity to drive future growth. We'll continue to act with urgency and purpose to overcome the challenges we face. And as always, we will keep you informed of our progress. Thanks again for joining us. Have a great day."
285467,97242168,96466,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International",70,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International participants may dial area (320)365-3844. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation using AT&T Executive TeleConference Service. You may now disconnect. Have great day."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",39,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 earnings conference call [Operator Instructions] I'd now like to turn this conference over to our host, Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chie",1697,"Good morning. Thanks for taking the time to join us for Eli Lilly and Company's Fourth Quarter 2010 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me are our President, CEO and Chairman, John Lechleiter; our Chief Financial officer, Derica Rice, our President of Lilly Research Laboratories, Dr. Jan Lundberg; and Ronika Pletcher; and Jill Thoren from Investor Relations.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
We accomplished a great deal in 2010, while rapidly adapting to significant external and internal challenges. Here are some highlights.  For the full year, we again delivered strong financial performance, generating 6% revenue growth, and we were able to leverage this 6% revenue growth into 8% non-GAAP net income growth, as we made substantial progress reducing headcount and containing costs.
Our strong operating performance, along with prudent management of working capital generated nearly $7 billion of operating cash flow, easily covering capital expenditures of about $700 million, and our dividend of roughly $2.2 billion.
During the year, we did experience pipeline disappointments with semagacestat, teplizumab and tasisulam. However, our scientists remain focused on speeding innovation to patients, making significant pipeline progress. Advancing 16 new molecules into Phase I testing, nine molecules into Phase II testing, and two molecules into Phase III testing.
We also concluded a number of business development deals with a bias towards those that provide current or potential near-term revenues.
Our strong financial performance, focus on speeding innovation to patients and targeted use of business development all support our goal of successfully navigating our upcoming patent explorations and emerging with an even greater strength and capacity to drive future growth.
Since our last earnings call, we've made significant progress on a number of fronts. In clinical news, we began Phase III trials of our antibac antibody for both rheumatoid arthritis and lupus. Based on an interim review of long-term safety data, and after complication with the FDA, we made the decision to begin Phase III trials later this year of mGlu2/3 of monotherapy treatment for schizophrenia. And along with our partner, Incyte Pharmaceuticals, we disclosed promising Phase IIa data in rheumatoid arthritis for our JAK-1/JAK-2 inhibitor.
In regulatory news, we received FDA approval of Cymbalta for the management of chronic musculoskeletal pain based on clinical trials in patients with chronic low back pain and chronic pain due to osteoarthritis. And we'll begin active promotion for this indication next week.
We also received FDA approval for Axiron as replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. And we expect to launch the product midyear after building sufficient launch quantities.
Health Canada approved Byetta to improve glycemic control in patients with type 2 diabetes. And we also submitted sNDAs for Byetta used in combination with basal insulin and for Cialis for benign prostatic hyperplasia.
On the legal front, the U.S. District Court ruled that judgment would be entered in Lilly's favor in the Alimta compound patent challenge. Including a recently obtained six-month pediatric exclusivity, this patent provides protection for Alimta until January 2017. And the Court of Appeals for the Federal Circuit heard our appeal of the U.S. District Court's ruling invalidating our Strattera method-of-use patent. As argued at the appeal hearing, we feel there is a strong basis for the CAFC to overturn the district court ruling. We are awaiting a decision by the CAFC. And in the meantime, an injunction from the CAFC prevents generics from launching.
Finally in business development news, we announced and completed the acquisition of Avid Radiopharmaceuticals. Avid's lead asset, florbetapir, was assigned a priority review by the FDA. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if certain conditions are met related to physician training and re-reading of existing brain scans.
Along with Boehringer Ingelheim, we announced a broad strategic alliance to develop and commercialize two oral diabetes compounds from BI and two basal analog insulins from Lilly. As we've done in previous calls, we'll focus our comments on the non-GAAP results, which we believe brought insights in some underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges.
On Slide 7, you can see the revenue grew 4% in Q4 to nearly $6.2 billion. As I'll show more detail in a minute, volume continue to be the major driver of our revenue growth. Gross margin as a percent of revenue increased 4.2 percentage points from 75.9% to 80.1%. Roughly 2/3 of this increase was due to the favorable effect of changes in foreign currency exchange rates on international inventory sold. Specifically, changes in the foreign currency value of the U.S. dollar substantially increased cost of sales in Q4 2009 but slightly decreased cost of sales in Q4 2010. The remaining improvement in gross margin as a percent of revenue was due to lower manufacturing costs, a tangible result of our ongoing productivity improvement efforts.
This quarter's total operating expense, defined as the sum of R&D and SG&A, grew 8%. Within operating expense, marketing, selling and administrative expenses grew only 2% as higher marketing and selling expenses outside the U.S. were partially offset by lower administrative expenses and a company-wide cost containment efforts. R&D expense, on the other hand, grew 18%. Approximately 2/3 of this increase was due to higher than normal charges related to business development activities and termination of clinical trials. Other income and deductions improved due to primarily to lower miscellaneous other expense and, to a lesser extent, lower net interest expense. In addition, our tax rate fell by four percentage points largely due to the recognition in Q4 2010 of the full year impact of the extension of the R&D tax credit. Net income and earnings per share increased 24% and 22% respectively.
For the year, you can see that we generated leverage between revenue and net income, as revenue grew 6% while net income grew 8%. We achieved this leverage between revenue and net income despite foreign exchange being a drag on our gross margin percent for the full year, higher than normal charges flowing through R&D in 2010 and a 1.6 percentage point increase in the full year tax rate, largely due to the $85 million tax charge taken in Q1 2010 as a result of U.S. healthcare reform.
Slide 8 shows our reported income statement, while Slide 9 provides a reconciliation between reported and non-GAAP earnings per share. Additional details about our reported earnings are available in today's earnings press release.
As you can see on Slide 10, for both the fourth quarter and the full year, foreign exchange had little effect on revenue growth as a weaker euro was offset by strength in other foreign currencies, including the Japanese Yen.
Consequently, performance growth and total revenue of 5% for both the quarter and the year was driven by 3% volume growth and a favorable 2% impact from price. In both periods, we saw robust, double-digit volume growth in our Japanese Human Pharmaceutical business and our Global Animal Health business. Now let's look at the rest of the income statement.
Slide 11 shows the year-on-year growth of select line items of our non-GAAP income statement with and without the effective changes in foreign exchange rates. The numbers in the first column are the same as those you saw earlier on our non-GAAP income statement. If you look at the top of the second column of numbers, you'll see the 5% performance growth in revenue I mentioned previously. Below that, you'll see the cost of sales actually decreased 2% excluding the effect of foreign exchange. As a result, gross margin grew 7%. Operating expenses grew faster than revenue this quarter. The larger than normal R&D charge, as mentioned earlier, drove the majority of the 9% performance growth in operating expenses. As a result of this increase in operating expenses, our 5% performance growth in revenue translated into 3% performance growth in operating income, while the lower tax rate this quarter boosted growth in EPS to 10%.
Finally, you'll see in the last column that for the year, we've leveraged 5% performance growth in revenue into 7% and 8% growth in operating income and earnings per share, respectively. We achieved this leverage due primarily to lower manufacturing costs. For your information, on Slide 12, we provided the year-on-year growth of select line items of our reported income statement with and without the effect of foreign exchange rates. 
Next, I'll briefly cover some highlights from our quarterly pipeline update.
Slide 13 shows our pipeline as of January 24 and highlights changes since our last earnings call on October 21. Movement of molecules to the next phase of development are shown by green arrows and additions from business development are shown by green stars. They both demonstrate our focus on addressing our upcoming patent expirations through innovation, both that coming from our own labs, as well as from outside our walls. You can see that we added two compounds under regulatory review: florbetapir, the beta-amyloid imaging agent from Avid and linagliptin, the oral DPP-4 inhibitor for diabetes from BI. The BI alliance also brought a Phase III compound, BI 10773, an oral SGLT-2 inhibitor. We also saw significant movement in the pipeline as Axiron was approved. We began Phase III testing of our antibac antibody for both rheumatoid arthritis and lupus. Four molecules began Phase II testing, three new molecules began Phase I testing, and we terminated development of five molecules and sold one molecule to a third-party. 
Now, I'll turn the call over to Derica to cover some of the key events we anticipate in 2011 and a detailed discussion of our 2011 financial guidance. Derica?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU",2549,"Thanks, Phil. Having received FDA approvals late last year, we're preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency. We have a large number of potential regulatory approvals, including Bydureon in the EU and a number pending here in the U.S.; linagliptin for type 2 diabetes in collaboration with BI; liprotamase, our recombinant pancreatic enzyme replacement therapy, and florbetapir, Cialis for BPH and Byetta in combination with basal insulin.
Expected regulatory submissions include our response to the FDA complete response letter for Bydureon and sBLAs for Erbitux, a first-line metastatic colorectal cancer, head and neck cancer, and non-small cell lung cancer. In terms of Phase III trials, we'll complete the DURATION 6 trial comparing Bydureon to Victoza. We also expect to present initial results from the Phase III trial and advanced nonsquamous, non-small cell lung cancer of Alimta induction followed by Alimta maintenance therapy. Following the initiation of Phase III trials late last year for both NERI and depression and our antibac antibody in RA and lupus, Phase III trials are slated to begin this year for mGlu2/3 in schizophrenia, our novel basal insulin analog and our new insulin glargine product and potentially for our anti-IL 17 antibody in RA.
Now as I move on to guidance, I'm going to take a bit more time today than I have in the past to walk you through it, as I want to make sure you understand how we expect some of the more substantial drivers to affect our results in 2011. Now clearly, more sales of Zyprexa and Gemzar outside of Japan due primarily to global patent expiration as well as the incremental impact of U.S. healthcare reform will have a significant negative impact on our 2011 results. In addition, we'll face some near-term earnings dilution from our strategic diabetes alliance with Boehringer Ingelheim. At the same time, we expect continued strong performance in the rest of our business in 2011 including the three countercyclical growth engines we've discussed for some time, Japan, Emerging Markets and Animal Health, as well as and a number of our patent-protected products in the U.S. and in Europe.
In addition, we expect to see continued benefit from our cost reduction and productivity efforts. I want to make sure you have good visibility into this growth within our business. 
I'll start with a discussion of our bottom line EPS expectations and then review our individual line item guidance. As you've seen in our press release, we expect 2011 non-GAAP earnings per share between $4.15 and $4.30. Our 2011 reported EPS guidance range is $0.23 lower due to the estimated IP R&D charge from the BI alliance. On a non-GAAP basis, this represents a decline of between 9% and 12% when compared to 2010. So how does this 9% to 12% EPS decline break out between the negative EPS impact of the items I mentioned earlier and the continued growth in the rest of our business? I'll start with the latter. The underlying EPS growth we expect to see from our business before factoring in expected sales decline in Zyprexa and Gemzar outside of Japan due primarily to patent expirations and U.S. healthcare reform and the BI Alliance. Now as we've discussed before, we've been making targeted investments in Japan, our Emerging Markets and Animal Health and more broadly in our remaining patent protected products. And also, we've been aggressively reducing headcount and controlling expenses as we re-base the size of our business. We've seen these efforts pay off in 2010 and expect to see the same in 2011 and beyond. In fact, our 2011 non-GAAP EPS guidance of $4.15 to $4.30 implies a growth contribution of roughly 15% from these parts of our business.
In Japan, our sales growth has been outstanding at recent years fueled by the launch of products and indications that we're launch more earlier in the U.S. and Europe. On a local currency basis, sales in Japan grew 15% in 2009 and 25% in 2010. As reported by IMS, currently we are far and away the fastest-growing major pharmaceutical company in this important market. And we're seeing strong growth from a host of products in Japan. Please note that, going forward, I'll be citing local currency growth for certain products in Japan, as well as in Europe. The effect of foreign exchange for any individual product is similar to that shown on Slide 10 for that relevant geography.
Now Zyprexa, our largest-selling product, grew 8% on a local currency basis in 2010, and we expect continued growth. In Q4 last year, Zyprexa became the first atypical antipsychotic approved in Japan for bipolar mania. And later this year, we plan to submit for approval in bipolar depression. Now remember, we maintain exclusivity in Japan for Zyprexa until December of 2015, and we expect Japan to help drive what we hope will be a significant tail of Zyprexa sales post 2011.
Alimta was approved for non-small cell lung cancer in Japan in Q2 of 2009 and achieved the best share of market uptake in the first line nonsquamous segment of any market in the world. It is now our second-largest product in Japan, and we see continued room for growth, as we believe more patients with nonsquamous cell histology can benefit from the treatment with Alimta. 
We've also been driving increased share of market with Humalog. This product has been growing at roughly twice the insulin market growth rate and registered 14% growth in local currency in 2010. We are focused on continuing the strong momentum. And we expect to seek significant growth contributions from Cymbalta, which was launched in Q2 of last year, and FORTEO and Byetta, both launched this past quarter.
Now turning to emerging markets. Revenue grew 10% in 2010 on a local currency basis. As we've shared with you in the past, we've been making targeted investments in six markets: China, Russia, Turkey, Korea, Brazil and Mexico. And these investments are paying off. Volume growth has accelerated in each of these markets with the exception of Brazil. From 2009 to 2010, volume growth accelerated from 18% to 21% in China, from a minus 7% to a positive 21% in Russia, from 4% to 20% in Turkey and from a minus 2% to a positive 19% in Korea, and from 1% to 7% in Mexico.
More broadly, for the 12 months ending September 2010, IMS showed that Lilly ranked first in sales growth at 12% among the 10 leading multinational companies across five emerging markets: China, Turkey, Korea, Brazil and Mexico.
We remain focused on driving profitable growth in emerging markets. We see significant opportunities to do so with our core assets, including Cymbalta, Cialis, Humalog and Alimta. While the majority of our efforts will be concentrated on maximizing opportunities from our core assets, we will continue to look to supplement this organic growth with targeted business development. 
On a local currency basis, our Elanco Animal Health business grew 12% in 2009 and 14% in 2010, significantly outpacing overall industry growth. This solid growth was driven by our Food Animal business and by Comfortis, our oral flea control products for companion animals, which has had a strong uptake here in the United States.
Going forward, we expect Animal Health revenue growth to benefit from international launches of Comfortis, including in the EU this quarter.
In addition, Elanco has built a robust innovation pipeline and is poised to maintain double-digit growth in the coming years with launch as expected for multiple products targeting high-value markets, such as livestock immune enhancement, control of parasites in companion animals and pain control. This quarter in the U.S., we'll launch Assurity, a topical flea treatment for cats, and Trifexis, an oral flea and heartworm treatment for dogs. We've also built a substantial development capability in animal health vaccine and have demonstrated a willingness to drive the growth to this business via business development. Apart from continued strength in these three countercyclical growth engines, we also see opportunities for growth in a number of patent-protected product outside of the emerging markets in Japan.
Now let me cite a few examples. On a local currency basis, Cymbalta grew 15% in Europe last year. Here in the U.S., Cymbalta continues to fare well in its existing mood and pain indications in a market dominated by generics. And we'll begin active promotional efforts next week for Cymbalta's latest FDA-approved indication, management of chronic musculoskeletal pain.
2010 local currency growth of Alimta was 20% in Europe and 17% in the U.S. This year, we anticipate submitting the results of our S124 study to the FDA for approval of Alimta induction treatment followed by Alimta maintenance treatment in patients with advanced nonsquamous, non-small cell lung cancer.
In our Diabetes business, Humalog registered solid 6% local currency growth in Europe in 2010. Now while sales in the U.S. were essentially flat, in the second half of the year, we saw sustained growth in our new prescription share of rapid and middle time analog market for the first time in years. We've also improved Humalog access, which should reinforce the positive sharemarket trend as we begin 2011.
Now for Cialis, in Europe we have continued to extend our leading DOT and cash share market. While in the U.S., Cialis has continued to gain market share in a declining ED market.
At the end of last year, we've submitted Cialis for the treatment of benign prostatic hyperplasia to the FDA and could have an action before the end of this year. Finally, we continue to seek consistent growth in shared market for Effient in the U.S. and in Europe. 2010 sales total $115 million, and sales in the fourth quarter were $47 million. We remain committed to this product, and based on the clinical data we've generated along with Daichi Sankyo, we believe Effient has an important role to play in the treatment of ACS patients undergoing PCI.
In addition to maximizing opportunities to drive top line revenue growth for the company, we've also been focused on driving greater productivity. Through deliberate and determined actions, we're tracking to achieve the headcount and cost containment goals we laid out in September of 2009. As of December 31, 2010, excluding strategic headcount additions in key emerging markets in Japan and business development, we had reduced headcount by 3,450 or nearly 2/3 of our goal of 5,500. And we're on track to meet or exceed our goal of reducing our projected 2011 cost by $1 billion. We saw some of those benefits of these efforts in the leverage we generated in 2010 between revenue growth and net income growth, and we expect to see an even greater benefit in 2011. Now hopefully, the information I've shared illustrates the opportunities we see for many areas of our company to generate future top line growth and to deliver on our productivity improvement goal. It is through these opportunities and efforts that we expect to generate mid-teens earnings per share growth, excluding the impact of the Zyprexa and Gemzar sales reductions outside of Japan, U.S. healthcare reform and the BI alliance.
Now let me turn to those other items. Outside of Japan, we estimate that Zyprexa and Gemzar sales will decline significantly in 2011 compared to 2010 driven by patent expirations. In total, we anticipate this will lower EPS growth by approximately 15 to 17 percentage points. We are already seeing rapid erosion of Gemzar sales in the US and expect to see some continued erosion in international sales where we lost patent protection in many markets in early 2009. We also anticipate Zyprexa sales to decline rapidly post patent expiration, which occurs in April for some international markets and September for most major European countries, and in October, in the United States.
Compared to 2010, U.S. healthcare reform could lower 2011 revenue by an incremental $170 to $270 million and add an additional $150 million to $200 million in non-tax-deductible operating commitments through the pharmaceutical industry fee. Combined, we estimate this could reduce 2011 EPS growth by approximately 4.5 to 5.5 percentage points.
Finally, we expect our strategic diabetes alliance with Boehringer Ingelheim to reduce 2011 non-GAAP EPS to increase SG&A and R&D expenses. Specifically, we expect this alliance to reduce 2011 non-GAAP EPS growth by approximately 4.5 to 5.5 percentage points. However, we view this near-term earnings dilution very differently than that from patent expirations or governmental actions. Clearly, we've anticipated that the near-term earnings dilution is a precursor to longer term EPS accretion. And that this alliance adds economic value to Lilly and its shareholders and is thus a good investment for the business.
So while we face major headwinds in 2011, we've taken a number of actions designed to significantly mitigate this negative impact and position the company to continue to invest in our long-term growth potential, while funding our dividends, capital expenditures and targeted business development. 
Now I'll provide some color commentary on our [ph] guidance. In terms of the top line, we anticipate 2011 revenue will be flat to slightly increasing compared to 2010. Excluding the anticipated decline in Zyprexa and Gemzar sales outside of Japan and the incremental impact of U.S. healthcare reform, we would expect 2011 revenue to grow in the mid- to high-single-digits. We expect gross margin as a percent of revenue to decline approximately two percentage points due to the negative effect of patent losses, the Puerto Rican export tax and the anticipated negative effect of foreign exchange on international inventories sold.
Marketing, selling and administrative expenses are projected to grow in the low- to mid- single-digits. Now it is important to note that the new pharmaceutical industry fee will be booked in this line item of our income statement. In addition, we expect to have substantial additional marketing and selling expenses as a result of the alliance with BI. Excluding anticipated expenses from the pharmaceutical industry fee and the BI alliance, we would anticipate marketing, selling and administrative expenses to be essentially flat. Research and development expenses are expected to be relatively flat. This growth rate is affected by the higher than normal charges in 2010 that flowed through R&D. Excluding these charges from the base period, R&D expenses would be expected to grow in the mid-single-digits with much of this growth driven by our portion of the anticipated clinical trials spent for BI's DPP-4 and SGLT-2 inhibitors.
For the year, other income and deductions are expected to be a net expense of between $50 million and $150 million driven largely by net interest expense. The tax rate is anticipated to be approximately 21.5% for the year, while the IRS has not provided a final ruling on U.S. tax treatment of the Puerto Rican export tax. For the purposes of our guidance, we have assumed that this export tax will be creditable in the U.S.
Finally, we expect operating cash flow to be more than sufficient to fund capital expenditures of approximately $800 million to $900 million, as well as the dividend and continued business development.
Slide 19 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our 2011 guidance. 
This concludes our prepared remarks. And now, we'll take your questions. Operator, first caller, please."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seiz",137,"I wanted to ask you on the product side about the mGlu program. Obviously decision to advance out into Phase III is a positive sign in regards to some of the issues that surfaced in some of the earlier work. I was wondering if you could talk about if seizures were not an issue in the data such that you felt comfortable moving forward. And when we'll be able to see a Phase II data? If the profile similar to what was sort of hypothesized in the nature article that was published on the compound back in time? And then just one other question I'd like to ask you which is about Bydureon. I'm wondering if the MEA has come back to you with any more questions on the QT front since the FDA decision was handed?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU.",26,"Catherine thank you for your questions. We'll have Ronika handle the question on mGlu2/3. And either Jan or I will talk about Bydureon in the EU."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","But you might remember back in 2009, we started a safety and tolerability study for mGlu2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That st",179,"But you might remember back in 2009, we started a safety and tolerability study for mGlu2/3. It started out as a six-month study. And in that study, our intent was to get better understanding on some of the earlier observations on the mGlu trials. That study, we now have six-month data on that study, which we plan to actually disclose at a European event in April. That study actually did have two additional seizures in that study. Of those two, one of the patients had the seizure actually before they were randomized the drug. And the second patient actually had their seizure after they came off of the study drug and before initiating the typical. So we are now getting that additional information to help us understand. But we feel confident in the data that we have so far on that six-month study to now go ahead and move ahead with our Phase III program. And that's also in combination with our prior Phase II, or Phase II studies that were presented and published back in 2007 and 2009."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?",36,"Catherine, before Jan answers the question on Bydureon in the EU, we also did have a discussion with FDA to review this interim data in coming to the decision to move forward into Phase III. Jan?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by t",55,"We are, as you know, in a regulatory review in that area. And we will receive some more comments the first half of this year. We are quite confident that we are on track with the EU submission. And so far, the QT issue has not been raised as an issue by the EU regulators."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that",135,"One other thing for Catherine for the mGlu trials. In the shorter term of the QT phase studies earlier, as you're aware, we did have a number of occurrences of these seizure-type events. I believe the total number was 8. I think this longer-term data that we're generating only having had two events to date, again, one prior to randomization and the other one coming after the patient has discontinued for lack of efficacy and started up the typical -- gives us hope that this is actually something that will not be a particular issue for the drug. Again patient's age is extremely important to monitor, going forward. We've extended that to go out 12 months. I look forward to presenting our six-month data in April, but the 12 month data subsequently when that's matured."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Tony Butler with Barclays Capital.",13,"We have a question from the line of Tony Butler with Barclays Capital."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction,",164,"Two brief questions, principally for John. One is, can you give us some idea of how you're going to go out and market the chronic pain indication in Cymbalta? Clearly a positive. The question is, I'm assuming that's more PCP or have greater PCP direction, and what would that message be distant from its use as an antidepressant? And then second, again, staying with you, John, if possible. I'm just curious how you think or if you could provide some color around a couple of institutions, principally in India and Korea, have made comments or seem to be gearing up for the introduction in Europe, possibly generic insulins or generic alternatives. And while generic insulin may not necessarily be a focus proper to Lilly -- I guess, it could be over into Humalog. And I'm just curious about how you think those potential generic biologic entries into the European market over the next couple of years? And if you think that's really a possibility?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right physi",326,"Tony, this is John. I'll take both your questions. First of all, we'll be launching Cymbalta for chronic pain next week. Here in the U.S., we feel well prepared for that launch, and we feel like we've got the right sales force coverage for the right physicians to make sure that the appropriate message is getting out there. I'm not, right now, at liberty to discuss the range of tactics, et cetera. But it's obviously a very important new indication for, as you know, for a molecule that now has five or six approved indications in different countries around the world. It's going to be Cymbalta, as Derica pointed out. It's going to be an important growth driver for us in this beginning of this YZ period. With respect to insulins, I think it really remains to be seen how big of a threat so-called generic versions of insulins will be. We're not blind to this. We're keeping a careful eye on it, as you know. Insulins are a different kind of biologic product. Their production outputs are in the thousands of kilos, as opposed to molecules like EPO and others. The capital investments required, the complexity of the technology around insulins, I think, serve as more of a barrier to entry perhaps for would-be competitors, then it's going to be the case in other therapeutic categories. But obviously, we're going to stay very plugged in to this. I think it's very important to keep in mind that we believe the world can benefit from new and improved insulins, which is why we're excited about our two insulin analogs that we disclosed. We were now partnering with BI to bring to the market. In addition, delivery technology has moved a considerable ways since the era of the violent syringe. And Lilly going to continue to pioneer new and more convenient ways to administer insulin as part of our value proposition for all those products going forward."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Our next question comes from the line of Bert Hazlett with BMO Capital Markets."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-r",77,"I have a quick one on insulins and then just two pipeline questions. On the insulins, how much did the Wal-Mart deal add to the Humulin franchise? And is that sustainable? Then just briefly, regarding Amyvid, could you talk about the timeline for the re-read of the Phase II studies for Amyvid? And is that the gating item for resubmission? And then when is the next interim safety look for solanezumab, [ph] the A beta Alzheimer compound?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","If you want, I'll take initial shot and then Derica [ph] on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's",138,"If you want, I'll take initial shot and then Derica [ph] on the insulins and then Jan will take you to questions for the pipeline. On the insulins for Wal-Mart, I don't believe we're going to be quantifying the specific impact from that. Clearly, there's going to be a ramp up in that business. So I wouldn't take some of the initial data necessarily being the run rate for growth going forward. But clearly, it's a very important deal that we struck with Wal-Mart. We're very pleased with the initial results. I'd also say that in general, it seems that globally, we're having a very good run growth of Humulin, which for very strategic reasons, I believe that [ph] been taking as the market is opening itself up a bit to our Humulin. So, Jan, for the pipeline?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to -- solanezumab, as you know, most of the Phase III studies have now been enro",81,"Yes. In relation to Amyvid, the time line for re-read, as we have stated before, it's like it's been months, not longer. So we are looking positively on that one. In relation to -- solanezumab, as you know, most of the Phase III studies have now been enrolled, and the duration is 18 months. And we will have an interim readout. I don't want to comment on exactly when, but we are following, I think, on track to deliver this molecule."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able",57,"And just to be clear, Bert, there is an asset to end of -- when Jan was saying months. So it's a matter of months. We don't really have a specific time. Obviously we're working through expeditiously with the FDA. But it is something we think we'll be able to address here in the relatively near term."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Bernstein.",12,"Our next question comes from the line of Tim Anderson with Bernstein."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then",92,"On the tax rate guidance for 2011, that is below 2010 and it's below where you previously suggested. The tax rate might ultimately creep up, too, and I'm wondering what's driving this in 2011 and what we should again expect over the longer term? And then second question on 2014 guidance that you've given before. I got on the call late, but I'm not sure if you've talked about 2014 or not. Is that still on track? And then third question, a quick one, just Emerging Market revenue growth in fourth quarter?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the sec",132,"Sure. Tim, in regards to your question about the tax rate, let me remind you, there's three moving pieces here. First of all, with the patent expirations with Zyprexa and Gemzar, the mix effect of that create upward pressure on our tax rate. Also, the second factor affecting our tax rate, which also creates upward pressure, is the pharmaceutical industry fee, which is non-tax-deductible. What's creating a lowering pressure on our effective tax rate is the assumption that we'll be able to credit the Puerto Rico excise tax. So that's how we get to the tax rate that you saw. In regards to the 2014 guidance, Tim, we did not discuss that on the call today. And we still look forward to update that at our June Analyst Meeting in New York."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage poi",221,"One other thing to keep in mind, Tim, for the 2010 effective tax rate is that we did have in Q1 that $85 million charge due to the future taxation of the retiree drug subsidy that drove up the overall tax rate for the full year by about 1.3 percentage points. That will not be recurring in our 2011 or going forward numbers. And then in terms of the emerging market, as we've said in the call, the full year growth rate was 14% total. Well, actually it's 10% performance, a very robust growth. We did have a spike in Q3 that came down a little bit in Q4 due to timing of orders. Specifically in Q4, we had about 6% total growth, nearly all of which was from performance despite -- we have references that compares to 18% growth in Q3, 16% of which was performance. Some of the things that we saw, for example, Tim, to give some color. There would've been some Zyprexa orders, for example, in Brazil but would have expected to come through in Q4. They did not come through in Q4. They did come through early this Q1. So again, we think, by looking at that full-year number gives you a better trend for how the emerging markets are growing. And again that's 10% performance."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Next question comes from the line of John Boris with Citi.",11,"Next question comes from the line of John Boris with Citi."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second",131,"First question for Derica, on international sales in 2010, total international sales for 2010. Is it possible to get some information on percent of sales of that international component that's coming out of Japan and coming out of emerging markets? Second question on your Diabetes portfolio, Byetta in particular. If you look at the Canadian label, it does increase a small increase in QTC that they've highlighted in that label. Can you just help us understand that and also maybe walk through what the implications are on that for the U.S. label and for Bydureon? And then last, is it possible just to get an update on where you are at with your own fully humanized GLP-1 program going forward? Any update on enrollment and timing of release of results there?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you loo",194,"John, let me start with how to characterize our international sales. So today, about a little over 45% of our total revenue base is outside of the U.S. And if you were referring back to -- if you refer back to Slide 10, you'll see from the PRV, if you look at just the total year here what was really driving our overall revenue growth. So in Europe for the year, we had 3% volume growth. In Japan, we had 26% volume growth. And the rest of the world, so in those markets outside the U.S., we had 6% of volume growth. And when you break that down, you really saw even in Europe where we are already in some YZ aspect in terms of Gemzar erosion, we still were able to drive good volume growth. And so when we look forward, we really see those markets, like the emerging market in Japan, really acting in a countercyclical manner compared to what we're going to see in the U.S. in 2011, as well as in Europe major markets in 2011 with the Zyprexa effect. So this is where we anticipate driving the future growth."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Real quick in terms of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as",102,"Real quick in terms of the sales numbers on that Slide, John, 10, which is the effective price rate in volume on revenue. You'll see that the full year revenue for Japan actually passed $1.5 billion for the year. And then in terms of emerging markets, as we commented during the prepared remarks, over 10%, essentially roughly 10% of our sales now are coming from emerging markets. I don't have the exact percentages for you broken out by the international, but I think hopefully those two numbers will allow you to make that calculation. And then for John for the Canada Byetta."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own qu",107,"Yes, John, I think -- first of all, we're very pleased to have Byetta approved in Canada. And I don't have the label language in front of me but my recollection is this is not a counterindication or a warning. The fact is that the FDA is asking its own questions for Bydureon on QT. And whether or not that's connected with questions that Canadians might have. It's something I can't speculate on, but we're obviously well along with meeting what we understand to be FDA's requirements, so that we can refile Bydureon in the second half of this year, and ultimately hopefully gain approval for that."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. As well as, we had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably",69,"Program? We are really pleased with that program. We've actually initiated four of the award studies, all of last year. As well as, we had an ongoing thing with adaptive trial that is progressing well as well. We plan later this year to actually probably start a CD study. So we're pretty pleased with the progress of that program and look forward to sharing some data in early '12."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger with Morgan Stanley.",13,"Our next question comes from the line of David Risinger with Morgan Stanley."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. First, maybe you could just help us understand the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly i",102,"A couple of questions. First, maybe you could just help us understand the solanezumab interim look for 2011. What are the scenarios for that interim look? Typically Phase III trials have to run to completion. Is it a DSMB interim look or -- what exactly is the interim look? That's the first question. Second, in terms of other key late stage pipeline results to watch in 2011, what are the few that are most important that you're focused on in terms of Phase III results? And then third, could you just update us on the Strattera and Cymbalta patent litigation outlooks, please?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to c",277,"Sure, Dave. I'll take a shot at your first two questions. Maybe ask Ronika to help on the last one. So for solanezumab, the interim look, your question. I think you're tracking exactly correctly that for efficacy, these trials need to run all the way to completion to be able to have in this particular case statistical powering to be able to show the slowing of progression of the disease. So this will be a look that's a safety look. So these trials can only be stopped early for either safety issues or for very curious signals that there's no way the primary endpoint could be met. They cannot be stopped early for efficacy. In terms of the Phase III data, a couple of the major ones that were mentioned on the call are private ones, I would highlight to you, as well, which would be the DURATION-6 data head-to-head with Bydureon versus Victoza. I believe that should be becoming here probably in the first half of the year. Expectation would be much like we have the past. You probably have the top line results press release with subsequent presentation at a medical meeting. Timing of that medical meeting is difficult to know if that might be ADA or EASD. And then obviously with Alimta, we continue to build out that franchise and are very hopeful that we'll be able to do so with the S124 study that Derica mentioned that is Alimta induction, followed by Alimta maintenance therapy. You may recall that the current maintenance indication that we have is for Alimta used in the maintenance setting followed by a first line treatment with platinum agents."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or a",69,"Just to add to that with regards to Cialis for BPH, we have plans. I'm disclosing data here in the first quarter. We have already been accepted with an abstracted EAU in March. As well as -- and the European Association of Neurology will have a combo or at least a co-administrative study with the alpha blockers and develop with BPH. Those are another set of Phase III data."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with A",44,"I just want to mention that we've got FDA action dates for florbetapir, which received a priority review status. This is the Avid beta-amyloid imaging agent. For Linagliptin, this is BI DPP-4. And also for liprotamase, the molecule that we acquired with Alnara."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've iss",74,"So Strattera, as we mentioned on the call, we're awaiting the decision. We feel very confident that the CAFC should in fact overturn the district court ruling and have included the assumption that we maintain the Strattera patent in the guidance we've issued for 2011. Cymbalta, last update we had, we remain on track for a trial to start here in the U.S. District Court for Southern Indiana on June 6 of this year."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Our last question comes from the line of Chris Schott with JPMorgan.",12,"Our last question comes from the line of Chris Schott with JPMorgan."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Analysts","My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the",135,"My first on the gross margin and the two percentage point decline, can you just give us a little bit more granularity on how we should think about the magnitude of the impact of the loss of Zyprexa and Gemzar sales on gross margin relative to some of the factors you mentioned? I guess you said those two products had much of the impact or some of the things like Puerto Rico play a bigger role? And then the second question was on SG&A expense. You mentioned flat SG&A x healthcare reform and the BI announcement. With the restructuring initiatives you've announced, I guess I would've anticipated a bit more of a decline in 2011. Can you just help us a little bit better the pushes and pulls that are going into SG&A in 2011?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a",247,"Chris, this is Derica. Let me try to address both of your questions. In regards to gross margin, we will see a downward pressure on our gross margin driven by the mix effect due to the loss of the Zyprexa and Gemzar patent. And so that's going to create a negative pressure. You're also going to see negative pressure on gross margins attributable to the Puerto Rico excise tax. Because it's an excise tax, it will actually flow through comps or manufacturing costs, thus reducing our gross margins. And then obviously it's offset or credited through the tax rate in the line item below that. And those are the two factors that's driving the decline in our gross margin by approximately two percentage points in aggregate. I'm not prepared to break those out into pieces. In regards to the SG&A and being flat, if you exclude the Pharmaceutical industry fee as well as the BI alliance aligns expenses, what you see is kind of a mix-up in the U.S. and our European markets. You are seeing a dramatic decline in our overall operating expense base in terms of SG&A. But as I highlighted on the call, we are making strategic investments in some of our key emerging markets, like China, as well as in markets like Japan, where we are expecting to drive significant countercyclical growth as we go through this period of YZ. So that's what's driving the overall effect of SG&A being essentially flat. John?"
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Executives","Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post",486,"Well I want to thank everyone for taking time for taking time this morning for this update on Eli Lilly and Company. As always, we appreciate your continued interest in our company. We fought, and for the most part, overcame significant headwinds to post strong financial performance in 2010. This was highlighted by volume-driven revenue growth. On a performance basis, we delivered increasing gross margin as a percent of revenue. We gained leverage between revenue and operating income growth and posted a robust 8% net income growth. We prudently managed working capital and capital expenditures, and once again generated strong operating cash flow. We're pleased with our performance and our progress in 2010. We're excited about the opportunities before us in 2011.
As Derica discussed, we entered this year with a keen awareness of the challenges posed by the patent expirations we faced in the YZ period ahead. But we have a focused strategy centered on innovation that we're aggressively pursuing. Over the last year, we advanced 16 new molecules into Phase I clinical testing, nine molecules into Phase II testing, and two molecules NERI for depression and our antibac antibody for rheumatoid arthritis and lupus into Phase III testing. We concluded a number of business development deals with a bias toward those that provide current or potential near-term revenues. We acquired florbetapir with our acquisition of Avid Radiopharmaceuticals. And just last week, an FDA advisory committee recommended approval of the beta-amyloid imaging agent if we provide appropriate physician training and successfully re-read existing brain scans. And our strategic alliance with Boehringer Ingelheim includes the development and commercialization of two oral diabetes compounds from BI, including linagliptin, which could be approved this year and two basal analog insulins from Lilly. 
In addition, we are preparing to launch Cymbalta for chronic musculoskeletal pain and Axiron for testosterone deficiency and have a number of potential regulatory approvals, including Bydureon in the EU and several pending here in the U.S. At the same time, we expect continued strong performance in the rest of our business in 2011, including the three countercyclical growth engines we've discussed for some time. Lilly is, today, the fastest-growing pharma company in Japan and the fastest-growing among the top 10 multinational companies in key emerging markets, while Elanco Animal Health is outpacing its industries growth, as well. We'll continue to take advantage of this countercyclical growth, as well as the growth in a number of our patent protected products in the U.S. and Europe. Our strong financial performance, our focus on speeding innovations to patients and targeted use of business development all support our goal of successfully traversing   and emerging with even greater strength and the capacity to drive future growth. We'll continue to act with urgency and purpose to overcome the challenges we face. And as always, we will keep you informed of our progress. Thanks again for joining us. Have a great day."
285467,97242168,96467,"Eli Lilly & Co., Q4 2010 Earnings Call, Jan 27, 2011",2011-01-27,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International",70,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern today until February 3, 2011, at midnight. You may access the AT&T executive playback service by dialing 1(800)475-6701 and entering access code 186408. International participants may dial area (320)365-3844. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation using AT&T Executive TeleConference Service. You may now disconnect. Have great day."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly and Co.'s first quarter 2011 earnings conference call. I'm Phil Johnson, Vice President of Investor Relations.Joining me are our President, CEO andChairman, John Lechleiter; our Chief Financial off",1006,"Good morning, and thanks for joining us for Eli Lilly and Co.'s first quarter 2011 earnings conference call. I'm Phil Johnson, Vice President of Investor Relations.
Joining me are our President, CEO and
Chairman, John Lechleiter; our Chief Financial officer, Derica Rice, our President of Lilly Research Laboratories, Dr. Jan
Lundberg; and Ronika Pletcher; and Jill Thoren from Investor Relations.
Today's Q1 earnings call coincides with our annual shareholder meeting. As a result, our CEO, John Lechleiter is not available to participate in today's call. 
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is to the benefit of the investment community. It is not intended to be promotional and is not sufficient for describing decisions.
Since the Q4 earnings call in late January, we've continued to bolster our operations through business development, to leverage our marketing products and to advance our pipeline. We announced our offer to acquire the Animal Health business of Janssen Pharmaceutica from Johnson & Johnson. This business is primarily European focused targeting disease segments and combating animals and livestock, with special emphasis on swine and poultry. The deal closing, which is expected by mid-year, we would maintain a portfolio of roughly 50 marketed animal health products. 
Here in the U.S., we began active promotion for Cymbalta for the management of chronic musculoskeletal pain. And we launched Axiron, the first and only testosterone replacement therapy applied to the underarm. On the regulatory front, we submitted our response to the FDA's complete response letter for the use of Erbitux in the first-line head and neck cancer. 
We receive a complete response letter from the FDA for florbetapir, our PET imaging agent being studies for the detection of beta-amyloid plaque. We are working closely with the FDA to address their questions on the reader training program to ensure reading accuracy and consistency of interpretations of beta-amyloid plaque images. 
Late last week, we also received the complete response letter from the FDA for the proteomics, a pancreatic enzyme replacement therapy, and we'll be working diligently to address the agency's questions.
In Europe, we submitted our application for the use of Alimta induction treatment followed by Alimta maintenance treatment in advance, non-squamos, non-small cell lung cancer. And also in Europe, we recently received the CHMP recommendation for approval of Bydureon for the treatment of type 2 diabetes. Based on this recommendation, we anticipate receiving easy approval by late June.
On the clinical front, we disclosed positive top line results on the Phase II trial of the once monthly formulation of exenatide. We plan to met with regulatory authorities to determine next steps for this program. We also disclosed top line results for the Phase III duration six trial comparing Bydureon to the highest approved dose of Victoza. Bydureon demonstrated a robust reduction on HbA1c baseline, however, it did not meet the primary endpoint of non-inferiority to Victoza 1.8 milligram in the reduction HbA1c. Additional data from the trial is plan to be disclosed at a later date. And we began the first Phase III trial for our mGlu2/3 prodrug for schizophrenia. 
Lastly, on the legal front, while we received a favorable ruling on the Cymbalta patent challenge. Lockhart voluntarily consented to entery of judgment in favor of Lilly on all pending issues, which the judge so ordered. The judge asked the remaining parties to indicate if they intend to proceed to trial and all nine defendants failed to indicate that they intend to proceed. As a result, we remain that there'll be no generic costs in product coming to market until the Cymbalta patent expires. However, a trial date remain on the court's docket for June of this year. A meeting with the court, Lilly and the defendants will be held later this month to determine next steps in this litigation.
While not specific to Lilly, perhaps one of the most notable events since our last earnings call is the disaster Japan caused by the March 11 earthquake and its aftermath. Because Japan is such a big part of our growth strategy, I'd like to provide you with some details. First and foremost, we were relieved that within hours, we were able to account for the safety of all Lilly Japan employees. We're also proud of the support, both monetary and product donations that Lilly Japan, the Lilly Foundation and Eli Lilly and Co. have provided to help those affected by this strategy. 
From a business perspective, our Japanese affiliate headquarters and development center of excellence are located in Kobe, and we have a manufacturing plant in Seshing just outside of Kobe. These operations are approximately 500 miles southwest of the disaster zone. As a result, we had no damages or other issues at these sites.
In terms of product supply, we've encountered no issues getting manufacturing products into or out of Japan. And we have not had and do not anticipate having any issues with the supplier of raw materials, intermediate or finished products from our Japanese suppliers. 
Prior to the earthquake, we had robust inventory levels throughout our supply chain for materials sourced from Japan. In terms of domestic sales, we did receive what appeared to have been precautionary orders from customers totaling $30 million to $35 million in the quarter. We expect that this will wash out in future quarters. 
Our thoughts are with the Japanese people and what will surely be a long and difficult recovery. We will continue to provide them our support, and we'll continue to ensure that Lilly products reach the patients who need them. 
Now at this background, Veronica will discuss our Q1 results and provide our pipeline update and Derek will cover key events for the remainder of 2011 and financial guidance for the year. Veronica?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on our previous calls, we'll focused our comments on non-GAAP results, which we believe provides insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairm",1022,"Thanks, Phil. As we've done on our previous calls, we'll focused our comments on non-GAAP results, which we believe provides insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairment and other special charges. I'll start on Slide 7 with a quick look at our Q1 income statement.
On a non-GAAP basis, you can see that we generated solid revenue growth of 6% this quarter. Excluding Gemzar outside of Japan and the effect of the U.S. healthcare reform, revenue would have grown 10%. Gross margin as a percentage of revenue increased slightly from 79.5% to 79.8%. 
Operating expenses defined as a sum of R&D and SG&A grew 10% this quarter. Drivers for the increase included: higher administrative expenses, driven by the pharmaceutical manufacturers fee associated with the U.S. Healthcare Reform and higher litigation expenses. Higher marketing and selling expenses driven by o-U.S. investments primarily in the emerging markets and higher R&D expense due primarily to increased late stage clinical trial expenses.
In addition, both SG&A and R&D expenses increased due to the BI alliance. Excluding the effect of U.S. healthcare reform and the BI alliance, operating expenses would have grown 7%. Other income and deductions was a net expense this year compared to net income last year. You may remember that we had substantial in coming Q1 2010 related to the recovery of damages from generic Atlanta premarketers in Germany and from gains on the sales of securities acquired in the ImClone acquisition. 
Our tax rate was 20.9% this quarter considerably lower than 27.3% from last year's Q1. Last year's Q1 rate included an $85.1 million charge related to the future taxation of the retiree drug subsidy and did not benefit from the R&D tax credit as it left. This year, we did benefit from the R&D tax credit, as well, as from the resolution of certain IFRS tax matters. 
At the bottom line, our non-GAAP EPS increased 5% to $1.24. As indicated, Lilly provided the 2011 guidance in January, we felt robust EPS growth in our business in Q1 excluding U.S. healthcare reform, the effect of the Gemzar patent exploration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would have grown low double digit. 
Slide 8 shows our reported income statement while Slide 9 provides reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now let's look at how foreign exchange affected our Q1 revenue. As you can see on Slide 10, total revenue growth of 6% was driven by solid volume growth of 5% and foreign exchange contributing the remaining 1%. Price had no impact on the worldwide revenue growth. We continue to see strong volume growth from our three countercyclical growth engines: Japan, Elanco Animal Health and emerging markets. 
Volume growth in Japan was 34% driven by recent launches of Cymbalta and Forteo as well as continued strong growth of Alimta, Gemzar and Humalog. In addition, roughly a quarter of the Q1 volume growth was attributable to precautionary buying Phil mentioned earlier. 
Elanco Animal Health volume growth of 25% in Q1 driven by the increased demand for food animal products globally, as well, as by the launch of Trifexis in the U.S. and the acquisition of certain European Animal Health assets from Pfizer. 
Going forward, we expect Animal Health revenue growth to benefit from international launches of Trifexis. In addition, Elanco has build a robust innovative pipeline and is poised to maintain double-digit growth in the coming years with launch as expected in multiple products targeting high-value markets such as livestock immune enhancement, control of parasites in companion animals and pain controls.
We also built a substantial development capability in animal health vaccine, and as demonstrated by our recent offer to acquire Genesis Animal Health business, we will continue to look externally for opportunities to drive growth in this business. 
Finally, you'll see strong 14% volume growth from our human pharma products in the rest of the world line. Emerging market countries represented about three quarters of the sales in Q1, and as a group also registered 14% volume growth. In terms of products, growth in emerging markets countries was driven by Alimta, Cymbalta, Humalog and Humulin. In terms of geographies, we saw robust growth across the host of geographies in Asia, Latin America and of course, China. 
Given a very small effect of foreign exchange on our results this quarter, we provided our summarized non-GAAP and reported income statements within and without the effect of foreign exchange in our supplementary slides.
Now before I turn the call over to Derek, let me provide a brief update on our pipeline. On Slide 11, you'll find a view of our portfolio of new molecular entities in clinical development as of April 11, inclusive of changes since our January 27 earnings call. 
Our clinical stage portfolio now stands at 69 to state maybe including 31 compounds in Phase II and Phase III. Biotechnologies represent nearly half of our late stage Phase II and Phase III assets in over a third of our overall clinical portfolio. Advancing our pipeline remains our number one priority, as reflected by the arrows on Slide 11 since our January update we have began Phase III testing of  HbA1c for schizophrenia. Bringing our total Phase III portfolio to nine entities. We continue to be on track to meet our goal of having 10 entities in Phase III by the end of the year. Other molecules that could begin Phase III in 2011 include our novel base insulin analogs, our new insulin like products and our IL-17 antibody. 
We also advanced two molecules into Phase II and two in Phase I. Finally, both sBLAs and io-beta antibodies continue early stage development after we terminated clinical trials in their lead indications, and we terminated one molecule in Phase I development.
With this current pipeline and our continued business development effort, our goal is still to launch on average two molecular entities per year beginning in 2013 providing a foundation for future growth. Derica?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Veronica. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now receive the CHMP recommendation for approval of Bydureon, we look forward to launching the produc",835,"Thanks, Veronica. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now receive the CHMP recommendation for approval of Bydureon, we look forward to launching the product in Europe later this year. We have a number of other potential regulatory approval this year including: Linagliptin in the U.S., Europe and Japan. And here in the U.S., sBLAs for BPH, Byetta in combination with basal insulin and Erbitux for first-line head and neck cancer.
Expected regulatory submissions include: our response to the FDA complete response letter for Bydureon; sBLA for Erbitux and first-line metastatic colorectal cancer; and for first-line, non-small cell lung cancer. Byetta in combination with basal insulin in Europe and our response to the FDA complete response letter for Amyvid. 
Upcoming clinical trials data disclosures include: Initial results from the Phase III trial of Alimta induction treatment followed by Alimta maintenance treatment in advance nonsquamous, non-small cell lung cancer at ASCO. At the UR Meeting in London in May, we will present data on the two Phase II trials of our vast antibody and rheumatoid arthritis. And lastly, data from a study assessing the safety of Cialis when administered with alpha blockers will be presented in May at the American Association of Neurology Meeting in Washington. 
Just late last month, data from the clinical trial evaluating Dialycell in bandwidth EDN and with signs and symptoms of BPH was presented at the European Association of Eurology.
Finally, as mentioned earlier, Phase III trials could begin this year for our novel basal insulin analog and our new insulin Larkin product and for our own anti-IL-17 antibody. 
In terms of our 2011 financial guidance. As you've seen in our press release, we still expect 2011's non-GAAP earnings per share of between $4.15 and $4.30. Our 2011 reported EPS guidance range of $3.86 to $4.01 reflects a $0.23 IPR in charge from the BI alliance and $0.06 restructuring charge. The business fundamentals underlying our guidance are essentially unchanged since our last update in January. However, a number of foreign currencies, in particular, the euro, have appreciated in recent months. 
As a result, we're updating our revenue growth and growth margin percentage guidance. Assuming rates remain at current levels, we now expect 2011 revenue to grow in the low single digits. And we expect 2011 gross margins, as a percent of revenues to decline by approximately 3 percentage points. Also, we're now estimating that the 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 21% on a reported basis. Both of these rates reflected benefit from the resolution of certain IRS audit matters. In addition, the reported tax rate for the full year reflect the tax benefit of the in-process R&D charge associated with the BI alliance. All other elements of our line item guidance remain unchanged.
Now Slide 14 provides a consolation between reported and non-GAAP EPS for 2010. And the associated growth rate from these numbers to our revised 2011 guidance. Now in summary, so far, 2011 is playing out as anticipated. We're making progress advancing our pipeline, and we're delivering solid financial results. With the initiation of Phase III trials for mGlu2/3 for schizophrenia, we now have nine molecules in Phase III development, putting us on track to meet our goal of having 10 molecules in Phase III development by the end of this year, with more coming behind. Along with continued business development, this pipeline serves as the foundation of our growth post years.
During Q1, we also made progress on our productivity goals and are in tract to meet our 2011 headcount and expense containment goals. When we discuss our 2011 guidance in detail on the January call, I shared that we faced a number of headwinds this year, as patent exploration, lower sales outside of Japan for first for Gemzar, and later for Zyprexa. U.S. healthcare reform will exact a higher cost this year than it did in 2010, and we'll face some near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. 
I also shared that we expect to see continued strong performance in the rest of our business. We did see the negative impact in Q1 of these items, and we delivered strong growth in the rest of our business as promised. Excluding these items, on a non-GAAP basis, we posted revenue growth of 10%, operating expense growth of 7% and low double-digit EPS growth. We saw robust revenue growth from our three countercyclical growth engines with Japan growing 41%, Elanco growing 28% and emerging markets growing 15%.
Moving forward, we will continue to focus on delivering strong financial results, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline and on speeding the next generation of Lilly molecules to market to provide growth post years YZ. This concludes our prepared remarks. And now we open the call for the Q&A session. Operator, first caller please?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Derek, a question for you on Bydureon and congratulations getting your approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results? And then also included in",115,"Derek, a question for you on Bydureon and congratulations getting your approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results? And then also included in the recommendation for approval was a former code vigilance program and I'm wondering if you could elaborate on that. And just lastly, just as we experienced here on the gross margin, the delta in the gross margin, the delta in terms of your new guidance for the full year reflect a $0.17 hit. And I'm wondering if that is all related to foreign currency or is there cushion related to Zyprexa going generic?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Javan, you may want to deal with the pharmaceutical vigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to",117,"Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Javan, you may want to deal with the pharmaceutical vigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to disclose what our pricing strategy would be behind this brand before we've even launched it. But what I can say is we still feel very confident in the commercial prospects for Bydureon given the label that we would anticipate. As it relates to your growth margin question, regarding FX, it is all attributable to FX rate. In terms of our revised guidance of minus 2 percentage points to minus 3 percentage points decline."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to risk management for Bydureon, of course we have very high safety on the agenda. And we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need. And I'm pa",59,"In relation to risk management for Bydureon, of course we have very high safety on the agenda. And we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need. And I'm particularly looking for if there are increase in pancreatitis, thyroid tumors, et cetera."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmaceutical vigilance plan, those are things that need to comment on until the EC provides its formal approval of t",193,"A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmaceutical vigilance plan, those are things that need to comment on until the EC provides its formal approval of the CHMP recommendation, which we expect to come hopefully in late June. And then in terms of pricing, do keep in mind that the DURATION-6 trial was against the 1.8 milligram dose of Victoza. Rough numbers in many of the European numbers it would appear that the 1.2 was launched out roughly parity to Byetta, which means that the 1.8 would be the substantial premium. So as we enter those discussions with pricing authorities in Europe, we'll be looking at the full and half duration trials that we have very strong data against insulin enlarging, against lactose, against ingenuity and against Byetta, all of which have a price that's out in the marketplace. Then as you mentioned, Jami, we'll also have the DURATION-6 data against the 1.8 milligram dose of Victoza that we enter in both discussions as well. So again, as Derica said, a very strong overall package."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Sanford Bernstein.",13,"Our next question comes from the line of Tim Anderson with Sanford Bernstein."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health Products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in Animal Health or other areas that mig",89,"On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health Products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in Animal Health or other areas that might provide you with a greater level of diversification. And then on silyezyme, can you narrow down the timing of when we likely see results and also where you are with the interim looks and whether you'll announce one of those interim looks will be complete."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And then if you can just comment respectively on the general and Animal Health acquisition landscape. And then Jan and Ronika maybe the sylunab up",47,"Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And then if you can just comment respectively on the general and Animal Health acquisition landscape. And then Jan and Ronika maybe the sylunab update would be great."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset. Both our top line, as well, as bottom line. In regards to this development, we continue to be active in this space. But I think we've b",135,"Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset. Both our top line, as well, as bottom line. In regards to this development, we continue to be active in this space. But I think we've been also very clear about our intent. We're not in the market for large-scale M&A, but we are looking for opportunities to continue to enhance our business, both from the standpoint of defining molecules that complement our development pipeline portfolio or finding those product opportunities that we can bring in, that bring sales and cash with it. And then, that's clearly what we also saw as we looked at the Janssen acquisition in terms of animal health. We're bolstering our Animal Health business with Jeff can respond to further."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, Tim, I would say we've made four acquisitions in four years. Lilly has and it's all playing around this countercyclical growth engines that was made in the comments. We will continue to be opportunistic. But it really has to drive three things. One i",115,"Yes, Tim, I would say we've made four acquisitions in four years. Lilly has and it's all playing around this countercyclical growth engines that was made in the comments. We will continue to be opportunistic. But it really has to drive three things. One is growth, strategically has to drive growth. Diversity and bring capability. And I will say all four acquisitions in the past have done that. That's what we will continue to look for as we go forward. Although the organic growth that we see over the next two or three years in Animal Health is going to be significant with six new launches this year and more launches to come in 2012."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to syemab, our EBITDA antibody then for progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we will dis",50,"In relation to syemab, our EBITDA antibody then for progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we will disclose the data at an appropriate event."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","One of the thing I will add, Tim, you see we had, in an effort to give you guys some more exposure to the operational heads of our various areas of the company. Enrique, on the call last quarter, Jeff this quarter, we'll likely have Jacques Tapiero, Head",108,"One of the thing I will add, Tim, you see we had, in an effort to give you guys some more exposure to the operational heads of our various areas of the company. Enrique, on the call last quarter, Jeff this quarter, we'll likely have Jacques Tapiero, Head of our Emerging Markets area on next quarter. That is an area in emerging markets country as where your question on M&A probably could last 24 months or so. We've seen pricing very high. Frankly, more likely you'll see things that are of the collaboration and licensing. In the short term, until those trends reverse in the emerging markets properties."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Greg Gilbert with Merrill Lynch.",13,"Our next question comes from the line of Greg Gilbert with Merrill Lynch."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your desk to move it into Phase III? What was the",96,"Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your desk to move it into Phase III? What was the bar there? With any specific you care to share? And thirdly, more strategically, should we view the Amyvid acquisition as a sign of things to come for Lilly or more as a one-off that will take you some time to assess before you really answer that question to yourselves?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Derica take your first and third questions, Gregg. And then we'll have Hannah handle the question you asked as well.",23,"We'll have Derica take your first and third questions, Gregg. And then we'll have Hannah handle the question you asked as well."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Greg, we actually have -- we saw two types of activity that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as we can tell even at the retail level as well",221,"Greg, we actually have -- we saw two types of activity that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as we can tell even at the retail level as well in the first quarter. So that destocking sort to dampen our revenue growth in the U.S. in Q1. At the same time, given the disaster that we all witnessed in Japan, we saw a buy end on the part of wholesalers or distributors there in the case of emergency. And that buy end in Japan was probably in the range of around $30 million to $35 million in the quarter. So it was of 41% of Japan growth that we saw in the quarter, about 25% of that was related to this buy end. As it relates to your third question around the Abbott acquisition. Just a reminder to everyone, when we did the Abbott acquisition, it was solely based upon the prospect of that compound itself. And our thesis behind that is that we saw an interesting therapeutic that could complement our portfolio. Clearly as that played out, it gives us an opportunity to ponder other alternatives. But for right now, we're planning and progressing as though it's around Avid itself."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Now regarding your second question, Greg. You mentioned glib moving into Phase III. We actually moved glib into Phase III quite a while ago. I think you may have meant to say mGlu2/3, which we move into Phase III in this part quarter. If that is your ques",102,"Now regarding your second question, Greg. You mentioned glib moving into Phase III. We actually moved glib into Phase III quite a while ago. I think you may have meant to say mGlu2/3, which we move into Phase III in this part quarter. If that is your question, I'm not actually going to turn the call over to Jan to give some more clarity. But we actually presented some six-month safety study beginning of April at the I-CO Meeting, the International Congress for Schizophrenia Research, which discharge some of the risk. But again, I'll turn it over to Jan to answer further."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 as our optional treatment for these patients. The study mentioned discharged the r",132,"The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 as our optional treatment for these patients. The study mentioned discharged the risk in relation to seizures as we see it in relation to standard of care. It's known that patients with schizophrenia do have an increase to risk of seizures, but our agents did not seem to have any more effects than the standard of care. And we should remember there are some potential clear advantages with our mGlu2/3 agent less risk for extrapyramidal symptoms and also it has a much better metabolic profile in relation then to a typical antipsychotics, with even with a potential weight loss, not the weight gain."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Lastly, Greg, on the U.S. piece, with the numbers around what Derica had mentioned, we typically would end within the guidelines we have with the wholesaler, the higher end of the days on hand, wholesalers, the end of the calendar year, and we typically c",81,"Lastly, Greg, on the U.S. piece, with the numbers around what Derica had mentioned, we typically would end within the guidelines we have with the wholesaler, the higher end of the days on hand, wholesalers, the end of the calendar year, and we typically come down in Q1. That was the case both in 2010 and in 2011. However, the decline was a bit steeper in 2011 and that a trend to one percentage point off of the U.S. growth rate."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger from Morgan Stanley.",13,"Our next question comes from the line of David Risinger from Morgan Stanley."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","I have a couple of questions. First, I missed that question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to solanezumab, I think that Jan mentione",110,"I have a couple of questions. First, I missed that question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to solanezumab, I think that Jan mentioned that there is a utility analysis this year. Could you please comment on what are that the first half such that we are able to comment on attribute on analyst meeting or not until the second half. And then third, with respect to your long-term earnings outlook, Derica, could you expect to continue as of June 30 analyst meeting or prior to the meeting on a separate call?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. David, I'll take your first and third question. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance of contract that we put out there in December of '0",73,"Okay. David, I'll take your first and third question. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance of contract that we put out there in December of '09, David, I would see ourselves coming back to that at our June Analyst Meeting. I don't anticipate us giving any more color on that prior to our June meeting."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the timing of the utility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that the safety profile so far in these trials look better than for me say my guess is that and they're ac",61,"In relation to the timing of the utility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that the safety profile so far in these trials look better than for me say my guess is that and they're actually less patients that has stop the trial because of safety disease."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Steve Scala with Cowen and Company.",14,"Our next question comes from the line of Steve Scala with Cowen and Company."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","I have two questions. Again on shomolimab, how is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group. And if that is the case, is that a risk for this trial? And then second, when",67,"I have two questions. Again on shomolimab, how is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group. And if that is the case, is that a risk for this trial? And then second, when in 2013 might you file GLP, might have be a first-half event or might it be a second half event?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Well, I think I've said what I want to save. But still until the Asimov we need to wait for the data.",22,"Well, I think I've said what I want to save. But still until the Asimov we need to wait for the data."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","With regards to glib FC, we have provided no specifics with regard to timing on filing. We have initiated all forward studies. So we're pleased with the progress there, but no additional information on timing.",35,"With regards to glib FC, we have provided no specifics with regard to timing on filing. We have initiated all forward studies. So we're pleased with the progress there, but no additional information on timing."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of John Boris with Citi.",12,"We have a question from the line of John Boris with Citi."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","First question for Derica, on the Animal Health business. Just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China in particular and your diabetes franchise there. Might b",110,"First question for Derica, on the Animal Health business. Just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China in particular and your diabetes franchise there. Might be winter if there's about 92 million diabetics there and your market share relative to your competition. It's a little bit lower than your competition? What are you going to remedy that potentially going forward? And then one question for Jan, within the 2013 time period, aside from glib 1 FC, what are the other one or two assets that might be positioned for launch at that time?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and the size of the China. And then Derica on the China, diabetes question. And then on to Jan.",37,"Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and the size of the China. And then Derica on the China, diabetes question. And then on to Jan."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes so we have the engine has represented sagittal independent health data that tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which is about $25 million, the",86,"Yes so we have the engine has represented sagittal independent health data that tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which is about $25 million, their distributor sales. So it represents a little level that's higher that what really Janssen and we will recognize. So that number is a little bit high. And then the actual margins would be very much average for the industry and Animal Health."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","John, in regards to China. As I stated -- in the interview morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly having a smaller share of market position versus our competition",187,"John, in regards to China. As I stated -- in the interview morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly having a smaller share of market position versus our competition. We have taken decisive actions to improve our competitive position going forward. We've recently commissioned a new diabetes research facility in operation there. In addition to that, we are actually, we commissioned also building a second manufacturing facility in China, which will be diabetes-related as well. And then thirdly, we've more than doubled the size of our commercial footprint. So we believe that we are positioned ourselves to take advantage of this significant opportunity in that marketplace. And we see ourselves with the opportunity gain share. And partly the learning for that is also what we've seen here in the U.S. So even in the market where you could say, it's fairly saturated, in the U.S., we have seen a significant uptick in our diabetes share of market both on an interact and trex if you look at the last year. Jan?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two enemy launches per year from 2013 should potentially come from growth both from internal and",74,"Yes, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two enemy launches per year from 2013 should potentially come from growth both from internal and in-licensing or acquisitions. So those are three options. There are some programs with the right data that could deliver ahead of time, potentially stimulus could be one of them."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a question from Bert Hazlett from BMO Capital Markets.",12,"We do have a question from Bert Hazlett from BMO Capital Markets."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","I have one question on Japan and another on the pipeline. First on Japan, you did have some buy end but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Erbitux and Zyprexa, could you discuss your expectations f",132,"I have one question on Japan and another on the pipeline. First on Japan, you did have some buy end but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Erbitux and Zyprexa, could you discuss your expectations for growth and the potential kind of countercyclical nature in terms of additional product launches that would be coming down the road there? And then secondly, in terms of the pipeline for Jan, I see you're moving the IL-17 program forward in rheumatoid arthritis. My count is this will be at least the third program in our INI, you have the oral JAK1/JAK2. You have the antibac antibody NRA and now the IL-17. Could you talk about this positioning RA and vis--vis the bath antibody in particular?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","This is Veronica with regards to Japan and launches. You might remember earlier in the decade, we have mentioned last decade, we have mentioned that our goal was to launch a lot of the products we have not yet launched in Japan that had already been launc",144,"This is Veronica with regards to Japan and launches. You might remember earlier in the decade, we have mentioned last decade, we have mentioned that our goal was to launch a lot of the products we have not yet launched in Japan that had already been launch in the U.S. And those include several that you mentioned. Alimat and Strattera, which was in 2009, As well as Cymbalta, Forteo, Byetta that also launched in Japan in 2010. Also keep in mind, part of the countercyclical nature of Japan include the fact that we have Zyprexa in Japan through 2015. So products that could also be launched in the near term in Japan include our partnership with BI, specifically, linagliptin. There's a potential launch in Japan in 2011 or approval, I should say, in 2011. So those are the highlights with regards to Japan. Jan?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, we are very excited about our opportunities in rheumatoid arthritis and also now in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1, JAK2 inhibitor partner with inside could be I think a ve",236,"Yes, we are very excited about our opportunities in rheumatoid arthritis and also now in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1, JAK2 inhibitor partner with inside could be I think a very competitive agent in relation to Pfizer's recent Phase III agent which have received so much attention to cost with a positive recent data. We are currently exploring them, the JAK1/JAK2 component Phase II in relation to those safety and efficacy. Oral agents will be placed earlier most likely than in the treatment of rheumatoid arthritis completing with metatries as a key initial agent. Our two biological, the anti and IL-17 represents very normal agents with new mechanized to influence the immune system. The bass against that the cells in the IL-17 more as an inflammatory from time to time that is released. Both of these agents have positive Phase II data in rheumatoid arthritis and they will be positioned in patients that actually are failing to TNF. And we know that there is substantial proportion of patients up to 50% that don't respond well enough to TNF blockers and even if you did switch to another TNF agent, the efficacy goes away with time. So we see both the vast and the IL-17 as potential new treatment options in acts that, quite a large patient population that have been failing TNF agents."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Mark, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion. So we surpass the $1.5 billion. That's a business that we believe we can double the size of that business",167,"Mark, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion. So we surpass the $1.5 billion. That's a business that we believe we can double the size of that business over the next four to five years. And you look at, as Veronica said, you got brands like Cymbalta, Dave Burks a 15 and Alimta but you're also seeing the impact for the recent launch for Trifexis as well as the continued growth around Alimta, Humalog and Gemzar. So that gives you some idea what we're expecting in terms of that countercyclical growth that we've been talking about along with emerging markets as well as Elanco that's helping to mute the impact of patent exploration like Gemzar in Q1 and later effects of this year. I would still remind everyone that top line grew 6%, 5% volume and that includes the impact of the generic erosion for Gemzar in the quarter."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","And the generic erosion of Gemzar shaded about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact.",29,"And the generic erosion of Gemzar shaded about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Seamus Fernandez with Leerink Swann.",13,"We have a question from the line of Seamus Fernandez with Leerink Swann."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Can you just update us on the neglected and whether or not Lilly expects to panel to be fielded for the product prior to approval? It looks like there won't a panel for this drug. Maybe just give us your recent specifically for that. Second, you've moved",128,"Can you just update us on the neglected and whether or not Lilly expects to panel to be fielded for the product prior to approval? It looks like there won't a panel for this drug. Maybe just give us your recent specifically for that. Second, you've moved a CTP inhibitor forward, I believe or haven't a CTP inhibitor in Phase II in actual schoolers. Can you just update us on your thoughts with regards to that mechanism? And what you believe is necessary to move that product into Phase III safely? And then the last question is actually, can you just update us on the status of Necitumumab, I believe one of the studies there was actually placed on clinical hold, so just looking for an update there."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. In relation to our BD four inhibitor clinical together with Behringer, that was filed last year and we have no further comment, I think on dates and potential advisory board, et cetera. We see this agent as a very promising oral, anti-diabetic compo",193,"Okay. In relation to our BD four inhibitor clinical together with Behringer, that was filed last year and we have no further comment, I think on dates and potential advisory board, et cetera. We see this agent as a very promising oral, anti-diabetic compound of that complements our offering to patients making Lilly very broad, if not the broadest suffering in the whole therapeutic area of diabetes across major pharma. We are quite enthusiastic about our CTP inhibitor, which now are in Phase II trials, in combination with Stockton's. We based this on our Phase I data. But also, we're actually at the clause, the competitor molecules both from Mark and Ross, as you know are moving ahead with Phase III trials. We feel that we have a competitive agent based on what we've seen so far. What area is than to avoid the problems that Pfizer had with the -- mainly the increasing blood pressure. We have not seen this for our compound and we are enthusiastically moving it forward. I think we can say currently. Necitumumab, we assume pursuing this claim is not a small lung cancer indication in Phase III."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Catherine Arnold from Credit Suisse.",13,"Our next question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. I wanted to ask you about your U.S. price increase if it has not been for Health Care Reform impact. And then I wanted more specifics, you guys have given more numbers about the effect of the world before. But I wasn't clear -- or h",126,"A couple of questions. I wanted to ask you about your U.S. price increase if it has not been for Health Care Reform impact. And then I wanted more specifics, you guys have given more numbers about the effect of the world before. But I wasn't clear -- or how we're going to be recording those is this going to be discuss argumentative you? Or are you sort of a grown-ups petition across four quarters. And then, on Sulyn, I just wanted to just one more question that hasn't been asked yet, which is as far as at the end of this trial, is there going to be severity of the disease stratification in the discussed analysis in addition I would presume to carrier and non-carrier."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Catherine, this is Derica. I think you're aware what the dollar impact of Health Care Reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece, which wa",110,"Catherine, this is Derica. I think you're aware what the dollar impact of Health Care Reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece, which was we believe the Health Care Reform impact will be in the range of $400 million to $500 million, that includes the impact of the anticipated impact of the. And then as you recall, the pharmaceutical excise fee will then impact us and the administrative OpEx line. And that's being to a tune of about $150 million to $200 million for the year."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. Their primary endpoint here is clearly reducing the disease progression and we will look mutation status as a second opportunity.",38,"Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. Their primary endpoint here is clearly reducing the disease progression and we will look mutation status as a second opportunity."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Couple of additional comments for you Catherine, the $90 million impact of U.S. healthcare reform on revenue this quarter, if you're looking at the impact of the growth rate, do recall that we have said approximately $60 million was the impact to revenue",234,"Couple of additional comments for you Catherine, the $90 million impact of U.S. healthcare reform on revenue this quarter, if you're looking at the impact of the growth rate, do recall that we have said approximately $60 million was the impact to revenue in Q1 of 2010. I think if you look in the queue, you'll find it was $62.4 million was the number. So it turned about 1 percentage point off of the U.S. revenue growth rate about 0.5 percentage point of the worldwide growth rate for the quarter. And then in terms of the doughnut hole, I think there different practices at the various companies. You might want to check on this. But essentially for the doughnut hole, we've done our best to try to model. We think we might actually be occurring. In other words, the charts that we would have recognizing Q1 we assume that a whole host of people would not have used that donut hole during this quarter. And if you look at approximately $90 million for the year compared to $400 million to $500 million for the year, you'll see that assume a bump up in Q2 through Q4 compared to Q1. That bump up is due to higher expect a terse that we will be recognizing for the doughnut hole, as more seniors and Medicare hit that part of the benefit from the U.S. healthcare reform."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Derica, can you give us a little more flavor of what's going on there restructuring? How much has been done so far, where's the impact and how much more there is? And as you've gotten in there to cut cost, are you finding more areas that got me just give",83,"Derica, can you give us a little more flavor of what's going on there restructuring? How much has been done so far, where's the impact and how much more there is? And as you've gotten in there to cut cost, are you finding more areas that got me just give us a little more detail on that. Then, the other question was, what was the key product that was ordered so much in differently was it Zyprexa? Or was it all the products?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Mark, this is Derica. With regard to update our restructuring. As it relates to our $1 billion cost savings go, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And then in addition",218,"Mark, this is Derica. With regard to update our restructuring. As it relates to our $1 billion cost savings go, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And then in addition to that, on the headcount front, we've talked about reducing our headcount including strategic acquisitions to strategic investments by about 5,500. We are about 75% of our way to that goal as well. So both of those we anticipate meeting by the end of the year, if not exceeding. As it relates to other additional insights, you know, I think that we have instruments and tools like Six Sigma that we've been utilizing since 2004, where as we approach the end of the year of 2011, that's not going to be the end of our efforts to drive further efficiency gains throughout our business. We know that our pattern challenges don't go away at the end of '11. So I think there'll be further opportunity. How much? I'm not prepared to define that for you guys here today. But recognize, we believe that we will have the capacity to make the investments necessary in our pipeline, as well as sustained dividend. And that is all predicated to this year. Jill?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In terms of the sales, product orders in Japan. The sales were actually increased across the board driven by Cymbalta, Forteo and Alimta.",23,"In terms of the sales, product orders in Japan. The sales were actually increased across the board driven by Cymbalta, Forteo and Alimta."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Chris Schott with JPMorgan.",12,"We have a question from the line of Chris Schott with JPMorgan."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","My quest mentioned was a quarterly progression of gross margin. And I can get a viable to quarter-over-quarter on your gross margin. So those of you more clarity on the progression this year. I guess base on your guidance here that is some somewhere betwe",136,"My quest mentioned was a quarterly progression of gross margin. And I can get a viable to quarter-over-quarter on your gross margin. So those of you more clarity on the progression this year. I guess base on your guidance here that is some somewhere between 77%, 78% for the rent of this year but I would -- a disproportionate hit from FX, and then also, just what it is made a meaningful job in the fourth quarter gross margins is a generic Zyprexa impact ramps the second question, just the also just with the bamboo walk through the timeline Phase III program. And that answer would also touch on an incremental data that might be requested by the FDA to address somebody they see any chichi data points that may be included that Phase III program."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay Chris, I'll go ahead. Let me start with a mGlu2/3 first. We don't have with us the specific time of the trial. But I would think -- right to mention the presentation over this year of the six-month safety data. We'll have probably late this year, the",265,"Okay Chris, I'll go ahead. Let me start with a mGlu2/3 first. We don't have with us the specific time of the trial. But I would think -- right to mention the presentation over this year of the six-month safety data. We'll have probably late this year, the best maybe early next year. The opportunity to present the 12 month to safety data from that child. So that's going to be the next major data readout that I would point you to for mGlu2/3. And then in terms of the gross margin percent dynamics. With the strengthening of foreign currency seer the first quarter particularly of the euro, we would expect that for the full year, we have a substantial additional cost booked to cost of sales from this FX impact on international inventory sold. If you recall, there was some pretty different dynamics last year, quarter-by-quarter. But the best thing I can do is point you to Slide 17 in the supplemental portion of our slide deck for the day, where at the bottom, you'll see for each discreet quarter, how much FX affected gross margin in those particular quarter is for the year. At a high level, we have a modest benefit the cost of sales booked to Q2 last year, a significant benefit to cost of sales booked in Q3. So at current rate, if you have a very unfavorable compare until the Q3 number. And then actually we've put them to having a modest division booked to cost of sales in the fourth quarter. Hope that helps. Brad, next call please."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","You had a question about Zyprexa and its impacts on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our gro",50,"You had a question about Zyprexa and its impacts on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our gross margin."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a final question from the line of Damien Cameron with Goldstar.",14,"We do have a final question from the line of Damien Cameron with Goldstar."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","The question, I just wanted to follow-up on the comment on acquired products coming from the animal into the animal health division industry average margins. Can you just remind us what those margins are? And also, how Lilly's margins in the animal health",50,"The question, I just wanted to follow-up on the comment on acquired products coming from the animal into the animal health division industry average margins. Can you just remind us what those margins are? And also, how Lilly's margins in the animal health business stock up into the industry average?"
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","So industry average is, if you look at kind of a higher level with what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing costs. So we're slightly off from the bottom line. So the industry average is some",248,"So industry average is, if you look at kind of a higher level with what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing costs. So we're slightly off from the bottom line. So the industry average is somewhere on the margin line between 20% and 25%. So Janssen is in that lower on in that range. We would be in that range as well. When you step back and look at the business though, I think why we're quite excited about going forward. First, Janssen does give us more of a global footprint, gives us more capability inside of Europe. As well, as we got a hundred pending registrations so different products across all the countries internationally. It was a very or can business we're going to take global. And then kind of a macro level, how we're going to continue to see margin improvement and above industry growth rate in Elanco is just looking at the three big areas in animal health, there's higher margin, companion animals, we're about 10%, the industry is at 40%; Europe, we're about 10%, 11% exactly. And the industry is about 30%; and vaccines we're very small with our Pfizer acquisition and the industry is about 25%. So we see tremendous upside at higher-margin areas in these three segments. So that's what gives us a lot of optimism and growth as we go forward the next three to five years in Animal Health."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Having exhausted the callers on the line, I'll go ahead and turn over to Derica to close our call for today.",21,"Having exhausted the callers on the line, I'll go ahead and turn over to Derica to close our call for today."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. First, I want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once aga",214,"Thanks, Phil. First, I want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once again, just so far this year, in 2011, it's playing out as we anticipated. We're clearly making progress in advancing our pipeline, standing at nine Phase III molecule versus our goal of 10 again of this year. I think our solid financial results is evident. And we continue to seek the countercyclical growth areas performing as we had anticipated as well. As I talked about Japan, Animal Health and our emerging markets. These are the things that's going to allow us to be able to weather the impact of the erosions at an emergence of product like Gemzar and Strattera going forward. But hopefully, you found this to be insightful. We look forward to seeing many of you at our Investor Meeting in New York City at June 30 and to our continued interactive throughout the year. Our IR team will be available to answer any questions that you guys may have at the conclusion of this call. I hope everyone has a great day. Take care."
285467,97242184,115441,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay today after 11:00 a.m. lasting through midnight on April 25. You may access the AT&T executive teleconference replay system at anytime by dialing 1(800)475-6701, entering the access code 1",69,"Ladies and gentlemen, this conference will be available for replay today after 11:00 a.m. lasting through midnight on April 25. You may access the AT&T executive teleconference replay system at anytime by dialing 1(800)475-6701, entering the access code 197298. International participants may dial 320-365-5844. That does conclude your conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service . You may now disconnect."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly and Co.'s first quarter 2011 earnings conference call. I'm Phil Johnson, Vice President of Investor Relations.Joining me today are our Chief Financial officer, Derica Rice; our President of Lilly Res",1009,"Good morning, and thanks for joining us for Eli Lilly and Co.'s first quarter 2011 earnings conference call. I'm Phil Johnson, Vice President of Investor Relations.
Joining me today are our Chief Financial officer, Derica Rice; our President of Lilly Research Laboratories, Dr. Jan Lundberg; our President of Elanco Animal Health, Jeff Simmons; and Ronika Pletcher; and Jill Thoren from Investor Relations. 
Today's Q1 earnings call coincides with our annual shareholder meeting. As a result, our CEO, John Lechleiter is not available to participate in today's call. 
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
Since the Q4 earnings call in late January, we've continued to bolster our operations through business development, to leverage our marketed products and to advance our pipeline. We announced our offer to acquire the Animal Health business of Janssen Pharmaceutica from Johnson & Johnson. This business is primarily European-focused, targeting disease segments in companion animals and livestock, with special emphasis on swine and poultry. Upon deal closing, which is expected by mid-year, we would obtain a portfolio of roughly 50 marketed Animal Health products. 
Here in the U.S., we began active promotion for Cymbalta for the management of chronic musculoskeletal pain and we launched Axiron, the first and only testosterone replacement therapy applied to the underarm. On the regulatory front, we submitted our response to the FDA's Complete Response Letter for the use of Erbitux in first-line head and neck cancer. 
We received a Complete Response Letter from the FDA for florbetapir, our PET imaging agent being studied for the detection of beta-amyloid plaque. We are working closely with the FDA to address their questions on the reader training program to ensure reader accuracy and consistency of interpretations of beta-amyloid plaque images. 
Late last week, we also received a Complete Response Letter from the FDA for liprotamase, a pancreatic enzyme replacement therapy, and we'll be working diligently to address the agency's questions.
In Europe, we submitted our application for the use of Alimta induction treatment followed by Alimta maintenance treatment in advanced nonsquamous, non-small cell lung cancer. And also in Europe, we recently received the CHMP recommendation for approval of Bydureon for the treatment of type 2 diabetes. Based on this recommendation, we anticipate receiving EC approval by late June.
On the clinical front, we disclosed positive top line results for the Phase II trial of the once-monthly formulation of exenatide. We plan to meet with the regulatory authorities to determine next steps for this program. We also disclosed top line results of the Phase III DURATION-6 trial comparing Bydureon to the highest approved dose of Victoza. Bydureon demonstrated a robust reduction on HbA1c from baseline. However, it did not meet the primary endpoint of noninferiority to Victoza 1.8 milligram in the reduction of HbA1c. Additional data from the trial is planned to be disclosed at a later date. And we began the first Phase III trial for our mGlu2/3 prodrug for schizophrenia. 
Lastly, on the legal front, Lilly received a favorable ruling on the Cymbalta patent challenge. Wockhardt voluntarily consented to entry of judgment in favor of Lilly on all pending issues, which the judge so ordered. The judge asked the remaining parties to indicate if they intend to proceed to trial and all nine defendants failed to indicate that they intend to proceed. As a result, we remain of the view that there will be no generic duloxetine product coming to market until the Cymbalta patent expires. However, a trial date remained on the court's docket for June of this year. A meeting with the court, Lilly and the defendants will be held later this month to determine next steps in this litigation.
While not specific to Lilly, perhaps one of the most notable events since our last earnings call was the disaster in Japan caused by the March 11 earthquake and its aftermath. Because Japan is such a big part of our growth strategy, I'd like to provide you with some details. First and foremost, we were relieved that within hours we were able to account for the safety of all Lilly Japan employees. We're also proud of the support, both monetary and product donations that Lilly Japan, the Lilly Foundation and Eli Lilly & Co. have provided to help those affected by this strategy. 
From a business perspective, our Japanese affiliate headquarters and development center of excellence are located in Kobe, and we have a manufacturing plant in Seishin just outside of Kobe. These operations are approximately 500 miles southwest of the disaster zone. As a result, we had no damages or other issues at these sites.
In terms of product supply, we've encountered no issues getting manufacturing products into or out of Japan. And we have not had and do not anticipate having any issue with the supply of raw materials, intermediate or finished product from our Japanese suppliers. Prior to the earthquake, we had robust inventory levels throughout our supply chain for materials sourced from Japan. 
In terms of domestic sales, we did receive what appeared to have been precautionary orders from customers totaling $30 million to $35 million in the quarter. We expect that this will wash out in future quarters. 
Our thoughts are with the Japanese people in what will surely be a long and difficult recovery. We'll continue to provide them our support, and we'll continue to ensure that Lilly products reach the patients who need them. 
Now at this background, Ronika will discuss our Q1 financial results and provide our pipeline update, and Derica will cover key events for the remainder of 2011 and our financial guidance for the year. Ronika?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on our previous calls, we'll focus our comments on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairment",1027,"Thanks, Phil. As we've done on our previous calls, we'll focus our comments on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. I'll start on Slide 7 with a quick look at our Q1 income statement.
On a non-GAAP basis, you can see that we generated solid revenue growth of 6% this quarter. Excluding Gemzar outside of Japan and the effect of the U.S. health care reform, revenue would have grown 10%. Gross margin as a percentage of revenue increased slightly from 79.5% to 79.8%. 
Operating expenses defined as a sum of R&D and SG&A grew 10% this quarter. Drivers for the increase included: higher administrative expenses, driven by the pharmaceutical manufacturers fee associated with the U.S. health care reform and higher litigation expenses; higher marketing and selling expenses driven by o U.S. investments primarily in the emerging markets; and higher R&D expense due primarily to increased late-stage clinical trials expenses.
In addition, both SG&A and R&D expenses increased due to the BI [Boehringer Ingelheim] alliance. Excluding the effect of U.S. health care reform and the BI alliance, operating expenses would have grown 7%. Other income and deductions was a net expense this year compared to net income last year. You may remember that we had substantial income in Q1 2010 related to the recovery of damages from generic olanzapine marketers in Germany and from gains on the sales of securities acquired in the ImClone acquisition. 
Our tax rate was 20.9% this quarter, considerably lower than 27.3% from last year's Q1. Last year's Q1 rate included an $85.1 million charge related to the future taxation of the retiree drug subsidy and did not benefit from the R&D tax credit as it had left. This year, we did benefit from the R&D tax credit, as well as from the resolution of certain IRS tax matters. 
At the bottom line, our non-GAAP EPS increased 5% to $1.24. As indicated, Lilly provided the 2011 guidance in January, we felt robust EPS growth in our business in Q1 excluding U.S. health care reform, the effect of the Gemzar patent exploration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would have grown low double digits. 
Slide 8 shows our reported income statement while Slide 9 provides reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now let's look at how foreign exchange affected our Q1 revenue. As you can see on Slide 10, total revenue growth of 6% was driven by solid volume growth of 5% and foreign exchange contributing the remaining 1%. Price had no impact on the worldwide revenue growth. We continue to see strong volume growth from our three countercyclical growth engines: Japan, Elanco Animal Health and Emerging Markets. 
Volume growth in Japan was 34% driven by recent launches of Cymbalta and FORTEO, as well as continued strong growth of Alimta, Zyprexa, Gemzar and Humalog. In addition, roughly 1/4 quarter of the Q1 volume growth was attributable to precautionary buying Phil mentioned earlier; Elanco Animal Health volume growth of 25% in Q1 driven by the increased demand for food animal products globally, as well as by the launch of Trifexis in the U.S. and the acquisition of certain European Animal Health assets from Pfizer. 
Going forward, we expect Animal Health revenue growth to benefit from international launches of Comfortis. In addition, Elanco has a robust innovative pipeline and is poised to maintain double-digit growth in the coming years with launches expected in multiple products targeting high-value markets such as livestock immune enhancements, control of parasites in companion animals and pain control. We also built a substantial development capability in Animal Health vaccines, and as demonstrated by our recent offer to acquire Janssen's Animal Health business, we will continue to look externally for opportunities to drive growth in this business. 
Finally, you'll see strong 14% volume growth from our Human Pharma [Human Pharmaceuticals] products in the rest of the world lines. Emerging market countries represented about 3/4 of the sales in Q1, and as a group also registered 14% volume growth. In terms of products, growth in emerging market countries was driven by Alimta, Cymbalta, Humalog and Humulin. In terms of geographies, we saw robust growth across the host of geographies in Asia, Latin America and of course, China. 
Given the very small effect of foreign exchange on our results this quarter, we provided our summarized non-GAAP and reported income statements with and without the effect of foreign exchange in our supplementary slides.
Now before I turn the call over to Derica, let me provide a brief update on our pipeline. On Slide 11, you'll find a view of our portfolio of new molecular entities in clinical development as of April 11, inclusive of changes since our January 27 earnings call. 
Our clinical stage portfolio now stands at 69 distinct NMEs including 31 compounds in Phase II and Phase III. Biotechnology will represent nearly half of our late-stage Phase II and Phase III assets in over 1/3 of our overall clinical portfolio. Advancing our pipeline remains our number one priority, as reflected by the arrows on Slide 11. Since our January update, we have began Phase III testing of mGlu2/3 for schizophrenia, bringing our total Phase III portfolio to nine NMEs. We continue to be on track to meet our goal of having 10 NMEs in Phase III by the end of the year. Other molecules that could begin Phase III in 2011 include our novel basal insulin analogs, our new insulin glargine product and our IL-17 antibody. 
We also advanced two molecules into Phase II and two into Phase I. Finally, both tasisulam and IL-1 antibodies continued earlier stage development after we terminated clinical trials in their lead indications, and we terminated one molecule in Phase I development.
With this current pipeline and our continued business development effort, our goal is still to launch on average two molecular entities per year beginning in 2013 providing a foundation for future growth. Derica?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now received the CHMP recommendation for approval of Bydureon, we look forward to launching the product",839,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now received the CHMP recommendation for approval of Bydureon, we look forward to launching the product in Europe later this year. We have a number of other potential regulatory approvals this year including: linagliptin in the U.S., Europe and Japan; and here in the U.S., Cialis for DPH, Byetta in combination with basal insulin and Erbitux for first-line head and neck cancer.
Expected regulatory submissions include: our response to the FDA Complete Response Letter for Bydureon; sBLA for Erbitux in first-line metastatic colorectal cancer and for first-line, non-small cell lung cancer; Byetta in combination with basal insulin in Europe; and our response to the FDA Complete Response Letter for Amyvid. 
Upcoming clinical trial data disclosures include initial results from the Phase III trial of Alimta induction treatment followed by Alimta maintenance treatment in advanced nonsquamous, non-small cell lung cancer at ASCO. At the EULAR meeting in London in May, we will present data on the two Phase II trials of our BAFF antibody and rheumatoid arthritis. And lastly, data from a study assessing the safety of Cialis when co-administered with alpha blockers will be presented in May at the American Association of Urology meeting in Washington. 
Just late last month, data from the clinical trial evaluating tadalafil in men with ED and with signs and symptoms of BPH was presented at the European Association of Urology.
Finally, as mentioned earlier, Phase III trials could begin this year for our novel basal insulin analog and our new insulin glargine product and for our own anti-IL-17 antibody. 
In terms of our 2011 financial guidance. As you've seen in our press release, we still expect 2011 non-GAAP earnings per share of between $4.15 and $4.30. Our 2011 reported EPS guidance range of $3.86 to $4.01 reflects a $0.23 IPR&D charge from the BI alliance and the $0.06 restructuring charge. 
The business fundamentals underlying our guidance are essentially unchanged since our last update in January. However, a number of foreign currencies, in particular, the euro, have appreciated in recent months. As a result, we're updating our revenue growth and gross margin percent guidance. Assuming rates remain at current levels, we now expect 2011 revenue to grow in the low single digits. And we expect 2011 gross margin as a percent of revenue to decline by approximately 3 percentage point. 
Also, we're now estimating that the 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. Both of these rates reflected benefit from the resolution of certain IRS audit matters. In addition, the reported tax rate for the full year reflects the tax benefit of the in-process R&D charge associated with the BI alliance. All other elements of our line item guidance remain unchanged.
Now Slide 14 provides a reconciliation between reported and non-GAAP EPS for 2010 And the associated growth rate from these numbers to our revised 2011 guidance. 
Now in summary, so far, 2011 is playing out as anticipated. We're making progress advancing our pipeline, and we're delivering solid financial results. With the initiation of Phase III trials for mGlu2/3 for schizophrenia, we now have nine molecules in Phase III development, putting us on track to meet our goal of having 10 molecules in Phase III development by the end of this year, with more coming behind. Along with continued business development, this pipeline serves as the foundation of our growth post years ZY.
During Q1, we also made progress on our productivity goals and are in tract to meet our 2011 headcount and expense containment goals. When we discussed our 2011 guidance in detail on the January call, I shared that we face a number of headwinds this year, as patent expirations will lower sales outside of Japan for first for Gemzar and later for Zyprexa. U.S. health care reform will exact a higher cost this year than it did in 2010, and we'll face some near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. 
I also shared that we expect to see continued strong performance in the rest of our business. We did see the negative impact in Q1 of these items, and we delivered strong growth in the rest of our business as promised. Excluding these items, on a non-GAAP basis, we posted revenue growth of 10%, operating expense growth of 7% and low double-digit EPS growth. We saw robust revenue growth from our three countercyclical growth engines with Japan growing 41%, Elanco growing 28% and Emerging Markets growing 15%.
Moving forward, we will continue to focus on: delivering strong financial results, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline, and on speeding the next generation of Lilly molecules to market to provide growth post Years YZ. 
This concludes our prepared remarks. And now we open the call for the Q&A session. Operator, first caller please?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. Derica, a question for you on Bydureon and congratulations getting CHMP approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results. And then also",116,"Thank you. Derica, a question for you on Bydureon and congratulations getting CHMP approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results. And then also included in the recommendation for approval was a pharmacovigilance program and I'm wondering if you can elaborate on that. And just lastly, just to switch gears here on the gross margin, the delta in the gross margin, the delta in terms of your new guidance for the full year reflect a $0.17 hit, and I'm wondering if that is all related to foreign currency or is there cushion related to Zyprexa going generic. Thanks."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Jan, you may want to deal with the pharmacovigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to dis",118,"Sure. Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Jan, you may want to deal with the pharmacovigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to disclose what our pricing strategy would be behind this brand before we've even launched it. But what I can say is we still feel very confident in the commercial prospects for Bydureon given the label that we would anticipate. As it relates to your growth margin question, regarding FX, it is all attributable to FX rate and in terms of our revised guidance of minus 2 percentage points to minus 3 percentage points decline."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to risk management for Bydureon, of course, we have safety very high on the agenda, and we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need and partic",58,"In relation to risk management for Bydureon, of course, we have safety very high on the agenda, and we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need and particularly looking for if there are increase in pancreatitis, thyroid tumors, et cetera."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmacovigilance plan, those are things we'll need to wait comment on until the EC provides its formal approval of th",194,"A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmacovigilance plan, those are things we'll need to wait comment on until the EC provides its formal approval of the CHMP recommendation, which we expect to come hopefully in late June. And then in terms of pricing, do keep in mind that the DURATION-6 trial was against the 1.8 milligram dose of Victoza. Rough numbers in many of the European numbers, it would appear that the 1.2 was launched at roughly parity to Byetta, which means that the 1.8 would be the substantial premium. So as we enter those discussions with pricing authorities in Europe, we'll be looking at the full raft of DURATION trials where we have very strong data against insulin glargine, against ACTOS, against Januvia and against Byetta, all of which have a price that's out in the marketplace. And then as you're mentioning, Jami, we'll also have the DURATION-6 data against the 1.8 milligram dose of Victoza that we'll enter into those discussions as well. So again, as Derica said, a very strong overall package."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Sanford Bernstein.",13,"Our next question comes from the line of Tim Anderson with Sanford Bernstein."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in the Animal Health or other",96,"Thank you. On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in the Animal Health or other areas that might provide you with a greater level of diversification? And then on solanezumab, can you narrow down the timing of when we'll likely see results and also where you are with the interim looks and whether you'll announce one of those -- well, once those interim looks have been completed?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay, great. Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And maybe you and Jeff can comment respectively on the general and then Animal Health acquisition landscape. And then Jan and Ronika,",50,"Okay, great. Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And maybe you and Jeff can comment respectively on the general and then Animal Health acquisition landscape. And then Jan and Ronika, maybe the solanezumab update would be great."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset, both top line, as well as bottom line. In regards to this development, we continue to be active in this space. But I think we've been a",137,"Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset, both top line, as well as bottom line. In regards to this development, we continue to be active in this space. But I think we've been also very clear about our intent. We're not in the market for large-scale M&A, but we are looking for opportunities to continue to enhance our business both from the standpoint of either finding molecules that complement our development pipeline portfolio or finding those product opportunities that we can bring in that bring sales and cash with it. And then, that's clearly what we also saw as we looked at the Janssen acquisition in terms of Animal Health, a way of bolstering our Animal Health business with Jeff can respond to further."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, Tim, I would say we'd made four acquisitions in four years, Lilly has, and it's all playing around this countercyclical growth engine that was made in the comments. We will continue to be opportunistic. But it really has to drive three things: one is",115,"Yes, Tim, I would say we'd made four acquisitions in four years, Lilly has, and it's all playing around this countercyclical growth engine that was made in the comments. We will continue to be opportunistic. But it really has to drive three things: one is growth; strategically, it has to drive growth; diversity; and bring capability. And I would say all four acquisitions in the past have done that. That's what we'll continue to look for as we go forward. Although the organic growth that we see over the next 2 or 3 years in Animal Health is going to be significant with six new launches this year and more launches to come in 2012."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to solanezuma, our A-beta antibody and to stop progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we w",51,"In relation to solanezuma, our A-beta antibody and to stop progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we will disclose the data at an appropriate event."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","One of the thing I'd add, Tim, you see we had, in an effort to give you guys some more exposure to -- of operational heads of our various areas of the company, Enrique, on the call last quarter, Jeff this quarter. We'll likely have Jacques Tapiero, Head o",111,"One of the thing I'd add, Tim, you see we had, in an effort to give you guys some more exposure to -- of operational heads of our various areas of the company, Enrique, on the call last quarter, Jeff this quarter. We'll likely have Jacques Tapiero, Head of our Emerging Markets area on next quarter. That is an area in Emerging Markets countries where on your question of M&A probably for the last 24 months or so, we've seen pricing very high frankly, and more likely you'll see things that are of the collaboration and licensing in the short term until those trends reverse in the Emerging Markets properties."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Gregg gilbert with Merrill Lynch.",13,"Our next question comes from the line of Gregg gilbert with Merrill Lynch."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your GLP-1 to move it into Phase III?",98,"Thank you. Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your GLP-1 to move it into Phase III? What was the bar there? With any specifics you care to share? And thirdly, more strategically, should we view the Avid acquisition as a sign of things to come for Lilly or more as a one-off that will take you some time to assess before you really answer that question for yourselves?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Derica take your first and third questions, Gregg. Then we'll go ahead and handle the GLP question you asked as well.",24,"We'll have Derica take your first and third questions, Gregg. Then we'll go ahead and handle the GLP question you asked as well."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Gregg, we actually had -- we saw two types of activities that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as best as we can tell, even at the retail lev",222,"Gregg, we actually had -- we saw two types of activities that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as best as we can tell, even at the retail level as well in the first quarter. So that destocking served to dampen our revenue growth in the U.S. in Q1. At the same time, given the disaster that we all witnessed in Japan, we saw a buy-in on the part of wholesalers or distributors there in the case of emergency. And that buy-in Japan was probably in the range of around $30 million to $35 million in the quarter. So it was -- of the 41% of Japan growth that we saw in the quarter, about 25% of that was related to this buy-in. As it relates to your third question around the Avid acquisition -- just a reminder to everyone, when we did the Avid acquisition, it was solely based upon the prospect of that compound itself. And our thesis behind that is that we saw an interesting therapeutic that could complement our portfolio. Clearly as that plays out, it gives us an opportunity to ponder other alternatives. But for right now, we're planning and progressing as though it's around Avid itself."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Now regarding to your second question, Gregg. You mentioned GLP moving into Phase III, we actually moved GLP into Phase III quite a while ago. I think you may have meant to say mGlu2/3, in which we moved into Phase III in this past quarter. If that is you",106,"Now regarding to your second question, Gregg. You mentioned GLP moving into Phase III, we actually moved GLP into Phase III quite a while ago. I think you may have meant to say mGlu2/3, in which we moved into Phase III in this past quarter. If that is your question, I'm going to actually turn the call over to Jan to give some more clarity. But we actually presented some 6-month safety study data at the beginning of April at the ICOSR meeting, the International Congress for Schizophrenia Research, which discharged some of the risk. But again, I'll turn it over to Jan to answer further."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thank you. The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 agonist as our optional treatment for these patients. The study mention",134,"Thank you. The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 agonist as our optional treatment for these patients. The study mentioned discharged the risk in relation to seizures as we see it in relation then to standard of care. It's known that patients with schizophrenia do have an increased risk of seizures, but our agents did not seem to have any more effects than standard of care. And we should remember there are some potential clear advantages with our mGlu2/3 agent, less risk for extrapyramidal symptoms and also it has a much better metabolic profile in relation then to a typical antipsychotics, even with with a potential weight loss, not the weight gain."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Jan. And lastly, Gregg, on the U.S. piece just to put some numbers around what Derica had mentioned, each year we typically would end within the guidelines we have with the wholesaler, at the higher end of the days on hand, the wholesalers, the en",91,"Thanks, Jan. And lastly, Gregg, on the U.S. piece just to put some numbers around what Derica had mentioned, each year we typically would end within the guidelines we have with the wholesaler, at the higher end of the days on hand, the wholesalers, the end of the calendar year, and we typically come down in Q1. That was the case both in 2010 and in 2011. However, the decline was a bit steeper in 2011 and that would have trimmed about 1 percentage point off of the U.S. growth rate."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger from Morgan Stanley.",13,"Our next question comes from the line of David Risinger from Morgan Stanley."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks very much. I have a couple of questions. First, I missed the beautiful question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to solanezumab",120,"Thanks very much. I have a couple of questions. First, I missed the beautiful question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to solanezumab, I think that Jan mentioned that there is a futility analysis this year. Could you please comment on whether that's in the first half or such that you'll be able to comment on at your June 30 analyst meeting or not until the second half? And then third, with respect to your long-term earnings outlook, Derica, do you expect to communicate that at the June 30 analyst meeting or prior to the meeting on a separate call? Thank you."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. David, I'll take your first and third questions. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance or construct that we put out there in December of",73,"Okay. David, I'll take your first and third questions. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance or construct that we put out there in December of '09, David, I would see ourselves coming back to that at our June analyst meeting. I don't anticipate us giving any more color on that prior to our June meeting."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the timing of the futility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that this safety profile so far in these trials look better than for semagacestat, and they're actually l",56,"In relation to the timing of the futility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that this safety profile so far in these trials look better than for semagacestat, and they're actually less patients that have stopped the trial because of safety disease."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Steve Scala with Cowen.",12,"Our next question comes from the line of Steve Scala with Cowen."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. I have two questions again on solanezumab. How is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group? And if that is the case, is that a risk for these trials? And then",73,"Thank you. I have two questions again on solanezumab. How is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group? And if that is the case, is that a risk for these trials? And then second, when in 2013 might you file GLP Fc? Might it be a first half event or might it be a second half event? Thank you."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Well, I think I have said what I want to say about solanezumab, but we now need to wait for the data.",22,"Well, I think I have said what I want to say about solanezumab, but we now need to wait for the data."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","With regards to GLP FC, we have provided no specifics with regard to timing on filing. We have initiated all four award studies. So we're pleased with the progress there, but no additional information on timing.",36,"With regards to GLP FC, we have provided no specifics with regard to timing on filing. We have initiated all four award studies. So we're pleased with the progress there, but no additional information on timing."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a question from the line of John Boris with Citi.",13,"We do have a question from the line of John Boris with Citi."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks for taking the questions. First question for Derica, on the Animal Health business with Janssen. Can you -- just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China",125,"Thanks for taking the questions. First question for Derica, on the Animal Health business with Janssen. Can you -- just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China in particular and your diabetes franchise there. I think the New England Journal of Medicine cited that there's about 92 million diabetics there and your market share relative to your competition is a little bit lower than your competition? What are you going to remedy that potentially going forward? And then one question for Jan, within the 2013 time period, aside from GLP-1 Fc, what are the other one or two assets that might be positioned for launch at that time?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and the size of the Janssen business. And then with Derica on the China diabetes question. And then on to Jan.",40,"Okay. Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and the size of the Janssen business. And then with Derica on the China diabetes question. And then on to Jan."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, so we have Janssen is represented in the Vetnosis, the actual independent health data that's tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which is abou",90,"Yes, so we have Janssen is represented in the Vetnosis, the actual independent health data that's tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which is about $25 million, their distributor sales. So it represents a little bit level that's higher than what really Janssen and we will recognize. So that number is a little bit high. And then the actual margins would be very much average for the industry in Animal Health."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. John, in regards to China, as I stated -- well, actually with the time of interview this morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly have a smaller share of mark",194,"Okay. John, in regards to China, as I stated -- well, actually with the time of interview this morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly have a smaller share of market position versus our competition, we have taken decisive actions to improve our competitive position going forward. We've recently commissioned a new diabetes research facility in operation there. In addition to that, we are actually -- we commissioned also building a second manufacturing facility in China, which will be diabetes-related as well. And then thirdly, we've more than doubled the size of our commercial footprint. So we believe that we are positioned ourselves to take advantage of this significant opportunity in that marketplace. And we see ourselves with the opportunity gain share. And partly the learning for that is also with what we've seen here in the U.S. So even in the market where you could say it's fairly saturated, in the U.S., we've seen a significant uptick in our diabetes share of market both on an NRx and a TRx if you look at the last year."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, well, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two NME launches per year from 2013 should potentially come both from internal and in-licen",73,"Yes, well, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two NME launches per year from 2013 should potentially come both from internal and in-licensing or acquisitions. So those are three options. There are some programs with the right data that could deliver ahead of time. Potentially solanezumab could be one of them."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a question from Bert Hazlett from BMO Capital Markets.",12,"We do have a question from Bert Hazlett from BMO Capital Markets."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks. I have one question on Japan and another on the pipeline. First on Japan, you did have some buy-in but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Evista and Strattera. Could you discuss your expect",138,"Thanks. I have one question on Japan and another on the pipeline. First on Japan, you did have some buy-in but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Evista and Strattera. Could you discuss your expectations for growth and the potential kind of countercyclical nature in terms of additional product launches that would be coming down the road there? And then secondly, in terms of the pipeline for Jan, I see you're moving the IL-17 program forward in rheumatoid arthritis. But my count is this will be at least the third program in our RA. You have the orals JAK1/JAK2. You have the anti-BAFF antibody NRA and now the IL-17. Could you talk about its positioning in RA and vis--vis the BAFF antibody in particular? Thank you very much."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Bert, this is Ronika. With regards to Japan and launches, you might remember earlier in the decade, we had mentioned -- early last decade, we had mentioned that our goal was to launch a lot of the products we had not yet launched in Japan that had already",147,"Bert, this is Ronika. With regards to Japan and launches, you might remember earlier in the decade, we had mentioned -- early last decade, we had mentioned that our goal was to launch a lot of the products we had not yet launched in Japan that had already been launched in the U.S. And those include several that you mentioned Alimta and Strattera, which launched in 2009, as well as Cymbalta, FORTEO, Byetta that also launched in Japan in 2010. Also keep in mind, part of the countercyclical nature of Japan includes the fact that we have Zyprexa in Japan through 2015. So products that could also be launched in the near term in Japan include our partnership with BI, specifically, linagliptin. It's a potential launch in Japan in 2011 or approval, I should say, in 2011. So those are the highlights with regards to Japan. Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, we are very excited about our opportunities in rheumatoid arthritis and the autoimmune area in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1/JAK2 inhibitor partnered with Incyte could be",234,"Yes, we are very excited about our opportunities in rheumatoid arthritis and the autoimmune area in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1/JAK2 inhibitor partnered with Incyte could be I think a very competitive agent in relation to Pfizer's recent Phase III agent which have received so much attention, tofacitinib, with a positive recent data. We are currently exploring them, the JAK1/JAK2 component Phase IIb in relation to those safety and efficacy. Oral agents will be placed earlier most likely than in the treatment of rheumatoid arthritis, completing with methotrexate as a key initial agent. Our two biologicals, the anti-BAFF and IL-17 represents very novel agents with new mechanism to influence then the immune system; the BAFF against that B-cells and the IL-17 more as an inflammatory cytokine that is released. And both of these agents have positive Phase II data in rheumatoid arthritis, and they will be positioned then in patients that actually are failing to TNF. And we know that there is substantial proportion of patients, up to 50%, that don't respond well enough to TNF blockers. And even if you then can switch to another TNF agent, the efficacy goes away with time. So we see both the BAFF and the IL-17 as potential new treatment options in actually quite a large patient populations that have been failing TNF agents."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Bert, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion mark, so we surpassed the $1.5 billion. That's a business that we believe we can double the size of that bu",170,"Bert, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion mark, so we surpassed the $1.5 billion. That's a business that we believe we can double the size of that business over the next four to five years. And you look at, as Ronika said, you got brands like Cymbalta, Zyprexa through '15 and Alimta, but you're also seeing the impact of the recent launch of FORTEO as well as the continued growth around Alimta, Humalog and Gemzar. So that gives you some idea of what we're expecting in terms of that countercyclical growth engine we've been talking about along with Emerging Markets, as well as Elanco that's helping to mute the impact of patent expirations like Gemzar in Q1 and later Zyprexa this year. And I would still remind everyone that we -- top line grew 6%, 5% volume and that includes the impact of the generic erosion for Gemzar in the quarter."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","And the generic erosion of Gemzar shaded about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact.",29,"And the generic erosion of Gemzar shaded about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Seamus Fernandez with Leerink Swann.",13,"We have a question from the line of Seamus Fernandez with Leerink Swann."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks very much. So just a couple of quick pipeline questions. Can you just update us on linagliptin and whether or not Lilly expects to -- that panel to be fielded for the product prior to approval? It looks like there won't a panel on this drug. And ma",140,"Thanks very much. So just a couple of quick pipeline questions. Can you just update us on linagliptin and whether or not Lilly expects to -- that panel to be fielded for the product prior to approval? It looks like there won't a panel on this drug. And maybe just give us your reasons specifically for that. Second, you've moved a CETP inhibitor forward, I believe or have a CETP inhibitor in Phase II in atherosclerosis. Can you just update us on your thoughts with regard to that mechanism and what you believe is necessary to move that product into Phase III safely? And then the last question is actually, can you just update us on the status of necitumumab? I believe one of the studies there was actually placed on clinical hold, so just looking for an update there."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. In relation to our DPP-4 inhibitor in linagliptin together with Boehringer, that was filed last year and we have no further comment, I think, on dates and potential advisory board, et cetera. We see this agent as a very promising oral anti-diabetic",194,"Okay. In relation to our DPP-4 inhibitor in linagliptin together with Boehringer, that was filed last year and we have no further comment, I think, on dates and potential advisory board, et cetera. We see this agent as a very promising oral anti-diabetic compound that complements our offering to patients, making Lilly very broad, if not the broadest offering in the whole therapeutic area of diabetes across major pharma. We are quite enthusiastic about our CETP inhibitor, which now are in Phase II trials, in combination with statins. We based this on our Phase I data but also, we're actually at the clause of the competitor molecules both from Merck and Roche, as you know are moving ahead with Phase III trials. We feel we have a competitive agent based on what we have seen so far, what area is then to avoid the problems that Pfizer had with the torcetrapib, mainly the increasing blood pressure. We have not seen this for our compound, and we are enthusiastically moving it forward, I think, we can say currently. At necitumumab, we are still pursuing this claim as non-small cell lung cancer indication in Phase III."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Catherine Arnold from Credit Suisse.",13,"Our next question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. One, I wanted to ask you about your U.S. price increase if it had not been for health care reform impacts. And then I wanted more specifics, you guys have given numbers about the effect of the overall reform, but I wasn't clear of w",142,"A couple of questions. One, I wanted to ask you about your U.S. price increase if it had not been for health care reform impacts. And then I wanted more specifics, you guys have given numbers about the effect of the overall reform, but I wasn't clear of whether what you said included doing it whole, or how you're going to be recording those? Is this going to be as those discounts are demanded of you? Are you sort of accruing an expectation across four quarters? And then on solanezumab, I wanted to just ask one more question that hasn't been asked yet, which is as far as when the pre-specified analysis is done at the end of the trial, is there going to be severity of disease stratification in the pre-specified analysis in addition I would presume to carrier and non-carrier."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Derica will handle the first two and then Jan the last one solanezumab?",14,"Okay. Derica will handle the first two and then Jan the last one solanezumab?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Catherine, this is Derica. I think you're aware of what the dollar impact of health care reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece,",115,"Sure. Catherine, this is Derica. I think you're aware of what the dollar impact of health care reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece, which was, we believe, the health care reform impact will be in the range of $400 million to $500 million, that includes the impact of -- the anticipated impact of the doughnut hole. And then as you recall, the pharmaceutical excise fee will then impact us in the administrative OpEx line. And that's being to the tune of about $150 million to $200 million for the year."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. The primary endpoint here is clearly reducing the disease progression, and we will look at mutation status as a secondary opportunity.",39,"Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. The primary endpoint here is clearly reducing the disease progression, and we will look at mutation status as a secondary opportunity."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","A couple of additional comments maybe, Catherine, the $90 million impact of U.S. health care reform on revenue this quarter, if you're looking at the impact on the growth rate, do recall that we had said approximately $60 million was the impact to revenue",238,"A couple of additional comments maybe, Catherine, the $90 million impact of U.S. health care reform on revenue this quarter, if you're looking at the impact on the growth rate, do recall that we had said approximately $60 million was the impact to revenue in Q1 of 2010. I think if you look in the Q, you'll actually find it was $62.4 million was the number. So it turned about 1 percentage point off of the U.S. revenue growth rate, about 0.5 percentage point off of the worldwide growth rate for the quarter. And then in terms of the doughnut hole, I think there may be different practices at the various companies. You may; want to check on this. But essentially for the doughnut hole, we've done our best to try to model. We think we'll actually be occurring. In other words, the charge that we would have recognized in Q1 would assume that a whole host of people would not yet have hit the doughnut hole during this quarter. And if you look at approximately $90 million for the year and compared to $400 million to $500 million for the year, you'll see that assumes a bump-up in Q2 through 4 compared to Q1. That bump-up is due to the higher expected charge that we'll be recognizing for the doughnut hole, as more seniors and Medicare hit that part of the benefit from U.S. health care reform."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Yes, Derica, can you give us a little more flavor of what's going on on the restructuring? How much has been done so far? Where's the impact and how much more there is? And as you've gotten in there to cut cost, does it -- are you finding more areas to cu",90,"Yes, Derica, can you give us a little more flavor of what's going on on the restructuring? How much has been done so far? Where's the impact and how much more there is? And as you've gotten in there to cut cost, does it -- are you finding more areas to cut? And just give us a little more detail on that. And then the other question was, what was the key product that was ordered so much of in Japan? Was it Zyprexa? Or was it all the products?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Mark, this is Derica. In regards to update our restructuring, as it relates to our $1 billion cost savings goal, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And in additi",219,"Okay. Mark, this is Derica. In regards to update our restructuring, as it relates to our $1 billion cost savings goal, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And in addition to that, on the headcount front, we've talked about reducing our headcount excluding strategic acquisitions and strategic investments by about 5,500. We're about 75% of our way to that goal as well. So both of those we anticipate meeting by the end of the year, if not exceeding. As it relates to other additional insights, I think that we have instruments and tools like Six Sigma that we've been utilizing since 2004, where as we approach the end of the year of 2011, that's not going to be the end of our efforts to drive further efficiency gains throughout our business. We know that our patent challenges don't go away at the end of '11. So I think there'll be further opportunities. How much? I'm not prepared to define that for you guys here today. But recognize, we believe that we will have the capacity to make the investments necessary in our pipeline, as well as sustaining the dividend. And that was all predicated on us to achieve this year. Jill?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In terms of the sales, product ordered in Japan. The sales were actually increased across the board driven by Cymbalta, FORTEO and Alimta.",23,"In terms of the sales, product ordered in Japan. The sales were actually increased across the board driven by Cymbalta, FORTEO and Alimta."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Chris Schott with JPMorgan.",12,"We have a question from the line of Chris Schott with JPMorgan."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Great. Thanks very much. My first question was on the quarterly progression of gross margins. I know we can get a lot of variability quarter-to-quarter in your gross margins. So I was just looking for a little bit more clarity on the progressions here. I",177,"Great. Thanks very much. My first question was on the quarterly progression of gross margins. I know we can get a lot of variability quarter-to-quarter in your gross margins. So I was just looking for a little bit more clarity on the progressions here. I guess, based on your new guidance, it looks like you have an average somewhere between 77%, 78% for the remainder of this year. I guess is there any one quarter that's going to be seeing a disproportionate hit from FX? And then also, just going -- it's an earlier question, are you anticipating a meaningful drop in fourth quarter gross margins as the generic Zyprexa impact ramps? Second question just was -- can you also just, with the mGlu, walk through the timeline and the scope of that Phase III program? And then answer, would you also touch on any incremental data that might be requested by the FDA to address some of the basic earlier seizure data points the products saw that might be included in that Phase III program? Thanks."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay, Chris, I'll go ahead and try -- let me start with the mGlu2/3 first. We don't have with us the specific timing for the trial. The one thing I would highlight is Ronika had mentioned, the presentation earlier this year of the 6-month safety data. We'",264,"Okay, Chris, I'll go ahead and try -- let me start with the mGlu2/3 first. We don't have with us the specific timing for the trial. The one thing I would highlight is Ronika had mentioned, the presentation earlier this year of the 6-month safety data. We'll have probably late this year, at the best maybe early next year, the opportunity to present the 12-month safety data from that trial. So that's sort of would be the next major data readout that I would point you to for mGlu2/3. And then in terms of the gross margin percent dynamics. With the strengthening of foreign currency here in the first quarter particularly of the euro, we would expect that for the full year, we have a substantial additional cost booked to cost of sales from this FX impact on international inventories sold. If you recall, there were some pretty different dynamics last year, quarter-by-quarter. Probably the best thing I can do is point you to Slide 17 in the supplemental portion of our slide deck for the day, where at the bottom you'll see for each discreet quarter how much FX affected gross margin in those particular quarters for the year. At a high level, we had a modest benefit to cost of sales booked Q2 last year, a significant benefit to cost of sales booked in Q3, so at current rates, you have a very unfavorable compare to the Q3 number. And then actually we've flipped then to having a modest addition booked to cost of sales in the fourth quarter. Hope that helps."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","And you had a question about Zyprexa and its impacts on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our",51,"And you had a question about Zyprexa and its impacts on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our gross margin."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a final question from the line of Damien Conover with the Morningstar.",15,"We do have a final question from the line of Damien Conover with the Morningstar."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Great. Jeff?",2,"Great. Jeff?"
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Yes, so industry average is, if you look at kind of at a higher level what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing cost. So we're slightly off from the bottom line. So the industry average",256,"Sure. Yes, so industry average is, if you look at kind of at a higher level what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing cost. So we're slightly off from the bottom line. So the industry average is somewhere on the margin line between 20% and 25%. So Janssen's on the lower end of that range, and we would be in that range as well. When you step back and look at the business though, I think why we're quite excited about going forward: First, Janssen does give us more of a global footprint, gives us more capability inside of Europe, as well as we've got a hundred pending registrations of different products across all the countries internationally. So it was a very European business we're going to take global. And then at kind of a macro level, how we're going to continue to see margin improvement. And above industry growth rates in Elanco is just looking at the three big areas: in Animal Health, where there's higher margin; companion animals, we're at about 10%, the industry is at 40%; Europe, we're at about 10%, 11% exactly, and the industry is about 30%; and vaccines we're very small with our Pfizer acquisition and the industry is about 25%. So we see tremendous upside at higher-margin areas in these three segments. So that's what gives us some -- a lot of optimism and growth as we go forward the next three to five years in Animal Health."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Great. Thanks. Having exhausted the callers on the line, I'll go ahead and turn it over to Derica to close our call for today.",24,"Great. Thanks. Having exhausted the callers on the line, I'll go ahead and turn it over to Derica to close our call for today."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. I first want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once agai",214,"Thanks, Phil. I first want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once again, just so far this year, in 2011, it's playing out as we anticipated. We're clearly making progress in advancing our pipeline, standing at 9 Phase III molecule versus our goal of 10 by the end of this year. I think our solid financial results is evident. And we continue to see the countercyclical growth areas performing as we had anticipated as well as I talked about Japan, Animal Health and our Emerging Markets. These are the things that's going to allow us to be able to weather the impact of the patent erosions of products like Gemzar and Strattera going forward. So hopefully, you found this to be insightful. We look forward to seeing many of you at our investor meeting in New York City on June 30 and to our continued interaction throughout the year. Our IR team will be available to answer any questions that you guys may have at the conclusion of this call. I hope everyone has a great day. Take care."
285467,97242184,115502,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","And ladies and gentlemen, this conference will be available for replay today after 11:00 a.m., lasting through midnight on April 25. You may access the AT&T Executive Teleconference replay system at anytime by dialing 1(800)475-6701, entering the access c",70,"And ladies and gentlemen, this conference will be available for replay today after 11:00 a.m., lasting through midnight on April 25. You may access the AT&T Executive Teleconference replay system at anytime by dialing 1(800)475-6701, entering the access code 197298. International participants may dial 320-365-3844. That does conclude your conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service . You may now disconnect."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 earnings conference call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly & Co. Q1 earnings conference call. [Operator Instructions] I would now like to turn the conference over to Vice President of Investor Relations, Mr. Phil Johnson. Please go ahead."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly and Co.'s First Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations.Joining me today are our Chief Financial officer, Derica Rice; our President of Lilly Res",1010,"Good morning, and thanks for joining us for Eli Lilly and Co.'s First Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations.
Joining me today are our Chief Financial officer, Derica Rice; our President of Lilly Research Laboratories, Dr. Jan Lundberg; our President of Elanco Animal Health, Jeff Simmons; and Ronika Pletcher; and Jill Thoren from Investor Relations. 
Today's Q1 earnings call coincides with our annual shareholder meeting. As a result, our CEO, John Lechleiter is not available to participate in today's call. 
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
Since the Q4 earnings call in late January, we've continued to bolster our operations through business development, to leverage our marketed products and to advance our pipeline. We announced our offer to acquire the Animal Health business of Janssen Pharmaceutica from Johnson & Johnson. This business is primarily European-focused, targeting disease segments in companion animals and livestock, with special emphasis on swine and poultry. Upon deal closing, which is expected by mid-year, we would obtain a portfolio of roughly 50 marketed Animal Health products. 
Here in the U.S., we began active promotion for Cymbalta for the management of chronic musculoskeletal pain and we launched Axiron, the first and only testosterone replacement therapy applied to the underarm. On the regulatory front, we submitted our response to the FDA's Complete Response Letter for the use of Erbitux in first-line head and neck cancer. 
We received a Complete Response Letter from the FDA for florbetapir, our PET imaging agent being studied for the detection of beta-amyloid plaque. We are working closely with the FDA to address their questions on the reader training program to ensure reader accuracy and consistency of interpretations of beta-amyloid plaque images. 
Late last week, we also received a Complete Response Letter from the FDA for liprotamase, a pancreatic enzyme replacement therapy, and we'll be working diligently to address the agency's questions.
In Europe, we submitted our application for the use of Alimta induction treatment followed by Alimta maintenance treatment in advanced nonsquamous, non-small cell lung cancer. And also in Europe, we recently received the CHMP recommendation for approval of Bydureon for the treatment of type 2 diabetes. Based on this recommendation, we anticipate receiving EC approval by late June.
On the clinical front, we disclosed positive top line results for the Phase II trial of the once-monthly formulation of exenatide. We plan to meet with the regulatory authorities to determine next steps for this program. We also disclosed top line results of the Phase III DURATION-6 trial comparing Bydureon to the highest approved dose of Victoza. Bydureon demonstrated a robust reduction in HbA1c from baseline. However, it did not meet the primary endpoint of noninferiority to Victoza 1.8 milligram in the reduction of HbA1c. Additional data from the trial is planned to be disclosed at a later date. And we began the first Phase III trial for our mGlu2/3 prodrug for schizophrenia. 
Lastly, on the legal front, Lilly received a favorable ruling on the Cymbalta patent challenge. Wockhardt voluntarily consented to entry of judgment in favor of Lilly on all pending issues, which the judge so ordered. The judge asked the remaining parties to indicate if they intend to proceed to trial and all nine defendants failed to indicate that they intend to proceed. As a result, we remain of the view that there will be no generic duloxetine product coming to market until the Cymbalta patent expires. However, a trial date remained on the court's docket for June of this year. A meeting with the court, Lilly and the defendants will be held later this month to determine next steps in this litigation.
While not specific to Lilly, perhaps one of the most notable events since our last earnings call was the disaster in Japan caused by the March 11 earthquake and its aftermath. Because Japan is such a big part of our growth strategy, I'd like to provide you with some details. First and foremost, we were relieved that within hours we were able to account for the safety of all Lilly Japan employees. We're also proud of the support, both monetary and product donations that Lilly Japan, the Lilly Foundation and Eli Lilly & Co. have provided to help those affected by this strategy. 
From a business perspective, our Japanese affiliate headquarters and development center of excellence are located in Kobe, and we have a manufacturing plant in Seishin just outside of Kobe. These operations are approximately 500 miles southwest of the disaster zone. As a result, we had no damages or other issues at these sites.
In terms of product supply, we've encountered no issues getting manufacturing products into or out of Japan. And we have not had and do not anticipate having any issue with the supply of raw materials, intermediate or finished product from our Japanese suppliers. Prior to the earthquake, we had robust inventory levels throughout our supply chain for materials sourced from Japan. 
In terms of domestic sales, we did receive what appeared to have been precautionary orders from customers totaling $30 million to $35 million in the quarter. We expect that this will wash out in future quarters. 
Our thoughts are with the Japanese people in what will surely be a long and difficult recovery. We'll continue to provide them our support, and we'll continue to ensure that Lilly products reach the patients who need them. 
Now with this background, Ronika will discuss our Q1 financial results and provide our pipeline update, and Derica will cover key events for the remainder of 2011 and our financial guidance for the year. Ronika?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on our previous calls, we'll focus our comments on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairment",1025,"Thanks, Phil. As we've done on our previous calls, we'll focus our comments on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. I'll start on Slide 7 with a quick look at our Q1 income statement.
On a non-GAAP basis, you can see that we generated solid revenue growth of 6% this quarter. Excluding Gemzar outside of Japan and the effect of U.S. health care reform, revenue would have grown 10%. Gross margin as a percentage of revenue increased slightly from 79.5% to 79.8%. 
Operating expenses defined as a sum of R&D and SG&A grew 10% this quarter. Drivers for the increase included: higher administrative expenses, driven by the pharmaceutical manufacturers fee associated with U.S. health care reform and higher litigation expenses; higher marketing and selling expenses driven by o U.S. investments primarily in the emerging markets; and higher R&D expense due primarily to increased late-stage clinical trials expenses.
In addition, both SG&A and R&D expenses increased due to the BI [Boehringer Ingelheim] alliance. Excluding the effect of U.S. health care reform and the BI alliance, operating expenses would have grown 7%. Other income and deductions was a net expense this year compared to net income last year. You may remember that we had substantial income in Q1 2010 related to the recovery of damages from generic olanzapine marketers in Germany and from gains on the sales of securities acquired in the ImClone acquisition. 
Our tax rate was 20.9% this quarter, considerably lower than 27.3% from last year's Q1. Last year's Q1 rate included an $85.1 million charge related to the future taxation of the retiree drug subsidy and did not benefit from the R&D tax credit as it had lapsed. This year, we did benefit from the R&D tax credit, as well as from the resolution of certain IRS tax matters. 
At the bottom line, our non-GAAP EPS increased 5% to $1.24. As indicated, Lilly provided the 2011 guidance in January, we felt robust EPS growth in our business in Q1 excluding U.S. health care reform, the effect of the Gemzar patent exploration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would have grown low double digits. 
Slide 8 shows our reported income statement while Slide 9 provides reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now let's look at how foreign exchange affected our Q1 revenue. As you can see on Slide 10, total revenue growth of 6% was driven by solid volume growth of 5% and foreign exchange contributing the remaining 1%. Price had no impact on the worldwide revenue growth. We continue to see strong volume growth from our three countercyclical growth engines: Japan, Elanco Animal Health and Emerging Markets. 
Volume growth in Japan was 34% driven by recent launches of Cymbalta and FORTEO, as well as continued strong growth of Alimta, Zyprexa, Gemzar and Humalog. In addition, roughly 1/4 quarter of the Q1 volume growth was attributable to precautionary buying Phil mentioned earlier; Elanco Animal Health volume growth of 25% in Q1 driven by the increased demand for food animal products globally, as well as by the launch of Trifexis in the U.S. and the acquisition of certain European Animal Health assets from Pfizer. 
Going forward, we expect Animal Health revenue growth to benefit from international launches of Comfortis. In addition, Elanco has a robust innovative pipeline and is poised to maintain double-digit growth in the coming years with launches expected in multiple products targeting high-value markets such as livestock immune enhancements, control of parasites in companion animals and pain control. We also built a substantial development capability in Animal Health vaccines, and as demonstrated by our recent offer to acquire Janssen's Animal Health business, we will continue to look externally for opportunities to drive growth in this business. 
Finally, you'll see strong 14% volume growth from our Human Pharma [Human Pharmaceuticals] products in the rest of the world lines. Emerging market countries represented about 3/4 of the sales in Q1, and as a group also registered 14% volume growth. In terms of products, growth in emerging market countries was driven by Alimta, Cymbalta, Humalog and Humulin. In terms of geographies, we saw robust growth across the host of geographies in Asia, Latin America and of course, China. 
Given the very small effect of foreign exchange on our results this quarter, we provided our summarized non-GAAP and reported income statements with and without the effect of foreign exchange in our supplementary slides.
Now before I turn the call over to Derica, let me provide a brief update on our pipeline. On Slide 11, you'll find a view of our portfolio of new molecular entities in clinical development as of April 11, inclusive of changes since our January 27 earnings call. 
Our clinical stage portfolio now stands at 69 distinct NMEs including 31 compounds in Phase II and Phase III. Biotech molecules represent nearly half of our late-stage Phase II and Phase III assets in over 1/3 of our overall clinical portfolio. Advancing our pipeline remains our number one priority, as reflected by the arrows on Slide 11. Since our January update, we have began Phase III testing of mGlu2/3 for schizophrenia, bringing our total Phase III portfolio to nine NMEs. We continue to be on track to meet our goal of having 10 NMEs in Phase III by the end of the year. Other molecules that could begin Phase III in 2011 include our novel basal insulin analogs, our new insulin glargine product and our IL-17 antibody. 
We also advanced two molecules into Phase II and two into Phase I. Finally, both tasisulam and IL-1 antibodies continued earlier stage development after we terminated clinical trials in their lead indications, and we terminated one molecule in Phase I development.
With this current pipeline and our continued business development efforts, our goal is still to launch on average two molecular entities per year beginning in 2013 providing a foundation for future growth. Derica?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now received the CHMP recommendation for approval of Bydureon, we look forward to launching the product",839,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key pipeline events for the remainder of the year. Having now received the CHMP recommendation for approval of Bydureon, we look forward to launching the product in Europe later this year. We have a number of other potential regulatory approvals this year including: linagliptin in the U.S., Europe and Japan; and here in the U.S., Cialis for BPH, Byetta in combination with basal insulin and Erbitux for first-line head and neck cancer.
Expected regulatory submissions include: our response to the FDA Complete Response Letter for Bydureon; sBLA for Erbitux in first-line metastatic colorectal cancer and for first-line, non-small cell lung cancer; Byetta in combination with basal insulin in Europe; and our response to the FDA Complete Response Letter for Amyvid. 
Upcoming clinical trial data disclosures include initial results from the Phase III trial of Alimta induction treatment followed by Alimta maintenance treatment in advanced nonsquamous, non-small cell lung cancer at ASCO. At the EULAR meeting in London in May, we will present data on the two Phase II trials of our BAFF antibody and rheumatoid arthritis. And lastly, data from a study assessing the safety of Cialis when co-administered with alpha blockers will be presented in May at the American Association of Urology meeting in Washington. 
Just late last month, data from the clinical trial evaluating tadalafil in men with ED and with signs and symptoms of BPH was presented at the European Association of Urology.
Finally, as mentioned earlier, Phase III trials could begin this year for our novel basal insulin analog and our new insulin glargine product and for our own anti-IL-17 antibody. 
In terms of our 2011 financial guidance. As you've seen in our press release, we still expect 2011 non-GAAP earnings per share of between $4.15 and $4.30. Our 2011 reported EPS guidance range of $3.86 to $4.01 reflects a $0.23 IPR&D charge from the BI alliance and the $0.06 restructuring charge. 
The business fundamentals underlying our guidance are essentially unchanged since our last update in January. However, a number of foreign currencies, in particular, the euro, have appreciated in recent months. As a result, we're updating our revenue growth and gross margin percent guidance. Assuming rates remain at current levels, we now expect 2011 revenue to grow in the low single digits. And we expect 2011 gross margin as a percent of revenue to decline by approximately 3 percentage point. 
Also, we're now estimating that the 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. Both of these rates reflected benefit from the resolution of certain IRS audit matters. In addition, the reported tax rate for the full year reflects the tax benefit of the in-process R&D charge associated with the BI alliance. All other elements of our line item guidance remain unchanged.
Now Slide 14 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our revised 2011 guidance. 
Now in summary, so far, 2011 is playing out as anticipated. We're making progress advancing our pipeline, and we're delivering solid financial results. With the initiation of Phase III trials for mGlu2/3 for schizophrenia, we now have nine molecules in Phase III development, putting us on track to meet our goal of having 10 molecules in Phase III development by the end of this year, with more coming behind. Along with continued business development, this pipeline serves as the foundation of our growth post years YZ.
During Q1, we also made progress on our productivity goals and are in tract to meet our 2011 headcount and expense containment goals. When we discussed our 2011 guidance in detail on the January call, I shared that we face a number of headwinds this year, as patent expirations will lower sales outside of Japan for first for Gemzar and later for Zyprexa. U.S. health care reform will exact a higher cost this year than it did in 2010, and we'll face some near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. 
I also shared that we expect to see continued strong performance in the rest of our business. We did see the negative impact in Q1 of these items, and we delivered strong growth in the rest of our business as promised. Excluding these items, on a non-GAAP basis, we posted revenue growth of 10%, operating expense growth of 7% and low double-digit EPS growth. We saw robust revenue growth from our three countercyclical growth engines with Japan growing 41%, Elanco growing 28% and Emerging Markets growing 15%.
Moving forward, we will continue to focus on: delivering strong financial results, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline, and on speeding the next generation of Lilly molecules to market to provide growth post years YZ. 
This concludes our prepared remarks. And now we open the call for the Q&A session. Operator, first caller please?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of Jami Rubin from Goldman Sachs."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. Derica, a question for you on Bydureon and congratulations getting CHMP approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results. And then also",116,"Thank you. Derica, a question for you on Bydureon and congratulations getting CHMP approval. But I'm wondering if you could share us sort of generally how you're thinking about pricing relative to Victoza in light of the DURATION-6 results. And then also included in the recommendation for approval was a pharmacovigilance program and I'm wondering if you can elaborate on that. And just lastly, just to switch gears here on the gross margin, the delta in the gross margin, the delta in terms of your new guidance for the full year reflect a $0.17 hit, and I'm wondering if that is all related to foreign currency or is there cushion related to Zyprexa going generic. Thanks."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Jan, you may want to deal with the pharmacovigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to dis",118,"Sure. Jami, I'll take the Bydureon pricing question and the question also in terms of the gross margin. Jan, you may want to deal with the pharmacovigilance question. As it relates to Bydureon pricing, clearly at this stage, we're not in a position to disclose what our pricing strategy would be behind this brand before we've even launched it. But what I can say is we still feel very confident in the commercial prospects for Bydureon given the label that we would anticipate. As it relates to your gross margin question, regarding FX, it is all attributable to FX rate and in terms of our revised guidance of minus 2 percentage points to minus 3 percentage points decline."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to risk management for Bydureon, of course, we have safety very high on the agenda, and we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need and partic",58,"In relation to risk management for Bydureon, of course, we have safety very high on the agenda, and we know that there are certain special issues that have been discussed in the past. But in general, we have our safety surveillance that we need and particularly looking for if there are increase in pancreatitis, thyroid tumors, et cetera."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmacovigilance plan, those are things we'll need to wait comment on until the EC provides its formal approval of th",194,"A couple of quick things as well, in terms of additional details on the potential label coming out of Europe and specific details on the pharmacovigilance plan, those are things we'll need to wait comment on until the EC provides its formal approval of the CHMP recommendation, which we expect to come hopefully in late June. And then in terms of pricing, do keep in mind that the DURATION-6 trial was against the 1.8 milligram dose of Victoza. Rough numbers in many of the European markets, it would appear that the 1.2 was launched at roughly parity to Byetta, which means that the 1.8 would be the substantial premium. So as we enter those discussions with pricing authorities in Europe, we'll be looking at the full raft of DURATION trials where we have very strong data against insulin glargine, against ACTOS, against Januvia and against Byetta, all of which have a price that's out in the marketplace. And then as you're mentioning, Jami, we'll also have the DURATION-6 data against the 1.8 milligram dose of Victoza that we'll enter into those discussions as well. So again, as Derica said, a very strong overall package."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Tim Anderson with Sanford Bernstein.",13,"Our next question comes from the line of Tim Anderson with Sanford Bernstein."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in the Animal Health or other",96,"Thank you. On the 2011 guidance, is that likely to be impacted by the pending purchase of the Animal Health products? And more generally, what is the landscape looking like for Lilly in terms of additional acquisitions either in the Animal Health or other areas that might provide you with a greater level of diversification? And then on solanezumab, can you narrow down the timing of when we'll likely see results and also where you are with the interim looks and whether you'll announce one of those -- well, once those interim looks have been completed?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay, great. Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And maybe you and Jeff can comment respectively on the general and then Animal Health acquisition landscape. And then Jan and Ronika,",50,"Okay, great. Maybe Derica, you can comment on the '11 guidance and how that might be impacted by the Janssen acquisition. And maybe you and Jeff can comment respectively on the general and then Animal Health acquisition landscape. And then Jan and Ronika, maybe the solanezumab update would be great."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset, both top line, as well as bottom line. In regards to this development, we continue to be active in this space. But I think we've been a",137,"Tim, this is Derica. Our 2011 guidance does fully take into account the acquisition of the Janssen Animal Health asset, both top line, as well as bottom line. In regards to this development, we continue to be active in this space. But I think we've been also very clear about our intent. We're not in the market for large-scale M&A, but we are looking for opportunities to continue to enhance our business both from the standpoint of either finding molecules that complement our development pipeline portfolio or finding those product opportunities that we can bring in that bring sales and cash with it. And then, that's clearly what we also saw as we looked at the Janssen acquisition in terms of Animal Health, a way of bolstering our Animal Health business with Jeff can respond to further."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, Tim, I would say we've made four acquisitions in four years, Lilly has, and it's all playing around this countercyclical growth engine that was made in the comments. We will continue to be opportunistic. But it really has to drive three things: one i",115,"Yes, Tim, I would say we've made four acquisitions in four years, Lilly has, and it's all playing around this countercyclical growth engine that was made in the comments. We will continue to be opportunistic. But it really has to drive three things: one is growth; strategically, it has to drive growth; diversity; and bring capability. And I would say all four acquisitions in the past have done that. That's what we'll continue to look for as we go forward. Although the organic growth that we see over the next two or three years in Animal Health is going to be significant with six new launches this year and more launches to come in 2012."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to solanezuma, our A-beta antibody then to stop progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we",51,"In relation to solanezuma, our A-beta antibody then to stop progression of Alzheimer's disease, we would have an interim analysis this year in relation to utility and safety. The final data from the two Phase III trials are expected mid-2012. And then we will disclose the data at an appropriate event."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","One of the thing I'd add, Tim, you see we had, in an effort to give you guys some more exposure to -- of operational heads of our various areas of the company, Enrique, on the call last quarter, Jeff this quarter. We'll likely have Jacques Tapiero, Head o",111,"One of the thing I'd add, Tim, you see we had, in an effort to give you guys some more exposure to -- of operational heads of our various areas of the company, Enrique, on the call last quarter, Jeff this quarter. We'll likely have Jacques Tapiero, Head of our Emerging Markets area on next quarter. That is an area in Emerging Markets countries where on your question of M&A probably for the last 24 months or so, we've seen pricing very high frankly, and more likely you'll see things that are of the collaboration and licensing in the short term until those trends reverse in the Emerging Markets properties."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Greg Gilbert with Merrill Lynch.",13,"Our next question comes from the line of Greg Gilbert with Merrill Lynch."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your GLP-1 to move it into Phase III?",98,"Thank you. Three quick ones. First, Derica, were there any wholesaler or retailer inventory level changes of note that affected sales in the quarter in the U.S.? Secondly, can you talk about what you needed to see on your GLP-1 to move it into Phase III? What was the bar there? With any specifics you care to share? And thirdly, more strategically, should we view the Avid acquisition as a sign of things to come for Lilly or more as a one-off that will take you some time to assess before you really answer that question for yourselves?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Derica take your first and third questions, Greg. Then we'll go ahead and handle the GLP question you asked as well.",24,"We'll have Derica take your first and third questions, Greg. Then we'll go ahead and handle the GLP question you asked as well."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Greg, we actually had -- we saw two types of activities that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as best as we can tell, even at the retail leve",222,"Greg, we actually had -- we saw two types of activities that relates to wholesalers stocking and destocking in the first quarter. In the U.S., we did see a level of destocking on the part of wholesalers. And as best as we can tell, even at the retail level as well in the first quarter. So that destocking served to dampen our revenue growth in the U.S. in Q1. At the same time, given the disaster that we all witnessed in Japan, we saw a buy-in on the part of wholesalers or distributors there in the case of emergency. And that buy-in Japan was probably in the range of around $30 million to $35 million in the quarter. So it was -- of the 41% of Japan growth that we saw in the quarter, about 25% of that was related to this buy-in. As it relates to your third question around the Avid acquisition -- just a reminder to everyone, when we did the Avid acquisition, it was solely based upon the prospect of that compound itself. And our thesis behind that is that we saw an interesting therapeutic that could complement our portfolio. Clearly as that plays out, it gives us an opportunity to ponder other alternatives. But for right now, we're planning and progressing as though it's around Avid itself."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Now regarding to your second question, Greg. You mentioned GLP moving into Phase III, we actually moved GLP into Phase III quite a while ago. I think you may have meant to say mGlu2/3, in which we moved into Phase III in this past quarter. If that is your",106,"Now regarding to your second question, Greg. You mentioned GLP moving into Phase III, we actually moved GLP into Phase III quite a while ago. I think you may have meant to say mGlu2/3, in which we moved into Phase III in this past quarter. If that is your question, I'm going to actually turn the call over to Jan to give some more clarity. But we actually presented some 6-month safety study data at the beginning of April at the ICOSR meeting, the International Congress for Schizophrenia Research, which discharged some of the risk. But again, I'll turn it over to Jan to answer further."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thank you. The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 agonist as an optional treatment for these patients. The study mentione",133,"Thank you. The whole schizophrenia area is in desperate need of some new agents than in addition to the currently used typical antipsychotics. So we are very interested in our mGlu2/3 agonist as an optional treatment for these patients. The study mentioned discharged the risk in relation to seizures as we see it in relation then to standard of care. It's known that patients with schizophrenia do have an increased risk of seizures, but our agents did not seem to have any more effects than standard of care. And we should remember there are some potential clear advantages with our mGlu2/3 agent, less risk for extrapyramidal symptoms and also it has a much better metabolic profile in relation then to a typical antipsychotics, even  with a potential weight loss, not the weight gain."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Jan. And lastly, Greg, on the U.S. piece just to put some numbers around what Derica had mentioned, each year we typically would end within the guidelines we have with the wholesaler, at the higher end of the days on hand, the wholesalers, the end",91,"Thanks, Jan. And lastly, Greg, on the U.S. piece just to put some numbers around what Derica had mentioned, each year we typically would end within the guidelines we have with the wholesaler, at the higher end of the days on hand, the wholesalers, the end of the calendar year, and we typically come down in Q1. That was the case both in 2010 and in 2011. However, the decline was a bit steeper in 2011 and that would have trimmed about 1 percentage point off of the U.S. growth rate."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of David Risinger from Morgan Stanley.",13,"Our next question comes from the line of David Risinger from Morgan Stanley."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks very much. I have a couple of questions. First, I missed the beginning [ph] of the question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to",122,"Thanks very much. I have a couple of questions. First, I missed the beginning [ph] of the question about whether the guidance already assumes the inclusion of the Animal Health business later this year, so that's my first question. Second, with respect to solanezumab, I think that Jan mentioned that there is a futility analysis this year. Could you please comment on whether that's in the first half such that you'll be able to comment on at your June 30 analyst meeting or not until the second half? And then third, with respect to your long-term earnings outlook, Derica, do you expect to communicate that at the June 30 analyst meeting or prior to the meeting on a separate call? Thank you."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. David, I'll take your first and third questions. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance or construct that we put out there in December of",73,"Okay. David, I'll take your first and third questions. This is Derica. As I stated earlier, our guidance for 2011 does fully contemplate the Animal Health transaction. In regards to the long-term guidance or construct that we put out there in December of '09, David, I would see ourselves coming back to that at our June analyst meeting. I don't anticipate us giving any more color on that prior to our June meeting."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the timing of the futility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that the safety profile so far in these trials look better than for semagacestat, and they're actually le",56,"In relation to the timing of the futility analysis, we have decided not to comment exactly when this happened during this year. But what I can say is that the safety profile so far in these trials look better than for semagacestat, and they're actually less patients that have stopped the trial because of safety issues."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Steve Scala with Cowen.",12,"Our next question comes from the line of Steve Scala with Cowen."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thank you. I have two questions again on solanezumab. How is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group? And if that is the case, is that a risk for these trials? And then",73,"Thank you. I have two questions again on solanezumab. How is futility defined in these trials since that 12 months one might not expect the material cognitive decline in any patient group? And if that is the case, is that a risk for these trials? And then second, when in 2013 might you file GLP Fc? Might it be a first half event or might it be a second half event? Thank you."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Well, I think I have said what I want to say about solanezumab, but we now need to wait for the data.",22,"Well, I think I have said what I want to say about solanezumab, but we now need to wait for the data."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","With regards to GLP FC, we have provided no specifics with regard to timing on filing. We have initiated all four award studies. So we're pleased with the progress there, but no additional information on timing.",36,"With regards to GLP FC, we have provided no specifics with regard to timing on filing. We have initiated all four award studies. So we're pleased with the progress there, but no additional information on timing."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a question from the line of John Boris with Citi.",13,"We do have a question from the line of John Boris with Citi."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks for taking the questions. First question for Derica, on the Animal Health business from Janssen. Can you just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China in",123,"Thanks for taking the questions. First question for Derica, on the Animal Health business from Janssen. Can you just give us some color on the size of that business especially in light of it being incorporated in your guidance. Second question on China in particular and your diabetes franchise there. I think the New England Journal of Medicine cited there's about 92 million diabetics there and your market share relative to your competition is a little bit lower than your competition? What are you going to remedy that potentially going forward? And then one question for Jan, within the 2013 time period, aside from GLP-1 Fc, what are the other one or two assets that might be positioned for launch at that time?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and size of the Janssen business. And then maybe Derica on the China diabetes question. And then on to Jan.",39,"Okay. Firstly, John I think we're going to have Jeff comment on your first question on the Animal Health and size of the Janssen business. And then maybe Derica on the China diabetes question. And then on to Jan."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, so we have Janssen is represented in the Vetnosis, the actual independent animal health data that's tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which",91,"Yes, so we have Janssen is represented in the Vetnosis, the actual independent animal health data that's tracked by this company. It represents $200 million this past year, $170 million the year before. I would note though that outside of the U.S., which is about $25 million, their distributor sales. So it represents a little bit level that's higher than what really Janssen and we will recognize. So that number is a little bit high. And then the actual margins would be very much average for the industry in Animal Health."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. John, in regards to China, as I stated -- well, actually there was a ton of interview this morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly have a smaller share of ma",198,"Okay. John, in regards to China, as I stated -- well, actually there was a ton of interview this morning. Our China business grew 23% in the first quarter. And if you look at the diabetes opportunity, while today, we are clearly have a smaller share of market position versus our competition, we have taken decisive actions to improve our competitive position going forward. We've recently commissioned a new diabetes research facility and operation there. In addition to that, we are actually -- we commissioned also building a second manufacturing facility in China, which will be diabetes-related as well. And then thirdly, we've more than doubled the size of our commercial footprint. So we believe that we are -- positioned ourselves to take advantage of this significant opportunity in that marketplace. And we see ourselves with the opportunity to gain share. And part of the learning for that is also with what we've seen here in the U.S. So even in a market where you could say it's fairly saturated, in the U.S., we've seen a significant uptick in our diabetes share of market both on a NRx and a TRx if you look at the last year."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, well, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two NME launches per year from 2013 should potentially come both from internal and in-licen",73,"Yes, well, over my years, I've learned to speculate on timing for launch dates, it's one of the most difficult things we have. And we should also remember that the two NME launches per year from 2013 should potentially come both from internal and in-licensing or acquisitions. So those are three options. There are some programs with the right data that could deliver ahead of time. Potentially solanezumab could be one of them."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a question from Bert Hazlett from BMO Capital Markets.",12,"We do have a question from Bert Hazlett from BMO Capital Markets."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks. I have one question on Japan and another on the pipeline. First on Japan, you did have some buy-in but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Evista and Strattera. Could you discuss your expect",137,"Thanks. I have one question on Japan and another on the pipeline. First on Japan, you did have some buy-in but there do seem to be some products that are growing fairly robustly I guess Cymbalta, Alimta, Evista and Strattera. Could you discuss your expectations for growth and the potential kind of countercyclical nature in terms of additional product launches that would be coming down the road there? And then secondly, in terms of the pipeline for Jan, I see you're moving the IL-17 program forward in rheumatoid arthritis. But my count is this will be at least the third program in RA. You have the orals JAK1/JAK2. You'll have the anti-BAFF antibody NRA and now the IL-17. Could you talk about its positioning in RA and vis--vis the BAFF antibody in particular? Thank you very much."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Bert, this is Ronika. With regards to Japan and launches, you might remember earlier in the decade, we had mentioned -- last decade, we had mentioned that our goal was to launch a lot of the products we had not yet launched in Japan that had already been",146,"Bert, this is Ronika. With regards to Japan and launches, you might remember earlier in the decade, we had mentioned -- last decade, we had mentioned that our goal was to launch a lot of the products we had not yet launched in Japan that had already been launched in the U.S. And those include several that you mentioned Alimta and Strattera, which launched in 2009, as well as Cymbalta, FORTEO, Byetta that also launched in Japan in 2010. Also keep in mind, part of the countercyclical nature of Japan includes the fact that we have Zyprexa in Japan through 2015. So products that could also be launched in the near term in Japan include our partnership with BI, specifically, linagliptin. It's a potential launch in Japan in 2011 or approval, I should say, in 2011. So those are the highlights with regards to Japan. Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Yes, we are very excited about our opportunities in rheumatoid arthritis and the autoimmune area in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1/JAK2 inhibitor partnered with Incyte could be",234,"Yes, we are very excited about our opportunities in rheumatoid arthritis and the autoimmune area in general. Having these three agents, it's actually an opportunity, not a problem. First of all, the oral JAK1/JAK2 inhibitor partnered with Incyte could be I think a very competitive agent in relation to Pfizer's recent Phase III agent which have received so much attention, tofacitinib, with a positive recent data. We are currently exploring them, the JAK1/JAK2 component Phase IIb in relation to dose safety and efficacy. Oral agents will be placed earlier most likely than in the treatment of rheumatoid arthritis, competing with methotrexate as a key initial agent. Our two biologicals, the anti-BAFF and IL-17 represents very novel agents with new mechanist to influence then the immune system; the BAFF against that B-cells and the IL-17 more as an inflammatory cytokine that is released. And both of these agents have positive Phase II data in rheumatoid arthritis, and they will be positioned then in patients that actually are failing to TNF. And we know that there is substantial proportion of patients, up to 50%, that don't respond well enough to TNF blockers. And even if you then can switch to another TNF agent, the efficacy goes away with time. So we see both the BAFF and the IL-17 as potential new treatment options in actually quite a large patient population that have been failing TNF agents."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Bert, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion mark, so we surpassed the $1.5 billion. That's a business that we believe we can double the size of that bu",169,"Bert, this is Derica. Just to expound a little bit more on your question regarding Japan. If you recognize last year Japan crossed the $1.5 billion mark, so we surpassed the $1.5 billion. That's a business that we believe we can double the size of that business over the next four to five years. And you look at, as Ronika said, you got brands like Cymbalta, Zyprexa through '15 and Alimta, but you're also seeing the impact of the recent launch of FORTEO as well as the continued growth around Alimta, Humalog and Gemzar. So that gives you some idea of what we're expecting in terms of that countercyclical growth engine we've been talking about along with Emerging Markets, as well as Elanco that's helping to mute the impact of patent expirations like Gemzar in Q1 and later Zyprexa this year. And I'll still remind everyone that we -- top line grew 6%, 5% volume and that includes the impact of the generic erosion for Gemzar in the quarter."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","And the generic erosion for Gemzar shaved about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact.",29,"And the generic erosion for Gemzar shaved about 3 percentage points nearly off of the worldwide growth rate for the quarter as well. So it's a pretty significant impact."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Seamus Fernandez with Leerink Swann.",13,"We have a question from the line of Seamus Fernandez with Leerink Swann."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Thanks very much. So just a couple of quick pipeline questions. Can you just update us on linagliptin and whether or not Lilly expects to -- that panel to be fielded for the product prior to approval? It looks like there won't a panel on this drug. And ma",140,"Thanks very much. So just a couple of quick pipeline questions. Can you just update us on linagliptin and whether or not Lilly expects to -- that panel to be fielded for the product prior to approval? It looks like there won't a panel on this drug. And maybe just give us your reasons specifically for that. Second, you've moved a CETP inhibitor forward, I believe or have a CETP inhibitor in Phase II in atherosclerosis. Can you just update us on your thoughts with regard to that mechanism and what you believe is necessary to move that product into Phase III safely? And then the last question is actually, can you just update us on the status of necitumumab? I believe one of the studies there was actually placed on clinical hold, so just looking for an update there."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. In relation to our DPP-4 inhibitor in linagliptin together with Boehringer, that was filed last year and we have no further comment, I think, on dates or potential advisory boards, et cetera. We see this agent as a very promising oral anti-diabetic",190,"Okay. In relation to our DPP-4 inhibitor in linagliptin together with Boehringer, that was filed last year and we have no further comment, I think, on dates or potential advisory boards, et cetera. We see this agent as a very promising oral anti-diabetic compound that complements our offering to patients, making Lilly very broad, if not the broadest offering in the whole therapeutic area of diabetes across major pharma. We are quite enthusiastic about our CETP inhibitor, which now are in Phase II trials, in combination with statins. We based this on our Phase I data but also actually as a class the competitor molecules both from Merck and Roche, as you know are moving ahead with Phase III trials. We feel we have a competitive agent based on what we have seen so far, what area is then to avoid the problems that Pfizer had with the torcetrapib, mainly the increasing blood pressure. We have not seen this for our compound, and we are enthusiastically moving it forward, I think, we can say currently. Necitumumab, we are still pursuing this squamous non-small cell lung cancer indication in Phase III."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Catherine Arnold from Credit Suisse.",13,"Our next question comes from the line of Catherine Arnold from Credit Suisse."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","A couple of questions. One, I wanted to ask you about your U.S. price increase if it had not been for health care reform impacts. And then I wanted more specifics, you guys have given numbers about the effect of the overall reform, but I wasn't clear if w",141,"A couple of questions. One, I wanted to ask you about your U.S. price increase if it had not been for health care reform impacts. And then I wanted more specifics, you guys have given numbers about the effect of the overall reform, but I wasn't clear if whether what you said included doughnut hole, or how you're going to be recording those? Is this going to be as those discounts are demanded of you? Are you sort of accruing an expectation across four quarters? And then on solanezumab, I wanted to just ask one more question that hasn't been asked yet, which is as far as when the pre-specified analysis is done at the end of the trial, is there going to be severity of disease stratification in that pre-specified analysis in addition I would presume to carrier and non-carrier."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Derica you want to handle the first two and then Jan the last one solanezumab?",16,"Okay. Derica you want to handle the first two and then Jan the last one solanezumab?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Catherine, this is Derica. I think you're aware of what the dollar impact of health care reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece,",115,"Sure. Catherine, this is Derica. I think you're aware of what the dollar impact of health care reform as it relates to revenue growth was in the first quarter, it was about $90 million. If you look at our guidance for the year, both for the revenue piece, which was, we believe, the health care reform impact will be in the range of $400 million to $500 million, that includes the impact of -- the anticipated impact of the doughnut hole. And then as you recall, the pharmaceutical excise fee will then impact us in the administrative OpEx line. And that's being to the tune of about $150 million to $200 million for the year."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. The primary endpoint here is clearly reducing the disease progression, and we will look at mutation status as a secondary opportunity.",39,"Right. I appreciate your interest in solanezumab. It certainly could be a tremendous agent for patients with Alzheimer. The primary endpoint here is clearly reducing the disease progression, and we will look at mutation status as a secondary opportunity."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","A couple of additional comments maybe, Catherine, the $90 million impact of U.S. health care reform on revenue this quarter, if you're looking at the impact on the growth rate, do recall that we had said approximately $60 million was the impact to revenue",242,"A couple of additional comments maybe, Catherine, the $90 million impact of U.S. health care reform on revenue this quarter, if you're looking at the impact on the growth rate, do recall that we had said approximately $60 million was the impact to revenue in Q1 of 2010. I think if you look in the Q, you'll actually find it was $62.4 million was the number. So it turned about 1 percentage point off of the U.S. revenue growth rate and about 0.5 percentage point off of our worldwide growth rate for the quarter. And then in terms of the doughnut hole, I think there may be different practices at the various companies. You may want to check on this. But essentially for the doughnut hole, we've done our best to try to model. We think will actually be occurring. In other words, the charge that we would have recognized in Q1 would assume that a whole host of people would not yet have hit the doughnut hole during this quarter. And if you look at the approximately $90 million for the year and compare it to $400 million to $500 million for the full year, you'll see that assumes a bump-up in Q2 through 4 compared to Q1. That bump-up is due to the higher expected charge that we'll be recognizing for the doughnut hole, as more seniors and Medicare hit that part of the benefit from U.S. health care reform."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Yes, Derica, can you give us a little more flavor on what's going on, on the restructuring? How much has been done so far? Where's the impact and how much more there is? And as you've gotten in there to cut cost, does it -- are you finding more areas to c",90,"Yes, Derica, can you give us a little more flavor on what's going on, on the restructuring? How much has been done so far? Where's the impact and how much more there is? And as you've gotten in there to cut cost, does it -- are you finding more areas to cut? And just give us a little more detail on that. And then the other question was, what was the key product that was ordered so much of in Japan? Was it Zyprexa? Or was it all the products?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Mark, this is Derica. In regards to update our restructuring, as it relates to our $1 billion cost savings goal, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And in additi",218,"Okay. Mark, this is Derica. In regards to update our restructuring, as it relates to our $1 billion cost savings goal, we are very much on track to achieve that. In fact, I anticipate that we're going to exceed that goal, okay, for the year. And in addition to that, on the headcount front, we've talked about reducing our headcount excluding strategic acquisitions and strategic investments by about 5,500. We're about 75% of our way to that goal as well. So both of those we anticipate meeting by the end of the year, if not exceeding. As it relates to other additional insights, I think that we have instruments and tools like Six Sigma that we've been utilizing since 2004, where as we approach the end of the year of 2011, that's not going to be the end of our efforts to drive further efficiency gains throughout our business. We know that our patent challenges don't go away at the end of '11. So I think there'll be further opportunities. How much? I'm not prepared to define that for you guys here today. But recognize, we believe that we will have the capacity to make the investments necessary in our pipeline, as well as sustaining the dividend. And that was all predicated on us to achieve this year."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Jill?",1,"Jill?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","In terms of the sales, products ordered in Japan. The sales were actually increased across the board driven by Cymbalta, FORTEO and Alimta.",23,"In terms of the sales, products ordered in Japan. The sales were actually increased across the board driven by Cymbalta, FORTEO and Alimta."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We have a question from the line of Chris Schott with JPMorgan.",12,"We have a question from the line of Chris Schott with JPMorgan."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Analysts","Great. Thanks very much. My first question was on the quarterly progression of gross margins. I know we can get a lot of variability quarter-to-quarter in your gross margins. So I was just looking for a little bit more clarity on the progressions here. I",178,"Great. Thanks very much. My first question was on the quarterly progression of gross margins. I know we can get a lot of variability quarter-to-quarter in your gross margins. So I was just looking for a little bit more clarity on the progressions here. I guess, based on your new guidance, it looks like you have an average somewhere between 77%, 78% for the remainder of this year. I guess is there any one quarter that's going to be seeing a disproportionate hit from FX? And then also, just going -- it's an earlier question, are you anticipating a meaningful drop in fourth quarter gross margins as the generic Zyprexa impact ramps? Second question just was -- can you also just, with the mGlu, walk through the timeline and the scope of that Phase III program? And in that answer, would you also touch on any incremental data that might be requested by the FDA to address some of the basic earlier seizure data points the products saw that might be included in that Phase III program? Thanks."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Okay, Chris, I'll go ahead and try -- let me start with the mGlu2/3 first. We don't have with us the specific timing for the trial. The one thing I would highlight is Ronika had mentioned, the presentation earlier this year of the 6-month safety data. We'",263,"Okay, Chris, I'll go ahead and try -- let me start with the mGlu2/3 first. We don't have with us the specific timing for the trial. The one thing I would highlight is Ronika had mentioned, the presentation earlier this year of the 6-month safety data. We'll have probably late this year, at the best maybe early next year, the opportunity to present the 12-month safety data from that trial. So that will sort of be the next major data readout that I would point you to for mGlu2/3. And then in terms of the gross margin percent dynamics. With the strengthening of foreign currencies here in the first quarter particularly of the euro, we would expect for the full year, we would have a substantial additional cost booked to cost of sales from this FX impact on international inventories sold. If you recall, there were some pretty different dynamics last year, quarter-by-quarter. Probably the best thing I can do is point you to Slide 17 in the supplemental portion of our slide deck for today, where at the bottom you'll see for each discreet quarter how much FX affected gross margin in those particular quarters for the year. At a high level, we had a modest benefit to cost of sales booked Q2 last year, a significant benefit to cost of sales booked in Q3, so at current rates, you have a very unfavorable compare to the Q3 number. And then actually we've flipped then to having a modest addition booked to cost of sales in the fourth quarter. Hope that helps."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","And you had a question about Zyprexa and its impact on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our",51,"And you had a question about Zyprexa and its impact on gross margin. So yes, when we lose Zyprexa and as we go throughout the year but more profoundly in the fourth quarter, when we lose the U.S., it will also have a detrimental or negative impact on our gross margin."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","We do have a final question from the line of Damien Conover with the Morningstar.",15,"We do have a final question from the line of Damien Conover with the Morningstar."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Great. Jeff?",2,"Great. Jeff?"
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Sure. Yes, so industry average is, if you look at kind of at a higher level what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing cost. So we're slightly off from the bottom line. So the industry average",257,"Sure. Yes, so industry average is, if you look at kind of at a higher level what you have is usually in Animal Health lower SG&A, so lower sales and admin cost, higher manufacturing cost. So we're slightly off from the bottom line. So the industry average is somewhere on the margin line between 20% and 25%. So Janssen's on the lower end of that range, and we would be in that range as well. When you step back and look at the business though, I think why we're quite excited about going forward: First, Janssen does give us more of a global footprint, gives us more capability inside of Europe, as well as we've got a hundred pending registrations of different products across all the countries internationally. So it was a very European business we're going to take global. And then at kind of a macro level, how we're going to continue to see margin improvement and above industry growth rates in Elanco is just looking at the three big areas: in Animal Health, where there's higher margin; companion animals, we're at about 10%, the industry is at 40%; Europe, we're at about 10%, 11% exactly, and the industry is about 30%; and vaccines we're very small with our Pfizer acquisition and the industry is at about 25%. So we see tremendous upside at higher-margin areas in these three segments. So that's what gives us some -- a lot of optimism and growth as we go forward the next three to five years in Animal Health."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Great. Thanks. Having exhausted the callers on the line, I'll go ahead and turn it over to Derica to close our call for today.",24,"Great. Thanks. Having exhausted the callers on the line, I'll go ahead and turn it over to Derica to close our call for today."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. I first want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once agai",214,"Thanks, Phil. I first want to say thanks to all of you for joining us today. We very much appreciate your interest in our company. And we hope that you found the information we shared today about our products and our pipeline to be very helpful. Once again, just so far this year, in 2011, it's playing out as we anticipated. We're clearly making progress in advancing our pipeline, standing at nine Phase III molecule versus our goal of 10 by the end of this year. I think our solid financial results is evident. And we continue to see the countercyclical growth areas performing as we had anticipated as well as I talked about Japan, Animal Health and our Emerging Markets. These are the things that's going to allow us to be able to weather the impact of the patent erosions of products like Gemzar and Strattera going forward. So hopefully, you found this to be insightful. We look forward to seeing many of you at our investor meeting in New York City on June 30 and to our continued interaction throughout the year. Our IR team will be available to answer any questions that you guys may have at the conclusion of this call. I hope everyone has a great day. Take care."
285467,97242184,115524,"Eli Lilly & Co., Q1 2011 Earnings Call, Apr 18, 2011",2011-04-18,"Earnings Calls","Eli Lilly and Company","Operator","And ladies and gentlemen, this conference will be available for replay today after 11:00 a.m., lasting through midnight on April 25. You may access the AT&T Executive Teleconference replay system at anytime by dialing 1(800)475-6701, entering the access c",70,"And ladies and gentlemen, this conference will be available for replay today after 11:00 a.m., lasting through midnight on April 25. You may access the AT&T Executive Teleconference replay system at anytime by dialing 1(800)475-6701, entering the access code 197298. International participants may dial 320-365-3844. That does conclude your conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service . You may now disconnect."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q2 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Please go ahead.",35,"Ladies and gentlemen, thank you for standing by. Welcome to the Q2 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Please go ahead."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly Company's second quarter 2011 conference call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer, Docto",923,"Good morning, and thanks for joining us for Eli Lilly Company's second quarter 2011 conference call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer, Doctor Jan Lundberg; and Ronika Pletcher and Jill Thoren for Investor Relations.
Since we just provided a comprehensive overview of our business at our investment community meeting on June 30, today, we'll limit our prepared remarks leaving more time for the Q&A session. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors including those listed on Slide 3 and those outlined in our latest forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional, and is not sufficient for prescribing decisions.
Since the Q1 earnings call in April, we've had a number of significant events, many of them in our diabetes business. On the regulatory front, we had important news for Bydureon. The European commission granted final approval of Bydureon, the long acting formula of and the first treatment for adults with Type 2 Diabetes. We launched in the U.K. last week and launches in other European countries expected over the course of 2011 in the first half of 2012. We submitted Bydureon to regulatory authorities in Japan and along with Amylin, we completed thorough Q3 study to support the U.S. M.B.A. for Bydureon. In this study, when administered at and above therapeutic levels, except I did not prolong the expected QT interval in healthy individuals. Further, the study found no relationship between QTc interval and plasma exenatide concentrations. we've had to submit our reply to the FDA Complete Response Letter in Q3.
We also had quite a bit of regulatory news on the. The FDA approval under the training project for the treatment of adults with type 2 diabetes. Along with Boehringer Ingelheim, we launched the product here in the U.S. in May. Presenting the first DPP4 inhibitor to be approved at 1 dosage strength with no those adjusted recommended for patients with kidney or liver impairment.
The Japanese Ministry of Health and welfare approved linagliptin under the trade name. Along with the eye, we expect to launch the product in Japan later this quarter.
Continuing the string of rapid approvals, regulatory authorities in Mexico and Brazil also proved linagliptin known there as Trayenta. and launches in these countries are also expected in Q3.
In Europe, the CHMP recommended approval of agenda and we expect final EC  approval later this quarter. Clearly, we're very pleased with the significant progress achieved during Q2 in our diabetes business.
In non-diabetes regulatory news, along with Bristol-Myers Squib, we submitted the SPLA for Erbitux and first-line non-small cell lung cancer. On the clinical content at ASCO, we presented positive data from PARAMOUNT, the second study to evaluate the use of Alimta's maintenance therapy in patients with advanced non-squamous non-small cell lung cancer. And the first study to evaluate the use of continuation maintenance with Alimta following first-line Alimta platinum therapy. Based on data from PARAMOUNT, we submitted our dossier in Europe earlier this year and we plan to submit here in the U.S. once we have more mature overall survival data.
On the Business Development front, we received final EC approval for and finally closed on our acquisition of animal health business. We signed an exclusive worldwide collaboration agreement with since these on which the 2 companies will jointly develop site-specific bone healing products. The companies will also conduct and fund the evaluation of additional orthopedic uses for Forteo. In addition to the development component of the agreement, the collaboration includes the co-promotion of Forteo to orthopedic surgeons in the U.S. and in select U.S. countries.
We signed agreements with private investors to establish  BioCritica. Based in Indianapolis, BioCritica initially focus in the development of
Diacritical acquired the U.S. development commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-something developer. The collaboration of the agreement also includes an option for BioCritica to acquire the development and commercialization rights to Xigris outside the U.S. at a later date.
We entered into a collaboration with Medtronic to research and development new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using implantable drug delivery system. Specifically, the goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lily's biologic, a modified form of glial cell derived neurotrophic factor with Medtronic's implantable drug infusion system technology. Lastly on the legal front, the Supreme Court denied release petition to reconsider a federal appeals court ruling invalidated something GEMZAR abuse patent. And to judge for the U.S. District Court for the Southern District of Indiana ordered all generic drug manufacturers challenging the validity of the compound for Cymbalta to sell a generic version of until the patent expires. As a result, we do not expect to market duloxetine in the market until patent expires in June 2013th or December 2013 if we're successful in obtaining the six-month pediatric exclusivity.
Now as a background, Veronica will discuss our Q2 financial results and provide our pipeline update; and Derica will then cover key events to our major 2011 and our financial guidance for the year. Ronika?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done in previous calls, we'll focus our comment to non-GAAP results underlined Henson our business. This view excludes certain items such as restructuring charges asset impairments and other special charges. I'll start on Slide 6 wi",1171,"Thanks, Phil. As we've done in previous calls, we'll focus our comment to non-GAAP results underlined Henson our business. This view excludes certain items such as restructuring charges asset impairments and other special charges. I'll start on Slide 6 with a quick look at our Q2 income statement. On a non-GAAP basis, you can see that we generated robust revenue growth of 9% this quarter. Excluding GEMZAR outside of Japan and the effective view of health reform, revenue would've grown 13%. Compared to Q2 2010, gross margin as a percentage of revenue decreased 1.8 percentage points, but were are still strong at 80.4%. This decrease is entirely due to the effective changes in foreign exchange rates on inventories international inventories sold. Operating expenses defined as a sum of R&D and SG&A grew 12% this quarter. This increase is driven primarily by SG&A which increased 15% over increasing R&D was 6%. Drivers of the increase in operating expense included expenses related to our diabetes alliance with Boehringer Ingelheim, the unfavorable effect of changes in foreign exchange rate, higher sales and marketing expenses to support launches of new products and new indications as well as the pharmaceutical manufacturers fee associated with U.S. healthcare reform which was roughly $45 million.
Excluding the effective healthcare reform in the BIL alliance, operating expenses would've grown 7%.
Other income and deductions was in net expense of $58 million this quarter which was higher than it was last year. The higher net expense was due to a write-down of the value of the proteinase assets as a result of the FDA Complete Response Letter we received in April in which the agency requested additional clinical data. Our tax rate was 20.9% this quarter, or 1.6 percentage points lower than in Q2 2010. This reduction is primarily due to the R&D tax credit that was not in effect during Q2 2010 but was in effect during Q2 2011. At the bottom line, our non-GAAP EPS decreased 5% from $1.24 to $1.18.
Consistent with the 2011 guidance we provided in January, we saw robust EPS growth in our business in Q2 excluding U.S. healthcare reform, the effect of GEMZAR patent expiration should outside of Japan and investments related to the DI diabetes alliance.
Excluding these items, EPS would've grown in the high teens.
Slide 7 shows our purported income statement while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release.
Now let's look at foreign exchange in and its effect in our Q2 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 5%. This quarter, foreign exchange contributed to remain 4% while price had virtually no impact on worldwide revenue growth.
We continue to see strong volume growth from our 3 counter cyclical growth drivers: Japan, Animal Health and emerging markets. Volume growth in Japan was 15% driven by the recent launches of Cymbalta and Forteo. Recall that the Q1 precautionary buying as a result of the Japanese earthquake and its aftermath increased Q1 sales by about $30 million to $35 million. As expected, this was largely worse in Q2 trimming Japan's volume growth this quarter by about 6 percentage points.
Going to Animal Health volume growth were 16% in Q2 driven by the increase of demand for food animal products globally as well as the launch of something in the U.S., the continued expense expansion of our animal business globally and the acquisition of certain European Animal Health assets from Pfizer.
Finally, embedded within the Rest of World line is our emerging markets revenue growth of 11% in volume and 13% over overall. Particularly noteworthy was China's revenue growth of 20% volume and 26% overall.
This quarter, it is worth reviewing the effect of foreign exchange and the rest of our income statement. While FX did not have large effect on EPS growth, it did affect individual line items.
Slide 10 shows the year on year growth of select line items of our non-GAAP income statement, both with and without the effective changes in foreign exchange currency. The numbers in the first column are the same as those used on the last call on Slide 6. Let's focus on the second column of the numbers which groups out the effect of foreign exchange rate. First you'll see the 5% growth in revenue I mentioned earlier. Below that come you'll see that cost of sales and gross margin also grew 5%. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was entirely due to the effect of foreign exchange on international inventories sold.
In total, operating expenses grew 9% excluding FX. This increase was driven by the DI deal, the launch of new products and indications, and the pharmaceutical industry fees. Since increasing operating Spence exceeded increase in gross margin, operating income declined 3% and EPS declined 4%. You can see that while FX had a material impact on revenue, cost of sales and operating expense, it really almost had no impact on operating income for the EPS of this quarter. So while FX didn't have much of an impact on EPS growth, U.S. healthcare reform, the effect of expiry outside of Japan and the investments related to the DI something certainly did. As mentioned earlier, excluding these items, EPS would've grown in the high teens.
On Slide 11, you'll find year-on-year your growth of these same items in our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. On Slide 12, you'll find a view of our portfolio of new modular and something clinical development as of July 11 inclusive of changes since our April date. Our clinical phase portfolio now stands at 70 including 33 compounds in Phase II and Phase III. Biotech molecules represent over 40% of our Phase II and Phase III assets as well as our overall clinical portfolio.
Advancing our pipeline remains our number 1 priority. As reflected by the arrows, you can see that since our April date we received FDA approval for and launched Tadjenta. We've something to assets and phase testing. We advanced an additional 3 assets in the Phase I testing including our basil we expect to begin pivotal trials for this molecule before your ends and we terminated develop of 1 Phase I asset.
As Doctor Lundberg shared during our investment community meeting on June 3rd, we are very pleased with the progress we've made over in a robust, high-quality pipeline with many potential opportunities to advance patient care and diseases with large unmet needs as well as commercial opportunities. We're on track to meet or exceed our goal of having 10 enemies by Phase III of believe that our that our current pipeline provides the foundation for Lily to return to growth post 2014.
Derica?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the E",860,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the European commission approval later this quarter and then launching the product in Europe later this year.
In addition to our successes so far this year, we have a number of other potential regulatory approvals in the U.S. this year including Cialis for BPH; by aide in combination with basal insulin; and Erbitux for first-line head and neck cancer.
Expect the regulatory submissions include our response to the FDA complete response letter for Bydureon. The FBL 8 for Erbitux and first-line metastatic colorectal cancer, and our response to the FDA complete response letter for Amyvid.
We continue to expect a chewing of our mid to late stage pipeline as Phase III trials could begin this year for 1, our novel basal insulin analog and our new insulin something product as well as our anti-IL 17 monoclonal antibody.
Finally, on the legal front, at anytime, we could have rulings from the CAFC on the Strattera patent challenge and from the District Court in Delaware on the Alimta patent challenge. Now you may recall that in the Alimta case, the judge had indicated from the bench that a ruling would be issued in Lily's favor. 
Now in terms of our 2011 financial guidance, we updated the guidance issued in April for a number of factors including: Continued strong volume growth in revenue-driven by our 3 counter cyclical growth engines in our patent protected brands; secondly, stronger foreign currencies which drives up the expected growth rates of revenue, SG&A and R&D; thirdly, very prompt approvals to linagliptin in most markets which driving an increase in expected SG&A spend in 2011 as well as some additional expected revenue; and fourthly, the write-down of the intangible value of liprotamase which is driving higher expected net other expense for the year.
In total, these changes result in an increase in narrowing of our non-GAAP EPS guidance. We now expect 2011 non-GAAP earnings per share of between $4.25 and $4.35. Our 2011 reported EPS guidance range of $3.85 to $3.95 reflects the $0.23 I charge from the DI alliance and $0.17 in restructuring charges for the first half of the year.
Now these changes resulted in updates that most of the individual line items as well. Revenue is now expected to grow in the mid-single-digits while we expect the gross margin as a percent of revenue to decline by 2 to 3 percentage points. SG&A growth is now expected to be in the high-single-digits and R&D growth is now expected to be the low-single-digits.
Other income is now forecasted to be a net loss in the range of $100 million to $175 million. We still expect our 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. And we expect capital expenditures to be in the range of $700 million to $800 million.
Now Slide 15 provides insulation between reported and non-GAAP EPS for 2011 and the associated with growth rates from these numbers to our revised 2011 guidance.
In summary, 2011 continues to play out as we had anticipated. We're making progress advancing our pipeline and we're delivering solid financial results. We remain on track to meet our goal of having 10 molecules in Phase III development by the end of this year. And as John articulated on June 30, we're seeing promising signs that in addition to increasing in numbers, our mid to late stage pipeline is increasing in quality as well. We firmly believe that our current pipeline serves as the foundation to return to growth post years YZ
We also remain on track to meet our 2011 headcount as expense containment goals helping to create the financial flexibility to invest in our pipeline, our counter cyclical growth engines in current brands, as well as maintain the dividend. In Q2, we saw this impact of the headwinds that we had anticipated when we issued our 2011 financial guidance in January. And when we updated that guidance on our Q1 earnings call in April. These headwinds are: Patent expirations that are lowering sales of GEMZAR outside of Japan; U.S. healthcare reform which is exacting a higher cost this year than it did in 2010; and near-term dilution for our strategic diabetes alliance with Boehringer Ingelheim. While we did see the negative impact in Q2 of these items, we again delivered strong growth in the remainder of our business.
Excluding those 3 items, on a non-GAAP basis, we posted revenue growth of 13%, operating expense growth of 7%, and high teens EPS growth.
Moving forward, we will continue to focus on delivering solid financial results, improving productivity to allow for appropriate investments in our patent-protected products and our pipeline, and out-speeding the next generation of Lily molecules for the market to provide growth post YZ. 
Now this concludes our prepared remarks and we will open the call for the Q&A session. Operator, first caller please."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] First question comes from the line of Marc Goodman from UBS.",13,"[Operator Instructions] First question comes from the line of Marc Goodman from UBS."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Can you give us a little more flavor for the volume growth of product in Japan, Cymbalta, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the 1 growth rate for overall, but can you g",69,"Can you give us a little more flavor for the volume growth of product in Japan, Cymbalta, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the 1 growth rate for overall, but can you give us a sense, besides China, what else is going on, what of the launches of driving the business there?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay Mark, thank you for the question. For emerging markets first, as we mentioned in the call, we definitely had very strong growth in China. But in addition to that, we are seeing growth in a number of other emerging markets spread across the Asian regi",165,"Okay Mark, thank you for the question. For emerging markets first, as we mentioned in the call, we definitely had very strong growth in China. But in addition to that, we are seeing growth in a number of other emerging markets spread across the Asian regions and also very good growth still -- from the South America countries. We do have some upcoming patent exposures. We'll begin to see for example in Brazil weighted more heavily. But we continue to see strong growth across a number of those geographies. In Japan, Mark, it really is pretty so widespread. Forteo, for example, is off to a very strong start with the launch of the second half of last year. Cymbalta is doing very well. The insulins are doing extremely well. Olympus share growth has been extremely good since the launch there. Going back I think that would be earlier in 2010, late 2009. So really broad-based growth across a number of products driving the Japanese performance."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Mark, this is Derica. The only thing I would add is, If you look at Japan not only do we have a good growth but it's been sustained or so we have, for about 40, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter, but we knew",102,"Mark, this is Derica. The only thing I would add is, If you look at Japan not only do we have a good growth but it's been sustained or so we have, for about 40, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter, but we knew that had some buy-in as a result of the earthquake and tsunami. But if you were to normalize for that with a de-stocking that we saw on the second quarter, we basically were about 30% to 31% growth in each of the first 2 quarters of this year."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We had about as something mentioned $30 million to $31 million of buying the first quarter, $20 million, anyone million dollars worked its way out in the second quarter.",29,"We had about as something mentioned $30 million to $31 million of buying the first quarter, $20 million, anyone million dollars worked its way out in the second quarter."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Your next caller comes from the line of Tim Anderson from Sanford Bernstein.",13,"Your next caller comes from the line of Tim Anderson from Sanford Bernstein."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Pfizer said it would be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lily to go after that. Would it just be an antitrust issue? Second question is",107,"Pfizer said it would be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lily to go after that. Would it just be an antitrust issue? Second question is on your Phase III trials for your version of insulin glargine. Are you going to have Lantos as an active comparator? And then the last question, just in the Janssen animal health business. I don't believe we have any financial details there and I'm wondering how that ties into the 2011 guidance. Is that deal an accretive transaction for you?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Tim, thank you for your questions will have their to take your first and then comment on the third and then Joe and Jan, you want to handle question Erika?",30,"Tim, thank you for your questions will have their to take your first and then comment on the third and then Joe and Jan, you want to handle question Erika?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, Tim, in regards to our animal health business, you 2 questions, 1 in regards to Pfizer decision around our own animal health business I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whethe",225,"Good morning, Tim, in regards to our animal health business, you 2 questions, 1 in regards to Pfizer decision around our own animal health business I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether it'll be a sale, a spend or an outright IPO I think it's still to be determined. So I think at this stage will be released that it would've on our part. Clearly, we will watch how that situation evolves and if there are some assets that become available that we're interested in, then yes, we would pursue them. But we're very happy as well with our -- the current state of our going to animal health business. And right now, we're the fastest growing entity in that space and we feel very good about that launches that Jeff talked about in New York where we've had 6 launches so far this year coming from our own pipeline. So with or without an additional transaction, we do believe we have the capacity sustained attack of growth we've seen through this point. And in fact in the second quarter this year and in the second quarter, Linco actually grew 20%. In regards to the impact of the Janssen deal that we just closed this year, it's basically neutral to the bottom-line."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In terms of the financial this is when you look at the industry sources like something, you obviously see that the something sales roughly $200 million for 2010. We would encourage you to keep in mind that does include sales of their products in markets w",74,"In terms of the financial this is when you look at the industry sources like something, you obviously see that the something sales roughly $200 million for 2010. We would encourage you to keep in mind that does include sales of their products in markets where they are actually going to a distributor, the actual sales that they would have prior or we going forward would be less than that $200 million-type level. Jan?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to our insulin something product in relation to something testing we would use Lantos is comparator first Phase III trial.",22,"In relation to our insulin something product in relation to something testing we would use Lantos is comparator first Phase III trial."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","our next question comes from the line of Jami Rubin from Goldman Sachs.",13,"our next question comes from the line of Jami Rubin from Goldman Sachs."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Derica, my question relates to the Ingelheim deal. Majesta sales posted by particularly this quarter obviously very early to tell. But if you could just remind us of how that the works? Because I think you had talked about achieving accretion next year or",152,"Derica, my question relates to the Ingelheim deal. Majesta sales posted by particularly this quarter obviously very early to tell. But if you could just remind us of how that the works? Because I think you had talked about achieving accretion next year or the year after. I don't remember but I'm wondering if that is dependent on you reaching a certain level of sales with Tradjenta is there possibility built into the contract to reduce spending if you are not getting to the level that you anticipate. And also, so you're increasing your SG&A spend for the back half of the year, i'm just wondering what's changed because we -- that be ideal it has been known the pharmacy fees have been known, et cetera, et cetera. So if you could just provide a little bit more granularity of what additional levels of spend and is it behind the Tradjenta launch?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Jami. In regards to the be ideal, essentially, it's a target share. If you look in terms of the deal structure itself, really, we've had very good news around that brand. So we got -- received an earlier something expect to launch both in the U.S. a",120,"Sure, Jami. In regards to the be ideal, essentially, it's a target share. If you look in terms of the deal structure itself, really, we've had very good news around that brand. So we got -- received an earlier something expect to launch both in the U.S. as well as some of the key markets outside the U.S. like Mexico, like Brazil, like Japan. So when you look at our SG&A spend guidance for the year, the primary driver of the increase is FX-related. Similar to what we talked about on the top line. But at the same time, we are supporting the earlier launches of Tradjenta in those key markets that I highlighted. So those are the 2 factors."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And in terms of characterization we have been getting in the past, we talked about their dilution obviously higher this year driven by the upfront charge that we had in the first quarter and an lessening in 2012 and 2013 and then turning positive 2014 and",107,"And in terms of characterization we have been getting in the past, we talked about their dilution obviously higher this year driven by the upfront charge that we had in the first quarter and an lessening in 2012 and 2013 and then turning positive 2014 and beyond. We obviously would have a likely have a bit more dilution this year given the incremental investment of some of these approvals and launches is coming towards the earlier and if a spectrum of what was contemplated. However, we're potentially making for that and more in our full year guidance by the way of the something of a non-GAAP basis."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And now we'll go to the line of Steve Stallion from Cowen.",13,"And now we'll go to the line of Steve Stallion from Cowen."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","three something in the press release clearly states it is difficult to put it predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generic. This language was not in the Q1 release to my knowledge. May I ask why",100,"three something in the press release clearly states it is difficult to put it predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generic. This language was not in the Q1 release to my knowledge. May I ask why will he believes it is difficult to predict the timing and magnitude? What is unusual about the situation? There was no similar language, for instance, in the Strattera paragraph. And what percent of U.S. Zyprexa sales are protected by contracts that extend and 2012 and therefore will not be impacted by the patent expiration?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see, probably as we go through this. There will be an impact on our returns policy. So for, a",165,"Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see, probably as we go through this. There will be an impact on our returns policy. So for, at the time of the product goes generic, how much inventory will actually be sitting out retail channel which creates an exposure towards of returns. The second is with the actual adoption rate in terms of generic utilization will be in terms of buying patterns of wholesalers as well as formularies. So that's where the unpredictable nature of this comes in. But we think we've accounted for a reasonable estimate of that in the guidance range that we provided. And even with those types of uncertainties, as you heard from Phil earlier in the call, we still have strong enough underlying business fundamentals that has enabled us to be in a position to raise our guidance overall."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And the next caller will go to the line of David Risinger from Morgan Stanley.",15,"And the next caller will go to the line of David Risinger from Morgan Stanley."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","So first of all, is a financial question for Derica and then I have to product questions. With respect to Slide 9, indicates that U.S. price had a 0% impact on year-over-year revenue growth. Can you just explain to us how you reflected the negative impact",146,"So first of all, is a financial question for Derica and then I have to product questions. With respect to Slide 9, indicates that U.S. price had a 0% impact on year-over-year revenue growth. Can you just explain to us how you reflected the negative impact of health care reform in that line? I'm assuming that is what brought that down to 0% given numerous list pricing increases for U.S. products. Second, how do you see competing with Rowenta? And could you characterize how we should think about the competition playing out in the U.S. differently from x U.S. market? And then third, how much of a positive read should investors take away from a futility analysis later this year that results in continuing to completion? Meaning, you give us a sense for how low or how high the efficacy bar is in the futility assessment."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In regards to the U.S. price, it's really been affected by 2 factors. One is the incremental impact of U.S. healthcare forms, both the full year effective U.S. healthcare reform as well as the introduction of a donut whole provision. The second being that",77,"In regards to the U.S. price, it's really been affected by 2 factors. One is the incremental impact of U.S. healthcare forms, both the full year effective U.S. healthcare reform as well as the introduction of a donut whole provision. The second being that impacting is also the erosion of GEMZAR in the U.S., the price erosion. Those are the 2 things that are allowing our net effect of selling price impact of the 0. Jan?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So let me start with the anti-platelet agents. As you all know, FE is a universal, once daily anti-platelet while Brilinta is a reversible price daily agent. A key difference is that in the Effiant studies, which of course are not the same as the Brilinta",316,"So let me start with the anti-platelet agents. As you all know, FE is a universal, once daily anti-platelet while Brilinta is a reversible price daily agent. A key difference is that in the Effiant studies, which of course are not the same as the Brilinta studies and to really compare them, we need direct head-to-head studies. But if the U.S. patients in the Effiant an studies did better than. For some, still unclear reason in Brilinta to the U.S. patients actual actually did better on it's a discrepancy for Brilinta to do the whole world data. There is also some dyspnea some of side effects with Brilinta that Effiant doesn't have. So for the moment, I think we have here to effective anti-platelet agents in the whole world populations while in the U.S. population, Effiant did better. And the FTA I think to that interpretation into actually saying that Brilinta should not be used to have a high aspirin dose which clearly Effiant could be used when you have I think the U.S. treatment paradigm today has a high number of high aspirin in combinations. It's actually with Effiant. But overall on your own we need head-to-head studies to really direct comparison. In relation to futility analysis that will come later this year, this is the judgment of the DNC of the benefits risk component they will look clearly at safety as well as futility on efficacy. And this is their judgment. But my interpretation is that since Alzheimer's disease is a very serious disease, there is no real treatment to stop progression of the disease and we don't really know today when would the potential effect start of preventing that amyloid. So my feeling is this will be a judgment call for the DMC in whatever the outcome, we need to wait for the full study before we can draw any clear conclusions."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of John Boris from Citi.",12,"Our next question comes from the line of John Boris from Citi."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","First question just in light of budget negotiations in Washington, there is some risk that we somewhat believe that's been weighing on the group that the government may come back and look for some additional funds and obviously, to my knowledge to do beli",142,"First question just in light of budget negotiations in Washington, there is some risk that we somewhat believe that's been weighing on the group that the government may come back and look for some additional funds and obviously, to my knowledge to do believe that provision could be potentially pulled during budget negotiations. Is just your thoughts around what the risk is around that and what the impact would be. And then one question for Jan, has to do with as SGL-2, the profile, does he believe the increased platter cancer risk is a classic set? Is that something that we might see with a boring. Compound along with the liver toxicity we've been seeing? And then when final question, just has to do with a sheet using an authorized generic something with a stem and Cymbalta. Just your thoughts around that"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have to take your first question, and I'll handle your age question.",14,"We'll have to take your first question, and I'll handle your age question."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","John. As it relates to the debate or discussion around the deficit reduction challenge in the U.S., clearly, it's still very early and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of, for the kinds of things that are b",184,"John. As it relates to the debate or discussion around the deficit reduction challenge in the U.S., clearly, it's still very early and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of, for the kinds of things that are being debated and if they were want to produce a Medicaid type rebates into Medicare Part D, that would be a profound impact, not only for Lily but also for the industry. So that's something that we would not support and I don't think our industry peers would either. Along those same lines, we also would not be supportive of reducing the bio -- data protection from biologics and the data strengthening of the position of iPad. So these all our concerns that we have and obviously we continue to engage in discussion and dialogue with the parties at hand. If any of those were to move forward, then they would clearly have an impact on jobs in the U.S. and I don't think that's where we all want to given the budget discussions to stimulate the economy."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to the SGLT class, it is important to remember that this is an is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial a",166,"With regards to the SGLT class, it is important to remember that this is an is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attributes. In relation to the reported increase in cancer in EMS Seneca compound we have no evidence so far that this is happening with the amp life flow. Clearly, we only have more short-term observations and we really need to have all the Phase III data before giving any definite answers. We observed also single case of the high, we have not seen that in our studies. And just a final comment to come back to the cancer reports here that there is no clinical data or hypothesis that would support that there is an increased risk of liver cancer. It's a finding like always, safety is paramount and we need to observe this and be cautious about the future."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And John In response to your question about generic something what will be doing each and every time that we do have a patent expiration whether it be a injectable like we have with GEMZAR or oral molecule like Zyprexa or Cymbalta will definitely look at",225,"And John In response to your question about generic something what will be doing each and every time that we do have a patent expiration whether it be a injectable like we have with GEMZAR or oral molecule like Zyprexa or Cymbalta will definitely look at a host of different options and I think it's safe to assume that we have both locations already done planning looking at different things to see what is the most appropriate late life cycle strategy for the molecule. I would say that is not the case where an AG would always be a preferred approach, so it really will be on the molecule by molecule basis. If we were to elect not to do 1, on the next 1, for example, I would take that as an indication we didn't like the way something with GEMZAR. In fact we have felt that have done quite well. And if we would be 1, for example, on a proxy, I don't know if that would be necessary. We would do well and Cymbalta. It really does come down to what the lines of business the customer groups of these products go to, capabilities, or partners, et cetera. We'll keep you posted but at that this time we have no comment specifically on what will be planned looking for the Zyprexa."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We'll go to the line of Seamus Fernandez from Leerink Swann.",12,"We'll go to the line of Seamus Fernandez from Leerink Swann."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","One for Jan. I do know if there was any reason to think about the molecular structure of the bag of frozen to succeed look aside versus the molecular structure of the boring during what I'm compound relative to possible liver effects. So maybe you can wei",93,"One for Jan. I do know if there was any reason to think about the molecular structure of the bag of frozen to succeed look aside versus the molecular structure of the boring during what I'm compound relative to possible liver effects. So maybe you can weigh in on that. And then separately, you just update us on any price changes that have occurred incrementally in Europe versus your expectations? And update us on any proposals that may actually be out there as we work through the incremental possibilities of the debt crisis."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll go to Jan for the first question and then I'll pack and your question in the looking forward for that we'll be expecting what's happened very recently.",29,"We'll go to Jan for the first question and then I'll pack and your question in the looking forward for that we'll be expecting what's happened very recently."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to structural activity relationships in relation to potential liver effects of the agents, I think it's too early to make any conclusions based on a single case, that that's the first comment. And then secondly, history tells us that this live",87,"In relation to structural activity relationships in relation to potential liver effects of the agents, I think it's too early to make any conclusions based on a single case, that that's the first comment. And then secondly, history tells us that this liver effects could be direct, but they could also be in direct to where the immune system, et cetera, could respond. But I think you for the moment, we have to get our data for our compound before we do any conclusions about liver risks."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, in terms of Europe, the really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in l",198,"Seamus, in terms of Europe, the really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in line with our expectations and do not have a significant impact on something products. The newest 1 I'm aware of probably would be some legislation passed in Poland that will take effect actually in January of 2012. So no impact to this year. Where there will be agreement to go ahead and cap the governments expenditures on pharmaceuticals as a percent of the overall healthcare spend provide rebates on exceeds those levels. Clearly, with continued budget pressures in a number of countries, we'll continue to monitor the situation. We do think there are a degree of substantial cuts taken, particularly on the pharmaceutical side of some of the healthcare broader something spending European nations so I would expect that to be necessarily the first place for them to go but again, we might have situations. We're clearly not out of the woods with the overall situation for the global economy."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We'll now go to the line of Catherine Arnold from Credit Suisse.",13,"We'll now go to the line of Catherine Arnold from Credit Suisse."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I'd like a question or 2 about the pipeline. if you could comment on where we are on the trilogy study for effiant is that still on track. And we just completed the first half of last year and if data could beat presented in the second half of next year,",102,"I'd like a question or 2 about the pipeline. if you could comment on where we are on the trilogy study for effiant is that still on track. And we just completed the first half of last year and if data could beat presented in the second half of next year, was there anything about the Brilinta label that would be surprising relative to what your expectations were internally? And then lastly, is in your pipeline chart but I don't know if we've heard anything about that for a long time and I'm wondering why what's happening with this particular product?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Catherine, to take your first question instead is an trilogy now handled a little us to.",17,"Thanks, Catherine, to take your first question instead is an trilogy now handled a little us to."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to trilogy, keep in mind it's an event driven trial but the current estimate than we typically stick to its estimated in the late clinical trials go estimated right now to be completed in April of '12 so that's something progressive and we lo",50,"With regards to trilogy, keep in mind it's an event driven trial but the current estimate than we typically stick to its estimated in the late clinical trials go estimated right now to be completed in April of '12 so that's something progressive and we look forward to that data."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And with regard to the label on Brilinta probably a little bit later today after we finished the call had a chance to debrief more fully with the team. We'll evaluate that when it came out in the close yesterday. So at this point, I don't have a specific",69,"And with regard to the label on Brilinta probably a little bit later today after we finished the call had a chance to debrief more fully with the team. We'll evaluate that when it came out in the close yesterday. So at this point, I don't have a specific comment for you or any items that versus back since it to be heard from the team met or not?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","I think for the moment we're still discussing.",9,"I think for the moment we're still discussing."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And in terms of something Catherine, as you're probably aware, number of years ago, we had submitted to the FDA for the diabetic retinopathy indication have received I think what would now be called a complete response letter to basically asking us to pro",125,"And in terms of something Catherine, as you're probably aware, number of years ago, we had submitted to the FDA for the diabetic retinopathy indication have received I think what would now be called a complete response letter to basically asking us to provide them with more substantive data around the visual acuity. So we're in the process of completing the last time that such a diabetic macular edema study that could potentially furnish the date the FDA is looking for. Last step I had is in something trial that concludes late this year once we have that data in hand, and will either decide we submit to the FDA, ask them to reconsider the application or do we pull the NBA with the agency?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Let's go to the line of Greg Gilbert from Bank of America.",13,"Let's go to the line of Greg Gilbert from Bank of America."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","First I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lily and if you don't have anything specific to say, maybe could offer conceptually what types of things you're going to look into to be able to answer",69,"First I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lily and if you don't have anything specific to say, maybe could offer conceptually what types of things you're going to look into to be able to answer that question down the line? And secondly, Derica, could you offer any color in SG&A and R&D lumpiness between 3Q and 4Q?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Greg, thanks. With regards to the Medco Express, it's still early. We do not and typically going to have a material impact on Lily. I think the bigger impact is actually be on the health plans themselves, but they served in terms of going from reducing th",215,"Greg, thanks. With regards to the Medco Express, it's still early. We do not and typically going to have a material impact on Lily. I think the bigger impact is actually be on the health plans themselves, but they served in terms of going from reducing the number of players. For us, we obviously feel very good about the attributes of our brand and maybe in the therapeutic area where we compete today, there is already low cost generic options available, yet our brands have held up very well. So in cases like depression or even in schizophrenia, we've with being generic. So we're not going to anticipate that this is going to have a material impact on lately it this day. But once again, still early. In regards to the Q3 or Q4 impact of SG&A and R&D, I think it's pretty much embedded in our guidance and the color I provided earlier. If you you're looking at SG&A, primarily what you're seeing in terms of our change in our line item guidance is the impact of exchange rate, both in SG&A and R&D and then more specifically for SG&A, it's also the impact of the earlier spend, launch spend behind Tradjenta. And we can sensibly considered that to be a huge positive force."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We now go to the line of Chris Schott of JPMorgan.",11,"We now go to the line of Chris Schott of JPMorgan."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Zyprexa, maybe the first 1 would be in Europe can you talk about the severity of generic erosion you're anticipating here given that some of these markets obviously historically have had lower rates of generic penetration. My second question on a practice",81,"Zyprexa, maybe the first 1 would be in Europe can you talk about the severity of generic erosion you're anticipating here given that some of these markets obviously historically have had lower rates of generic penetration. My second question on a practice at ZYPREXA with the upcoming patent expiration, can you help us a little bit better the impacted gross margins and quantify how much of an impact the gross margin we should expect due to the loss of that franchise?"
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So with regards to ZYPREXA in the patent in Europe and Asia, you might keep in mind that in the major route Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion, but expect to see addit",85,"So with regards to ZYPREXA in the patent in Europe and Asia, you might keep in mind that in the major route Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion, but expect to see additional erosion as we go through the year. With regards to the rest of major Europe, the patent will actually expire in September. And keep in mind, we will again expect to see additional erosion as that occurs."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Chris, in terms of the impact of the gross margin as well, I cannot ratify specific determinable impact and its detriment will. So when we lose a brand like ZYPREXA and with its level of profitability, you'll see an unfavorable impact to our gross margin",54,"Chris, in terms of the impact of the gross margin as well, I cannot ratify specific determinable impact and its detriment will. So when we lose a brand like ZYPREXA and with its level of profitability, you'll see an unfavorable impact to our gross margin line as that placed through our P&L financial results."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","One of the other things, Chris, I had to keep in mind for European erosion, we may be in a bit of a different environment now than some of the countries in the past may be apparent to many of the payers that there would be very large brands and a large nu",185,"One of the other things, Chris, I had to keep in mind for European erosion, we may be in a bit of a different environment now than some of the countries in the past may be apparent to many of the payers that there would be very large brands and a large number of them coming off patent. And they've effectively positioned themselves to benefit as they should from those patent expirations. So much of the action that you saw in 2010 even was really directed against reducing prices generics and setting up situations where once they stopped at a branded product goes generic, the initial price for those generics will come out lower. You probably permission this in detail but many press in the past, branded price have been lower in Europe than here in the U.S. But actually the generic price will be substantially higher in Europe than here in the U.S. So again, think you're going to see a stronger push to use generics more quickly and more fully as of the markets in the past may have been slow erosion markets."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And that will go to the lineSeamus Fernandez.",9,"And that will go to the line
Seamus Fernandez."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just a quick follow up on the FES versus Brilinta situation. can you just at least in terms of the launch trajectory and the percentage share that you currently have with the incident ACS patient population, can you guys update us on that? I think earlier",75,"Just a quick follow up on the FES versus Brilinta situation. can you just at least in terms of the launch trajectory and the percentage share that you currently have with the incident ACS patient population, can you guys update us on that? I think earlier he had given us an early estimate of 11 shares and 1.and I'm just wondering where we sit today at least in the U.S. market on a relative basis."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So you might remember Seamus, we've got some excitingly so traction with regards to over the last proxy over the last quarters. What we're seeing there as we're seeing quarter-over-quarter nice trends with our TRx. We're still seeing continued growth with",119,"So you might remember Seamus, we've got some excitingly so traction with regards to over the last proxy over the last quarters. What we're seeing there as we're seeing quarter-over-quarter nice trends with our TRx. We're still seeing continued growth with regards to knew to brand which has been very impressive given where we are in the current launch. Right now, that exceeds about 13%. Again, we are seeing about 1 in 5 ACS patients in STEMI type specifically are receiving effiant which is pretty effective so we hope that traction continues and we are seeing quarter-to-quarter growth in NRx on something and are excited by this trend as doctors continue to accept and try proxy grill or effiant."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","With no further questions in the queue will go ahead and turn over to Derica to wrap up the call.",20,"With no further questions in the queue will go ahead and turn over to Derica to wrap up the call."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Well let me include by first of all right-thinking all of you for joining us on today's this morning's call and more specifically for questions. We hope that the information we provided today is hopeful for your investment of Lily's financial performance",86,"Well let me include by first of all right-thinking all of you for joining us on today's this morning's call and more specifically for questions. We hope that the information we provided today is hopeful for your investment of Lily's financial performance and for the end of our future prospects. As always, the IR team will be available to answer any additional questions you may have. And I look forward to our continued dialogue and I hope you all have a great day. Take care."
285467,97242192,143760,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern time today through July 28th. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code of 207464. I",74,"Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern time today through July 28th. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code of 207464. International participants dial (320) 365-3844. With the access code of 207464. That does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Ple",43,"Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Please go ahead."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer",962,"Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer, Doctor Jan Lundberg; and Ronika Pletcher and Jill Thoren for Investor Relations.
Since we just provided a comprehensive overview of our business at our investment community meeting on June 30, today, we'll limit our prepared remarks, leaving more time for the Q&A session. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decision.
Since the Q1 earnings call in April, we've had a number of significant event, many of them in our diabetes business. On the regulatory front, we had important news for Bydureon. The European Commission granted final approval of BYDUREON, the long-acting formulation of exenatide and the first once-weekly treatment for adults with type 2 diabetes. We launched in the U.K. last week, with launches in other European countries expected over the course of 2011 in the first half of 2012. 
We submitted BYDUREON to regulatory authorities in Japan and, along with Amylin, we completed the thorough QT study to support the U.S. NDA for BYDUREON. In the study, when administered at and above therapeutic levels, exenatide did not prolong the corrected QT interval in healthy individuals. Further, the study found no relationship between QTc interval and plasma exenatide concentrations. We intend to submit our reply to the FDA's Complete Response Letter in Q3.
We also had quite a bit of regulatory news on the linagliptin, the FDA approval of linagliptin, under the trade name Tradjenta, for the treatment of adults with type 2 diabetes. Along with Boehringer Ingelheim, we launched the product here in the U.S. in May. Presented as the first DPP4 inhibitor to be approved at one dosage strength, with no dose adjustment is recommended for patients with kidney or liver impairment.
The Japanese Ministry of Health and Welfare (sic) [Ministry of Health, Labor and Welfare] approved linagliptin under the trade name Trazenta. Along with the eye [ph], we expect to launch the product in Japan later this quarter. Continuing the string of rapid approvals, regulatory authorities in Mexico and Brazil also approved linagliptin, known there as Trayenta, and launches in these countries are also expected in Q3. In Europe, the CHMP recommended approval of Trajenta, and we expect final EC approval later this quarter. Clearly, we're very pleased with the significant progress achieved during Q2 in our diabetes business.
In non-diabetes regulatory news, along with Bristol-Myers Squibb, we submitted the sBLA for Erbitux in first-line, non-small cell lung cancer. On the clinical front, at ASCO, we presented positive data from PARAMOUNT, the second study to evaluate the use of Alimta's maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer and the first study to evaluate the use of continuation maintenance with Alimta, following first-line Alimta plus cisplatin therapy. Based on data from PARAMOUNT, we submitted our dossier [ph] in Europe earlier this year. And we plan to submit here in the U.S. once we have more mature, overall survival data.
On the business development front, we received final EC approval for and finally closed on our acquisition of Janssen's animal health business. We signed an exclusive worldwide collaboration agreement with Synthes, under which the 2 companies will jointly develop site-specific bone-healing products. The companies will also conduct and fund the evaluation of additional orthopedic uses for Forteo. In addition to the development component of the agreement, the collaboration includes the co-promotion of Forteo to orthopedic surgeons in the U.S. and in select o U.S. countries.
We signed agreements with private investors to establish  BioCritica. Based in Indianapolis, BioCritica will initially focus on the continued U.S. development and commercialization of Xigris for severe sepsis. BioCritica 
will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development of Lilly. The collaboration agreement also includes an option for BioCritica to acquire the development and commercialization rights to Xigris outside the U.S. at a later date.
We entered into a collaboration with Medtronic to research and development new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system. Specifically, the goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lily's biologic, a modified form of glial cell derived neurotrophic factor with Medtronic's implantable drug infusion system technology. 
Lastly on the legal front, the Supreme Court denied Lilly's petition to reconsider a federal appeals court ruling invalidating the Gemzar method of used patent. And the judge for the U.S. District Court for the Southern District of Indiana ordered all generic drug manufacturers, challenging the validity of the crack compound patent for Cymbalta not to sell a generic version of duloxetine until the patent expires. As a result, we do not expect generic duloxetine come into market until the Cymbalta patent expires in June 2013 or December 2013, if we're successful in obtaining the six-month pediatric exclusivity.
Now as a background, Ronika will discuss our Q2 financial results and provide our pipeline update, and Derica will then cover key events to our major 2011 and our financial guidance for the year. Ronika?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments an",1198,"Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments and other special charges. I'll start on Slide 6 with a quick look at our Q2 income statement. 
On a non-GAAP basis, you can see that we generated robust revenue growth of 9% this quarter. Excluding Gemzar outside of Japan and the effective view of health care reform, revenue would've grown 13%. Compared to Q2 2010, gross margin as a percentage of revenue decreased 1.8 percentage points but we're still strong at 80.4%. This decrease is entirely due to the effective changes in foreign exchange rates on international inventories sold. 
Operating expenses, defined as the sum of R&D and SG&A, grew 12% this quarter. This increase was driven primarily by SG&A, which increased 16%, over an increase in R&D with 6%. Drivers of the increase in operating expense include expenses related to our diabetes alliance with Boehringer Ingelheim, the unfavorable effect of changes in foreign exchange rates, higher sales and marketing expenses to support launches of new products and new indications, as well as the pharmaceutical manufacturers fee associated with U.S. health care reform, which was roughly $45 million. Excluding the effect of U.S. health care reform and the BI alliance, operating expenses would've grown 7%.
Other income and deductions was in net expense of $58 million this quarter, which was higher than it was last year. The higher net expense was due to a write-down in the value of the liprotamase asset as a result of the FDA Complete Response Letter we received in April, in which the agency requested additional clinical data. 
Our tax rate was 20.9% this quarter or 1.6 percentage points lower than in Q2 2010. This reduction is primarily due to the R&D tax credit that was not in effect during Q2 2010 but was in effect during Q2 2011. At the bottom line, our non-GAAP EPS decreased 5% from $1.24 to $1.18.
Consistent with the 2011 guidance we provided in January, we saw a robust EPS growth in our business in Q2, excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would've grown in the high teens.
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release.
Now let's look at foreign exchange and its effect on our Q2 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 5%. This quarter, foreign exchange contributed the remaining 4%, while price had virtually no impact on worldwide revenue growth.
We continue to see strong volume growth from our 3 counter cyclical growth drivers: Japan, Animal Health and emerging market. Volume growth in Japan was 15%, driven by the recent launches of Cymbalta and Forteo. Recall that the Q1 precautionary buying as a result of the Japanese earthquake and its aftermath increased Q1 sales by about $30 million to $35 million. As expected, this was largely worse in Q2, trimming Japan's volume growth this quarter by about 6 percentage points.
Unlike the Animal Health, volume growth was 16% in Q2, driven by the increase in demand for food animal products globally as well as the launch of Trifexis in the U.S., the continued expansion of our PA [ph] animal business globally and the acquisition of certain European animal health assets from Pfizer.
Finally, embedded within the Rest of World line is our emerging markets revenue growth of 11% in volume and 13% overall. Particularly noteworthy was China's revenue growth of 20% volume and 26% overall. This quarter, it is worth reviewing the effect of foreign exchange on the rest of our income statement. While FX did not have a large effect on EPS growth, it did affect individual line item.
Slide 10 shows the year-on-year growth of select line items of our non-GAAP income statement, both with and without the effective changes in foreign exchange currencies. The numbers in the first column are the same as those used on the last column on Slide 6. Let's focus on the second column of the numbers which groups out the effect of foreign exchange rate. 
First, you'll see the 5% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin also grew 5%. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was entirely due to the effect of foreign exchange on international inventories sold. In total, operating expenses grew 9%, excluding FX. This increase was driven by the BI deal, the launch of new products and indications and the pharmaceutical industry fee. 
Since the increase in operating expense exceeded the increase in gross margin, operating income declined 3% and EPS declined 4%. You can see that while FX had a material impact on revenue, cost of sales and operating expense, it really almost had no impact on operating income for the EPS this quarter. So while FX didn't have much of an impact on EPS growth, U.S. health care reform, the effect of due of our patent expirations outside of Japan and the investments related to the BI, Eli [ph] certainly did. As mentioned earlier, excluding these items, EPS would've grown in the high teens.
On Slide 11, you'll find year-on-year growth of these same items on our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our portfolio of new molecular entities in clinical development as of July 11 inclusive of the changes since our April update. Our clinical phase portfolio now stands at 70 to state [ph], including 33 compounds in Phase II and Phase III. Biotech molecules represent over 40% of our Phase II and Phase III assets as well as our overall clinical portfolio.
Advancing our pipeline remains our number one priority. As reflected by the arrows, you can see that since our April update, we received FDA approval for and launched Tradjenta; we've had two assets in the Phase II testing; we advanced an additional 3 assets in the Phase I testing, including our basal insulin RGs [ph]. We expect to begin pivotal trials for this molecule before year end, and we terminated development of one Phase I asset.
As Doctor Lundberg shared during our investment community meeting on June 30, we're very pleased with the progress we've made, building a robust, high-quality pipeline with many potential opportunities to advance patient care and nasal [ph] diseases, with large, unmet needs as well as commercial opportunity. We're on track to meet or exceed our goal of having 10 entities in Phase III by year end and believe that our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the",862,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. 
As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the European Commission approval later this quarter and then launching the product in Europe later this year. In addition to our successes so far this year, we have a number of other potential regulatory approvals in the U.S. this year, including Cialis for BPH, by aide in combination with basal insulin; and Erbitux for first-line head and neck cancer. Expect the regulatory submissions include our response to the FDA Complete Response Letter for BYDUREON, the sBLA for Erbitux and first-line metastatic colorectal cancer, and our response to the FDA Complete Response Letter for Amyvid. We continue to expect a maturing of our mid to late stage pipeline as Phase III trials could begin this year for, one, our novel basal insulin analog and our new insulin glargine product, as well as our anti-IL-17 monoclonal antibody.
Finally, on the legal front, at anytime, we could have rulings from the CAFC on the Strattera patent challenge and from the District Court in Delaware on the Alimta patent challenge. Now you may recall that in the Alimta case, the judge had indicated from the bench that a ruling would be issued in Lily's favor. 
Now in terms of our 2011 financial guidance, we've updated the guidance issued in April for a number of factors, including continued strong volume growth in revenue, driven by our 3 counter-cyclical growth engines and our patent-protected brand; secondly, stronger foreign currencies, which drives up the expected growth rates of revenue, SG&A and R&D; thirdly, very prompt approval to linagliptin in multiple market, which is driving an increase in expected SG&A spend in 2011, as well as some additional expected revenue; and fourthly, the write-down of the intangible value of liprotamase, which is driving higher expected net other expense for the year.
In total, these changes result in an increase in narrowing of our non-GAAP EPS guidance. We now expect 2011 non-GAAP earnings per share of between $4.25 and $4.35. Our 2011 reported EPS guidance range of $3.85 to $3.95 reflects the $0.23 IPR&D charge from the BI alliance and $0.17 in restructuring charges for the first half of the year.
Now these changes have resulted in updates to the most of the individual line items as well. Revenue is now expected to grow in the mid-single digits, while we expect the gross margin as a percent of revenue to decline by 2 to 3 percentage points. SG&A growth is now expected to be in the high single digits, and R&D growth is now expected to be in the low single digits.
Other income is now forecast to be a net loss in the range of $100 million to $175 million. We still expect our 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. And we expect capital expenditures to be in the range of $700 million to $800 million. Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2011 and the associated growth rates from these numbers to our revised 2011 guidance.
In summary, 2011 continues to play out as we had anticipated. We're making progress advancing our pipeline, and we're delivering solid financial result. We remain on track to meet our goal of having 10 molecules in Phase III development by the end of this year. 
And as John articulated on June 30, we're seeing promising signs that, in addition to increasing in numbers, our mid- to late-stage pipeline is increasing in quality as well. We firmly believe that our current pipeline serves as the foundation to return to growth post-Years YZ.
We also remain on track to meet our 2011 headcount as expense containment goals, helping to create the financial flexibility to invest in our pipeline, our counter-cyclical growth engines in current brands, as well as maintain the dividend. In Q2, we saw this impact of the headwinds that we anticipated when we issued our 2011 financial guidance in January, and when we updated that guidance on our Q1 earnings call in April. These headwinds are patent expirations that are lowering sales of Gemzar outside of Japan; U.S. health care reform, which is exacting a higher cost this year than it did in 2010; and near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. While we did see the negative impact in Q2 of these items, we again delivered strong growth in the remainder of our business. Excluding those 3 items, on a non-GAAP basis, we posted revenue growth of 13%, operating expense growth of 7% and high-teens EPS growth.
Moving forward, we will continue to focus on delivering a solid financial result, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline and outspeeding the next generation of Lilly molecules to market to provide growth post-Years YZ. 
Now this concludes our prepared remarks, and we will open the call for the Q&A session. Operator, first caller please."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS.",15,"[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one gro",75,"Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one growth rate for overall, but can you give us a sense of, besides China, what else is going on, what other launches are driving the business there?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to tha",188,"Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to that, we're seeing growth in a number of other emerging markets spread across the Asia region. And also, very good growth still from the South American countries. We do have some upcoming patent exposures. We'll begin to see, for example, in Brazil, weigh more heavily. But we continue to see a very strong growth across a number of those geographies. In Japan, Marc, it really is still pretty widespread and good growth. Forteo, for example, is off to a very strong start with the launch on the second half of last year. Cymbalta is doing very well. The insulins are doing extremely well. Alimta share growth has been extremely good since the launch there. Going back, I think, that would have been earlier in 2010, again, late 2009, so really broad-based growth across a number of products driving the Japanese performance."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that",100,"Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that had some buy-in as a result of the earthquake and the tsunami. But if you were to normalize for that with a de-stocking that we saw in the second quarter, we basically about 30% to 31% growth in each of the first 2 quarters of this year."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter.",35,"Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And our next caller comes from the line of Tim Anderson from Sanford Bernstein.",14,"And our next caller comes from the line of Tim Anderson from Sanford Bernstein."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Sec",109,"A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Second question is on your Phase III trials for your version of insulin glargine. Are you going to have Lantus as an active comparator? And then the last question, just on the Janssen animal health business. I don't believe we have any financial details there, and I'm wondering how that ties into the 2011 guidance. Is that deal an accretive transaction for you?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?",34,"Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether",226,"Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether it'll be a sale, a spend or an outright IPO. I think it's still to be determined. So at this stage, it will be really stuck with tip on our part. Clearly, we will watch how that situation evolve. And if there are some assets that become available that we're interested in, then, yes, we will pursue them. But we're very happy as well with our -- the current state of our Elanco animal health business. And right now, we're the fastest growing entity in that space, and we feel very good about the launches that Jeff talked about in New York, where we've had 6 launches so far this year coming from our own pipeline. So with or without an additional transaction, we believe we have the capacity to sustain the type of growth that you've seen through this point. And in fact, in the second quarter this year and in the second quarter here, Elanco grew actually 20%. In regards to the impact of the Janssen deal that we just closed this year, it's basically neutral to the bottom line."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include",84,"And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include sales of their products in markets where they're actually going through a distributor, the actual sales that they would have prior, are we going forward, when we book, would be less than that $200 million-type level. Jan?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial.",23,"In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Jami Rubin from Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin from Goldman Sachs."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Derica, my question relates to the Boehringer Ingelheim deal. So projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accretio",154,"Derica, my question relates to the Boehringer Ingelheim deal. So projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accretion next year or the year after, I don't remember, but I'm wondering if that is dependent on you reaching a certain level of sales with Tradjenta? Or is there a flexibility built into the contract to reduce spending if you're not getting to the level that you anticipate? And also, so you're increasing your SG&A spend for the back half of the year. I'm just wondering what's changed? Because we -- the BI deal has been known, the pharmacy fees have been known, et cetera, et cetera. So just if you could just provide a little bit more granularity on what additional levels of spend, and is it behind the Tradjenta launch?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as wel",229,"Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as well as in some of the key markets outside the U.S. like Mexico, like Brazil, like Japan. So when you look at our SG&A spend guidance for the year, the primary driver of the increase is FX related, similar to what we talked about on the top line. But at the same time, we are supporting the earlier launches of Tradjenta in those key markets that I highlighted. So those are the 2 factors. And in terms of characterization we've been getting in the past, we talked about their being dilution obviously higher this year driven by the upfront charge that we had in the first quarter and then lessening between 2012 and '13, and then turning positive '14 and beyond. We obviously would have like it little more dilution this year given the incremental investment codes [ph] on some of these approval and launches coming towards the earlier end of the spectrum of what was contemplated. However, we're potentially making up for that and more in our full year guidance by the raise that you've seen on a non-GAAP basis."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And now, we'll go to the line of Steve Scala from Cowen.",12,"And now, we'll go to the line of Steve Scala from Cowen."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask w",100,"In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask why Lilly believes it is difficult to predict the timing and the magnitude? What is unusual about this situation? There was no similar language, for instance, in the Strattera paragraph. And what percent of U.S. Zyprexa sales are protected by contracts that extend into 2012 and therefore will not be impacted by the patent expiration?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for",172,"Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for, at the time of the product goes generic, how much inventory will actually be sitting out in the retail channel, which creates an exposure turn of returns. The second is with the actual adoption rate in terms of generic utilization will be, in terms of buying power and patterns of wholesalers, as well as formularies. So that's where the unpredictable nature of this comes in. But we think we've accounted for a reasonable estimate of that in the guidance range that we provided. And even with those types of uncertainties, if you heard from Phil earlier in on the call, we still have a strong enough underlying business fundamental that has enabled us to be in a position to raise our guidance overall."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And next caller goes to the line of David Risinger from Morgan Stanley.",13,"And next caller goes to the line of David Risinger from Morgan Stanley."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0%",172,"I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0% impact on year-over-year revenue growth. Can you just explain to us how you reflected the negative impact of health care reform in that line? I'm assuming that, that is what brought that down to 0% given numerous list price increases for U.S. products. Second, how do you see Effient competing with Rowenta [ph]? And could you characterize how we should think about the competition playing out in the U.S. differently from x U.S. market? And then third, how much of a positive read should investors take away from a futility analysis later this year that results in solanezumab continuing to completion, meaning, could you give us a sense for how low or high the efficacy bar is in the futility assessment?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica's on the first one, and Jan will handle your second 2 questions, Dave.",15,"Derica's on the first one, and Jan will handle your second 2 questions, Dave."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care forms, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second",81,"David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care forms, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second thing that impacting it is also the erosion of Gemzar in the U.S., the price erosion. Those are the 2 things that are allowing our net effect of selling price impact of the year. Jan?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same",324,"Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same as the Brilinta studies. And to really compare them, we need direct head-to-head studies. But the U.S. patients in the Effient studies did better than Plavix, but for some, still unclear reason in Brilinta. The U.S. patients actually did better on Plavix than on Brilinta, with which, it's a discrepancy for Brilinta to the whole world data. There is also some dyspnea some side effects with Brilinta that Effient doesn't have. So for the moment, I think we have here 2 effective antiplatelet agents in the more whole world populations, while in the U.S. population, Effient did better. And the FDA, I think, took that interpretation into actually saying that Brilinta should not be used when you have a high aspirin dose, which clearly Effient can be used when you have. And since, I think, the U.S. treatment paradigm today has a high number of high aspirin in combinations, it's actually would favor Effient. But overall, we need the head-to-head studies to really make a direct comparison. In relation to solanezumab and the futility analysis that will come up later this year, this is a judgment then of the DMC, of the benefit-risk component. They will look clearly at safety as well as futility of efficacy, and this is their judgment. But my interpretation is that, since Alzheimer's disease is a very serious disease, there is no real treatment to stop progression of disease. And we don't really know today when would the potential effect start of preventing than amyloid. So my feeling is, this will be a judgment call for the DMC. And whatever the outcome, we need to wait for the full study before we can draw any clear conclusions."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of John Boris from Citi.",12,"Our next question comes from the line of John Boris from Citi."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","First question, just in light of budget negotiations in Washington, there is some risk that we somewhat believe that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual side indicative",142,"First question, just in light of budget negotiations in Washington, there is some risk that we somewhat believe that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual side indicative point, do you believe that, that provision potentially could be pulled during budget negotiations? Just your thoughts around what the risk is around that and what the impact would be. And then one question for Jan has to do with the SGL-2. The profile, does he believe the increased bladder cancer risk is a class effect? Is that something that we might see with the Boehringer compound, along with the liver toxicity that we've seen? And then, one final question, just has to do with AG, using an authorized generics strategy on Zyprexa and Cymbalta, just your thoughts around that."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question.",23,"Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are be",188,"As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are being debated, if they were to want to introduce with Medicaid-type rebate into Medicare Part D, that would be a profound impact, not only for Lilly but for the industry. And so, that's something we would not support, and I don't think our industry peers would either. Along those same lines, we also would not be supportive of reducing the bio -- data protection from biologics or the strengthening of the position of iPad. So these all group concerns that we have. And obviously, we continue to engage in discussion and dialogue with the parties at hand. And if any of those were to move forward, then they would clearly have an impact on jobs in the U.S., and I don't think that's where we all want to go, given the budget discussions that we had in trying to stimulate the economy."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attri",168,"With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attributes. In relation to the reported increase in cancer then for the BMS-AstraZeneca compound, we have no evidence so far that this is happening with the empagliflozin. Clearly, we only have more short-term observations, and we really need to have all the Phase III data before giving any definite answers. We observed also single case of the high slow. We have not seen that in our studies. Just a final comment to come back to the cancer, the reports here, that there is no clinical data or mechanistic hypothesis that would support that there is an increased risk of, for instance, bladder cancer. It's a finding. Like always, safety is paramount, and we need to observe this and be cautious about the future."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be a injectable like we have wit",240,"And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be a injectable like we have with Gemzar, or oral small molecule like Zyprexa or Cymbalta. We'll definitely look at a host of different options, and I think it's safe to assume that we have, in both occasions, already done planning, looking at different things to see what is the most appropriate late life cycle strategy for the molecule. I would say that is not the case, where an AG would always be a preferred approach. So really, it will be molecule-by-molecule basis. If we were to elect not to do one, on the next one up, for example, I wouldn't take that as indication that we didn't like the way that AG went with Gemzar. In fact, we've felt that has gone quite well. And if we would be one, for example, on Zyprexa, I don't know if that would mean necessarily we would do well on Cymbalta. It really does come down to what the lines of business the customer groups that these products go to, capabilities or partners, et cetera. We'll keep you posted, but at that this time, we have no comment specifically on what would be planned, what would be likely for the Zyprexa."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And we'll go to the line of Seamus Fernandez from Leerink Swann.",13,"And we'll go to the line of Seamus Fernandez from Leerink Swann."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible li",96,"Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible liver effects. So maybe you can weigh in on that. And then separately, can you just update us on any price changes that have occurred incrementally in Europe versus your expectations? And update us on any proposals that may actually be out there as we work through the incremental possibilities of the debt crisis."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently.",33,"We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that live",86,"In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that liver effect can be direct but they can also be indirect to where the immune system, et cetera, could respond. But I think for the moment, we have to get our data for our compound before we do any conclusions about liver risks."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in",210,"Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in line with our expectations and do not have a significant impact on Lilly products. The newest one I'm aware of probably would be some legislation passed in Poland that will take effect actually in January of 2012, so no impact to this year. Where there will be agreement to go ahead and cap the government's expenditures on pharmaceuticals as a percent I believe of the overall health care spend, with the industry providing some rebates if spend exceeds those levels. Clearly, with continued budget pressures in a number of countries, we'll continue to monitor the situation. We do think that there are already some pretty substantial cuts taken, particularly on the pharmaceutical side of some of the health care and broader entitlement spending in European nations. So we wouldn't expect that to be necessarily the first place for them to go. But again, we might have situation. Clearly, we're not out of the wood with the overall situation for the global economy."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We'll now go to the line of Catherine Arnold from Credit Suisse.",13,"We'll now go to the line of Catherine Arnold from Credit Suisse."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of nex",105,"I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of next year, was there anything about the Brilinta label that would be surprising relative to what your expectations were internally? And then lastly, Arxxant is on your pipeline chart, but I don't know if we've heard anything about that for a long time. And I'm wondering why, what's happening with this particular product?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2.",19,"We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate, and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing, a",47,"With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate, and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing, and we look forward to that data."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't h",70,"And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't have a specific comment for you under any items that were surprising. If Jan, you've heard anything from the team or not?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","I think for the moment we are still discussing.",9,"I think for the moment we are still discussing."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking",136,"And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking us to provide them with more substantive data around the visual acuity. So we're in the process of completing the last diabetic macular edema study that could potentially furnish the date of the FDA is looking for. Last that I had was a petrol [ph] with concludes or late this year. I think, the latest may be early next year. Once we have that data in hand, then we will either decide, do we submit to the FDA, ask them to reconsider the application or do we pull the NDA with the agency?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Let's go to the line of Greg Gilbert from Bank of America.",13,"Let's go to the line of Greg Gilbert from Bank of America."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer a conceptually what types of things you're going",75,"I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer a conceptually what types of things you're going to look into to be able to answer that question down the line? And secondly, Derica, can you offer any color on SG&A and R&D lumpiness between 3Q and 4Q?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves, that they served in, in terms of going from reducing the number",209,"Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves, that they served in, in terms of going from reducing the number of players. For us, we obviously feel very good about the attributes of our brand. And then maybe at the therapeutic area, where we compete today, there is already low-cost generic options available, yet our brands have held up very well. So in cases like depression or even in schizophrenia, with reason all being generic. So we're not anticipating that this is going to have a material impact on Lilly at this stage. But once again, still early. In regard to the Q3 or Q4 impact of SG&A and R&D, I think it's pretty much embedded in our guidance and the color I've provided earlier. If you're looking at SG&A, primarily what you're seeing in terms of our change in our line item guidance is the impact of exchange rate, both in SG&A and R&D. And then, most specifically for SG&A, it's also the impact of the earlier spend, launch spend behind Tradjenta. And we've considered that to be a huge positive force."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We now go to the line of Chris Schott from JPMorgan.",11,"We now go to the line of Chris Schott from JPMorgan."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just the first couple of questions were on Zyprexa, maybe the first one would be, as I think about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically, hav",96,"Just the first couple of questions were on Zyprexa, maybe the first one would be, as I think about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically, have had lower rates of generic penetration. My second question on Zyprexa was, with the upcoming patent expiration, can you just help us a little bit to understand a lot better the impacted gross margin and quantify how much of an impact to gross margin we should expect to the loss of that franchise?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika handle the first one. I think Derica will take a shot at your second question.",19,"We'll have Ronika handle the first one. I think Derica will take a shot at your second question."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional er",82,"So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional erosion as we go through the year. With regard to the rest of major Europe, the patent will actually expire in September. And keep in mind, we would, again, expect to see additional erosion as that occurs."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica?",1,"Derica?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavorab",62,"Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavorable impact to our gross margin line as that placed through our P&L and financial results."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there wou",198,"One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there would be very large brand and a large number of them coming off patent. And then the fact that we've positioned themselves to benefit as they should from those patent expirations. So much of the action that you saw in 2010 even was really directed against reducing prices of generics and setting up situations, where once a branded product goes generic, so the initial price was for generics will come out lower. You probably put this in detail, that in many products, you've seen in the past that branded price will be a little lower in Europe than here in the U.S. But actually, the generic price will be substantially higher in Europe than here in the U.S. So again, I think you're going to see a stronger push to use generics more quickly and more fully, and so the markets in the past may have been slow-erosion markets."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And then, our final question comes from the line of Seamus Fernandez from Leerink Swann.",15,"And then, our final question comes from the line of Seamus Fernandez from Leerink Swann."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think",80,"Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think earlier, you had given us an estimate of I think about 11% share at one point, and I'm just wondering where we sit today at least in the U.S. market on a relative basis."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","All right. Seamus, we'll have Ronika to hear. You found some of the updated data?",15,"All right. Seamus, we'll have Ronika to hear. You found some of the updated data?"
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we're seeing quarter-over-quarter nice trend",133,"Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we're seeing quarter-over-quarter nice trends with our TRx. We're still seeing continued growth with regards to new to [ph] brand, which has been very impressive given where we are in the current launch. Right now, that exceeds about 13%. Again, we are seeing about 1 in 5 ACS patients, and STEMI type, specifically, are receiving Effient, which is pretty impressive. And so, we hope that, that traction continues. Again, we are seeing quarter-over-quarter growth in our NRx and TRx and are excited by this trend as doctors continue to accept and try prozigro [ph] or Effient."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call.",19,"With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Well, let me conclude by, first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and",85,"Well, let me conclude by, first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and for our end of our future prospect. As always, the IR team will be available to answer any additional questions you may have. And I look forward to our continued dialogue, and I hope you all have a great day. Take care."
285467,97242192,144200,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. Inter",75,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. International participants, dial (320) 365-3844 with the access code of 207464. That does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Ple",43,"Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Please go ahead."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer",962,"Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer, Doctor Jan Lundberg; and Ronika Pletcher and Jill Thoren for Investor Relations.
Since we just provided a comprehensive overview of our business at our investment community meeting on June 30, today, we'll limit our prepared remarks, leaving more time for the Q&A session. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decision.
Since the Q1 earnings call in April, we've had a number of significant event, many of them in our diabetes business. On the regulatory front, we had important news for Bydureon. The European Commission granted final approval of BYDUREON, the long-acting formulation of exenatide and the first once-weekly treatment for adults with type 2 diabetes. We launched in the U.K. last week, with launches in other European countries expected over the course of 2011 in the first half of 2012. 
We submitted BYDUREON to regulatory authorities in Japan and, along with Amylin, we completed the thorough QT study to support the U.S. NDA for BYDUREON. In the study, when administered at and above therapeutic levels, exenatide did not prolong the corrected QT interval in healthy individuals. Further, the study found no relationship between QTc interval and plasma exenatide concentrations. We intend to submit our reply to the FDA's Complete Response Letter in Q3.
We also had quite a bit of regulatory news on the linagliptin, the FDA approval of linagliptin, under the trade name Tradjenta, for the treatment of adults with type 2 diabetes. Along with Boehringer Ingelheim, we launched the product here in the U.S. in May, presented as the first DPP4 inhibitor to be approved at one dosage strength, with no dose adjustment is recommended for patients with kidney or liver impairment.
The Japanese Ministry of Health and Welfare (sic) [Ministry of Health, Labor and Welfare] approved linagliptin under the trade name Trazenta. Along with the eye [ph], we expect to launch the product in Japan later this quarter. Continuing the string of rapid approvals, regulatory authorities in Mexico and Brazil also approved linagliptin, known there as Trayenta, and launches in these countries are also expected in Q3. In Europe, the CHMP recommended approval of Trajenta, and we expect final EC approval later this quarter. Clearly, we're very pleased with the significant progress achieved during Q2 in our diabetes business.
In non-diabetes regulatory news, along with Bristol-Myers Squibb, we submitted the sBLA for Erbitux in first-line, non-small cell lung cancer. On the clinical front, at ASCO, we presented positive data from PARAMOUNT, the second study to evaluate the use of Alimta's maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer and the first study to evaluate the use of continuation maintenance with Alimta, following first-line Alimta plus cisplatin therapy. Based on data from PARAMOUNT, we submitted our dossier [ph] in Europe earlier this year. And we plan to submit here in the U.S. once we have more mature, overall survival data.
On the business development front, we received final EC approval for and finally closed on our acquisition of Janssen's animal health business. We signed an exclusive worldwide collaboration agreement with Synthes, under which the 2 companies will jointly develop site-specific bone-healing products. The companies will also conduct and fund the evaluation of additional orthopedic uses for Forteo. In addition to the development component of the agreement, the collaboration includes the co-promotion of Forteo to orthopedic surgeons in the U.S. and in select o U.S. countries.
We signed agreements with private investors to establish BioCritica. Based in Indianapolis, BioCritica will initially focus on the continued U.S. development and commercialization of Xigris for severe sepsis. BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development of Lilly. The collaboration agreement also includes an option for BioCritica to acquire the development and commercialization rights to Xigris outside the U.S. at a later date.
We entered into a collaboration with Medtronic to research and development new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system. Specifically, the goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lily's biologic, a modified form of glial cell derived neurotrophic factor with Medtronic's implantable drug infusion system technology. 
Lastly on the legal front, the Supreme Court denied Lilly's petition to reconsider a federal appeals court ruling invalidating the Gemzar method of used patent. And the judge for the U.S. District Court for the Southern District of Indiana ordered all generic drug manufacturers, challenging the validity of the crack compound patent for Cymbalta not to sell a generic version of duloxetine until the patent expires. As a result, we do not expect generic duloxetine come into market until the Cymbalta patent expires in June 2013 or December 2013, if we're successful in obtaining the six-month pediatric exclusivity.
Now as a background, Ronika will discuss our Q2 financial results and provide our pipeline update, and Derica will then cover key events to our major 2011 and our financial guidance for the year. Ronika?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments an",1197,"Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments and other special charges. I'll start on Slide 6 with a quick look at our Q2 income statement. 
On a non-GAAP basis, you can see that we generated robust revenue growth of 9% this quarter. Excluding Gemzar outside of Japan and the effective view of health care reform, revenue would've grown 13%. Compared to Q2 2010, gross margin as a percentage of revenue decreased 1.8 percentage points but we're still strong at 80.4%. This decrease is entirely due to the effective changes in foreign exchange rates on international inventories sold. 
Operating expenses, defined as the sum of R&D and SG&A, grew 12% this quarter. This increase was driven primarily by SG&A, which increased 16%, over an increase in R&D with 6%. Drivers of the increase in operating expense include expenses related to our diabetes alliance with Boehringer Ingelheim, the unfavorable effect of changes in foreign exchange rates, higher sales and marketing expenses to support launches of new products and new indications, as well as the pharmaceutical manufacturers fee associated with U.S. health care reform, which was roughly $45 million. Excluding the effect of U.S. health care reform and the BI alliance, operating expenses would've grown 7%.
Other income and deductions was in net expense of $58 million this quarter, which was higher than it was last year. The higher net expense was due to a write-down in the value of the liprotamase asset as a result of the FDA Complete Response Letter we received in April, in which the agency requested additional clinical data. 
Our tax rate was 20.9% this quarter or 1.6 percentage points lower than in Q2 2010. This reduction is primarily due to the R&D tax credit that was not in effect during Q2 2010 but was in effect during Q2 2011. At the bottom line, our non-GAAP EPS decreased 5% from $1.24 to $1.18.
Consistent with the 2011 guidance we provided in January, we saw a robust EPS growth in our business in Q2, excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would've grown in the high teens.
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release.
Now let's look at foreign exchange and its effect on our Q2 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 5%. This quarter, foreign exchange contributed the remaining 4%, while price had virtually no impact on worldwide revenue growth.
We continue to see strong volume growth from our 3 counter cyclical growth drivers: Japan, Animal Health and emerging market. Volume growth in Japan was 15%, driven by the recent launches of Cymbalta and Forteo. Recall that the Q1 precautionary buying as a result of the Japanese earthquake and its aftermath increased Q1 sales by about $30 million to $35 million. As expected, this was largely worse in Q2, trimming Japan's volume growth this quarter by about 6 percentage points.
Unlike the Animal Health, volume growth was 16% in Q2, driven by the increase in demand for food animal products globally as well as the launch of Trifexis in the U.S., the continued expansion of our PA [ph] animal business globally and the acquisition of certain European animal health assets from Pfizer.
Finally, embedded within the Rest of World line is our emerging markets revenue growth of 11% in volume and 13% overall. Particularly noteworthy was China's revenue growth of 20% volume and 26% overall. This quarter, it is worth reviewing the effect of foreign exchange on the rest of our income statement. While FX did not have a large effect on EPS growth, it did affect individual line item.
Slide 10 shows the year-on-year growth of select line items of our non-GAAP income statement, both with and without the effective changes in foreign exchange currencies. The numbers in the first column are the same as those used on the last column on Slide 6. Let's focus on the second column of the numbers which groups out the effect of foreign exchange rate. 
First, you'll see the 5% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin also grew 5%. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was entirely due to the effect of foreign exchange on international inventories sold. In total, operating expenses grew 9%, excluding FX. This increase was driven by the BI deal, the launch of new products and indications and the pharmaceutical industry fee. 
Since the increase in operating expense exceeded the increase in gross margin, operating income declined 3% and EPS declined 4%. You can see that while FX had a material impact on revenue, cost of sales and operating expense, it really almost had no impact on operating income for the EPS this quarter. So while FX didn't have much of an impact on EPS growth, U.S. health care reform, the effect of due of our patent expirations outside of Japan and the investments related to the BI alliance certainly did. As mentioned earlier, excluding these items, EPS would've grown in the high teens.
On Slide 11, you'll find year-on-year growth of these same items on our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our portfolio of new molecular entities in clinical development as of July 11 inclusive of the changes since our April update. Our clinical phase portfolio now stands at 70 to state [ph], including 33 compounds in Phase II and Phase III. Biotech molecules represent over 40% of our Phase II and Phase III assets as well as our overall clinical portfolio.
Advancing our pipeline remains our number one priority. As reflected by the arrows, you can see that since our April update, we received FDA approval for and launched Tradjenta; we've had two assets in the Phase II testing; we advanced an additional 3 assets in the Phase I testing, including our basal insulin RGs [ph]. We expect to begin pivotal trials for this molecule before year end, and we terminated development of one Phase I asset.
As Doctor Lundberg shared during our investment community meeting on June 30, we're very pleased with the progress we've made, building a robust, high-quality pipeline with many potential opportunities to advance patient care and nasal [ph] diseases, with large, unmet needs as well as commercial opportunity. We're on track to meet or exceed our goal of having 10 entities in Phase III by year end and believe that our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the",862,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. 
As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the European Commission approval later this quarter and then launching the product in Europe later this year. In addition to our successes so far this year, we have a number of other potential regulatory approvals in the U.S. this year, including Cialis for BPH, by aide in combination with basal insulin; and Erbitux for first-line head and neck cancer. Expect the regulatory submissions include our response to the FDA Complete Response Letter for BYDUREON, the sBLA for Erbitux and first-line metastatic colorectal cancer, and our response to the FDA Complete Response Letter for Amyvid. We continue to expect a maturing of our mid to late stage pipeline as Phase III trials could begin this year for, one, our novel basal insulin analog and our new insulin glargine product, as well as our anti-IL-17 monoclonal antibody.
Finally, on the legal front, at anytime, we could have rulings from the CAFC on the Strattera patent challenge and from the District Court in Delaware on the Alimta patent challenge. Now you may recall that in the Alimta case, the judge had indicated from the bench that a ruling would be issued in Lily's favor. 
Now in terms of our 2011 financial guidance, we've updated the guidance issued in April for a number of factors, including continued strong volume growth in revenue, driven by our 3 counter-cyclical growth engines and our patent-protected brand; secondly, stronger foreign currencies, which drives up the expected growth rates of revenue, SG&A and R&D; thirdly, very prompt approval to linagliptin in multiple markets, which is driving an increase in expected SG&A spend in 2011, as well as some additional expected revenue; and fourthly, the write-down of the intangible value of liprotamase, which is driving higher expected net other expense for the year.
In total, these changes result in an increase in narrowing of our non-GAAP EPS guidance. We now expect 2011 non-GAAP earnings per share of between $4.25 and $4.35. Our 2011 reported EPS guidance range of $3.85 to $3.95 reflects the $0.23 IPR&D charge from the BI alliance and $0.17 in restructuring charges for the first half of the year.
Now these changes have resulted in updates to the most of the individual line items as well. Revenue is now expected to grow in the mid-single digits, while we expect the gross margin as a percent of revenue to decline by 2 to 3 percentage points. SG&A growth is now expected to be in the high single digits, and R&D growth is now expected to be in the low single digits.
Other income is now forecast to be a net loss in the range of $100 million to $175 million. We still expect our 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. And we expect capital expenditures to be in the range of $700 million to $800 million. Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our revised 2011 guidance.
In summary, 2011 continues to play out as we had anticipated. We're making progress advancing our pipeline, and we're delivering solid financial result. We remain on track to meet our goal of having 10 molecules in Phase III development by the end of this year. 
And as John articulated on June 30, we're seeing promising signs that, in addition to increasing in numbers, our mid- to late-stage pipeline is increasing in quality as well. We firmly believe that our current pipeline serves as the foundation to return to growth post-Years YZ.
We also remain on track to meet our 2011 headcount as expense containment goals, helping to create the financial flexibility to invest in our pipeline, our counter-cyclical growth engines in current brands, as well as maintain the dividend. In Q2, we saw this impact of the headwinds that we anticipated when we issued our 2011 financial guidance in January, and when we updated that guidance on our Q1 earnings call in April. These headwinds are patent expirations that are lowering sales of Gemzar outside of Japan; U.S. health care reform, which is exacting a higher cost this year than it did in 2010; and near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. While we did see the negative impact in Q2 of these items, we again delivered strong growth in the remainder of our business. Excluding those 3 items, on a non-GAAP basis, we posted revenue growth of 13%, operating expense growth of 7% and high-teens EPS growth.
Moving forward, we will continue to focus on delivering a solid financial result, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline and outspeeding the next generation of Lilly molecules to market to provide growth post-Years YZ. 
Now this concludes our prepared remarks, and we will open the call for the Q&A session. Operator, first caller please."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS.",15,"[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one gro",75,"Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one growth rate for overall, but can you give us a sense of, besides China, what else is going on, what other launches are driving the business there?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to tha",188,"Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to that, we're seeing growth in a number of other emerging markets spread across the Asia region. And also, very good growth still from the South American countries. We do have some upcoming patent exposures. We'll begin to see, for example, in Brazil, weigh more heavily. But we continue to see a very strong growth across a number of those geographies. In Japan, Marc, it really is still pretty widespread and good growth. Forteo, for example, is off to a very strong start with the launch on the second half of last year. Cymbalta is doing very well. The insulins are doing extremely well. Alimta share growth has been extremely good since the launch there. Going back, I think, that would have been earlier in 2010, again, late 2009, so really broad-based growth across a number of products driving the Japanese performance."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that",100,"Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that had some buy-in as a result of the earthquake and the tsunami. But if you were to normalize for that with a de-stocking that we saw in the second quarter, we basically about 30% to 31% growth in each of the first 2 quarters of this year."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter.",35,"Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And our next caller comes from the line of Tim Anderson from Sanford Bernstein.",14,"And our next caller comes from the line of Tim Anderson from Sanford Bernstein."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Sec",109,"A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Second question is on your Phase III trials for your version of insulin glargine. Are you going to have Lantus as an active comparator? And then the last question, just on the Janssen animal health business. I don't believe we have any financial details there, and I'm wondering how that ties into the 2011 guidance. Is that deal an accretive transaction for you?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?",34,"Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether",224,"Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether it'll be a sale, a spend or an outright IPO. I think it's still to be determined. So at this stage, it will be really speculative on our part. Clearly, we will watch how that situation evolves. And if there are some assets that become available that we're interested in, then, yes, we will pursue them. But we're very happy as well with our -- the current state of our Elanco animal health business. And right now, we're the fastest growing entity in that space, and we feel very good about the launches that Jeff talked about in New York, where we've had 6 launches so far this year coming from our own pipeline. So with or without an additional transaction, we believe we have the capacity to sustain the type of growth that you've seen through this point. And in fact, in the second quarter this year and in the second quarter here, Elanco grew actually 20%. In regards to the impact of the Janssen deal that we just closed this year, it's basically neutral to the bottom line."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include",84,"And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include sales of their products in markets where they're actually going through a distributor, the actual sales that they would have prior, are we going forward, when we book, would be less than that $200 million-type level. Jan?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial.",23,"In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Jami Rubin from Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin from Goldman Sachs."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Derica, my question relates to the Boehringer Ingelheim deal. So, projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accreti",154,"Derica, my question relates to the Boehringer Ingelheim deal. So, projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accretion next year or the year after, I don't remember, but I'm wondering if that is dependent on you reaching a certain level of sales with Tradjenta? Or is there a flexibility built into the contract to reduce spending if you're not getting to the level that you anticipate? And also, so you're increasing your SG&A spend for the back half of the year. I'm just wondering what's changed? Because we -- the BI deal has been known, the pharmacy fees have been known, et cetera, et cetera. So just if you could just provide a little bit more granularity on what additional levels of spend, and is it behind the Tradjenta launch?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as wel",229,"Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as well as in some of the key markets outside the U.S. like Mexico, like Brazil, like Japan. So when you look at our SG&A spend guidance for the year, the primary driver of the increase is FX related, similar to what we talked about on the top line. But at the same time, we are supporting the earlier launches of Tradjenta in those key markets that I highlighted. So those are the 2 factors. And in terms of characterization we've been getting in the past, we talked about their being dilution obviously higher this year driven by the upfront charge that we had in the first quarter and then lessening between 2012 and '13, and then turning positive '14 and beyond. We obviously would have like it little more dilution this year given the incremental investment codes [ph] on some of these approval and launches coming towards the earlier end of the spectrum of what was contemplated. However, we're potentially making up for that and more in our full year guidance by the raise that you've seen on a non-GAAP basis."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And now, we'll go to the line of Steve Scala from Cowen.",12,"And now, we'll go to the line of Steve Scala from Cowen."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask w",100,"In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask why Lilly believes it is difficult to predict the timing and the magnitude? What is unusual about this situation? There was no similar language, for instance, in the Strattera paragraph. And what percent of U.S. Zyprexa sales are protected by contracts that extend into 2012 and therefore will not be impacted by the patent expiration?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for",172,"Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for, at the time of the product goes generic, how much inventory will actually be sitting out in the retail channel, which creates an exposure turn of returns. The second is with the actual adoption rate in terms of generic utilization will be, in terms of buying power and patterns of wholesalers, as well as formularies. So that's where the unpredictable nature of this comes in. But we think we've accounted for a reasonable estimate of that in the guidance range that we provided. And even with those types of uncertainties, if you heard from Phil earlier in on the call, we still have a strong enough underlying business fundamental that has enabled us to be in a position to raise our guidance overall."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And next caller goes to the line of David Risinger from Morgan Stanley.",13,"And next caller goes to the line of David Risinger from Morgan Stanley."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0%",172,"I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0% impact on year-over-year revenue growth. Can you just explain to us how you reflected the negative impact of health care reform in that line? I'm assuming that, that is what brought that down to 0% given numerous list price increases for U.S. products. Second, how do you see Effient competing with Rowenta [ph]? And could you characterize how we should think about the competition playing out in the U.S. differently from x U.S. market? And then third, how much of a positive read should investors take away from a futility analysis later this year that results in solanezumab continuing to completion, meaning, could you give us a sense for how low or high the efficacy bar is in the futility assessment?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica's on the first one, and Jan will handle your second 2 questions, Dave.",15,"Derica's on the first one, and Jan will handle your second 2 questions, Dave."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care reform, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second",81,"David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care reform, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second thing that impacting it is also the erosion of Gemzar in the U.S., the price erosion. Those are the 2 things that are allowing our net effect of selling price impact to be 0. Jan?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same",325,"Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same as the Brilinta studies. And to really compare them, we need direct head-to-head studies. But the U.S. patients in the Effient studies did better than Plavix, but for some, still unclear reason in Brilinta. The U.S. patients actually did better on Plavix than on Brilinta, with which, it's a discrepancy for Brilinta to the whole world data. There is also some dyspnea some side effects with Brilinta that Effient doesn't have. So for the moment, I think we have here 2 effective antiplatelet agents in the more whole world populations, while in the U.S. population, Effient did better. And the FDA, I think, took that interpretation into actually saying that Brilinta should not be used when you have a high aspirin dose, which clearly Effient can be used when you have. And since, I think, the U.S. treatment paradigm today has a high number of high aspirin in combinations, it is actually would favor Effient. But overall, we need the head-to-head studies to really make a direct comparison. In relation to solanezumab and the futility analysis that will come up later this year, this is a judgment then of the DMC, of the benefit-risk component. They will look clearly at safety as well as futility of efficacy, and this is their judgment. But my interpretation is that, since Alzheimer's disease is a very serious disease, there is no real treatment to stop progression of disease. And we don't really know today when would the potential effect start of preventing than amyloid. So my feeling is, this will be a judgment call for the DMC. And whatever the outcome, we need to wait for the full study before we can draw any clear conclusions."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of John Boris from Citi.",12,"Our next question comes from the line of John Boris from Citi."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","First question, just in light of budget negotiations in Washington, there is some risk, at least some would believe, that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual eligible s",147,"First question, just in light of budget negotiations in Washington, there is some risk, at least some would believe, that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual eligible side that could be pointed to, do you believe that, that provision potentially could be pulled during budget negotiations? Just your thoughts around what the risk is around that and what the impact would be. And then one question for Jan has to do with the SGLT-2. The profile, does he believe the increased bladder cancer risk is a class effect? Is that something that we might see with the Boehringer compound, along with the liver toxicity that we've seen? And then, one final question just has to do with AG, using an authorized generics strategy on Zyprexa and Cymbalta, just your thoughts around that."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question.",23,"Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are be",188,"As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are being debated, if they were to want to introduce with Medicaid-type rebate into Medicare Part D that would be a profound impact, not only for Lilly but for the industry. And so, that's something we would not support, and I don't think our industry peers would either. Along those same lines, we also would not be supportive of reducing the bio -- data protection from biologics or the strengthening of the position of iPad. So these all group concerns that we have. And obviously, we continue to engage in discussion and dialogue with the parties at hand. And if any of those were to move forward, then they would clearly have an impact on jobs in the U.S., and I don't think that's where we all want to go, given the budget discussions that we had in trying to stimulate the economy."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attri",168,"With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attributes. In relation to the reported increase in cancer then for the BMS-AstraZeneca compound, we have no evidence so far that this is happening with the empagliflozin. Clearly, we only have more short-term observations, and we really need to have all the Phase III data before giving any definite answers. We observed also single case of the high slow. We have not seen that in our studies. Just a final comment to come back to the cancer, the reports here, that there is no clinical data or mechanistic hypothesis that would support that there is an increased risk of, for instance, bladder cancer. It's a finding. Like always, safety is paramount, and we need to observe this and be cautious about the future."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be an injectable like we have wi",240,"And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be an injectable like we have with Gemzar, or oral small molecule like Zyprexa or Cymbalta. We'll definitely look at a host of different options, and I think it's safe to assume that we have, in both occasions, already done planning, looking at different things to see what is the most appropriate late life cycle strategy for the molecule. I would say that is not the case, where an AG would always be a preferred approach. So really, it will be molecule-by-molecule basis. If we were to elect not to do one, on the next one up, for example, I wouldn't take that as indication that we didn't like the way that AG went with Gemzar. In fact, we've felt that has gone quite well. And if we would be one, for example, on Zyprexa, I don't know if that would mean necessarily we would do well on Cymbalta. It really does come down to what the lines of business the customer groups that these products go to, capabilities or partners, et cetera. We'll keep you posted, but at that this time, we have no comment specifically on what would be planned, what would be likely for the Zyprexa."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And we'll go to the line of Seamus Fernandez from Leerink Swann.",13,"And we'll go to the line of Seamus Fernandez from Leerink Swann."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible li",96,"Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible liver effects. So maybe you can weigh in on that. And then separately, can you just update us on any price changes that have occurred incrementally in Europe versus your expectations? And update us on any proposals that may actually be out there as we work through the incremental possibilities of the debt crisis."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently.",33,"We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that live",86,"In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that liver effect can be direct but they can also be indirect to where the immune system, et cetera, could respond. But I think for the moment, we have to get our data for our compound before we do any conclusions about liver risks."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in",210,"Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in line with our expectations and do not have a significant impact on Lilly products. The newest one I'm aware of probably would be some legislation passed in Poland that will take effect actually in January of 2012, so no impact to this year. Where there will be agreement to go ahead and cap the government's expenditures on pharmaceuticals as a percent I believe of the overall health care spend, with the industry providing some rebates if spend exceeds those levels. Clearly, with continued budget pressures in a number of countries, we'll continue to monitor the situation. We do think that there are already some pretty substantial cuts taken, particularly on the pharmaceutical side of some of the health care and broader entitlement spending in European nations. So we wouldn't expect that to be necessarily the first place for them to go. But again, we might have situation. Clearly, we're not out of the wood with the overall situation for the global economy."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We'll now go to the line of Catherine Arnold from Credit Suisse.",13,"We'll now go to the line of Catherine Arnold from Credit Suisse."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of nex",105,"I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of next year, was there anything about the Brilinta label that would be surprising relative to what your expectations were internally? And then lastly, Arxxant is on your pipeline chart, but I don't know if we've heard anything about that for a long time. And I'm wondering why, what's happening with this particular product?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2.",19,"We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing and",47,"With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing and we look forward to that data."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't h",70,"And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't have a specific comment for you under any items that were surprising. If Jan, you've heard anything from the team or not?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","I think for the moment we are still discussing.",9,"I think for the moment we are still discussing."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking",136,"And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking us to provide them with more substantive data around the visual acuity. So we're in the process of completing the last diabetic macular edema study that could potentially furnish the date of the FDA is looking for. Last that I had was a petrol [ph] with concludes or late this year. I think the latest may be early next year. Once we have that data in hand, then we will either decide, do we submit to the FDA, ask them to reconsider the application or do we pull the NDA with the agency?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Let's go to the line of Greg Gilbert from Bank of America.",13,"Let's go to the line of Greg Gilbert from Bank of America."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer up conceptually what types of things you're going",75,"I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer up conceptually what types of things you're going to look into to be able to answer that question down the line? And secondly, Derica, can you offer any color on SG&A and R&D lumpiness between 3Q and 4Q?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves that they service in terms of going from reducing the number of",208,"Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves that they service in terms of going from reducing the number of players. For us, we obviously feel very good about the attributes of our brand. And then maybe at the therapeutic area, where we compete today, there is already low-cost generic options available, yet our brands have held up very well. So in cases like depression or even in schizophrenia, with reason all being generic. So we're not anticipating that this is going to have a material impact on Lilly at this stage but once again, still early. In regard to the Q3 or Q4 impact of SG&A and R&D, I think it's pretty much embedded in our guidance and the color I've provided earlier. If you're looking at SG&A, primarily what you're seeing in terms of our change in our line item guidance is the impact of exchange rate, both in SG&A and R&D. And then, more specifically for SG&A, it's also the impact of the earlier spend, launch spend behind Tradjenta. And we've considered that to be a huge positive force."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We now go to the line of Chris Schott from JPMorgan.",11,"We now go to the line of Chris Schott from JPMorgan."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just the first couple of questions were on Zyprexa. Maybe the first one would be, I was reading about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically,",97,"Just the first couple of questions were on Zyprexa. Maybe the first one would be, I was reading about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically, have had lower rates of generic penetration. My second question on Zyprexa was, with the upcoming patent expiration, can you just help us a little bit to understand a lot better the impacted gross margin and quantify how much of an impact to gross margin we should expect due to the loss of that franchise?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika handle the first one. I think Derica will take a shot at your second question.",19,"We'll have Ronika handle the first one. I think Derica will take a shot at your second question."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional er",82,"So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional erosion as we go through the year. With regard to the rest of major Europe, the patent will actually expire in September. And keep in mind, we would, again, expect to see additional erosion as that occurs."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica?",1,"Derica?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavo",62,"Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavorable impact to our gross margin line as that plays through our P&L and financial results."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there wou",199,"One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there would be very large brand and a large number of them coming off patent. And then the fact that we've positioned themselves to benefit as they should from those patent expirations. So much of the action that you saw in 2010 even was really directed against reducing prices of generic and setting up situations, where once a branded product goes generic, so the initial price was for generics will come out lower. You probably put this in detail, that in many products, you've seen in the past that branded price will be a little lower in Europe than here in the U.S. But actually, the generic price will be substantially higher in Europe than here in the U.S. So again, I think you're going to see a stronger push to use generics more quickly and more fully, in some of the markets in the past may have been slow-erosion markets."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And then, our final question comes from the line of Seamus Fernandez from Leerink Swann.",15,"And then, our final question comes from the line of Seamus Fernandez from Leerink Swann."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think",80,"Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think earlier, you had given us an estimate of I think about 11% share at one point, and I'm just wondering where we sit today at least in the U.S. market on a relative basis."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","All right. Seamus, we'll have Ronika to hear. You found some of the updated data?",15,"All right. Seamus, we'll have Ronika to hear. You found some of the updated data?"
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we've seeing quarter-over-quarter nice trend",132,"Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we've seeing quarter-over-quarter nice trends with our TRx. We're still seeing continued growth with regards to new to brand, which has been very impressive given where we are in the current launch. Right now, that exceeds about 13%. Again, we are seeing about 1 in 5 ACS patients, and STEMI type, specifically, are receiving Effient, which is pretty impressive. And so, we hope that, that traction continues. Again, we are seeing quarter-over-quarter growth in our NRx and TRx and are excited by this trend as doctors continue to accept and try prozigro [ph] or Effient."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call.",19,"With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Well, let me conclude by first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and",85,"Well, let me conclude by first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and for our end of our future prospect. As always, the IR team will be available to answer any additional questions you may have. And I look forward to our continued dialogue, and I hope you all have a great day. Take care."
285467,97242192,144723,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. Inter",75,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. International participants, dial (320) 365-3844 with the access code of 207464. That does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Ple",43,"Ladies and gentlemen, thank you for standing by. Welcome to the Q2 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the conference over to Vice President of Investor Relations, Phil Johnson. Please go ahead."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer",962,"Good morning, and thanks for joining us for Eli Lilly & Co.'s Second Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President of Investor Relations. Joining me today are our Chief Financial Officer, Derica Rice; our Chief Scientific Officer, Doctor Jan Lundberg; and Ronika Pletcher and Jill Thoren for Investor Relations.
Since we just provided a comprehensive overview of our business at our investment community meeting on June 30, today, we'll limit our prepared remarks, leaving more time for the Q&A session. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decision.
Since the Q1 earnings call in April, we've had a number of significant event, many of them in our diabetes business. On the regulatory front, we had important news for Bydureon. The European Commission granted final approval of BYDUREON, the long-acting formulation of exenatide and the first once-weekly treatment for adults with type 2 diabetes. We launched in the U.K. last week, with launches in other European countries expected over the course of 2011 in the first half of 2012. 
We submitted BYDUREON to regulatory authorities in Japan and, along with Amylin, we completed the thorough QT study to support the U.S. NDA for BYDUREON. In the study, when administered at and above therapeutic levels, exenatide did not prolong the corrected QT interval in healthy individuals. Further, the study found no relationship between QTc interval and plasma exenatide concentrations. We intend to submit our reply to the FDA's Complete Response Letter in Q3.
We also had quite a bit of regulatory news on the linagliptin, the FDA approval of linagliptin, under the trade name Tradjenta, for the treatment of adults with type 2 diabetes. Along with Boehringer Ingelheim, we launched the product here in the U.S. in May, presented as the first DPP4 inhibitor to be approved at one dosage strength, with no dose adjustment is recommended for patients with kidney or liver impairment.
The Japanese Ministry of Health and Welfare (sic) [Ministry of Health, Labor and Welfare] approved linagliptin under the trade name Trazenta. Along with the eye [ph], we expect to launch the product in Japan later this quarter. Continuing the string of rapid approvals, regulatory authorities in Mexico and Brazil also approved linagliptin, known there as Trayenta, and launches in these countries are also expected in Q3. In Europe, the CHMP recommended approval of Trajenta, and we expect final EC approval later this quarter. Clearly, we're very pleased with the significant progress achieved during Q2 in our diabetes business.
In non-diabetes regulatory news, along with Bristol-Myers Squibb, we submitted the sBLA for Erbitux in first-line, non-small cell lung cancer. On the clinical front, at ASCO, we presented positive data from PARAMOUNT, the second study to evaluate the use of Alimta's maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer and the first study to evaluate the use of continuation maintenance with Alimta, following first-line Alimta plus cisplatin therapy. Based on data from PARAMOUNT, we submitted our dossier [ph] in Europe earlier this year. And we plan to submit here in the U.S. once we have more mature, overall survival data.
On the business development front, we received final EC approval for and finally closed on our acquisition of Janssen's animal health business. We signed an exclusive worldwide collaboration agreement with Synthes, under which the 2 companies will jointly develop site-specific bone-healing products. The companies will also conduct and fund the evaluation of additional orthopedic uses for Forteo. In addition to the development component of the agreement, the collaboration includes the co-promotion of Forteo to orthopedic surgeons in the U.S. and in select o U.S. countries.
We signed agreements with private investors to establish BioCritica. Based in Indianapolis, BioCritica will initially focus on the continued U.S. development and commercialization of Xigris for severe sepsis. BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development of Lilly. The collaboration agreement also includes an option for BioCritica to acquire the development and commercialization rights to Xigris outside the U.S. at a later date.
We entered into a collaboration with Medtronic to research and development new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system. Specifically, the goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lily's biologic, a modified form of glial cell derived neurotrophic factor with Medtronic's implantable drug infusion system technology. 
Lastly on the legal front, the Supreme Court denied Lilly's petition to reconsider a federal appeals court ruling invalidating the Gemzar method of used patent. And the judge for the U.S. District Court for the Southern District of Indiana ordered all generic drug manufacturers, challenging the validity of the crack compound patent for Cymbalta not to sell a generic version of duloxetine until the patent expires. As a result, we do not expect generic duloxetine come into market until the Cymbalta patent expires in June 2013 or December 2013, if we're successful in obtaining the six-month pediatric exclusivity.
Now as a background, Ronika will discuss our Q2 financial results and provide our pipeline update, and Derica will then cover key events to our major 2011 and our financial guidance for the year. Ronika?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments an",1197,"Thanks, Phil. As we've done on previous calls, we'll focus our comment on non-GAAP results, which we believe provide insights into our underlying trends in our business. This view excludes certain items, such as restructuring charges, asset impairments and other special charges. I'll start on Slide 6 with a quick look at our Q2 income statement. 
On a non-GAAP basis, you can see that we generated robust revenue growth of 9% this quarter. Excluding Gemzar outside of Japan and the effective view of health care reform, revenue would've grown 13%. Compared to Q2 2010, gross margin as a percentage of revenue decreased 1.8 percentage points but we're still strong at 80.4%. This decrease is entirely due to the effective changes in foreign exchange rates on international inventories sold. 
Operating expenses, defined as the sum of R&D and SG&A, grew 12% this quarter. This increase was driven primarily by SG&A, which increased 16%, over an increase in R&D with 6%. Drivers of the increase in operating expense include expenses related to our diabetes alliance with Boehringer Ingelheim, the unfavorable effect of changes in foreign exchange rates, higher sales and marketing expenses to support launches of new products and new indications, as well as the pharmaceutical manufacturers fee associated with U.S. health care reform, which was roughly $45 million. Excluding the effect of U.S. health care reform and the BI alliance, operating expenses would've grown 7%.
Other income and deductions was in net expense of $58 million this quarter, which was higher than it was last year. The higher net expense was due to a write-down in the value of the liprotamase asset as a result of the FDA Complete Response Letter we received in April, in which the agency requested additional clinical data. 
Our tax rate was 20.9% this quarter or 1.6 percentage points lower than in Q2 2010. This reduction is primarily due to the R&D tax credit that was not in effect during Q2 2010 but was in effect during Q2 2011. At the bottom line, our non-GAAP EPS decreased 5% from $1.24 to $1.18.
Consistent with the 2011 guidance we provided in January, we saw a robust EPS growth in our business in Q2, excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and investments related to the BI diabetes alliance. Excluding these items, EPS would've grown in the high teens.
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release.
Now let's look at foreign exchange and its effect on our Q2 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 5%. This quarter, foreign exchange contributed the remaining 4%, while price had virtually no impact on worldwide revenue growth.
We continue to see strong volume growth from our 3 counter cyclical growth drivers: Japan, Animal Health and emerging market. Volume growth in Japan was 15%, driven by the recent launches of Cymbalta and Forteo. Recall that the Q1 precautionary buying as a result of the Japanese earthquake and its aftermath increased Q1 sales by about $30 million to $35 million. As expected, this was largely worse in Q2, trimming Japan's volume growth this quarter by about 6 percentage points.
Unlike the Animal Health, volume growth was 16% in Q2, driven by the increase in demand for food animal products globally as well as the launch of Trifexis in the U.S., the continued expansion of our PA [ph] animal business globally and the acquisition of certain European animal health assets from Pfizer.
Finally, embedded within the Rest of World line is our emerging markets revenue growth of 11% in volume and 13% overall. Particularly noteworthy was China's revenue growth of 20% volume and 26% overall. This quarter, it is worth reviewing the effect of foreign exchange on the rest of our income statement. While FX did not have a large effect on EPS growth, it did affect individual line item.
Slide 10 shows the year-on-year growth of select line items of our non-GAAP income statement, both with and without the effective changes in foreign exchange currencies. The numbers in the first column are the same as those used on the last column on Slide 6. Let's focus on the second column of the numbers which groups out the effect of foreign exchange rate. 
First, you'll see the 5% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin also grew 5%. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was entirely due to the effect of foreign exchange on international inventories sold. In total, operating expenses grew 9%, excluding FX. This increase was driven by the BI deal, the launch of new products and indications and the pharmaceutical industry fee. 
Since the increase in operating expense exceeded the increase in gross margin, operating income declined 3% and EPS declined 4%. You can see that while FX had a material impact on revenue, cost of sales and operating expense, it really almost had no impact on operating income for the EPS this quarter. So while FX didn't have much of an impact on EPS growth, U.S. health care reform, the effect of due of our patent expirations outside of Japan and the investments related to the BI alliance certainly did. As mentioned earlier, excluding these items, EPS would've grown in the high teens.
On Slide 11, you'll find year-on-year growth of these same items on our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our portfolio of new molecular entities in clinical development as of July 11 inclusive of the changes since our April update. Our clinical phase portfolio now stands at 70 to state [ph], including 33 compounds in Phase II and Phase III. Biotech molecules represent over 40% of our Phase II and Phase III assets as well as our overall clinical portfolio.
Advancing our pipeline remains our number one priority. As reflected by the arrows, you can see that since our April update, we received FDA approval for and launched Tradjenta; we've had two assets in the Phase II testing; we advanced an additional 3 assets in the Phase I testing, including our basal insulin RGs [ph]. We expect to begin pivotal trials for this molecule before year end, and we terminated development of one Phase I asset.
As Doctor Lundberg shared during our investment community meeting on June 30, we're very pleased with the progress we've made, building a robust, high-quality pipeline with many potential opportunities to advance patient care and nasal [ph] diseases, with large, unmet needs as well as commercial opportunity. We're on track to meet or exceed our goal of having 10 entities in Phase III by year end and believe that our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the",862,"Thanks, Ronika. To set the stage for our financial guidance, let me briefly cover some of the key events for the remainder of the year. 
As mentioned earlier, having now received the CHMP recommendation for approval of linagliptin, we look forward to the European Commission approval later this quarter and then launching the product in Europe later this year. In addition to our successes so far this year, we have a number of other potential regulatory approvals in the U.S. this year, including Cialis for BPH, by aide in combination with basal insulin; and Erbitux for first-line head and neck cancer. Expect the regulatory submissions include our response to the FDA Complete Response Letter for BYDUREON, the sBLA for Erbitux and first-line metastatic colorectal cancer, and our response to the FDA Complete Response Letter for Amyvid. We continue to expect a maturing of our mid to late stage pipeline as Phase III trials could begin this year for, one, our novel basal insulin analog and our new insulin glargine product, as well as our anti-IL-17 monoclonal antibody.
Finally, on the legal front, at anytime, we could have rulings from the CAFC on the Strattera patent challenge and from the District Court in Delaware on the Alimta patent challenge. Now you may recall that in the Alimta case, the judge had indicated from the bench that a ruling would be issued in Lily's favor. 
Now in terms of our 2011 financial guidance, we've updated the guidance issued in April for a number of factors, including continued strong volume growth in revenue, driven by our 3 counter-cyclical growth engines and our patent-protected brand; secondly, stronger foreign currencies, which drives up the expected growth rates of revenue, SG&A and R&D; thirdly, very prompt approval to linagliptin in multiple markets, which is driving an increase in expected SG&A spend in 2011, as well as some additional expected revenue; and fourthly, the write-down of the intangible value of liprotamase, which is driving higher expected net other expense for the year.
In total, these changes result in an increase in narrowing of our non-GAAP EPS guidance. We now expect 2011 non-GAAP earnings per share of between $4.25 and $4.35. Our 2011 reported EPS guidance range of $3.85 to $3.95 reflects the $0.23 IPR&D charge from the BI alliance and $0.17 in restructuring charges for the first half of the year.
Now these changes have resulted in updates to the most of the individual line items as well. Revenue is now expected to grow in the mid-single digits, while we expect the gross margin as a percent of revenue to decline by 2 to 3 percentage points. SG&A growth is now expected to be in the high single digits, and R&D growth is now expected to be in the low single digits.
Other income is now forecast to be a net loss in the range of $100 million to $175 million. We still expect our 2011 effective tax rate will be approximately 21% on a non-GAAP basis and approximately 20% on a reported basis. And we expect capital expenditures to be in the range of $700 million to $800 million. Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our revised 2011 guidance.
In summary, 2011 continues to play out as we had anticipated. We're making progress advancing our pipeline, and we're delivering solid financial result. We remain on track to meet our goal of having 10 molecules in Phase III development by the end of this year. 
And as John articulated on June 30, we're seeing promising signs that, in addition to increasing in numbers, our mid- to late-stage pipeline is increasing in quality as well. We firmly believe that our current pipeline serves as the foundation to return to growth post-Years YZ.
We also remain on track to meet our 2011 headcount as expense containment goals, helping to create the financial flexibility to invest in our pipeline, our counter-cyclical growth engines in current brands, as well as maintain the dividend. In Q2, we saw this impact of the headwinds that we anticipated when we issued our 2011 financial guidance in January, and when we updated that guidance on our Q1 earnings call in April. These headwinds are patent expirations that are lowering sales of Gemzar outside of Japan; U.S. health care reform, which is exacting a higher cost this year than it did in 2010; and near-term dilution from our strategic diabetes alliance with Boehringer Ingelheim. While we did see the negative impact in Q2 of these items, we again delivered strong growth in the remainder of our business. Excluding those 3 items, on a non-GAAP basis, we posted revenue growth of 13%, operating expense growth of 7% and high-teens EPS growth.
Moving forward, we will continue to focus on delivering a solid financial result, improving productivity to allow for appropriate investment in our patent-protected products and our pipeline and outspeeding the next generation of Lilly molecules to market to provide growth post-Years YZ. 
Now this concludes our prepared remarks, and we will open the call for the Q&A session. Operator, first caller please."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS.",15,"[Operator Instructions] And our first question comes from the line of Marc Goodman from UBS."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one gro",75,"Yes, I was hoping you could give us a little more flavor for the volume growth of the product in Japan, Cymbalta, Zyprexa, Alimta. And then secondly, can you give us a sense of a little more detail in the emerging markets? I know you mentioned the one growth rate for overall, but can you give us a sense of, besides China, what else is going on, what other launches are driving the business there?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to tha",188,"Okay, Mark, thank you for the question. I will go ahead and take that question, and Derica, if you're free to kind, if you like. For emerging markets first is, we mentioned on the call, we definitely had very strong growth in China. But in addition to that, we're seeing growth in a number of other emerging markets spread across the Asia region. And also, very good growth still from the South American countries. We do have some upcoming patent exposures. We'll begin to see, for example, in Brazil, weigh more heavily. But we continue to see a very strong growth across a number of those geographies. In Japan, Marc, it really is still pretty widespread and good growth. Forteo, for example, is off to a very strong start with the launch on the second half of last year. Cymbalta is doing very well. The insulins are doing extremely well. Alimta share growth has been extremely good since the launch there. Going back, I think, that would have been earlier in 2010, again, late 2009, so really broad-based growth across a number of products driving the Japanese performance."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that",100,"Marc, this is Derica. The only thing I would add is, if you look at Japan, not only do we have a good growth, but it's been sustained. So we had about 40%, 41% growth in the second quarter. But we knew -- excuse me, in the first quarter. But we knew that had some buy-in as a result of the earthquake and the tsunami. But if you were to normalize for that with a de-stocking that we saw in the second quarter, we basically about 30% to 31% growth in each of the first 2 quarters of this year."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter.",35,"Yes. We had about, as Ronika mentioned, $30 million to $35 million of buy-in. We think in the first quarter, about $20 million, $25 million, if I work its way out in the second quarter."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And our next caller comes from the line of Tim Anderson from Sanford Bernstein.",14,"And our next caller comes from the line of Tim Anderson from Sanford Bernstein."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Sec",109,"A few questions. Pfizer said it'll be getting rid of its animal health business, and that's obviously an area that you continue to invest in. And I'm wondering why it wouldn't make sense for Lilly to go after that? Would it just be an antitrust issue? Second question is on your Phase III trials for your version of insulin glargine. Are you going to have Lantus as an active comparator? And then the last question, just on the Janssen animal health business. I don't believe we have any financial details there, and I'm wondering how that ties into the 2011 guidance. Is that deal an accretive transaction for you?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?",34,"Okay. Tim, thanks for the questions. We'll have Derica go ahead and take maybe your first and a comment on the third. And then Jill and Jan will handle the glargine question, please. Derica?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether",224,"Okay. Tim, in regards to our animal health business, your 2 questions, one, in regards to Pfizer's decision around our own animal health business, I think it's very early to speculate as to what the nature of the transaction that we'll be seeking, whether it'll be a sale, a spend or an outright IPO. I think it's still to be determined. So at this stage, it will be really speculative on our part. Clearly, we will watch how that situation evolves. And if there are some assets that become available that we're interested in, then, yes, we will pursue them. But we're very happy as well with our -- the current state of our Elanco animal health business. And right now, we're the fastest growing entity in that space, and we feel very good about the launches that Jeff talked about in New York, where we've had 6 launches so far this year coming from our own pipeline. So with or without an additional transaction, we believe we have the capacity to sustain the type of growth that you've seen through this point. And in fact, in the second quarter this year and in the second quarter here, Elanco grew actually 20%. In regards to the impact of the Janssen deal that we just closed this year, it's basically neutral to the bottom line."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include",84,"And, Tim, in terms of the financial, this is one that, if you look at industry sources like that notes [ph], you'll likely see that Janssen sales indicated that roughly $200 million or so for 2010. We would encourage you to keep in mind that does include sales of their products in markets where they're actually going through a distributor, the actual sales that they would have prior, are we going forward, when we book, would be less than that $200 million-type level. Jan?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial.",23,"In relation to our insulin glargine product, which has an intense human testing, we will use Lantus as comparator in Phase III trial."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of Jami Rubin from Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin from Goldman Sachs."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Derica, my question relates to the Boehringer Ingelheim deal. So, projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accreti",154,"Derica, my question relates to the Boehringer Ingelheim deal. So, projected sales posted $5.6 million. This quarter, obviously, very early to tell. But if you could just remind us how that deal works? Because I think you had talked about achieving accretion next year or the year after, I don't remember, but I'm wondering if that is dependent on you reaching a certain level of sales with Tradjenta? Or is there a flexibility built into the contract to reduce spending if you're not getting to the level that you anticipate? And also, so you're increasing your SG&A spend for the back half of the year. I'm just wondering what's changed? Because we -- the BI deal has been known, the pharmacy fees have been known, et cetera, et cetera. So just if you could just provide a little bit more granularity on what additional levels of spend, and is it behind the Tradjenta launch?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as wel",229,"Sure, Jami. In regards to the BI ideal, essentially, it's a profit share if you look in terms of the deal structure itself. Clearly, we've had very good news around that brand. So we got -- received an earlier than expect to launch both in the U.S. as well as in some of the key markets outside the U.S. like Mexico, like Brazil, like Japan. So when you look at our SG&A spend guidance for the year, the primary driver of the increase is FX related, similar to what we talked about on the top line. But at the same time, we are supporting the earlier launches of Tradjenta in those key markets that I highlighted. So those are the 2 factors. And in terms of characterization we've been getting in the past, we talked about their being dilution obviously higher this year driven by the upfront charge that we had in the first quarter and then lessening between 2012 and '13, and then turning positive '14 and beyond. We obviously would have like it little more dilution this year given the incremental investment codes [ph] on some of these approval and launches coming towards the earlier end of the spectrum of what was contemplated. However, we're potentially making up for that and more in our full year guidance by the raise that you've seen on a non-GAAP basis."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And now, we'll go to the line of Steve Scala from Cowen.",12,"And now, we'll go to the line of Steve Scala from Cowen."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask w",100,"In the Zyprexa commentary in the press release, Lilly states it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales from the introduction of generics. This language was not in the Q1 release to my knowledge. May I ask why Lilly believes it is difficult to predict the timing and the magnitude? What is unusual about this situation? There was no similar language, for instance, in the Strattera paragraph. And what percent of U.S. Zyprexa sales are protected by contracts that extend into 2012 and therefore will not be impacted by the patent expiration?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for",172,"Steve, what's really centered around that is the nature of the erosion curb. I mean, we know exactly the date when we lose the official patent. But what you will see is, probably as we go through this, there will be an impact on our returns policy. So for, at the time of the product goes generic, how much inventory will actually be sitting out in the retail channel, which creates an exposure turn of returns. The second is with the actual adoption rate in terms of generic utilization will be, in terms of buying power and patterns of wholesalers, as well as formularies. So that's where the unpredictable nature of this comes in. But we think we've accounted for a reasonable estimate of that in the guidance range that we provided. And even with those types of uncertainties, if you heard from Phil earlier in on the call, we still have a strong enough underlying business fundamental that has enabled us to be in a position to raise our guidance overall."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And next caller goes to the line of David Risinger from Morgan Stanley.",13,"And next caller goes to the line of David Risinger from Morgan Stanley."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0%",172,"I have 3 questions. And I apologize if any of these have been asked. I joined the call a little late. So first of all is a financial question for Derica. And then, I have 2 product questions. With respect to Slide 9, it indicates that U.S. price had a 0% impact on year-over-year revenue growth. Can you just explain to us how you reflected the negative impact of health care reform in that line? I'm assuming that, that is what brought that down to 0% given numerous list price increases for U.S. products. Second, how do you see Effient competing with Rowenta [ph]? And could you characterize how we should think about the competition playing out in the U.S. differently from x U.S. market? And then third, how much of a positive read should investors take away from a futility analysis later this year that results in solanezumab continuing to completion, meaning, could you give us a sense for how low or high the efficacy bar is in the futility assessment?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica's on the first one, and Jan will handle your second 2 questions, Dave.",15,"Derica's on the first one, and Jan will handle your second 2 questions, Dave."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care reform, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second",81,"David, in regards to the U.S. price, it's really being affected by 2 factors. One is the incremental impact of U.S. health care reform, both the full year effect of U.S. health care reform, as well as the introduction of a donut hole provision. The second thing that impacting it is also the erosion of Gemzar in the U.S., the price erosion. Those are the 2 things that are allowing our net effect of selling price impact to be 0. Jan?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same",325,"Right. So let me start with the antiplatelet agents. As you all know, Effient is a irreversible, once-daily antiplatelet, while Brilinta is a reversible, twice-daily agent. A key difference is that, in the Effient studies, which of course are not the same as the Brilinta studies. And to really compare them, we need direct head-to-head studies. But the U.S. patients in the Effient studies did better than Plavix, but for some, still unclear reason in Brilinta. The U.S. patients actually did better on Plavix than on Brilinta, with which, it's a discrepancy for Brilinta to the whole world data. There is also some dyspnea some side effects with Brilinta that Effient doesn't have. So for the moment, I think we have here 2 effective antiplatelet agents in the more whole world populations, while in the U.S. population, Effient did better. And the FDA, I think, took that interpretation into actually saying that Brilinta should not be used when you have a high aspirin dose, which clearly Effient can be used when you have. And since, I think, the U.S. treatment paradigm today has a high number of high aspirin in combinations, it is actually would favor Effient. But overall, we need the head-to-head studies to really make a direct comparison. In relation to solanezumab and the futility analysis that will come up later this year, this is a judgment then of the DMC, of the benefit-risk component. They will look clearly at safety as well as futility of efficacy, and this is their judgment. But my interpretation is that, since Alzheimer's disease is a very serious disease, there is no real treatment to stop progression of disease. And we don't really know today when would the potential effect start of preventing than amyloid. So my feeling is, this will be a judgment call for the DMC. And whatever the outcome, we need to wait for the full study before we can draw any clear conclusions."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Our next question comes from the line of John Boris from Citi.",12,"Our next question comes from the line of John Boris from Citi."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","First question, just in light of budget negotiations in Washington, there is some risk, at least some would believe, that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual eligible s",147,"First question, just in light of budget negotiations in Washington, there is some risk, at least some would believe, that's been weighing on the group that the government may come back and look for some additional funds. And obviously, the dual eligible side that could be pointed to, do you believe that, that provision potentially could be pulled during budget negotiations? Just your thoughts around what the risk is around that and what the impact would be. And then one question for Jan has to do with the SGLT-2. The profile, does he believe the increased bladder cancer risk is a class effect? Is that something that we might see with the Boehringer compound, along with the liver toxicity that we've seen? And then, one final question just has to do with AG, using an authorized generics strategy on Zyprexa and Cymbalta, just your thoughts around that."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question.",23,"Great. So we'll have Derica take your first question, John, and then Jan for the SGLT-2 question. And I'll handle your AG question."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are be",188,"As it relates to the debate or discussion around the deficit-reduction challenge in the U.S., clearly, it's still very early, and it's hard to draw any conclusion based upon the dialogue, at least that I'm aware of. But for the kinds of things that are being debated, if they were to want to introduce with Medicaid-type rebate into Medicare Part D that would be a profound impact, not only for Lilly but for the industry. And so, that's something we would not support, and I don't think our industry peers would either. Along those same lines, we also would not be supportive of reducing the bio -- data protection from biologics or the strengthening of the position of iPad. So these all group concerns that we have. And obviously, we continue to engage in discussion and dialogue with the parties at hand. And if any of those were to move forward, then they would clearly have an impact on jobs in the U.S., and I don't think that's where we all want to go, given the budget discussions that we had in trying to stimulate the economy."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attri",168,"With regards to the SGLT-2 class, it is important to remember that this is an agent which has quite a unique action that is independent of insulin secretion. And also, this agent is lowering blood pressure and body weight. So it has clear beneficial attributes. In relation to the reported increase in cancer then for the BMS-AstraZeneca compound, we have no evidence so far that this is happening with the empagliflozin. Clearly, we only have more short-term observations, and we really need to have all the Phase III data before giving any definite answers. We observed also single case of the high slow. We have not seen that in our studies. Just a final comment to come back to the cancer, the reports here, that there is no clinical data or mechanistic hypothesis that would support that there is an increased risk of, for instance, bladder cancer. It's a finding. Like always, safety is paramount, and we need to observe this and be cautious about the future."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be an injectable like we have wi",240,"And John, to refer to your question on potential authorized generic for Zyprexa or Cymbalta, let me answer in sort of generally with. What we will be doing each and every time that we do have a patent expiration whether it be an injectable like we have with Gemzar, or oral small molecule like Zyprexa or Cymbalta. We'll definitely look at a host of different options, and I think it's safe to assume that we have, in both occasions, already done planning, looking at different things to see what is the most appropriate late life cycle strategy for the molecule. I would say that is not the case, where an AG would always be a preferred approach. So really, it will be molecule-by-molecule basis. If we were to elect not to do one, on the next one up, for example, I wouldn't take that as indication that we didn't like the way that AG went with Gemzar. In fact, we've felt that has gone quite well. And if we would be one, for example, on Zyprexa, I don't know if that would mean necessarily we would do well on Cymbalta. It really does come down to what the lines of business the customer groups that these products go to, capabilities or partners, et cetera. We'll keep you posted, but at that this time, we have no comment specifically on what would be planned, what would be likely for the Zyprexa."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And we'll go to the line of Seamus Fernandez from Leerink Swann.",13,"And we'll go to the line of Seamus Fernandez from Leerink Swann."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible li",96,"Just 2 questions. One for Jan. Jan, could you just -- I didn't know if there is any reason to think about the molecular structure of dapagliflozin as a C-glucoside versus the molecular structure of the Boehringer Ingelheim compound relative to possible liver effects. So maybe you can weigh in on that. And then separately, can you just update us on any price changes that have occurred incrementally in Europe versus your expectations? And update us on any proposals that may actually be out there as we work through the incremental possibilities of the debt crisis."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently.",33,"We'll go to Jan for the first question, and then I'll try to answer your question on the looking forward in Europe, what we're going to be expecting, what's happened very recently."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that live",86,"In relation to structural activity relationships in relation to potential liver effects of the SGLT-2 agents, I think it's too early to make any conclusions based on a single case. That's the first comment. And secondly, I think history tells us that liver effect can be direct but they can also be indirect to where the immune system, et cetera, could respond. But I think for the moment, we have to get our data for our compound before we do any conclusions about liver risks."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in",210,"Seamus, in terms of Europe, there really have not been any substance to changes of late. We have seen for example, as we have been expecting, sort of the next round of publishing of price referencing list in Greece in this June period. It was very much in line with our expectations and do not have a significant impact on Lilly products. The newest one I'm aware of probably would be some legislation passed in Poland that will take effect actually in January of 2012, so no impact to this year. Where there will be agreement to go ahead and cap the government's expenditures on pharmaceuticals as a percent I believe of the overall health care spend, with the industry providing some rebates if spend exceeds those levels. Clearly, with continued budget pressures in a number of countries, we'll continue to monitor the situation. We do think that there are already some pretty substantial cuts taken, particularly on the pharmaceutical side of some of the health care and broader entitlement spending in European nations. So we wouldn't expect that to be necessarily the first place for them to go. But again, we might have situation. Clearly, we're not out of the wood with the overall situation for the global economy."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We'll now go to the line of Catherine Arnold from Credit Suisse.",13,"We'll now go to the line of Catherine Arnold from Credit Suisse."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of nex",105,"I'd like to ask a question or 2 about the pipeline. If you could comment on where we are on the trilogy study for Effient, is that still on track? I think it's to complete the first half of next year, if data could be presented. And the second half of next year, was there anything about the Brilinta label that would be surprising relative to what your expectations were internally? And then lastly, Arxxant is on your pipeline chart, but I don't know if we've heard anything about that for a long time. And I'm wondering why, what's happening with this particular product?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2.",19,"We'll have Ronika to take your first question on the status trilogy, and I'll handle the last 2."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing and",47,"With regards to trilogy, keep in mind that, that an event-driven trial. But the current estimate and we typically stick to what's estimated in clinicalresults.gov. And that's estimated right now to complete in April of '12, so that trial's progressing and we look forward to that data."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't h",70,"And with regard to the label on Brilinta, we'll probably act a little bit later today after we finished the call, have a chance to debrief more fully with the team, who evaluated that when it came out after the close yesterday. So at this point, I don't have a specific comment for you under any items that were surprising. If Jan, you've heard anything from the team or not?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","I think for the moment we are still discussing.",9,"I think for the moment we are still discussing."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking",136,"And in terms of Arxxant, Catherine, so as you're probably aware, a number of years ago, we had submitted to the FDA for the diabetic retinopathy. Indication have received, I guess, what now would be called the Complete Response Letter to basically asking us to provide them with more substantive data around the visual acuity. So we're in the process of completing the last diabetic macular edema study that could potentially furnish the date of the FDA is looking for. Last that I had was a petrol [ph] with concludes or late this year. I think the latest may be early next year. Once we have that data in hand, then we will either decide, do we submit to the FDA, ask them to reconsider the application or do we pull the NDA with the agency?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Let's go to the line of Greg Gilbert from Bank of America.",13,"Let's go to the line of Greg Gilbert from Bank of America."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer up conceptually what types of things you're going",75,"I have 2 questions. First, I was hoping you could offer any preliminary thoughts on how the Medco express combo could affect Lilly. And if you don't have anything specific to say yet, maybe you could offer up conceptually what types of things you're going to look into to be able to answer that question down the line? And secondly, Derica, can you offer any color on SG&A and R&D lumpiness between 3Q and 4Q?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves that they service in terms of going from reducing the number of",208,"Regard to the Medco express, it's still early. We do not anticipate there's going to have a material impact on Lilly. I think the bigger impact may actually be on the health plans themselves that they service in terms of going from reducing the number of players. For us, we obviously feel very good about the attributes of our brand. And then maybe at the therapeutic area, where we compete today, there is already low-cost generic options available, yet our brands have held up very well. So in cases like depression or even in schizophrenia, with reason all being generic. So we're not anticipating that this is going to have a material impact on Lilly at this stage but once again, still early. In regard to the Q3 or Q4 impact of SG&A and R&D, I think it's pretty much embedded in our guidance and the color I've provided earlier. If you're looking at SG&A, primarily what you're seeing in terms of our change in our line item guidance is the impact of exchange rate, both in SG&A and R&D. And then, more specifically for SG&A, it's also the impact of the earlier spend, launch spend behind Tradjenta. And we've considered that to be a huge positive force."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","We now go to the line of Chris Schott from JPMorgan.",11,"We now go to the line of Chris Schott from JPMorgan."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just the first couple of questions were on Zyprexa. Maybe the first one would be, I was reading about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically,",97,"Just the first couple of questions were on Zyprexa. Maybe the first one would be, I was reading about Zyprexa in Europe, can you talk about the severity of generic erosion you're anticipating here, given that some of these market obviously, historically, have had lower rates of generic penetration. My second question on Zyprexa was, with the upcoming patent expiration, can you just help us a little bit to understand a lot better the impacted gross margin and quantify how much of an impact to gross margin we should expect due to the loss of that franchise?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","We'll have Ronika handle the first one. I think Derica will take a shot at your second question.",19,"We'll have Ronika handle the first one. I think Derica will take a shot at your second question."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional er",82,"So with regard to Zyprexa and the patent expirations in Europe, you might keep in mind that in major Europe, we actually lost patent in Spain and some smaller other countries in this past quarter. We didn't see much erosion but expect to see additional erosion as we go through the year. With regard to the rest of major Europe, the patent will actually expire in September. And keep in mind, we would, again, expect to see additional erosion as that occurs."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Derica?",1,"Derica?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavo",62,"Chris, in regard to the impact of the gross margin as well, I will not quantify the specific. I can give you a clear, directional impact and its detrimental. So when we lose a brand like Zyprexa and with its level of profitability, you'll see an unfavorable impact to our gross margin line as that plays through our P&L and financial results."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there wou",199,"One of the other things, Chris, I had to keep in mind for European erosion, we may be in a little bit different environment now in some of the countries in the past had slower erosion. I think it became pretty apparent to many of the payers that there would be very large brand and a large number of them coming off patent. And then the fact that we've positioned themselves to benefit as they should from those patent expirations. So much of the action that you saw in 2010 even was really directed against reducing prices of generic and setting up situations, where once a branded product goes generic, so the initial price was for generics will come out lower. You probably put this in detail, that in many products, you've seen in the past that branded price will be a little lower in Europe than here in the U.S. But actually, the generic price will be substantially higher in Europe than here in the U.S. So again, I think you're going to see a stronger push to use generics more quickly and more fully, in some of the markets in the past may have been slow-erosion markets."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","And then, our final question comes from the line of Seamus Fernandez from Leerink Swann.",15,"And then, our final question comes from the line of Seamus Fernandez from Leerink Swann."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Analysts","Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think",80,"Just a quick follow-up on the Effient versus the Brilinta situation. Can you just at least, in terms of the launch trajectory and the percentage share that you currently have of the incident ACS patient population, can you guys update us on that? I think earlier, you had given us an estimate of I think about 11% share at one point, and I'm just wondering where we sit today at least in the U.S. market on a relative basis."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","All right. Seamus, we'll have Ronika to hear. You found some of the updated data?",15,"All right. Seamus, we'll have Ronika to hear. You found some of the updated data?"
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we've seeing quarter-over-quarter nice trend",132,"Right. So you might remember, Seamus, we've gotten some excitingly so traction with regard to Brilinta over the last -- excuse me, with regard to proxy grow over the last couple of quarters. We've seen there as we've seeing quarter-over-quarter nice trends with our TRx. We're still seeing continued growth with regards to new to brand, which has been very impressive given where we are in the current launch. Right now, that exceeds about 13%. Again, we are seeing about 1 in 5 ACS patients, and STEMI type, specifically, are receiving Effient, which is pretty impressive. And so, we hope that, that traction continues. Again, we are seeing quarter-over-quarter growth in our NRx and TRx and are excited by this trend as doctors continue to accept and try prozigro [ph] or Effient."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call.",19,"With no further callers on the queue, I'll go ahead and turn over to Derica to wrap-up the call."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Executives","Well, let me conclude by first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and",85,"Well, let me conclude by first of all, thanking all of you for joining us for this morning's call and more specifically for your questions. We hope that the information we provided today is helpful for your investment of Lilly's financial performance and for our end of our future prospect. As always, the IR team will be available to answer any additional questions you may have. And I look forward to our continued dialogue, and I hope you all have a great day. Take care."
285467,97242192,145178,"Eli Lilly & Co., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. Inter",75,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through July 28. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code of 207464. International participants, dial (320) 365-3844 with the access code of 207464. That does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ahe",41,"Ladies and gentlemen, thank you for standing by and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ahead, sir."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Fi",679,"Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Financial Officer; Dr. Jan Lundberg, our Chief Scientific Officer; Dave, who's currently President of our U.S. affiliate and as announced last week, Dave will assume the role of President of our Biomedicine business upon -- retirement at the end of the year; and we have Ronika Pletcher for Investor Relations. 
During this conference call we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decision.
Let's begin with a recap of events since our Q2 earnings call. With multiple developments on the regulatory front, the European Commission granted final approval for Trajenta for adults with Type 2 diabetes. EU launches have begun starting with the U.K. Launches in other European countries are expected over the balance of 2011 and the first half of 2012. Despite initial impact we help to reach an agreement with local authorities that Trajenta be made available to German patients. 
The FDA approved Cialis for once daily use for the treatment of signs and symptoms of benign prostatic hyperplasia or BPH. And men who have both erectile dysfunction and signs and symptoms of BPH. Cialis is the only medication approved by the FDA to treat both ED and BPH. Just last night, the FDA approved Byetta for use with insulin glargine. Europe CHMP issued a positive opinion for use of Alimta as a continuation maintenance therapy in patients with non-squamous non small cell lung cancer after initial treatment with Alimta plus cisplatin. 
We expect EC approval during Q4. Along with Amlin and, we submitted our reply to the FDA's Complete Response Letter for Bydureon, and the FDA assigned a PDUFA date of January 28, 2012. We also submitted our reply to the FDA's Complete Response Letter for Amyvid, a imaging under investigation for the detection of beta-amyloid plaque in the brains of living patients. And finally, we submitted the sBLA for Erbitux in first-line metastatic colorectal cancer. On the business development front, we entered into 2 different agreements to bolster our diabetes presence in EMEA. First, we entered into collaboration with Lupin Limited under which Lupin will promote Humulin in India and Nepal. And we expanded our collaboration with Boehringer Ingelheim to include copromotion Linagliptin by Lilly and copromotion of Humalog by Boehringer Ingelheim. 
Also in earlier stage in this development initiative we launched a new platform called Open Innovation Drug Discovery to both build our own pipeline and identify molecules that may be useful in the treatment of multiple drug resistance tuberculosis. On the legal front, the Court of Appeals for the Federal Circuit ruled in Lilly's favor in the Strattera patent case, overturning a prior ruling by the U.S. District Court of New Jersey and upholding the Strattera method of use patent, which will expire in May 2017. 
The defendants filed a motion for rehearing, and earlier this week, the court denied their request. Lastly, an important news for our industry and for Lilly, the America Invents Act was signed into law. Not only will this new law align U.S. patent laws more closely to those of other countries but we believe it will improve U.S. competitiveness by reducing the backlog of patent applications, enhancing the quality of issued patents and providing greater certainty for those that invest in innovation. Now as background, Ronika will discuss our Q3 financial results and provide our pipeline update. And then Derica will cover our financial guidance for 2011 and key events for the remainder of 2011 and 2012. Ronika?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provides insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments an",1214,"Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provides insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. We'll also provide commentary on our Q3 results, excluding the effect of headwinds that were highlighted in previous discussions of both our quarterly performance and our 2011 guidance. 
I'll start on Slide 6 with a quick look at our Q3 income statement. On a non-GAAP basis, you can see that we generated robust revenue growth in this quarter, excluding Gemzar outside of Japan and the effective U.S. healthcare reform, revenue would have grown 15%. Compared to Q3 2010, gross margin as a percentage of revenue decreased 4.3 percentage points to 78.2%. This decrease is primarily due to the effective changes in foreign exchange rates on international inventories sold and to a lesser extent, negative mix effect. Operating expense defined as the sum of R&D and SG&A grew 10% this quarter. This increase was driven primarily by SG&A, which increased 13%, while the increase in R&D was 5%. 
Drivers in the increase in operating expenses included cost related to our diabetes alliance with Boehringer Ingelheim, including late-stage clinical trial expense. The effective changes in foreign exchange rates as well as the pharmaceutical manufacturing fee associated with U.S. healthcare reform, which was roughly $45 million. Excluding the effect of U.S. healthcare reform and the Boehringer Ingelheim alliance, operating expenses would have grown 3% with this amount entirely driven by foreign exchange. 
Other income and deductions was a net expense of $83.4 million this quarter, which was higher than last year. The higher net expense was due to a partial write-down and the IPR&D value of Amyvid due to revised assumptions for the timing of the potential regulatory approval and sales update. Our tax rate was 17.9% this quarter or 4.6 percentage points lower than Q3 2010. 
The largest items driving this reduction is the recognition of a discrete tax benefit of $45.4 million, primarily as a result of a resolution of the company's 2007 IRS tax audit. At the bottom line, our non-GAAP EPS decreased 7% from $1.21 to $1.13. Consistent with the 2011 guidance we provided in January we saw a robust EPS growth in our business in Q3. Excluding U.S. healthcare reform, the effective patent expiration outside of Japan and investments related to the Boehringer Ingelheim diabetes alliance. 
Excluding these items, EPS would have grown in the mid-20% range. Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. Now let's look at how foreign exchange affected our Q3 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 4%. This quarter, foreign exchange also contributed 4%, while price had a negligible impact on worldwide revenue growth. 
We continue to see strong volume growth from our 3 countercyclical engines: Japan, animal health and emerging market. In total, these businesses delivered 15% volume growth in the quarter. Volume growth continue to be strong in Japan at 20%, driven by recent launches of both Cymbalta and Forteo. Animal health volume grew 22% in Q3 driven primarily by organic growth, including increased demand for our food animal products and the continued expansion of our companion animal business. 
The launch of Trifexis in the U.S. has been particularly robust. To a lesser extent, this volume growth was driven by the acquisition of certain enhancements and animal health assets in Europe. Finally, embedded within the rest of world line, our emerging markets revenue grew 7% in volume and 5% overall. Although the growth in emerging markets moderated relative to previous quarters, particularly noteworthy was China's revenue growth of 22% in volume and 31% overall. This quarter, FX had a significant effect on EPS. Slide 10 shows the year-on-year growth of our select line item of our non-GAAP income statement, both with and without effects of changes in foreign exchange rate. The numbers in the first column are the same as those you saw on the last column on Page 6. Let's focus on the second column of numbers, which strip out the effect of foreign exchange. 
First you'll see that the 4% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin of 8% and 3%, respectively. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was primarily due to the effect of foreign exchange on international inventories sold. In total, operating expenses grew 7%, excluding FX. As mentioned earlier, the increase was driven entirely by the Boehringer Ingelheim deal and the pharmaceutical industry fees. 
Continuing on, you'll see that, excluding FX operating income declined 2% and EPS declined 1%. So you can clearly see that FX had a significant negative effect on EPS this quarter, lowering EPS growth by 6 percentage points to negative 7%. In other words, a favorable effect of FX on our foreign operating income was more than offset by the negative effect of FX on inventories sold, excluding U.S. health care reform, the effect of patent expiration outside of Japan and investments related to the BI diabetes alliance, EPS would have grown in the mid-20s. 
On Slide 11, you'll find year-on-year growth of the same item of our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. On Slide 12, you'll find a view of our new molecular entities in clinical development as of October 10th, inclusive of changes since our July update. Our clinical stage portfolio now stands at 66 distinct -- including 35 compounds about in Phase II and Phase III. 
Biotechnology represents half of our Phase II and Phase III assets as well as nearly half of our overall clinical portfolio. We continue to make progress in advancing our pipeline. Since July, we began Phase III testing of our new insulin products and we now have 10 distinct compounds in Phase III testing with 2 more likely to begin before year end. 
We advanced 3 assets in the Phase II testing including our myostatin, monoclonal antibody that Lon -- discussed at our June investment committee meeting. We advanced 2 assets in the Phase I testing and we terminated or suspended development of 6 assets across our Phase 1 and Phase II portfolio. In summary, we have already achieved our goal of having 10 NMEs [ph] in Phase III by year end. With Phase III starts expected this quarter for our innovative basal analog influence and for Anti-IL-17 monoclonal antibody for psoriasis, we could finish this year with 12 NMEs in Phase III testing. 
We're pleased with our progress we've made building a robust, high-quality, mid- to late-stage pipeline with many potential opportunities to advance patient care in diseases with large unmet needs as well as significant commercial opportunity. As outlined at our investment committee meeting in June, we believe our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. Before providing our updated guidance, I would like to talk through how these Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your model. Now clearly this patent exploration, which",1616,"Thanks, Ronika. Before providing our updated guidance, I would like to talk through how these Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your model. Now clearly this patent exploration, which is essentially a U.S. and European phenomenon will negatively affect our revenue and income causing our fourth quarter results to differ substantially from those we posted September year-to-date. 
We lost the Zyprexa patent in most European countries last month. This coming Sunday, October 23, we'll lose patent protection for Zyprexa here in the U.S. Now as you might expect during Q3, we saw the initial impact of the Zyprexa patent expiration. Specifically, we saw some reduction in wholesale purchases in anticipation of reduced future sales of branded Zyprexa. 
In addition, we also made accrual to account for the potential future return of products that were sold of the wholesalers during the third quarter. In European markets, we've already seen multiple generic companies enter the various markets, offering very large discounts. For example, in Germany, there are about 20 generic players and the initial generic pricing came in at about a 75% discount to Zyprexa's pre-patent expiry price. 
Now here in the U.S., while we expect rapid and significant erosion of the branded Zyprexa sales, the competitive dynamic will be a bit different as we will have a single generic company marketing each presentation of -- for the first 6 months post patent expiration. Also as part of our late life cycle planning, we've entered into an authorized generic agreement here in the U.S. with -- to allow them to market a generic version of Alanzapin [ph]. Now upon expiration of the 6 month exclusivity period in late April of 2012, we would expect additional companies to market their own generic -- leading to further sales erosion of Zyprexa. 
In summary, on the revenue line, we expect to see a significant negative impact in Q4. This is reflected in the fact that our worldwide revenue has grown 8% September year-to-date, while our full year guidance for 2011 is for revenue growth in the mid-single digits. As you think about the impact of the Zyprexa patent expiration on other line items in our income statement, you should keep in mind a few items. We do not expect Zyprexa related manufacturing expenses to decrease at the same rate as sales. While there will be some savings of variable production cost, other fixed costs that had been absorbed by the production of Zyprexa will remain. 
As a result, the expected decline of Zyprexa sales will put downward pressure in our gross margin as a percent of revenue. This is why we forecast gross margin as a percent of revenue for the full year 2011 to be between 78% and 79%, despite the fact that it is at 79.5% for the first 9 months of the year. Now in terms of marketing and selling expenses, we currently have very little variable marketing expense behind Zyprexa during this late stage of its lifecycle. 
Consequently, there will be minimal marketing savings post-patent expiration. The major spend behind Zyprexa has been the sales force. Now you should not expect to see a significant reduction in sales force expenses result of the Zyprexa patent expiration for 2 main reasons. First, beginning in late 2009, we restructured our U.S. and then our European neuroscience sales forces, among other factors, this restructuring took into account the CNS sales footprint needed post the Zyprexa patent expiration. Second, keep in mind the Cymbalta sold by these same sales forces and we committed to providing a competitive detailing effort behind this very important brand. 
In a nutshell, our strategy for managing cost leading up to the Zyprexa patent expiration has been to act early and not wait until the event itself was upon us. Since 2004, we've been reducing headcount and driving productivity improvements across all areas of our business. And since 2009, we've upped the pace of rightsizing our organization for the post the Zyprexa period significantly restructuring everything from our senior management layers to our back office operation to our sales and marketing organization. 
As a result of these efforts, we fully expect to meet our goal of reducing our expenses by $1 billion by the end of this year. This will essentially complete our restructuring effort. While we will continue to drive incremental productivity, we have no plans for a major restructuring. Hopefully this is commentary on the impact of the Zyprexa patent expiration is helpful as you update your models. 
Now let's review our updated 2011 financial guidance. At a high-level, our updated guidance is very consistent with the guidance we issued on our July earnings call. It reflects continued strong underlying performance over business. It also includes discrete tax benefit and additional charges recorded in Q3. In total, these changes result in an increase in narrowing of our EPS guidance. On a non-GAAP basis, we now expect 2011 EPS of between $4.30 and $4.35. Our 2011 reported EPS guidance range of $3.89 to $3.94 reflects the $0.23 IPR&D charge for the Boehringer Ingelheim alliance at $0.18 in restructuring recharges in the first 9 months of the year. 
Our guidance on individual line item is largely unchanged. Revenue still expected to grow in the mid-single digits and gross margin as a percent of revenue it is still expected to decline by 2 to 3 percentage points when compared to the full year of 2010. SG&A growth is still expected to be in high single digits and R&D growth is still expected to be in the low single digits. Our guidance for other income is now forecast to be a net loss in the range of $175 million to $225 million, reflecting the partial impairment of the acquired in-process R&D asset related to Amyvid. 
As a result of the discrete tax benefit recognized this quarter, we now expect our 2011 effective tax rate to be approximately 20% on a non-GAAP basis and approximately 19.5% on a reported basis. And we now expect capital expenditures to be approximately $700 million. Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010. And the associated growth rates from these numbers to our revised 2011 guidance. In terms of key future events, highlights for the balance of 2011 include potential FDA approval of Erbitux for first-line head and neck cancer. 
The anticipated European Commission approval of Alimta as continuation maintenance therapy in non-squamous non-small cell lung cancer. Expected Phase III starts for our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis. This would bring our Phase III portfolio to 12 new molecular entities, exceeding our goal of 10. We also expect to present key Phase II data on our CETP inhibitor at the American Heart Association meeting in November as well as for our anti-IL-17 and RA at the ACR meeting also in November. 
And in psoriasis at the -- clinic meeting in London in December. Now in the interest of time, I will not recite the full list of potential events for 2012. But as you can see, we have a significant number of -- we have a significant number of potential regulatory actions, phase III trial completions and potential data disclosures. 
We are clearly excited about the year ahead and are pleased with the progress we continue to make in advancing our pipeline. This will remain our number one priority. Now as I mentioned in our July earnings call, 2011 is playing out largely as we had expected. We are delivering solid financial results as we head into the patent expiration and importantly we are making progress in advancing our pipeline. 
As expected, in Q3 we saw the impact of known headwinds, including patent expirations that are lowering sales of Gemzar outside of Japan, U.S. health care reform, which is exacting a higher cost in 2011 than it did in 2010 and your dilution from expenses associated with our static diabetes alliance with Boehringer Ingelheim. 
Now, while these headwinds negatively impacted our Q3 results, we again delivered strong underlying growth in the rest of our business. Excluding these items, on a non-GAAP basis, we posted revenue growth of 15%, operating expense growth of 3% and mid-20s percent EPS growth. As you think about our future revenue, you will clearly need to factor in the patent expiration of Zyprexa in the U.S. and Europe. But I also like to highlight that in Q3, our countercyclical engine what of Japan, emerging markets and animal health collectively grew 19%. And we've got a number of key brands that posted double-digit worldwide revenue growth, including Cymbalta, Humalog, Strattera, Forteo, Cialis and Alimta. 
We've already achieved our goal of having 10 molecules in Phase III development by the end of the year. And we expect to begin Phase III testing of our innovative basal analog insulin and NR anti-IL-17 antibody in psoriasis before year end. We firmly believe that our current pipeline serves as the foundation for Lilly to return to growth post-year YZ. 
Moving forward, we will continue to focus on executing our 3-part strategy as we stated in June. Replenishing and inventing our pipeline, innovation-based biopharmaceutical company this is our future. Second, investing to drive growth in our countercyclical growth engines and currently marketed brands particularly those that do not lose patent protection in the YZ period. And third, continue to drive productivity gains across our business that allow us to fund R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Now this concludes our prepared remarks and we'll now open the call for the Q&A session. Operator, first caller please."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions]  First question from the line from the line of Steve Scala, Cowen.",14,"[Operator Instructions]  First question from the line from the line of Steve Scala, Cowen."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions, both of which are on solanezumab, does the delay in the futility look allow for a view of the data reflecting a longer duration of treatment such as say 15 months as opposed to have the look occurred in the current quarter when perhaps",140,"I have 2 questions, both of which are on solanezumab, does the delay in the futility look allow for a view of the data reflecting a longer duration of treatment such as say 15 months as opposed to have the look occurred in the current quarter when perhaps it would've been more like 12 months or regardless of when the look was taken as the duration of treatment is the same, that's the first question. And then the second question is for Dr. Lechleiter. Do you feel that the final solanezumab Phase III result in the second quarter of 12 as just another Phase III readout or is this perhaps the most important data point for Lilly in years and will dictate where you lead the business? And perhaps asked differently, is your current course viable if solanezumab should fail?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll go ahead and take your first question and have John answer the second. The futility analysis has been originally scheduled for December and for purely logistical reasons, the DMC rescheduled of that to January. So there is no particular change in the",78,"I'll go ahead and take your first question and have John answer the second. The futility analysis has been originally scheduled for December and for purely logistical reasons, the DMC rescheduled of that to January. So there is no particular change in the number of months, number of patients data that they will be reviewing at that particular review. It was simply a logistical change that led to the movement from this year to next year. John?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, with respect to your second question, obviously we're very interested in those results and we're very interested frankly in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention we have other molec",146,"Steve, with respect to your second question, obviously we're very interested in those results and we're very interested frankly in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention we have other molecules as well in various stages development in our portfolio. Looking at the beta-amyloid and other mechanisms associated with Alzheimer's disease, while this is a very important readout for us next year, it's not something whether it's positive or negative it's going to change our strategy or change the basic underlying assumptions that we're carrying forward as we go through YZ. Our future does not depend on any single molecule including solanezumab or soon-to-be 11 other molecules in Phase III. And we will go where the data takes us and proceed accordingly. But we are really interested in prosecuting and moving forward that entire portfolio."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","This is Phil. Before go to the next caller as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the investment committee meeting in June, we have said all along this is a high ris",139,"This is Phil. Before go to the next caller as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the investment committee meeting in June, we have said all along this is a high risk program. It's very interesting science. We are very hopeful of the potential outcome but we recognize that it's high risk. Essentially, for the financial modeling, what that means is it's a sign of relatively low probability of actually hitting, if you will, so that means for financial projections that low probability goes to 0, it really does not take them down very much. If on the other hand, it were to go ahead and go from that low probability to 1, it would have a substantial potential upside to those numbers. Hope that's helpful."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Seamus Fernandez, Leerink Swann.",11,"Next question is from the line of Seamus Fernandez, Leerink Swann."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Another pipeline question. As we think about the aspects for the spend as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III you. John, can just talk a little bit strate",113,"Another pipeline question. As we think about the aspects for the spend as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III you. John, can just talk a little bit strategically about your interest in the CETP inhibitor? And perhaps even there are many, many CETP inhibitors in development across the industry, will there be any interest in basically saying okay, let's look across the different CETP inhibitors, take the data and perhaps partner with someone else who has this and share the development cost given the risk profile associated with this still untested mechanism?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, I can't speak specifically to CETP inhibitor because we really need to wait and see as the data as we shared that in November. But I think as we look at our pipeline, obviously we're making decisions and looking at different things all the time th",146,"Seamus, I can't speak specifically to CETP inhibitor because we really need to wait and see as the data as we shared that in November. But I think as we look at our pipeline, obviously we're making decisions and looking at different things all the time that say should we go along with this or should we partner with that 1. Obviously we got a huge benefit I think from the deal we swapped with BI earlier this year we have announced 4 potential assets, one of which is now launched. Share between the 2 companies on a global basis. And as we move new molecules into Phase III, other programs begin to wind down. So we're looking at this all the time and obviously we'll do what we think is in the best interest of the company and the shareholders if we make these decisions."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question from the line of Marc Goodman, UBS.",9,"Next question from the line of Marc Goodman, UBS."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Can you give us a little more color on the emerging markets maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all maybe you can talk about some of the products that moved into Phase III a littl",70,"Can you give us a little more color on the emerging markets maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all maybe you can talk about some of the products that moved into Phase III a little bit, is there any color you can give us -- action and maybe just a little bit more color there."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Marc, this is Derica. We are still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effect of patent Zyprexa patent erosion in the",98,"Marc, this is Derica. We are still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effect of patent Zyprexa patent erosion in the emerging markets specifically in Brazil. In markets like China where we haven't seen that, that's why you saw the 22% volume growth there and the 31% growth overall. So the growth that you saw in the third quarter is accordingly -- it's according to the expectations that we have laid out."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the new Phase III startups as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for th",102,"In relation to the new Phase III startups as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the physicians then to different patients. We believe we have a very good agent and we are comparing this to Lantus in 2 Phase III trials both in type 1 and type 2 diabetes for non --. Furthermore, with our expertise in manufacturing and advanced devices, we think we can be really competitive in this area."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Marc, anything that you will see are some new names for what was previously on the mGlu2/3 and NERI, so you've got pomaglumothad methyanol which is mGlu2/3, so a new name but same molecule and then edovoxotin [ph] which is NERI.",41,"Marc, anything that you will see are some new names for what was previously on the mGlu2/3 and NERI, so you've got pomaglumothad methyanol which is mGlu2/3, so a new name but same molecule and then edovoxotin [ph] which is NERI."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Chris Scott, JPMorgan.",10,"Next question is from the line of Chris Scott, JPMorgan."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question was if you just elaborate a little bit more on the European pricing environment and how it's trending relative to your expectations. I think most importantly kind of as we go forward, how are you seeing 2012 and 13 shaping up from a pricing",120,"First question was if you just elaborate a little bit more on the European pricing environment and how it's trending relative to your expectations. I think most importantly kind of as we go forward, how are you seeing 2012 and 13 shaping up from a pricing perspective relative to 2011? Second question was on the insulin business. Can you talk about the competitive response you've seen in the market, you're obviously doing very well with volume trends here. Talk about are you seeing any different competitive response as you regain some share. And then finally, just color on Trajenta and how you see the EU opportunity for this product given some of the challenges that you highlighted in Germany?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll handle your first question, I'll take a shot at the second too.",14,"I'll handle your first question, I'll take a shot at the second too."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically as you look at our Q3 results, you can see price was down about 1%. Historically we typically see about a 1 to 2 percentag",157,"Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically as you look at our Q3 results, you can see price was down about 1%. Historically we typically see about a 1 to 2 percentage point erosion on an annual basis year-on-year, so very much aligned. Now obviously each government is acting in different points in time but we continue to be able to manage our way through that. As I think about 2012 and 2013, at least in Europe we still see things playing out more or less along those lines. Probably the biggest question from a pricing standpoint still remains in the U.S. and emerges from the discussion around the super budget committee and if there's any change as it relates to Healthcare Reform and so for the increases at rebate. That's probably the biggest unknown from a pricing standpoint facing the industry at this stage."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Pricing probably since last call, the one thing that would've changed that would be the largest impact was in Spain where they instituted a couple of new measures, one for those products that have been in the market for more than 10 years and for which th",420,"Pricing probably since last call, the one thing that would've changed that would be the largest impact was in Spain where they instituted a couple of new measures, one for those products that have been in the market for more than 10 years and for which there is no generic reference pricing group because there's no generic competition. They get asked for 15% rebate essentially on those products, that compares to the 7.5% that they had been requesting prior. And then probably more materially for us here, they want to have instead that innovative formulation even if they are protected by patent protection would still be subject to reference pricing. So specifically for us that will -- the rapid dissolving form of Zyprexa while we don't have generic competition in Spain, it has now been what to the reference pricing for the generic olanzapine group broadly. For the insulin competition, this is a sector that we dedicated a lot more focus to over the last couple of years. In particular I would say with the formation of our diabetes business in early 2010. And we intend to maintain that focus on that business. We have said before we are seeing that if it is more competitive, I think -- is seeing a more competitive Lilly and as we would expect, they're going to react and I would say though, while the influence business is one that is extremely important, it's going to be a very large part of overall diabetes treatment market, one that we intend to go ahead and very competitive in. Our goal of regaining leadership over time in diabetes is not predicated solely on insulin. It really doesn't encompass the glut space as well as the --. So our focus on building that broad-based portfolio and leveraging that is intact and we'll continue to execute that really diligently. Trajenta is really very early days, you may also be referring to the decision made in Germany where there were some very difficult comparables being applied to what the government would like to reimburse the product that did not make it appropriate for Boehringer Ingelheim or Lilly to move forward at this time. We definitely do anticipate we'll be able to reach some agreement with a government that provides this product to patients and also recognizes innovation benefit that it brings and compensates Boehringer Ingelheim and Lilly. So we remain very optimistic about this -- and about this product, again very early days in Europe on this particular front."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Catherine Arnold, Crdit Suisse.",11,"Next question is from the line of Catherine Arnold, Crdit Suisse."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are obviously some other innovators. Are you in a position that you can actually use t",117,"I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are obviously some other innovators. Are you in a position that you can actually use that portfolio for contracting purposes either to government particularly outside the United States or from the standpoint of private payers, if you could just comment on what you're able to do as you approach the customer on payment. And then I wanted to ask you on your insulin glargine aspirations, have you considered doing a combination with Byetta and would you need a separate contract with Amylin to move forward on that idea?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll go ahead and take a shot at the first 2 and if -- want to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of bundling, if you will, or using different products to go ahead and gain leverage",222,"I'll go ahead and take a shot at the first 2 and if -- want to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of bundling, if you will, or using different products to go ahead and gain leverage with payers that way. I think one of the main things that we have been focused on is the ability to approach the physician and talk about what their patients' needs are and those patients do have different needs over the course of their disease. So this clearly positions us to offer products that go from earlier stages with the oral treatment into the injectable phases with initially and then obviously you've got people who eventually will progress and will need therapy and obviously we have very strong offering which we hope to expand in the future with the 2 basals that we're developing. In terms of the combo, to my knowledge there have not been absolutely active discussions. I'm not familiar Catherine with the contract I would think if you introduced another molecule into that collaboration, we would need to probably have some discussion to figure how that would work as the current collaboration really is focused on the exenatide molecule whether that's Byetta, Bydureon or subsequent formulation."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tim Anderson, Sanford Bernstein.",6,"Next question Tim Anderson, Sanford Bernstein."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","You talked about having already pulled much of the sales and marketing spend from Zyprexa on the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these s",120,"You talked about having already pulled much of the sales and marketing spend from Zyprexa on the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these spend savings annualize compared to when you fully resourced the brand? And then looking forward to maybe the end of 2013 when Cymbalta looks like it's going to go away, that seems it's going to have an impact on Lilly that's about the same as what Zyprexa is likely have in the current year. Can you just confirm that the Cymbalta impact will be about the same as Zyprexa's a few years from now?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave comment on Zyprexa marketing spend and if you don't mind maybe talk about how you're thinking of the comments on the sales decline but just management of sales operations as Cymbalta we'll come to Derica for the financial piece.",41,"Dave comment on Zyprexa marketing spend and if you don't mind maybe talk about how you're thinking of the comments on the sales decline but just management of sales operations as Cymbalta we'll come to Derica for the financial piece."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","So with Zyprexa, this is a brand that for many years has had a very positioning in the minds of physicians and we've been able to taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last calendar year we can just",140,"So with Zyprexa, this is a brand that for many years has had a very positioning in the minds of physicians and we've been able to taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last calendar year we can just say that they were a fraction of that peak level already in 2010, in 2011 or even lower. For Derica's earlier comment, Cymbalta will see a very different picture in the U.S. This is a brand in a very competitive, highly genericized market with less clinical differentiation in the minds of physicians. We do plan on having a robust sales and marketing efforts, much closer to the exclusivity and therefore, as you think about modeling after LOE there will be a more significant expense impact post LOE with Cymbalta."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tim, when you think about the financial impact of -- so how do the numbers play out, some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, so -- for Al",130,"Tim, when you think about the financial impact of -- so how do the numbers play out, some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, so -- for Alzheimer's disease, mGlu2/3, pronounce the new name, I won't try it. But for schizophrenia as well as NERI for depression. So as those play out, we may see a re-purposing of some of those Cymbalta assets or resources to these new brands as we anticipate gearing up for the launches, assuming that we're successful in bringing those through the regulatory process. So this is how we're trying to manage our way through this period and seize the opportunities as they emerge."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question as David Risinger, Morgan Stanley.",7,"Next question as David Risinger, Morgan Stanley."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions for Derica and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add",164,"I have 3 questions for Derica and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add a little more color on your comment about Zyprexa product returns and what investor should expect in terms of fourth quarter U.S. Zyprexa sales. And then third, with respect to SG&A obviously spending continues to rise as you build businesses and that's clearly working to drive the top line. But maybe can just comment on the outlook for SG&A spending growth in coming years should we expect SG&A to continue to rise post a Zyprexa going generic? And then lighter maybe somebody else can comment wondering if you can provide any more collar on the diabetes formulary pressure going into 2012 and your ability to offset the loss of CVS Caremark as a partner."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product level projections are forecast. But what you could antic",230,"Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product level projections are forecast. But what you could anticipate when we think about just returns, we probably took about 1/3 of the impact and anticipate an impact in the third quarter. And we would anticipate about another 60% impact of returns in the fourth quarter. Clearly, as you have we go through the brunt of the erosion, the initial phase of the U.S. erosion curb. In regards to SG&A expenses, if you look at the third quarter, it was really driven by 3 elements, if you look at our total OpEx growth. FX was about 3 percentage points. The remaining 2 items was the pharma fixed fee okay, and the third was the expenses both in SG&A as well as R&D behind our BI collaboration. If you exclude those 3 items, our expense growth in the quarter was essentially flat, so 0. In fact, it was slightly negative in real terms. So when you think, projecting forward we're not at a stage of putting out guidance beyond this period from a line item standpoint. But what you can expect is we're going to be managing our SG&A very tightly okay."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","More commentary on that 7% non FX OpEx growth Derica mentioned 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy, you've got approximately 5% of total OpEx growth being driven by the Boehringer Ingelheim coll",188,"More commentary on that 7% non FX OpEx growth Derica mentioned 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy, you've got approximately 5% of total OpEx growth being driven by the Boehringer Ingelheim collaboration and about 1.5% or so is driven by the pharmacy. And then your last question Dave on the diabetes formularies axis here in the U.S., each and every year, there are some contracts that are not in all of them and each and every year we have seen a dynamic where we've maintained a vast majority of those that we have had, we've gained some additional ones and then we lost a few. That dynamic we expect to continue. In terms of talking about specific contracts, often in agreement with actual customers we don't disclose specific contracts that have been won or lost. And so they actually take effects, I can't provide specific commentary on ones that we may anticipate could come of in 12 or that we may be gaining in 12. We'll have that information for you in the January call with the Q4 results."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tony Butler, Barclays Capital.",6,"Next question Tony Butler, Barclays Capital."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with the price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And",71,"Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with the price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And then second, back to the Zyprexa returns, can you tell us what you're actually accruing for the amount that you're accruing for those returns?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tony, in regards to Japan, we continue once again to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to be very well. We're not in a position of providing pricing projections for Japan for 2012. Clearly, o",83,"Okay. Tony, in regards to Japan, we continue once again to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to be very well. We're not in a position of providing pricing projections for Japan for 2012. Clearly, on our call in January we'll be in a position to provide overall guidance for our outlook for 12, which would include Japan and the potential pricing. So if we can, we can put that off until then. John?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. One comment I would make is although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how that's going to continue to play ou",137,"Tony, this is John. One comment I would make is although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how that's going to continue to play out and how other products that don't fall in the category be effective remains to be seen. But actually in contrast to some other parts of the world, we actually see in the last 2 years and going forward a more favorable pricing environment in Japan as the government there recognizes the need to call out innovation and to value innovation and also continues with its intent to ensure that more medicines that are approved in Europe and the U.S. are approved and made available Japanese patients in a contemporaneous way."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter.",20,"Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question John Boris, Citi.",5,"Next question John Boris, Citi."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question is for Dave. Dave, can you maybe help frame or characterize the opportunity for Cialis in VPH, what percent of the business have you already shifted to the once daily size of the market opportunity and reimbursement going forward? second qu",132,"First question is for Dave. Dave, can you maybe help frame or characterize the opportunity for Cialis in VPH, what percent of the business have you already shifted to the once daily size of the market opportunity and reimbursement going forward? second question for Derica. You'd mentioned on the sequential growth for the emerging markets that it was largely attributed to Zyprexa, can you maybe give some color of the 500 basis points sequential decline, what percent of Zyprexa sales account for that in rest of world. And then third question just for John very quickly, in the environment in Washington, what do you find, John, that the industry is winning on going forward and what fo you think some of the challenges are in Washington that the industry continues to face?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","We're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once daily formulation, wh",110,"We're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once daily formulation, which is specific to the syndication, you need to take the medicine everyday prior to the DPH launch, about 1 in 4 Cialis prescriptions in the U.S. were for the once a day form. We would anticipate with BPH uptake to continue to grow and we see the BPH opportunity as a nice growth driver over the life of Cialis in the U.S."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay.",34,"John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the reduction focus in terms of patent reform, it's a huge win. It should in the medium to long-term restore a great deal of confidence",354,"John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the reduction focus in terms of patent reform, it's a huge win. It should in the medium to long-term restore a great deal of confidence for investors that our patents can be -- can remain valid, can be enforced and can be the basis for investor confidence in addition to clearing this huge backlog. I think there is still strong support for maintaining 12.5 years of data protection, for biologics, which is part of the affordable care act and it's the law and we want to keep it that way. And I think there's a general recognition appreciation to the fact that this industry employs directly and indirectly between 3 and 4 million people in this country. And it's the only way we're going to attack diseases like Alzheimer's and cancer, which not only cause suffering but help drive up a lot of the healthcare cost today and in the future. I think the area of concern for us right now is Part D. We're fighting and we're quite adamant in our opposition to imposing government price controls in Part D. This is a program that's working, premiums for seniors have remained low. The overall cost of the program is stunningly lower than any one forecast 5 or 6 years ago. And most seniors in Part D today have access to medicine. In terms of deficit reduction, party is making a difference in there too. A recent study published show that for every person enrolled in Part D, they have $1,200 a year less costs in other parts of the medical delivery system. That's more than $10 billion a year in savings and I think we have to attribute to the programs currently structured so we're going to continue to make sure that that message gets heard and understood as we go forward we will continue as well to express concerns we have about IPAD, the independent payment advisory board, as well as the way this 340 B program is being expanded, we believe, inappropriately."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Gregg Gilbert, Bank of America Merrill Lynch.",7,"Gregg Gilbert, Bank of America Merrill Lynch."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First I was hoping you could attempt to quantify your dual eligible exposure and maybe John you can handicap that specific item, what happened there? Secondly, for Jan as we head into AHA, can you frame your latest thinking on how your CTP product stacks",86,"First I was hoping you could attempt to quantify your dual eligible exposure and maybe John you can handicap that specific item, what happened there? Secondly, for Jan as we head into AHA, can you frame your latest thinking on how your CTP product stacks up against others in the category based on info that's been made public over time? And then third perhaps for Derica, or Dave, on Axiron, was there any abnormally high discounting or couponing in the quarter that will abate over time?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","This is Phil. I'll take your first question. In terms of the exposure on the dual eligible low income subsidy, today we have not provided a specific quantification. I guess one thing I would push it to consider is your Tranche A bracket how large this cou",158,"This is Phil. I'll take your first question. In terms of the exposure on the dual eligible low income subsidy, today we have not provided a specific quantification. I guess one thing I would push it to consider is your Tranche A bracket how large this could be. For the original healthcare reform that was $80 billion cost of the industry over a 10-year period, we'd actually estimate is probably closer to $115 billion cost over that 10-year period of the industry. And as we talked about earlier, we've estimated, you're probably talking about a $600 million to $700 million cost to Lilly in 2011 from healthcare reform. Numbers I've seen from the CBO I guess who scored Medicare, dual eligible low-income subsidy going to Medicaid pricing, I believe they scored this around $105 billion, $110 billion over a 10-year period. So as far as order of magnitude, without getting into specific numbers, I'll have you consider that."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Right, well only thing I can say is that listen to the presentation at the American Heart Association and secondly, what I stated in June was that in the interim analysis of the current where we now have the final data, monitoring committee said accelerat",49,"Right, well only thing I can say is that listen to the presentation at the American Heart Association and secondly, what I stated in June was that in the interim analysis of the current where we now have the final data, monitoring committee said accelerate progression of this agent."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Axiron in the U.S. and as you know, we launched the drug in Q2 and in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe",118,"Axiron in the U.S. and as you know, we launched the drug in Q2 and in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're doing that very successfully today in the U.S. about 1 in 4 in new starts in the testosterone class are going on to Axiron 6 months into the launch. Obviously co-pay cards, vouchers, samples are key partners of ensuring that positive early use experience. But through time, those dissipate as you get more refills. So we're tracking according to our plans and pleased with the early uptick."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","And next question is from Barbara Ryan, Deutsche Bank.",9,"And next question is from Barbara Ryan, Deutsche Bank."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Question is really on China where obviously it's been very successful in showing very strong sales growth. Although we read about various government initiated programs, the reduced price, et cetera and I wonder if you could share with us what you're seein",70,"Question is really on China where obviously it's been very successful in showing very strong sales growth. Although we read about various government initiated programs, the reduced price, et cetera and I wonder if you could share with us what you're seeing there, what your outlook is and maybe some split between what is actually part of the reimbursement list and what percentage of your business is private pay?"
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Barbara, I think that -- we think for us to be successful in China in the long run, formulary status of the national level of prevention of hospital level is going to be key to that. So we work very hard to ensure that our medicines are included in those",178,"Barbara, I think that -- we think for us to be successful in China in the long run, formulary status of the national level of prevention of hospital level is going to be key to that. So we work very hard to ensure that our medicines are included in those formularies all the way down to the local level. I think that there are going to be today and going forward a situation where we have price decrease in China. I think in some cases there's a focus on classes that we don't participate in and in some cases they are likely to affect us. I think as we look at our long-term model in China, we tried to account for that obviously not only as of the delivery healthcare changing China but I think the way in which healthcare is managed by the government we will continue to evolve in under any circumstance, our enthusiasm for the opportunity we have their to reach more patients with our products and to grow our business profitably have not diminished."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thank you very much. I'll go ahead as we approach the top of the hour and turn it over to Derica to close the meeting.",25,"Thank you very much. I'll go ahead as we approach the top of the hour and turn it over to Derica to close the meeting."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, thanks. Just to close out, one thing I would say to add to John's comment, is if you think about the therapeutic areas in which we compete, where we have a strong competitive position, diabetes, oncology and neuroscience, those are also 3 of the fas",237,"Sure, thanks. Just to close out, one thing I would say to add to John's comment, is if you think about the therapeutic areas in which we compete, where we have a strong competitive position, diabetes, oncology and neuroscience, those are also 3 of the fast-growing therapeutic areas in the China market. So today this is a lot of what's driving the strong volume growth that you're seeing in that business, in spite of the pricing environment that is present there. 
Thanks for everyone spending your time with us here this morning. And I guess in closing, I'd like to just maybe reiterate a few points. Q3 was another strong quarter of our underlying revenue growth and financial performance for Lilly. And it was much punctuated by double-digit growth for our countercyclical growth engines from 6 of our key brands. As we head into the teeth of our patent expiration period, we have positioned the company to fund the R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Finally, we continue to make progress in advancing our pipeline, which is the foundation of our future growth. We look forward to keeping you informed as we execute our strategy. And we thank you for your interest in Eli Lilly & Co. Our team will be available to answer any additional questions that you may have following this call. Have a great day."
285467,97242208,174476,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Thank you. ladies and gentlemen, this conference will also be available for replay and that's starting today at 11:00 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T executive playback service by dialing 1 (800) 475-6701",83,"Thank you. ladies and gentlemen, this conference will also be available for replay and that's starting today at 11:00 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T executive playback service by dialing 1 (800) 475-6701 with the access code 218233. International callers may dial area code (320) 365-3844, access code 218233. And that does conclude your conference. We do thank you for joining and using AT&T executive teleconference. You may now disconnect. Have a good day."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ah",41,"Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ahead, sir."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Fi",693,"Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Financial Officer; Dr. Jan Lundberg, our Chief Scientific Officer; Dave Ricks, who's currently President of our U.S. affiliate, and as announced last week, Dave will assume the role of President of our Biomedicine business upon the coming [ph] of his retirement at the end of the year; and we have Ronika Pletcher and Elisa Razner [ph] for Investor Relations. 
During this conference call we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined on latest forms 10-K and 10-Q filed for Securities and Exchange Commission. The information we provide about our product and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
Let's begin with a recap of events since our Q2 earnings call. With multiple developments on the regulatory front, the European Commission granted final approval for Trajenta for adults with type 2 diabetes. EU launches have begun starting with the U.K. Launches in other European countries are expected over the balance of 2011 and the first half of 2012. Despite initial impact, we hope to reach an agreement with local authorities that allows Trajenta to be made available to German patients. 
The FDA approved Cialis for once-daily use for the treatment of men who have signs and symptoms of benign prostatic hyperplasia or BPH, and men who have both erectile dysfunction and signs and symptoms of BPH. Cialis is the only medication approved by the FDA to treat both ED and BPH. 
Just last night, the FDA approved BYETTA for use with insulin glargine. Europe's CHMP issued a positive opinion for use of ALIMTA as a continuation maintenance therapy in patients with nonsquamous non-small-cell lung cancer after initial treatment with ALIMTA plus cisplatin.  We expect EC approval during Q4. 
Along with Amylin and Alkermes, we submitted our reply to the FDA's Complete Response Letter for Bydureon, and the FDA assigned a PDUFA goal date of January 28, 2012. We also submitted our reply to the FDA's Complete Response Letter for Amyvid, a PET imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. And finally, we submitted the sBLA for ERBITUX in first-line metastatic colorectal cancer. 
On the business development front, we entered into 2 different agreements to bolster our diabetes presence in EMEA. First, we entered into collaboration with Lupin Limited, under which Lupin will promote Humulin in India and Nepal. And we expanded our collaboration with Boehringer Ingelheim to include co-promotion Linagliptin by Lilly and copromotion of Humalog by Boehringer Ingelheim. 
Also, in earlier stage of this development initiative, we launched a new platform called Open Innovation Drug Discovery to both build our own pipeline and identify molecules that may be useful in the treatment of multiple-drug resistant tuberculosis. 
On the legal front, the Court of Appeals for the Federal Circuit ruled in Lilly's favor in the Strattera patent case, overturning a prior ruling by the U.S. District Court in New Jersey and upholding the Strattera method-of-use patent, which will expire in May 2017.  The defendants filed a motion for rehearing on en banc and earlier this week, the court denied their request. 
Lastly, an important news for our industry and for Lilly. The America Invents Act was signed into law. Not only will this new law align U.S. patent laws more closely to those of other countries, but we believe, it will improve U.S. competitiveness by: reducing the backlog of patent applications, enhancing the quality of issued patents; and providing greater certainty for those that invest in innovation. 
Now for the background, Ronika will discuss our Q3 financial results and provide our pipeline update. And then Derica will cover our financial guidance for 2011 and key events for the remainder of 2011 and 2012. Ronika?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provides insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments an",1222,"Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provides insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. We'll also provide commentary on our Q3 results, excluding the effect of headwinds that were highlighted in previous discussions of both our quarterly performance and our 2011 guidance. 
I'll start on Slide 6 with a quick look at our Q3 income statement. On a non-GAAP basis, you can see that we generated robust revenue growth in this quarter, excluding Gemzar outside of Japan and the effective U.S. healthcare reform, revenue would have grown 15%. Compared to Q3 2010, gross margin as a percentage of revenue decreased 4.3 percentage points to 78.2%. This decrease is primarily due to the effective changes in foreign exchange rates on international inventories sold and to a lesser extent, a negative mix effect. 
Operating expense defined as the sum of R&D and SG&A grew 10% this quarter. This increase was driven primarily by SG&A, which increased 13%, while the increase in R&D was 5%.  Drivers of the increase in operating expenses included cost related to our diabetes alliance with Boehringer Ingelheim, including late-stage clinical trial expense; the effective changes in foreign exchange rates as well as the pharmaceutical manufacturing fee associated with U.S. healthcare reform, which was roughly $45 million. Excluding the effect of U.S. healthcare reform and the Boehringer Ingelheim alliance, operating expenses would have grown 3%, with this amount entirely driven by foreign exchange. 
Other income and deductions was a net expense of $83.4 million this quarter, which was higher than last year. The higher net expense was due to a partial write-down and the IPR&D value of Amyvid due to a revised assumption for the timing of a potential regulatory approval and sales uptake. 
Our tax rate was 17.9% this quarter or 4.6 percentage points lower than Q3 2010.  The largest item driving this reduction is the recognition of a discrete tax benefit of $45.4 million, primarily as a result of a resolution of the company's 2007 IRS tax audit. 
At the bottom line, our non-GAAP EPS decreased 7% from $1.21 to $1.13. Consistent with the 2011 guidance we provided in January, we saw a robust EPS growth in our business in Q3, excluding U.S. healthcare reform, the effective Gemzar patent expiration outside of Japan and investments related to the Boehringer Ingelheim diabetes alliance.  Excluding these items, EPS would have grown in the mid-20% range. 
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now let's look at how foreign exchange affected our Q3 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 4%. This quarter, foreign exchange was -- also contributed 4%, while price had a negligible impact on worldwide revenue growth. 
We continue to see strong volume growth from our 3 countercyclical engines: Japan, animal health and emerging market. In total, these businesses delivered 15% volume growth in the quarter. Volume growth continued to be strong in Japan at 20%, driven by recent launches of both Cymbalta and Forteo. Elanco animal health volume grew 22% in Q3, driven primarily by organic growth, including increased demand for our food animal products and the continued expansion of our companion animal business.  The launch of Trifexis in the U.S. has been particularly robust. To a lesser extent, this volume growth was driven by the acquisition of certain enhancements and Pfizer animal health assets in Europe. 
Finally, embedded within the rest of the world line, our emerging markets revenue grew 7% in volume and 5% overall. Although the growth in emerging markets moderated relative to previous quarters, particularly noteworthy was China's revenue growth of 22% in volume and 31% overall. 
This quarter, FX had a significant effect on EPS. Slide 10 shows the year-on-year growth of our select line item of our non-GAAP income statement, both with and without effects of changes in foreign exchange rate. The numbers in the first column are the same as those you saw on the last column on Page 6. Let's focus on the second column of numbers, which strip out the effect of foreign exchange. 
First, you'll see that the 4% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin grew 8% and 3%, respectively. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was primarily due to the effect of foreign exchange on international inventories sold. In total, operating expense grew 7%, excluding FX. As mentioned earlier, the increase was driven entirely by the Boehringer Ingelheim deal and the pharmaceutical industry fees. 
Continuing on, you'll see that excluding FX, operating income declined 2% and EPS declined 1%. So you can clearly see that FX had a significant negative effect on EPS this quarter, lowering EPS growth by 6 percentage points to negative 7%. In other words, a favorable effect of FX on our foreign operating income was more than offset by the negative effect of FX on inventories sold. Excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and investments related to the BI diabetes alliance, EPS would have grown in the mid-20s. 
On Slide 11, you'll find year-on-year growth of the same items of our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our new molecular entities in clinical development as of October 10, inclusive of changes since our July update. Our clinical stage portfolio now stands at 66 distinct NMEs, including 34 compounds in Phase II and Phase III.  Biotechnology represents half of our Phase II and Phase III assets as well as nearly half of our overall clinical portfolio. We continue to make progress in advancing our pipeline. 
Since July, we began Phase III testing of our new insulin glargine products, and we now have 10 distinct compounds in Phase III testing, with 2 more likely to begin before year end.  We advanced 3 assets in the Phase II testing, including our Myostatin monoclonal antibody that Jan Lundberg discussed at our June investment committee meeting. We advanced 2 assets in the Phase I testing, and we terminated or suspended development of 6 assets across our Phase I and Phase II portfolio. 
In summary, we have already achieved our goal of having 10 NMEs in Phase III by year end. With Phase III starts expected this quarter for our innovative basal analog influence and for Anti-IL-17 monoclonal antibody for psoriasis, we could finish this year with 12 NMEs in Phase III testing. 
We're pleased with our progress we've made, building a robust, high-quality, mid- to late-stage pipeline, with many potential opportunities to advance patient care in diseases with large unmet need, as well as significant commercial opportunity. As outlined at our Investment Community Meeting in June, we believe our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent exploration, which",1620,"Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent exploration, which is essentially a U.S. and European phenomenon, will negatively affect our revenue and income, causing our fourth quarter results to differ substantially from those we posted September year-to-date. 
We lost the Zyprexa patent in most European countries last month. This coming Sunday, October 23, we'll lose patent protection for Zyprexa here in the U.S. Now as you might expect, during Q3, we saw the initial impact of the Zyprexa patent expiration. Specifically, we saw some reduction in wholesaler purchases in anticipation of reduced future sales of branded Zyprexa.  In addition, we also made accruals to account for the potential future return of products that were sold to wholesalers during the third quarter. 
In European markets, we've already seen multiple generic companies enter the various markets, offering very large discounts. For example, in Germany, there are about 20 generic players, and the initial generic pricing came in at about a 75% discount to Zyprexa's pre-patent expiry price.  
Now here in the U.S., while we expect rapid and significant erosion of the branded Zyprexa sale, the competitive dynamic will be a bit different, as we will have a single generic company marketing each presentation of olanzapine for the first 6 months, post patent expiration.  Also, as part of our late life-cycle planning, we've entered into an authorized generic agreement here in the U.S. with Prasco to allow them to market a generic version of olanzapine. Now upon expiration of the 6-month exclusivity period in late April of 2012, we would expect additional companies to market their own generic olanzapine, leading to further sales erosion of Zyprexa. 
In summary, on the revenue line, we expect to see a significant negative impact in Q4. This is reflected in the fact that our worldwide revenue had grown 8% September year-to-date, while our full year guidance for 2011 is for revenue growth in the mid-single digits. As you think about the impact of the Zyprexa patent expiration on other line items of our income statement, you should keep in mind a few items. We do not expect Zyprexa-related manufacturing expenses to decrease at the same rate as sales. While there will be some savings of variable production costs, other fixed costs that had been absorbed by the production of Zyprexa will remain.  As a result, the expected decline of Zyprexa sales will put downward pressure in our gross margin as a percent of revenue. This is why we forecast gross margin as a percent of revenue for the full year 2011 to be between 78% and 79%, despite the fact that it is at 79.5% for the first 9 months of the year. 
Now in terms of marketing and selling expenses, we currently have very little variable marketing spend behind Zyprexa during this late stage of its life cycle.  Consequently, there will be minimal marketing savings post patent expiration. The major spend behind Zyprexa has been the sales force. 
Now you should not expect to see a significant reduction in sales force expense as a result of the Zyprexa patent expiration for 2 main reasons. First, beginning in late 2009, we restructured our U.S. and then our European neuroscience sales forces. Among other factors, this restructuring took into account the CNS sales footprint needed post Zyprexa patent expiration. Second, keep in mind that Cymbalta's sold by these same sales forces, and we committed to providing a competitive detailing effort behind this very important brand.
In a nutshell, our strategy for managing costs, leading up to the Zyprexa patent expiration has been to act early and not wait until the event itself was upon us. Since 2004, we've been reducing headcount and driving productivity improvements across all areas of our business. And since 2009, we've upped the pace of rightsizing our organization for the post-Zyprexa period, significantly restructuring everything from our senior management layers to our back-office operation to our sales and marketing organization.  
As a result of these efforts, we fully expect to meet our goal of reducing our expenses by $1 billion by the end of this year. This will essentially complete our restructuring effort. While we will continue to drive incremental productivity, we have no plans for a major restructuring. Hopefully, this additional color commentary on the impact of the Zyprexa patent expiration is helpful as you update your models. 
Now let's review our updated 2011 financial guidance. At a high level, our updated guidance is very consistent with the guidance we issued on our July earnings call. It reflects continued strong underlying performance of our business. It also includes the discrete tax benefit and the additional charges recorded in Q3. In total, these changes result in an increase and narrowing of our EPS guidance. 
On a non-GAAP basis, we now expect 2011 EPS of between $4.30 and $4.35. Our 2011 reported EPS guidance range of $3.89 to $3.94 reflects the $0.23 IPR&D charge for the Boehringer Ingelheim alliance and $0.18 in restructuring recharges in the first 9 months of the year. 
Our guidance on individual line items is largely unchanged. Revenue is still expected to grow in the mid-single digits, and the gross margin as a percent of revenue it is still expected to decline by 2 to 3 percentage points when compared to the full year of 2010. SG&A growth is still expected to be in high-single digits, and R&D growth is still expected to be in the low-single digits. Our guidance for other income is now forecast to be a net loss in the range of $175 million to $225 million, reflecting the partial impairment of the acquired in-process R&D asset related to Amyvid. 
As a result of the discrete tax benefit recognized this quarter, we now expect our 2011 effective tax rate to be approximately 20% on a non-GAAP basis and approximately 19.5% on a reported basis. And we now expect capital expenditures to be approximately $700 million. 
Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010 and the associated growth rates from these numbers to our revised 2011 guidance. In terms of key future events, highlights for the balance of 2011 include potential FDA approval of ERBITUX for first-line head and neck cancer; the anticipated European Commission approval of ALIMTA as continuation maintenance therapy in non-squamous, non-small-cell lung cancer; expected Phase III starts for our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis. This would bring our Phase III portfolio to 12 new molecular entities, exceeding our goal of 10. 
We also expect to present key Phase II data on our CETP inhibitor at the American Heart Association meeting in November, as well as for our anti-IL-17 and RA at the ACR meeting also in November.  And in psoriasis at the Jane D. Clinic [ph] meeting in London in December. 
Now in the interest of time, I will not recite the full list of potential events for 2012. But as you can see, we have a significant number of -- we have a significant number of potential regulatory actions, Phase III trial completions and potential data disclosures.  We are clearly excited about the year ahead and are pleased with the progress we continue to make in advancing our pipeline. This will remain our #1 priority. 
Now as I mentioned on our July earnings call, 2011 is playing out largely as we had expected. We delivered a solid financial result, as we head into the Zyprexa patent expiration, and importantly, we are making progress in advancing our pipeline.  
As expected, in Q3 we saw the impact of known headwinds, including patent expirations that are lowering sales of Gemzar outside of Japan, U.S. health care reform, which is exacting a higher cost in 2011 than it did in 2010 and near-term dilution from expenses associated with our strategic diabetes alliance with Boehringer Ingelheim.  Now, while these headwinds negatively affected our Q3 results, we again delivered strong underlying growth in the rest of our business. Excluding these items, on a non-GAAP basis, we posted revenue growth of 15%, operating expense growth of 3% and mid-20s percent EPS growth. 
As you think about our future revenue, you'll clearly need to factor in the patent expiration of Zyprexa in the U.S. and Europe. But I also like to highlight that in Q3, our countercyclical growth engine of Japan, emerging markets and animal health collectively grew 19%. And we had a number of key brands that posted double-digit worldwide revenue growth, including Cymbalta, Humalog, Strattera, Forteo, Cialis and ALIMTA. 
We've already achieved our goal of having 10 molecules in Phase III development by the end of the year. And we expect to begin Phase III testing of our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis before year end. We firmly believe that our current pipeline serves as the foundation for Lilly to return to growth post-Years YZ.
Moving forward, we will continue to focus on executing our 3-part strategy as we stated in June. Replenishing and advancing our pipeline, and for innovation-based biopharmaceutical company, this is our future. Second, investing to drive growth in our countercyclical growth engines and key currently marketed brands, particularly, those that do not lose patent protection in the YZ period. And third, continue to drive productivity gains across our business that allow us to fund R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Now this concludes our prepared remarks, and we'll now open the call for the Q&A session. Operator, first caller please."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions]  First question's from the line of Steve Scala, Cowen.",11,"[Operator Instructions]  First question's from the line of Steve Scala, Cowen."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions, both of which were on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to have the look occurred in the current quarter, when pe",137,"I have 2 questions, both of which were on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to have the look occurred in the current quarter, when perhaps it would've been more like 12 months, or regardless of when the look was taken as the duration of treatment the same? That's the first question. And then second question is for Dr. Lechleiter. Do you feel the final solanezumab Phase III result in the second quarter of 12 as just another Phase III readout? Or is this perhaps the most important data point for Lilly in years, and will dictate where you lead the business? And perhaps asked differently, is your current course viable, if solanezumab should fail?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that January. So there is no particular change in the number o",76,"I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that January. So there is no particular change in the number of months, number of patient's type data that they would be reviewing at that particular review. It was simply a logistical change that led to the movement from this year to next year. John?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other",148,"Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other molecules as well in various stages of development in our portfolio, looking at the beta-amyloid and other mechanisms associated with Alzheimer's disease. While this is a very important readout for us next year, it's not something -- whether it's positive or negative is going to change our strategy or change the basic underlying assumptions that we're carrying forward as we go through YZ. Our future does not depend on any single molecule including solanezumab or soon to be 11 other molecules in Phase III. And we'll go where the data takes us and proceed accordingly, but we're really interested in prosecuting and moving forward that entire portfolio."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, this is Phil. Before go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is a",141,"Steve, this is Phil. Before go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is a high-risk program. It's very interesting science. We're very hopeful of the potential outcome, but we have recognized that it's high risk. Essentially, for the financial modeling, what that means is it's a sign of relatively low probability of actually hitting, if you will. So that means for our financial projections, if that low probability goes to 0, it really does not take them down very much. If on the other hand, it were to go ahead and go from that low probability to one, it would have a substantial potential upside to those numbers. Hope that's helpful."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Seamus Fernandez, Leerink Swann.",11,"Next question is from the line of Seamus Fernandez, Leerink Swann."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little",115,"Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little bit strategically about your interest in the CETP inhibitor? And perhaps even -- there are many, many CETP inhibitors in development across the industry, will there be any interest in basically saying, ""Okay, let's look across the different CETP inhibitors, take the data and perhaps partner with someone else who has this and share the development cost, given the risk profile associated with this still untested mechanism?"""
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time",150,"Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time and say, ""Should we alone with this, or should we partner that one."" Obviously, we got a huge benefit, I think, from a deal we used to have with BI earlier this year, where we, in essence got our 4 potential assets. One of which is now launched, Linagliptin, shared between the 2 companies on a global basis. And as we move new molecules into Phase III, other programs begin to wind down. So we're looking at this all the time, and obviously, we'll do what we think is in the best interest of the company and the shareholders, if we make these decisions."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question from the line of Marc Goodman, UBS.",9,"Next question from the line of Marc Goodman, UBS."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase II",73,"First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase III a little bit. Is there any color you can give us -- mechanism of action? And maybe just a little bit more color there."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, you want to handle the first question? Maybe Jan can have the second, please?",15,"Deric, you want to handle the first question? Maybe Jan can have the second, please?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in t",96,"Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in the emerging markets, and specifically, in Brazil. In markets like China, where we haven't seen that, that's why you saw the 22% volume growth there and the 31% growth overall. So the growth that you saw in the third quarter is according to the expectations that we have laid out."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the new Phase III startups, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for t",104,"In relation to the new Phase III startups, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the physicians then to different patients. We believe we have a very good agent, and we are comparing this to Lantus found in 2 Phase III trials both then in type 1 and type 2 diabetes for non-inferiority. Furthermore, with our expertise and in manufacturing and advanced devices, we think we can be really competitive in this area."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI.",43,"Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question's from the line of Chris Schott, JPMorgan.",10,"Next question's from the line of Chris Schott, JPMorgan."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 13 shaping up from a prici",122,"First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 13 shaping up from a pricing perspective relative to 2011? Second question was on the insulin business. Can you talk about the competitive response you've seen in the market? You're obviously doing very well with volume trends here. Can talk about -- again, are you seeing any different competitive response as you've regained some share? And then finally, just color on Trajenta and how you see the EU opportunity for this product, given some of the challenges that you highlighted in Germany?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, go handle your first question, I'll take a shot at the second too, Chris.",15,"Deric, go handle your first question, I'll take a shot at the second too, Chris."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 p",163,"Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 percentage point erosion on an annual basis, year-on-year, so very much aligned. Now, obviously, each government is acting at different points in time, but we continue to be able to manage our way through that. As I think about 2012 and 2013, at least in Europe, we still see things playing out more or less along those lines. Probably the biggest question from a pricing standpoint still remains in the U.S. and what emerges from the discussion around the super budget committee and if there's any change as it relates to healthcare reform and dual eligibiles are full board [ph] it increases in rebate. That's probably the biggest unknown from a pricing standpoint facing the industry at this stage."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Pricing probably since last call, the one thing that would've changed that would be the largest impact was in Spain, where they institute a couple of new measures, one for those products that have been in the market for more than 10 years and for which th",436,"Pricing probably since last call, the one thing that would've changed that would be the largest impact was in Spain, where they institute a couple of new measures, one for those products that have been in the market for more than 10 years and for which there is no generic reference pricing group, because there's no generic competition. They get asked for a 15% rebate essentially on those products, that compares to the 7.5% that they had been requesting prior. And then probably and more materially for us here, they want to have and said that innovative formulations, even if they are protected by patent protection would still be subject to reference pricing. So specifically for us, Velatab [ph], the rapid dissolving form of Zyprexa, while we not have generic competition in Spain, it probably has now been pegged to the reference pricing for the generic olanzapine group broadly. For the insulin competition, this is a sector that we dedicated a lot more focus to over the last couple of years, in particular, I'd say, with the formation of our diabetes business in early 2010. And we intend to maintain that focus on that business. And we have said before, we are seeing that, if it is more competitive, I think, know those and I see a [ph] more competitive Lilly. And as we would expect, they're going to react. And I would say though, while the influence business is one that is extremely important, it's going to be a very large part of the overall diabetes treatment market, one that we intend to go ahead and be very competitive in. Our goal of regaining leadership over time in diabetes is not predicated solely on insulin. It really does encompass the glut space as well as orals. So our focus on building that broad-based portfolio and leveraging that is intact, and we'll continue to execute that very diligently. Trajenta is really very early days. You may have been also referring to the decision made in Germany, where there were some very difficult comparables being applied to what the government does. If possible, we would like to reimburse the product, but it did not make it appropriate for Boehringer Ingelheim or Lilly to move forward at this time. We definitely do anticipate we'll be able to reach some agreement with the government that provides this product to patients and also recognizes innovation, the benefits that it brings and the appropriate  compensates Boehringer Ingelheim and Lilly. So we remain very optimistic about this class and about this product. Again, very early days in Europe on this particular front."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Catherine Arnold, Crdit Suisse.",11,"Next question is from the line of Catherine Arnold, Crdit Suisse."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, some other innovators. Are you in a position that you can actually use",117,"I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, some other innovators. Are you in a position that you can actually use that portfolio for contracting purposes either to government, particularly, outside the United States or from the standpoint of private payers? If you could just comment on what you're able to do as you approach the customer on payment. And then I wanted to ask you on your insulin glargine aspirations, have you considered doing a combination with BYETTA and would you need a separate contract with Amylin to move forward on that idea?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Catherine, I'll go ahead and take a shot at the first 2, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- been using different",234,"Okay. Catherine, I'll go ahead and take a shot at the first 2, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- been using different products to go ahead and gain leverage with payers that way. I think that one of the main things that we have been focused on is the ability to approach the physician and talk about what their patients' needs are, and those patients do have different needs over the course of their disease. So this clearly positions us to offer products that go from earlier stages with the oral treatments into the injectable phases with glut initially, and then, obviously, you've got people who eventually will progress to and will need them for a therapy, and obviously, we have very strong offerings, which we hope to expand in the future with the 2 basals that we're developing. In terms of the combo, to my knowledge there have not been any active discussions. I'm not familiar, Catherine, with the contract. I would think if you introduced another molecule into that collaboration, we would need to probably have some discussions to figure out how that would work, as the current collaboration Lilly is focused on the exenatide molecule whether that's BYETTA, Bydureon or subsequent formulation."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tim Anderson, Sanford Bernstein.",6,"Next question Tim Anderson, Sanford Bernstein."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","You talked about having already pulled much of the sales and marketing spend from Zyprexa on the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these s",122,"You talked about having already pulled much of the sales and marketing spend from Zyprexa on the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these spend savings annualize to compared to when you fully resourced the brand? And then looking forward to maybe the end of 2013 when Cymbalta looks like it's going to go away, that seems like it's going to have an impact on Lilly that's about the same as what Zyprexa's likely to have in the current year. Can you just confirm that the Cymbalta impact will be about the same as Zyprexa's a few years from now?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","How about Dave comment on the Zyprexa dual marketing spend. And if you don't mind, maybe, Dave, talk about how you're thinking of -- might as well to comment on the sales decline with just management of sales operations, as we go off Cymbalta and we'll co",53,"How about Dave comment on the Zyprexa dual marketing spend. And if you don't mind, maybe, Dave, talk about how you're thinking of -- might as well to comment on the sales decline with just management of sales operations, as we go off Cymbalta and we'll come to Derica for the financial piece."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Great. So with Zyprexa, this is a brand that for many years has had a varying trends positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last c",145,"Great. So with Zyprexa, this is a brand that for many years has had a varying trends positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last calendar year, we can just say that they were a fraction of that peak level already in 2010, in 2011 or even lower for Derica's earlier comment. Cymbalta will see a very different picture in the U.S. This is a brand in a very competitive, highly genericized market, with less clinical differentiation in the minds of physicians. We do plan on having a robust sales and marketing effort, much closer to the loss of exclusivity, and therefore, as you think about modeling after LOE, there will be a more significant expense impact post LOE with Cymbalta."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab",132,"Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab for Alzheimer's disease, mGlu2/3 or -- still pronounce the new name, I won't try it, but for schizophrenia, as well as NERI for depression. So as those play out, we may see a re-purposing of some of those Cymbalta assets and resources to these new brands as we anticipate gearing up for the launches, assuming that we're successful in bringing those through the regulatory process. So this is how we're trying to manage our way through this period and seize the opportunities as they emerge."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is David Risinger, Morgan Stanley.",7,"Next question is David Risinger, Morgan Stanley."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add",171,"I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add a little bit more color on your comment about Zyprexa product returns and what investors should expect in terms of fourth quarter U.S. Zyprexa sales. And then third, with respect to SG&A, obviously, spending continues to rise as you build businesses, and that's clearly working to drive the top line. But maybe you can just comment on the outlook for SG&A spending growth in coming years should we expect SG&A to continue to rise post Zyprexa going generic? And then if Enrique's on the line or maybe somebody else can comment, I'm just wondering if you can provide any more color on the diabetes formulary pressure going into 2012 and your ability to offset the loss of CVS Caremark as a partner."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipa",231,"Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipate, when we think about just returns, we probably took about 1/3 of the impact and anticipate an impact in the third quarter. And we would anticipate about another 60% impact of returns in the fourth quarter, clearly, as you have -- we go through the brunt of the erosion -- the initial phase of the U.S. erosion curb. In regards to SG&A expenses, if you look at the third quarter, it was really driven by 3 elements, if you look at our total OpEx growth. FX was about 3 percentage points. The remaining 2 items was the pharma fixed fee, okay? And the third was the expenses both in SG&A, as well as R&D behind our BI collaboration. If you exclude those 3 items, our expense growth in the quarter was essentially flat, so 0. In fact, it was slightly negative in real terms. So when you think, projecting forward, we're not at a stage of putting out guidance beyond this period from a line item standpoint. But what you can expect is we're going to be managing our SG&A very tightly, okay?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","And just a little quote commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the",199,"And just a little quote commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the Boehringer Ingelheim collaboration and about 1.5% or so is driven by the pharma fee. And then your last question Dave on the diabetes formularies axis here in the U.S., each and every year, there are some contracts that are not up, not all of them. And each and every year, we have seen a dynamic where we've maintained kind of a majority -- vast majority of those we have had. We've gained some additional ones, and then we lost a few. That dynamic we expect to continue. In terms of talking about specific contracts, often in agreement with the actual customers, we don't disclose specific contracts that have been won or lost. And so they actually take effects. I can't provide specific commentary on ones that we may anticipate could come off in '12 or that we may be gaining in '12. We'll have that information plot for you in the January call with the Q4 results."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tony Butler, Barclays Capital.",6,"Next question Tony Butler, Barclays Capital."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And the",71,"Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And then second, back to the Zyprexa returns, can you tell us what you're actually accruing for -- the amount that you're accruing for those returns?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to be very well. We're not in a position of providing our pricing projections for Japan for 2012. Clea",84,"Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to be very well. We're not in a position of providing our pricing projections for Japan for 2012. Clearly, on our call in January, we'll be in a position to provide overall guidance for our outlook for 12, which would include Japan and the potential pricing. So if we can, we can put that off until then. John?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. One comment I would make is although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play ou",139,"Tony, this is John. One comment I would make is although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play out and how will other products that don't fall in that category be affected remains to be seen. But actually, in contrast to some other parts of the world, we actually see in the last 2 years and going forward a more favorable pricing environment in Japan as the government there recognizes the need to call out innovation and to value innovation and also continues with its intent to ensure that more medicines that are approved in Europe and the U.S. are approved and made available to Japanese patients in a contemporaneous way."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter.",20,"Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question John Boris, Citi.",5,"Next question John Boris, Citi."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? sec",133,"First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? second question for Derica. You'd mentioned on the sequential growth for the emerging markets that it was largely attributed to Zyprexa. Can you maybe give some color of the 500 basis points sequential decline? What percent of Zyprexa sales have accounted for that and rest of world. And then third question just for John, very quickly. In the environment in Washington, what do you find, John, that the industry is winning on going forward? And what do you think some of the challenges are in Washington that the industry continues to face?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave?",1,"Dave?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily",111,"In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily formulation, which is specific to this indication, you need to take the medicine everyday prior to the DPH launch. About 1 in 4 Cialis prescriptions in the U.S. were for the once-a-day form. We would anticipate with BPH uptake that to continue to grow, and we see the BPH opportunity as a nice growth driver over the main life of Cialis in the U.S."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay.",34,"John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John?",1,"John?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal",363,"John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal of confidence for investors that our patents can be -- can remain valid, can be enforced and can be the basis for investor confidence in addition to clearing this huge backlog. I think there is still strong support for maintaining 12.5 years of data protection, for biologics, which is part of the Affordable Care Act, and we -- it's the law, and we want to keep it that way. And I think there's a general recognition, appreciation to the fact that this industry employs directly and indirectly between 3 and 4 million people in this country. And is the only way we're going to attack diseases like Alzheimer's and cancer, which not only cause immense suffering but help drive up a lot of the healthcare cost today and in the future. I think the area of concern for us right now is Part D. We're fighting, and we're quite adamant in our opposition to imposing government price controls in Part D. This is a program that's working. Premiums for seniors have remained low. The overall cost of program is stunningly lower than any one forecast 5 or 6 years ago. And most seniors in Part D today have access to medicines. In terms of deficit reduction, Part D is making a difference there too. A recent study published in Germany show that for every person enrolled in Part D, they have $1,200 a year less costs in other parts of the medical delivery system. That's more than $10 billion a year in savings. And I think we have to attribute to that program as it's currently structured. So we're going to continue to make sure that, that message gets heard and understood, as we go forward. We'll continue as well to express concerns we have about IPAB, the Independent Payment Advisory Board, as well as the way the 340 B program is being expanded, that we believe, inappropriately."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Gregg Gilbert, Bank of America Merrill Lynch.",7,"Gregg Gilbert, Bank of America Merrill Lynch."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what happened there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP product",85,"First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what happened there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP product stacks up against others in the category based on info that's been made public over time? And third perhaps for Derica, or Dave, on Axiron, was there any abnormally high discounting or couponing in the quarter that will abate over time?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to consider as your trying to bracket how",167,"This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to consider as your trying to bracket how large this could be, for the original healthcare reform that was to -- have been a $80 billion cost of the industry over a 10-year period, we'd actually estimate, it's probably closer to $115 billion cost over that 10-year period of the industry. And as we talked about earlier, we've estimated that this year, you're probably talking about a $600 million to $700 million cost to Lilly in 2011 from healthcare reform. Numbers I've seen from the CBO, I guess,  who scored Medicare dual eligible low-income subsidy going to Medicaid pricing, I believe they scored this at around $105 billion, $110 billion over a 10-year period. So as far as order of magnitude, without getting into specific numbers, I'll have you consider that. Jan?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Co",53,"Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Committee said accelerate progression of this agent."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave for Axiron?",3,"Dave for Axiron?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Axiron in the U.S., as you know, we launched the drug in Q2 and in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we",118,"Axiron in the U.S., as you know, we launched the drug in Q2 and in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're doing that very successfully today in the U.S., about 1 in 4 of new starts in the testosterone class are going on to Axiron just 6 months into the launch. Obviously co-pay cards, vouchers, samples, our key partners ensuring that positive early use experience. But through time, those dissipate as we get more refills. So we're tracking right according to our plans and pleased with the early uptick."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","And that question is from Barbara Ryan, Deutsche Bank.",9,"And that question is from Barbara Ryan, Deutsche Bank."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Question is really on China, where obviously, it's been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're se",69,"Question is really on China, where obviously, it's been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're seeing there, what your outlook is and maybe some split between what is actually part of the reimbursement list and what percentage of your business is private pay?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay, John?",2,"Okay, John?"
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary state is at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines",178,"Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary state is at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines are included in those formularies all the way down to the local level. I think that there are going to be, today and going forward, situations where we have price decrease in China. I think in some cases, there's a focus on classes that we don't participate in, and in some cases, they're likely to affect us. I think, as we look at our long-term model in China, we tried to account for that, obviously, not only as a delivery healthcare changing China, but I think the way in which healthcare is managed by the government will continue to evolve. And under any circumstance, our enthusiasm for the opportunity we have there to reach more patients with our products and to grow our business profitably has not diminished."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting.",25,"Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position, diabetes, oncology and neuroscience, those are also 3 of",236,"Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position, diabetes, oncology and neuroscience, those are also 3 of the fast-growing therapeutic areas in the China market. So today, this is a lot of what's driving the strong volume growth that you're seeing in that business, in spite of the pricing environment that's resonant there. 
Thanks for everyone spending your time with us here this morning. And I guess, in closing, I'd like to just maybe reiterate a few points. One, Q3 was another strong quarter of our underlying revenue growth and financial performance for Lilly. And it was punctuated by double-digit growth for our countercyclical growth engines from 6 of our key brands. As we head into the teeth of our patent expiration period, we have positioned the company to fund the R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Finally, we continue to make progress in advancing our pipeline, which is the foundation of our future growth. We look forward to keeping you informed as we execute our strategy. And we thank you for your interest in Eli Lilly & Co. Our team will be available to answer any additional questions you may have following this call. Have a great day."
285467,97242208,174684,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1 (800) 475-6701 w",83,"Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1 (800) 475-6701 with the access code 218233. International callers may dial area code (320) 365-3844, access code 218233. And that does conclude your conference. We do thank you for joining, while using AT&T Executive TeleConference. You may now disconnect. Have a good day."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ah",41,"Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ahead, sir."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Fi",690,"Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Financial Officer; Dr. Jan Lundberg, our Chief Scientific Officer; Dave Ricks, who's currently President of our U.S. affiliate, and as announced last week, Dave will assume the role of President of our Biomedicine business upon Bryce Carmee's [ph] retirement at the end of the year; and we have Ronika Pletcher and Elisa Razner [ph] for Investor Relations. 
During this conference call we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined on latest forms 10-K and 10-Q filed for Securities and Exchange Commission. The information we provide about our product and pipeline is for the benefit of investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
Let's begin with a recap of events since our Q2 earnings call. We had multiple developments on the regulatory front. The European Commission granted final approval for Trajenta for adults with type 2 diabetes. EU launches have begun, starting with the U.K. Launches in other European countries are expected over the balance of 2011 and the first half of 2012. Despite initial impasse, we hope to reach an agreement with local authorities that allows Trajenta to be made available to German patients. 
The FDA approved Cialis for once-daily use for the treatment of men who have signs and symptoms of benign prostatic hyperplasia or BPH, and men who have both erectile dysfunction and signs and symptoms of BPH. Cialis is the only medication approved by the FDA to treat both ED and BPH. 
Just last night, the FDA approved BYETTA for use with insulin glargine. Europe's CHMP issued a positive opinion for use of ALIMTA as a continuation maintenance therapy in patients with nonsquamous non-small-cell lung cancer after initial treatment with ALIMTA plus cisplatin.  We expect EC approval during Q4. 
Along with Amylin and Alkermes, we submitted our reply to the FDA's Complete Response Letter for Bydureon, and the FDA assigned a PDUFA goal date of January 28, 2012. We also submitted our reply to the FDA's Complete Response Letter for Amyvid, a PET imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. And finally, we submitted the sBLA for ERBITUX in first-line metastatic colorectal cancer. 
On the business development front, we entered into 2 different agreements to bolster our diabetes presence in India. First, we entered into collaboration with Lupin Limited, under which Lupin will promote Humulin in India and Nepal. And we expanded our collaboration with Boehringer Ingelheim to include co-promotion Linagliptin by Lilly and copromotion of Humalog by Boehringer Ingelheim. 
Also, in an earlier stage of this development initiative, we launched a new platform, called Open Innovation Drug Discovery, to both build our own pipeline, and identify molecules that may be useful in the treatment of multiple-drug resistant tuberculosis. 
On the legal front, the Court of Appeals for the Federal Circuit ruled in Lilly's favor in the Strattera patent case, overturning a prior ruling by the U.S. District Court in New Jersey and upholding the Strattera method-of-use patent, which will expire in May 2017.  The defendants filed a motion for rehearing en banc, and earlier this week, the court denied their request. 
Lastly, in important news for our industry and for Lilly. The America Invents Act was signed into law. Not only will this new law align U.S. patent laws more closely to those of other countries, but we believe, it will improve U.S. competitiveness by: reducing the backlog of patent applications, enhancing the quality of issued patents; and providing greater certainty for those that invest in innovation. 
Now with background, Ronika will discuss our Q3 financial results and provide our pipeline update. And then Derica will cover our financial guidance for 2011 and key events for the remainder of 2011 and 2012. Ronika?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provide insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and",1224,"Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provide insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. We'll also provide commentary on our Q3 results, excluding the effect of headwinds that were highlighted in previous discussions of both our quarterly performance and our 2011 guidance. 
I'll start on Slide 6 with a quick look at our Q3 income statement. On a non-GAAP basis, you can see that we generated robust revenue growth in this quarter, excluding Gemzar outside of Japan and the effect of U.S. healthcare reform, revenue would have grown 15%. Compared to Q3 2010, gross margin as a percentage of revenue decreased 4.3 percentage points to 78.2%. This decrease is primarily due to the effective changes in foreign exchange rates on international inventories sold and to a lesser extent, a negative mix effect. 
Operating expense defined as the sum of R&D and SG&A grew 10% this quarter. This increase was driven primarily by SG&A, which increased 13%, while the increase in R&D was 5%.  Drivers of increase in operating expenses included: costs related to our diabetes alliance with Boehringer Ingelheim, including late-stage clinical trial expense; the effect of changes in foreign exchange rates, as well as the pharmaceutical manufacturing fee associated with U.S. healthcare reform, which was roughly $45 million. Excluding the effect of U.S. healthcare reform and the Boehringer Ingelheim alliance, operating expenses would have grown 3%, with this amount entirely driven by foreign exchange. 
Other income and deductions was a net expense of $83.4 million this quarter, which was higher than last year. The higher net expense was due to a partial write-down and the IPR&D value of Amyvid, due to a revised assumption for the timing of a potential regulatory approval and sales uptake. 
Our tax rate was 17.9% this quarter or 4.6 percentage points lower than Q3 2010.  The largest item driving this reduction is the recognition of a discrete tax benefit of $45.4 million, primarily as a result of a resolution of the company's 2007 IRS tax audit. 
At the bottom line, our non-GAAP EPS decreased 7% from $1.21 to $1.13. Consistent with the 2011 guidance we provided in January, we saw robust EPS growth in our business in Q3, excluding U.S. healthcare reform, the effect of Gemzar patent expiration outside of Japan, and investments related to the Boehringer Ingelheim diabetes alliance.  Excluding these items, EPS would have grown in the mid-20% range. 
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now, let's look at how foreign exchange affected our Q3 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 4%. This quarter, foreign exchange was -- also contributed 4%, while price had a negligible impact on worldwide revenue growth. 
We continue to see strong volume growth from our 3 countercyclical engines: Japan, animal health and emerging market. In total, these businesses delivered 15% volume growth in the quarter. Volume growth continued to be strong in Japan at 20%, driven by recent launches of both Cymbalta and Forteo. Elanco Animal Health volume grew 22% in Q3, driven primarily by organic growth, including increased demand for our food animal products and the continued expansion of our companion animal business.  The launch of Trifexis in the U.S. has been particularly robust. To a lesser extent, this volume growth was driven by the acquisition of certain Hanson[ph] and Pfizer animal health assets in Europe. 
Finally, embedded within the rest of world line, our emerging markets revenue grew 7% in volume and 5% overall. Although the growth in emerging markets moderated relative to previous quarters, particularly noteworthy was China's revenue growth of 22% in volume and 31% overall. 
This quarter, FX had a significant effect on EPS. Slide 10 shows the year-on-year growth of our select line item of our non-GAAP income statement, both with and without the effects of changes in foreign exchange rate. The numbers in the first column are the same as those you saw on the last column on Page 6. Let's focus on the second column of numbers, which strip out the effect of foreign exchange. 
First, you'll see that the 4% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin grew 8% and 3%, respectively. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was primarily due to the effect of foreign exchange on international inventories sold. In total, operating expense grew 7%, excluding FX. As mentioned earlier, the increase was driven entirely by the Boehringer Ingelheim deal and the pharmaceutical industry fees. 
Continuing on, you'll see that excluding FX, operating income declined 2% and EPS declined 1%. So you can clearly see that FX had a significant negative effect on EPS this quarter, lowering EPS growth by 6 percentage points to negative 7%. In other words, a favorable effect of FX on our foreign operating income was more than offset by the negative effect of FX on inventories sold. Excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and the investments related to the BI diabetes alliance, EPS would have grown in the mid-20s. 
On Slide 11, you'll find year-on-year growth of the same items of our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our new molecular entities in clinical development as of October 10, inclusive of changes since our July update. Our clinical stage portfolio now stands at 66 distinct NMEs, including 34 compounds in Phase II and Phase III.  Biotechnology represents half of our Phase II and Phase III assets, as well as nearly half of our overall clinical portfolio. We continue to make progress in advancing our pipeline. 
Since July, we began Phase III testing of our new insulin glargine products, and we now have 10 distinct compounds in Phase III testing, with 2 more likely to begin before year end.  We advanced 3 assets in the Phase II testing, including our Myostatin monoclonal antibody that Jan Lundberg discussed at our June investment community meeting. We advanced 2 assets in the Phase I testing, and we terminated or suspended development of 6 assets across our Phase I and Phase II portfolio. 
In summary, we have already achieved our goal of having 10 NMEs in Phase III by year end. With Phase III starts expected this quarter for our innovative basal analog insulin and for Anti-IL-17 monoclonal antibody for psoriasis, we could finish this year with 12 NMEs in Phase III testing. 
We're pleased with our progress we've made, building a robust, high-quality, mid- to late-stage pipeline, with many potential opportunities to advance patient care in diseases with large unmet need, as well as significant commercial opportunity. As outlined at our Investment Community Meeting in June, we believe our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent expiration, which",1623,"Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent expiration, which is essentially a U.S. and European phenomenon, will negatively affect our revenue and income, causing our fourth quarter results to differ substantially from those we posted September year-to-date. 
We lost the Zyprexa patent in most European countries last month. This coming Sunday, October 23, we'll lose patent protection for Zyprexa here in the U.S. Now as you might expect, during Q3, we saw the initial impact of the Zyprexa patent expiration. Specifically, we saw some reduction in wholesaler purchases in anticipation of reduced future sales of branded Zyprexa.  In addition, we also made accruals to account for the potential future return of products that were sold to wholesalers during the third quarter. 
In European markets, we've already seen multiple generic companies enter the various markets, offering very large discounts. For example, in Germany, there are about 20 generic players, and the initial generic pricing came in at about a 75% discount to Zyprexa's pre-patent expiry price.  
Now here in the U.S., while we expect rapid and significant erosion of the branded Zyprexa sale, the competitive dynamic will be a bit different, as we will have a single generic company marketing each presentation of olanzapine for the first 6 months, post patent expiration.  Also, as part of our late life-cycle planning, we've entered into an authorized generic agreement here in the U.S. with Prasco to allow them to market a generic version of olanzapine. Now upon the expiration of the 6-month exclusivity period in late April of 2012, we would expect additional companies to market their own generic olanzapine, leading to further sales erosion of Zyprexa. 
In summary, on the revenue line, we expect to see a significant negative impact in Q4. This is reflected in the fact that our worldwide revenue has grown 8% September year-to-date, while our full year guidance for 2011 is for revenue growth in the mid-single digits. As you think about the impact of the Zyprexa patent expiration on other line items of our income statement, you should keep in mind a few items. We do not expect Zyprexa-related manufacturing expenses to decrease at the same rate as sales. While there will be some savings of variable production costs, other fixed costs that had been absorbed by the production of Zyprexa will remain.  As a result, the expected decline of Zyprexa sales will put downward pressure on our gross margin as a percent of revenue. This is why we forecast gross margin as a percent of revenue for the full year 2011 to be between 78% and 79%, despite the fact that it is at 79.5% for the first 9 months of the year. 
Now in terms of marketing and selling expenses, we currently have very little variable marketing spend behind Zyprexa during this late stage of its life cycle.  Consequently, there will be minimal marketing savings post patent expiration. The major spend behind Zyprexa has been the sales force. 
Now, you should not expect to see a significant reduction in sales force expense as a result of the Zyprexa patent expiration for 2 main reasons. First, beginning in late 2009, we restructured our U.S. and then our European neuroscience sales forces. Among other factors, this restructuring took into account the CNS sales footprint needed post Zyprexa patent expiration. Second, keep in mind that Cymbalta's sold by these same sales forces, and we remain committed to providing a competitive detailing effort behind this very important brand.
In a nutshell, our strategy for managing costs, leading up to the Zyprexa patent expiration, has been to act early and not wait until the event itself was upon us. Since 2004, we've been reducing headcount and driving productivity improvements across all areas of our business. And since 2009, we've upped the pace of rightsizing our organization for the post-Zyprexa period, significantly restructuring everything from our senior management layers to our back-office operation to our sales and marketing organization.  
As a result of these efforts, we fully expect to meet our goal of reducing our expenses by $1 billion by the end of this year. This will essentially complete our restructuring effort. While we will continue to drive incremental productivity, we have no plans for a major restructuring. Hopefully, this additional color commentary on the impact of the Zyprexa patent expiration is helpful as you update your models. 
Now let's review our updated 2011 financial guidance. At a high level, our updated guidance is very consistent with the guidance we issued on our July earnings call. It reflects continued strong underlying performance of our business. It also includes the discrete tax benefit and the additional charges recorded in Q3. In total, these changes result in an increase and narrowing of our EPS guidance. 
On a non-GAAP basis, we now expect 2011 EPS of between $4.30 and $4.35. Our 2011 reported EPS guidance range of $3.89 to $3.94 reflects the $0.23 IPR&D charge for the Boehringer Ingelheim alliance and $0.18 in restructuring recharges in the first 9 months of the year. 
Our guidance on individual line items is largely unchanged. Revenue is still expected to grow in the mid-single digits, and the gross margin as a percent of revenue it is still expected to decline by 2 to 3 percentage points when compared to the full year of 2010. SG&A growth is still expected to be in high-single digits, and R&D growth is still expected to be in the low-single digits. Our guidance for other income is now forecast to be a net loss in the range of $175 million to $225 million, reflecting the partial impairment of the acquired in-process R&D asset related to Amyvid. 
As a result of the discrete tax benefit recognized this quarter, we now expect our 2011 effective tax rate to be approximately 20% on a non-GAAP basis, and approximately 19.5% on a reported basis. And we now expect capital expenditures to be approximately $700 million. 
Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010, and the associated growth rates from these numbers to our revised 2011 guidance. In terms of key future events, highlights for the balance of 2011 include: potential FDA approval of ERBITUX for first-line head and neck cancer; the anticipated European Commission approval of ALIMTA as continuation maintenance therapy in non-squamous, non-small-cell lung cancer; expected Phase III starts for our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis. This would bring our Phase III portfolio to 12 new molecular entities, exceeding our goal of 10. 
We also expect to present key Phase II data on our CETP inhibitor at the American Heart Association meeting in November, as well as for our anti-IL-17 and RA at the ACR meeting, also in November.  And in psoriasis at the Jane D. Clinic [ph] meeting in London in December. 
Now in the interest of time, I will not recite the full list of potential events for 2012. But as you can see, we have made a significant number of -- we have a significant number of potential regulatory actions, Phase III trial completions and potential data disclosures.  We are clearly excited about the year ahead and are pleased with the progress we continue to make in advancing our pipeline. This will remain our #1 priority. 
Now as I mentioned on our July earnings call, 2011 is playing out largely as we had expected. We're delivering solid financial results, as we head into the Zyprexa patent expiration, and importantly, we are making progress in advancing our pipeline.  
As expected, in Q3 we saw the impact of known headwinds, including: patent expirations that are lowering sales of Gemzar outside of Japan, U.S. health care reform, which is exacting a higher cost in 2011 than it did in 2010, and near term dilution from expenses associated with our strategic diabetes alliance with Boehringer Ingelheim.  Now, while these headwinds negatively affected our Q3 results, we again deliver strong underlying growth in the rest of our business. Excluding these items, on a non-GAAP basis, we posted revenue growth of 15%, operating expense growth of 3% and mid-20s percent EPS growth. 
As you think about our future revenue, you'll clearly need to factor in the patent expiration of Zyprexa in the U.S. and Europe. But I also like to highlight that in Q3, our countercyclical growth engines of Japan, emerging markets and animal health collectively grew 19%. And we had a number of key brands that posted double-digit worldwide revenue growth, including: Cymbalta, Humalog, Strattera, Forteo, Cialis and ALIMTA. 
We've already achieved our goal of having 10 molecules in Phase III development by the end of the year. And we expect to begin Phase III testing of our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis before year end. We firmly believe that our current pipeline serves as the foundation for Lilly to return to growth post-Years YZ.
Moving forward, we will continue to focus on executing our 3-part strategy as we stated in June. Replenishing and advancing our pipeline, and for innovation-based biopharmaceutical company, this is our future. Second, investing to drive growth in our countercyclical growth engines and key currently marketed brands, particularly those that do not lose patent protection in the YZ period. And third, continue to drive productivity gains across our business that allow us to fund R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Now this concludes our prepared remarks, and we'll now open the call for the Q&A session. Operator, first caller please."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions]  First question's from the line of Steve Scala, Cowen.",11,"[Operator Instructions]  First question's from the line of Steve Scala, Cowen."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions, both of which are on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to, had the look occurred in the current quarter, when per",138,"I have 2 questions, both of which are on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to, had the look occurred in the current quarter, when perhaps it would've been more like 12 months, or regardless of when the look was taken is the duration of treatment the same? That's the first question. And then the second question is for Dr. Lechleiter. Do you view the final solanezumab Phase III result in the second quarter of 12 as just another Phase III readout? Or is this perhaps the most important data point for Lilly in years, and will dictate where you lead the business? And perhaps asked differently, is your current course viable, if solanezumab should fail?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that to January. So there is no particular change in the numbe",77,"I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that to January. So there is no particular change in the number of months, number of patients type data that they would be reviewing at that particular review. It was simply a logistical change that led to the movement from this year to next year. John?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other",149,"Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other molecules as well in various stages of development in our portfolio, looking at the beta-amyloid and other mechanisms associated with Alzheimer's disease. While this is a very important readout for us next year, it's not something -- whether it's positive or negative is going to change our strategy or change the basic underlying assumptions that we're carrying forward as we go through YZ. Our future does not depend on any single molecule including solanezumab, there are soon to be 11 other molecules in Phase III. And we'll go where the data takes us and proceed accordingly, but we're really interested in prosecuting and moving forward that entire portfolio."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, this is Phil. Before we go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is",142,"Steve, this is Phil. Before we go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is a high-risk program. It's very interesting science. We're very hopeful of the potential outcome, but we have recognized that it's high risk. Essentially, for the financial modeling, what that means is it's a sign of relatively low probability of actually hitting, if you will. So that means for our financial projections, if that low probability goes to 0, it really does not take them down very much. If on the other hand, it were to go ahead and go from that low probability to 1, it would have a substantial potential upside to those numbers. Hope that's helpful."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Seamus Fernandez, Leerink Swann.",11,"Next question is from the line of Seamus Fernandez, Leerink Swann."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little",115,"Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little bit strategically about your interest in the CETP inhibitor? And perhaps even -- there are many, many CETP inhibitors in development across the industry, would there be any interest in basically saying, ""Okay, let's look across the different CETP inhibitors, take the data and perhaps partner with someone else who has this and share the development cost, given the risk profile associated with this still untested mechanism?"""
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time",148,"Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time that say, ""Should we alone with this, or should we partner that one."" Obviously, we got a huge benefit, I think, from the deal we struck with BI earlier this year, where we, in essence got our 4 potential assets. One of which is now launched, Linagliptin, shared between the 2 companies on a global basis. And as we move new molecules into Phase III, other programs begin to wind down. So we're looking at this all the time, and obviously, we'll do what we think is in the best interest of the company and the shareholders, as we make these decisions."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question from the line of Marc Goodman, UBS.",9,"Next question from the line of Marc Goodman, UBS."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase II",73,"First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase III a little bit. Is there any color you can give us -- mechanism of action? And maybe just a little bit more color there."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, you want to handle the first question? Maybe Jan can have the second, please?",15,"Deric, you want to handle the first question? Maybe Jan can have the second, please?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in t",96,"Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in the emerging markets, and specifically, in Brazil. In markets like China, where we haven't seen that, that's why you saw the 22% volume growth there and the 31% growth overall. So the growth that you saw in the third quarter is according to the expectations that we had laid out."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the new Phase III starts, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the",104,"In relation to the new Phase III starts, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the physicians then to different patients. We believe we have a very good agent, and we are comparing this to Lantus statin in two Phase III trials, both then in type 1 and type 2 diabetes for non-inferiority. Furthermore, with our expertise and in manufacturing and advanced devices, we think we can be really competitive in this area."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI.",43,"Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question's from the line of Chris Schott, JPMorgan.",10,"Next question's from the line of Chris Schott, JPMorgan."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 2013 shaping up from a pri",124,"First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 2013 shaping up from a pricing perspective relative to 2011? Second question was on the insulin business. Can you talk about the competitive response you've seen in the market? You're obviously doing very well with volume trends here. Can you just talk about -- again, are you seeing any different competitive response as you've regained some share? And then finally, just color on Trajenta and how you see the EU opportunity for this product, given some of the challenges that you highlighted in Germany?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, go handle your first question, I'll take a shot at the second too, Chris.",15,"Deric, go handle your first question, I'll take a shot at the second too, Chris."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 p",162,"Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 percentage point erosion on an annual basis, year-on-year, so very much aligned. Now, obviously, each government is acting at different points in time, but we continue to be able to manage our way through that. As I think about 2012 and 2013, at least in Europe, we still see things playing out more or less along those lines. Probably the biggest question from a pricing standpoint still remains in the U.S., and what emerges from the discussion around the super budget committee and if there's any change as it relates to healthcare reform and dual eligibiles or so forth -- increases in rebate. That's probably the biggest unknown from a pricing standpoint facing the industry at this stage."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Also, on European pricing, Chris, probably since our last call, the one thing that would've changed that would be the largest impact was in Spain, where they instituted a couple of new measures, one for those products that have been on the market for more",438,"Also, on European pricing, Chris, probably since our last call, the one thing that would've changed that would be the largest impact was in Spain, where they instituted a couple of new measures, one for those products that have been on the market for more than 10 years, and for which there is no generic reference pricing group, because there's no generic competition. They had asked for a 15% rebate essentially on those products, that compares to the 7.5% that they had been requesting prior. And then probably and more materially for us here, they went ahead and said that innovative formulations, even if they are protected by patent protection would still be subject to reference pricing. So specifically for us, Velatab [ph], the rapid dissolving form of Zyprexa, while it will not have generic competition in Spain, it probably has now been pegged to the reference pricing for the generic olanzapine group broadly. For the insulin competition, this is a sector that we've dedicated a lot more focus to over the last couple of years, in particular, I'd say, with the formation of our diabetes business in early 2010. And we intend to maintain that focus on that business. And we have said before, we are seeing -- it is more competitive, I think, Nolos [ph] is now seeing a more competitive Lilly. And as we would expect, they're going to react. And I would say though, while the insulin business is one that is extremely important, it's going to be a very large part of the overall diabetes treatment market, one that we intend to go ahead and be very competitive in. Our goal of regaining leadership over time in diabetes is not predicated solely on insulin. It really does encompass the GLP space as well as orals. So our focus on building that broad-based portfolio and leveraging that is intact, and we'll continue to execute that very diligently. Trajenta is really very early days. You may have been also referring to the decision made in Germany, where there were some very difficult comparables being applied to what the government was espousing it would like to reimburse the product at, that did not make it appropriate for Boehringer Ingelheim or Lilly to move forward at this time. We definitely do anticipate we'll be able to reach some agreement with the government that provides this product to patients and also recognizes innovation, the benefits that it brings and the appropriate  compensates Boehringer Ingelheim and Lilly. So we remain very optimistic about this class and about this product. Again, very early days in Europe on this particular front."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Catherine Arnold, Crdit Suisse.",11,"Next question is from the line of Catherine Arnold, Crdit Suisse."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, from other innovators. Are you in a position that you can actually use",117,"I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, from other innovators. Are you in a position that you can actually use that portfolio for contracting purposes either to government, particularly, outside the United States or from the standpoint of private payers? If you could just comment on what you're able to do as you approach the customer on payment. And then I wanted to ask you on your insulin glargine aspirations, have you considered doing a combination with BYETTA and would you need a separate contract with Amylin to move forward on that idea?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Catherine, I'll go ahead and take a shot at the first two, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- using different pr",232,"Okay. Catherine, I'll go ahead and take a shot at the first two, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- using different products to go ahead and gain leverage with payers that way. I think that one of the main things that we have been focused on is the ability to approach the physician and talk about what their patients' needs are, and those patients do have different needs over the course of their disease. So this clearly positions us to offer products that go from earlier stages with the oral treatments into the injectable phases with GLP initially, and then, obviously, you've got people who eventually will progress to, and will need insulin therapy, and obviously, we have very strong offerings, which we hope to expand in the future with the 2 basals that we're developing. In terms of the combo, to my knowledge there have not been any active discussions. I'm not familiar, Catherine, enough with the contract. I would think if you introduced another molecule into that collaboration, we would need to probably have some discussions to figure out how that would work, as the current collaboration really is focused on the exenatide molecule whether that's BYETTA, Bydureon or subsequent formulation."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tim Anderson, Sanford Bernstein.",6,"Next question Tim Anderson, Sanford Bernstein."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","You talked about having already pulled much of the sales and marketing spend from Zyprexa. On the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these",180,"You talked about having already pulled much of the sales and marketing spend from Zyprexa. On the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these spend savings annualize to compared to when you fully resourced the brand? And then looking forward to maybe the end of 2013 when Cymbalta looks like it's going to go away, that seems like it's going to have an impact on Lilly that's about the same as what Zyprexa's likely to have in the current year. Can you just confirm that the Cymbalta impact will be about the same as Zyprexa's a few years from now?:p id=""E06"" name=""Philip Johnson"" type=""E"" />
How about Dave comment on the Zyprexa dual marketing spend. And if you don't mind, maybe, Dave, talking about how you're thinking of -- not necessarily the comment on the sales decline, but just the management of sales operations, as we go off Cymbalta and we'll come to Derica for the financial piece."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Great. So with Zyprexa, this is a brand that for many years has had a very entrenched positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last",145,"Great. So with Zyprexa, this is a brand that for many years has had a very entrenched positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last calendar year, we can just say that they were a fraction of that peak level already in 2010, in 2011 or even lower, per Derica's earlier comment. Cymbalta will see a very different picture in the U.S. This is a brand in a very competitive, highly genericized market, with less clinical differentiation in the minds of physicians. We do plan on having a robust sales and marketing effort, much closer to the loss of exclusivity, and therefore, as you think about modeling after LOE, there will be a more significant expense impact post LOE with Cymbalta."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab",133,"Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab for Alzheimer's disease, mGlu2/3 or -- still pronounce the new name, I won't try it, but for schizophrenia, as well as NERI stil for depression. So as those play out, we may see a re-purposing of some of those Cymbalta assets and resources to these new brands as we anticipate gearing up for their launches, assuming that we're successful in bringing those through the regulatory process. So this is how we're trying to manage our way through this period and seize the opportunities as they emerge."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is David Risinger, Morgan Stanley.",7,"Next question is David Risinger, Morgan Stanley."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add",171,"I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add a little bit more color on your comment about Zyprexa product returns and what investors should expect in terms of fourth quarter U.S. Zyprexa sales. And then third, with respect to SG&A, obviously, spending continues to rise as you build businesses, and that's clearly working to drive the top line. But maybe you can just comment on the outlook for SG&A spending growth in coming years should we expect SG&A to continue to rise post Zyprexa going generic? And then if Enrique's on the line, or maybe somebody else can comment, I'm just wondering if you can provide any more color on the diabetes formulary pressure going into 2012 and your ability to offset the loss of CVS Caremark as a partner."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipa",230,"Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipate, when we think about just return, we probably took about 1/3 of the impact -- anticipating impact in the third quarter. And we would anticipate about another 60% impact of returns in the fourth quarter, clearly, as you have -- we go through the brunt of the erosion -- the initial phase of the U.S. erosion curve. In regards to SG&A expenses, if you look at the third quarter, it was really driven by 3 elements, if you look at our total OpEx growth. FX was about 3 percentage points. The remaining 2 items was the pharma fixed fee, okay? And the third was the expenses both in SG&A, as well as R&D behind our BI collaboration. If you exclude those 3 items, our expense growth in the quarter was essentially flat, so 0. In fact, it was slightly negative in real terms. So when you think, projecting forward, we're not at a stage of putting out guidance beyond this period from a line item standpoint. But what you can expect is we're going to be managing our SG&A very tightly, okay?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","And just a little short commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the",197,"And just a little short commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the Boehringer Ingelheim collaboration and about 1.5% or so is driven by the pharma fee. And then your last question, Dave, on the diabetes formularies access here in the U.S., each and every year, there are some contracts that are up, not all of them. And each and every year, we have seen a dynamic where we've maintained probably the majority -- vast majority of those we have had. We've gained some additional ones, and then we've lost a few. That dynamic we expect to continue. In terms of talking about specific contracts, often in agreement with the actual customers, we don't disclose the specific contracts that have been won or lost until they actually take effect. I can't provide specific commentary on ones that we may anticipate could come off in '12 or that we may be gaining in '12. We'll have that information probably for you in the January call with the Q4 results."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tony Butler, Barclays Capital.",6,"Next question Tony Butler, Barclays Capital."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And the",71,"Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And then second, back to the Zyprexa returns, can you tell us what you're actually accruing for -- the amount that you're accruing for those returns?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to go very well. We're not in a position of providing our pricing projections for Japan for 2012. Clea",84,"Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to go very well. We're not in a position of providing our pricing projections for Japan for 2012. Clearly, on our call in January, we'll be in a position to provide overall guidance for our outlook for `12, which would include Japan and the potential pricing. So if we can, we can put that off until then. John?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. One comment I would make is, although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play o",139,"Tony, this is John. One comment I would make is, although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play out and how will other products that don't fall in that category be affected remains to be seen. But actually, in contrast to some other parts of the world, we actually see in the last 2 years and going forward a more favorable pricing environment in Japan as the government there recognizes the need to call out innovation and to value innovation, and also continues with its intent to ensure that more medicines that are approved in Europe and the U.S. are approved and made available to Japanese patients in a contemporaneous way."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter.",20,"Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question John Boris, Citi.",5,"Next question John Boris, Citi."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? Sec",132,"First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? Second question for Derica. You'd mentioned on the sequential growth for the emerging markets that it was largely attributed to Zyprexa. Can you maybe give some color of the 500 basis points sequential decline? What percent of Zyprexa sales accounted for that in rest of world. And then third question, just for John, very quickly. In the environment in Washington, what do you find, John, that the industry is winning on going forward? And what do you think some of the challenges are in Washington that the industry continues to face?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave?",1,"Dave?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily",112,"In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily formulation, which is specific to this indication, you need to take the medicine every day prior to the DPH launch. About 1 in 4 Cialis prescriptions in the U.S. were for the once-a-day form. We would anticipate with BPH uptake that to continue to grow, and we see the BPH opportunity as a nice growth driver over the main life of Cialis in the U.S."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay.",34,"John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John?",1,"John?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal",364,"John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal of confidence for investors that our patents can be -- can remain valid, can be enforced and can be the basis for investor confidence in addition to clearing this huge backlog. I think there is still strong support for maintaining 12.5 years of data protection, for biologics, which is part of the Affordable Care Act, and we -- it's the law, and we want to keep it that way. And I think there's a general recognition, appreciation to the fact that this industry employs directly and indirectly between 3 and 4 million people in this country. And is the only way we're going to attack diseases like Alzheimer's and cancer, which not only cause immense suffering, but help drive up a lot of the healthcare cost today and in the future. I think the area of concern for us right now is Part D. We're fighting, and we're quite adamant in our opposition to imposing government price controls in Part D. This is a program that's working. Premiums for seniors have remained low. The overall cost of the program is stunningly lower than any one forecast 5 or 6 years ago. And most seniors in Part D today have access to medicines. In terms of deficit reduction, Part D is making a difference there too. A recent study published in Jamma [ph] show that for every person enrolled in Part D, they have $1,200 a year less costs in other parts of the medical delivery system. That's more than $10 billion a year in savings that I think we have to attribute to that program as it's currently structured. So we're going to continue to make sure that, that message gets heard and understood, as we go forward. We'll continue as well to express concerns we have about IPAB, the Independent Payment Advisory Board, as well as the way the 340 B program is being expanded,  we believe, inappropriately."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Gregg Gilbert, Bank of America Merrill Lynch.",7,"Gregg Gilbert, Bank of America Merrill Lynch."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what will happen there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP produ",86,"First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what will happen there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP product stacks up against others in the category based on info that's been made public over time? And third, perhaps for Derica, or Dave, on Axiron, was there any abnormally high discounting or couponing in the quarter that will abate over time?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to, to consider as you're trying to bracke",167,"This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to, to consider as you're trying to bracket how large this could be, for the original healthcare reform that was to have been a $80 billion cost to the industry over a 10-year period, we'd actually estimate, it's probably closer to $115 billion cost over that 10-year period of the industry. And as we talked about earlier, we've estimated that this year, you're probably talking about a $600 million to $700 million cost to Lilly in 2011 from healthcare reform. Numbers I've seen from the CBO, I guess,  who scored Medicare dual eligible low-income subsidy going to Medicaid pricing, I believe they scored this at around $105 billion, $110 billion over a 10-year period. So as far as order of magnitude, without getting into specific numbers, I'll have you consider that. Jan?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Co",53,"Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Committee said accelerate progression of this agent."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave for Axiron?",3,"Dave for Axiron?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Axiron in the U.S., as you know, we launched the drug in Q2, in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're",117,"Axiron in the U.S., as you know, we launched the drug in Q2, in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're doing that very successfully today in the U.S., about 1 in 4 of new starts in the testosterone class are going on to Axiron just 6 months into the launch. Obviously co-pay cards, vouchers, samples, our key partners ensuring that positive early use experience. But through time, those dissipate as you get more refills. So we're tracking right according to our plans and pleased with the early uptick."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","And that question is from Barbara Ryan, Deutsche Bank.",9,"And that question is from Barbara Ryan, Deutsche Bank."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Question is really on China, where obviously, you've been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're",69,"Question is really on China, where obviously, you've been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're seeing there, what your outlook is and maybe some split between what is actually part of the reimbursement list and what percentage of your business is private pay?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay, John?",2,"Okay, John?"
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary status at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines ar",178,"Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary status at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines are included in those formularies all the way down to the local level. I think that there are going to be, today and going forward, situations where we have price decrease in China. I think in some cases, there's a focus on classes that we don't participate in, and in some cases, they're likely to affect us. I think, as we look at our long-term model in China, we tried to account for that, obviously, not only as the delivery of healthcare changing China, but I think the way in which healthcare is managed by the government will continue to evolve. And under any circumstance, our enthusiasm for the opportunity we have there to reach more patients with our products and to grow our business profitably has not diminished."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting.",25,"Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position: diabetes, oncology and neuroscience, those are also 3 of",236,"Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position: diabetes, oncology and neuroscience, those are also 3 of the fast-growing therapeutic areas in the China market. So today, this is a lot of what's driving the strong volume growth that you're seeing in that business, in spite of the pricing environment that's resonant there. 
Thanks for everyone spending your time with us here this morning. And I guess, in closing, I'd like to just maybe reiterate a few points. One, Q3 was another strong quarter of our underlying revenue growth and financial performance for Lilly. And it was punctuated by double-digit growth from our countercyclical growth engines from 6 of our key brands. As we head into the teeth of our patent expiration period, we have positioned the company to fund the R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Finally, we continue to make progress in advancing our pipeline, which is the foundation of our future growth. We look forward to keeping you informed as we execute our strategy. And we thank you for your interest in Eli Lilly & Co. Our team will be available to answer any additional questions you may have following this call. Have a great day."
285467,97242208,174862,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1(800) 475-6701 wi",81,"Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1(800) 475-6701 with the access code 218233. International callers may dial area code (320)365-3844, access code 218233. And that does conclude your conference. We do thank you for joining, while using AT&T Executive TeleConference. You may now disconnect. Have a good day."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ah",41,"Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. Your host and speaker, Vice President of Investor Relations, Phil Johnson. Please go ahead, sir."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Fi",690,"Good morning. And thanks for joining us for Eli Lilly & Co.'s Third Quarter 2011 Earnings Conference Call. I'm Phil Johnson, Vice President Of Investor Relations. Joining me today are John Lechleiter, our Chief Executive Officer; Derica Rice, our Chief Financial Officer; Dr. Jan Lundberg, our Chief Scientific Officer; Dave Ricks, who's currently President of our U.S. affiliate, and as announced last week, Dave will assume the role of President of our Biomedicine business upon Bryce Carmee's [ph] retirement at the end of the year; and we have Ronika Pletcher and Elisa Razner [ph] for Investor Relations. 
During this conference call we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined on latest forms 10-K and 10-Q filed for Securities and Exchange Commission. The information we provide about our product and pipeline is for the benefit of investment community. It is not intended to be promotional and is not sufficient for prescribing decisions.
Let's begin with a recap of events since our Q2 earnings call. We had multiple developments on the regulatory front. The European Commission granted final approval for Trajenta for adults with type 2 diabetes. EU launches have begun, starting with the U.K. Launches in other European countries are expected over the balance of 2011 and the first half of 2012. Despite initial impasse, we hope to reach an agreement with local authorities that allows Trajenta to be made available to German patients. 
The FDA approved Cialis for once-daily use for the treatment of men who have signs and symptoms of benign prostatic hyperplasia or BPH, and men who have both erectile dysfunction and signs and symptoms of BPH. Cialis is the only medication approved by the FDA to treat both ED and BPH. 
Just last night, the FDA approved BYETTA for use with insulin glargine. Europe's CHMP issued a positive opinion for use of ALIMTA as a continuation maintenance therapy in patients with nonsquamous non-small-cell lung cancer after initial treatment with ALIMTA plus cisplatin.  We expect EC approval during Q4. 
Along with Amylin and Alkermes, we submitted our reply to the FDA's Complete Response Letter for Bydureon, and the FDA assigned a PDUFA goal date of January 28, 2012. We also submitted our reply to the FDA's Complete Response Letter for Amyvid, a PET imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. And finally, we submitted the sBLA for ERBITUX in first-line metastatic colorectal cancer. 
On the business development front, we entered into 2 different agreements to bolster our diabetes presence in India. First, we entered into collaboration with Lupin Limited, under which Lupin will promote Humulin in India and Nepal. And we expanded our collaboration with Boehringer Ingelheim to include co-promotion Linagliptin by Lilly and copromotion of Humalog by Boehringer Ingelheim. 
Also, in an earlier stage of this development initiative, we launched a new platform, called Open Innovation Drug Discovery, to both build our own pipeline, and identify molecules that may be useful in the treatment of multiple-drug resistant tuberculosis. 
On the legal front, the Court of Appeals for the Federal Circuit ruled in Lilly's favor in the Strattera patent case, overturning a prior ruling by the U.S. District Court in New Jersey and upholding the Strattera method-of-use patent, which will expire in May 2017.  The defendants filed a motion for rehearing en banc, and earlier this week, the court denied their request. 
Lastly, in important news for our industry and for Lilly. The America Invents Act was signed into law. Not only will this new law align U.S. patent laws more closely to those of other countries, but we believe, it will improve U.S. competitiveness by: reducing the backlog of patent applications, enhancing the quality of issued patents; and providing greater certainty for those that invest in innovation. 
Now with background, Ronika will discuss our Q3 financial results and provide our pipeline update. And then Derica will cover our financial guidance for 2011 and key events for the remainder of 2011 and 2012. Ronika?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provide insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and",1224,"Thanks, Phil. As we've done on previous calls, we'll focus our comments on non-GAAP results, which we believe provide insight into the underlying trends in our business. This view excludes certain items such as restructuring charges, asset impairments and other special charges. We'll also provide commentary on our Q3 results, excluding the effect of headwinds that were highlighted in previous discussions of both our quarterly performance and our 2011 guidance. 
I'll start on Slide 6 with a quick look at our Q3 income statement. On a non-GAAP basis, you can see that we generated robust revenue growth in this quarter, excluding Gemzar outside of Japan and the effect of U.S. healthcare reform, revenue would have grown 15%. Compared to Q3 2010, gross margin as a percentage of revenue decreased 4.3 percentage points to 78.2%. This decrease is primarily due to the effective changes in foreign exchange rates on international inventories sold and to a lesser extent, a negative mix effect. 
Operating expense defined as the sum of R&D and SG&A grew 10% this quarter. This increase was driven primarily by SG&A, which increased 13%, while the increase in R&D was 5%.  Drivers of increase in operating expenses included: costs related to our diabetes alliance with Boehringer Ingelheim, including late-stage clinical trial expense; the effect of changes in foreign exchange rates, as well as the pharmaceutical manufacturing fee associated with U.S. healthcare reform, which was roughly $45 million. Excluding the effect of U.S. healthcare reform and the Boehringer Ingelheim alliance, operating expenses would have grown 3%, with this amount entirely driven by foreign exchange. 
Other income and deductions was a net expense of $83.4 million this quarter, which was higher than last year. The higher net expense was due to a partial write-down and the IPR&D value of Amyvid, due to a revised assumption for the timing of a potential regulatory approval and sales uptake. 
Our tax rate was 17.9% this quarter or 4.6 percentage points lower than Q3 2010.  The largest item driving this reduction is the recognition of a discrete tax benefit of $45.4 million, primarily as a result of a resolution of the company's 2007 IRS tax audit. 
At the bottom line, our non-GAAP EPS decreased 7% from $1.21 to $1.13. Consistent with the 2011 guidance we provided in January, we saw robust EPS growth in our business in Q3, excluding U.S. healthcare reform, the effect of Gemzar patent expiration outside of Japan, and investments related to the Boehringer Ingelheim diabetes alliance.  Excluding these items, EPS would have grown in the mid-20% range. 
Slide 7 shows our reported income statement, while Slide 8 provides a reconciliation between reported and non-GAAP EPS. Additional details about our reported earnings are available in today's earnings press release. 
Now, let's look at how foreign exchange affected our Q3 revenue. As you can see on Slide 9, total revenue growth of 9% was again driven by solid volume growth of 4%. This quarter, foreign exchange was -- also contributed 4%, while price had a negligible impact on worldwide revenue growth. 
We continue to see strong volume growth from our 3 countercyclical engines: Japan, animal health and emerging market. In total, these businesses delivered 15% volume growth in the quarter. Volume growth continued to be strong in Japan at 20%, driven by recent launches of both Cymbalta and Forteo. Elanco Animal Health volume grew 22% in Q3, driven primarily by organic growth, including increased demand for our food animal products and the continued expansion of our companion animal business.  The launch of Trifexis in the U.S. has been particularly robust. To a lesser extent, this volume growth was driven by the acquisition of certain Hanson[ph] and Pfizer animal health assets in Europe. 
Finally, embedded within the rest of world line, our emerging markets revenue grew 7% in volume and 5% overall. Although the growth in emerging markets moderated relative to previous quarters, particularly noteworthy was China's revenue growth of 22% in volume and 31% overall. 
This quarter, FX had a significant effect on EPS. Slide 10 shows the year-on-year growth of our select line item of our non-GAAP income statement, both with and without the effects of changes in foreign exchange rate. The numbers in the first column are the same as those you saw on the last column on Page 6. Let's focus on the second column of numbers, which strip out the effect of foreign exchange. 
First, you'll see that the 4% growth in revenue I mentioned earlier. Below that, you'll see that cost of sales and gross margin grew 8% and 3%, respectively. This is consistent with the statement that the reduction in gross margin as a percentage of revenue was primarily due to the effect of foreign exchange on international inventories sold. In total, operating expense grew 7%, excluding FX. As mentioned earlier, the increase was driven entirely by the Boehringer Ingelheim deal and the pharmaceutical industry fees. 
Continuing on, you'll see that excluding FX, operating income declined 2% and EPS declined 1%. So you can clearly see that FX had a significant negative effect on EPS this quarter, lowering EPS growth by 6 percentage points to negative 7%. In other words, a favorable effect of FX on our foreign operating income was more than offset by the negative effect of FX on inventories sold. Excluding U.S. health care reform, the effect of Gemzar patent expiration outside of Japan and the investments related to the BI diabetes alliance, EPS would have grown in the mid-20s. 
On Slide 11, you'll find year-on-year growth of the same items of our income statement on a reported basis, both with and without FX. Now before turning the call over to Derica, let me provide a brief update on our pipeline. 
On Slide 12, you'll find a view of our new molecular entities in clinical development as of October 10, inclusive of changes since our July update. Our clinical stage portfolio now stands at 66 distinct NMEs, including 34 compounds in Phase II and Phase III.  Biotechnology represents half of our Phase II and Phase III assets, as well as nearly half of our overall clinical portfolio. We continue to make progress in advancing our pipeline. 
Since July, we began Phase III testing of our new insulin glargine products, and we now have 10 distinct compounds in Phase III testing, with 2 more likely to begin before year end.  We advanced 3 assets in the Phase II testing, including our Myostatin monoclonal antibody that Jan Lundberg discussed at our June investment community meeting. We advanced 2 assets in the Phase I testing, and we terminated or suspended development of 6 assets across our Phase I and Phase II portfolio. 
In summary, we have already achieved our goal of having 10 NMEs in Phase III by year end. With Phase III starts expected this quarter for our innovative basal analog insulin and for Anti-IL-17 monoclonal antibody for psoriasis, we could finish this year with 12 NMEs in Phase III testing. 
We're pleased with our progress we've made, building a robust, high-quality, mid- to late-stage pipeline, with many potential opportunities to advance patient care in diseases with large unmet need, as well as significant commercial opportunity. As outlined at our Investment Community Meeting in June, we believe our current pipeline provides the foundation for Lilly to return to growth post-2014. Derica?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent expiration, which",1623,"Thanks, Ronika. Before providing our updated guidance, I would like to talk through how the Zyprexa patent expiration will affect our income statement. This may be particularly helpful as you update your models. Now clearly, this patent expiration, which is essentially a U.S. and European phenomenon, will negatively affect our revenue and income, causing our fourth quarter results to differ substantially from those we posted September year-to-date. 
We lost the Zyprexa patent in most European countries last month. This coming Sunday, October 23, we'll lose patent protection for Zyprexa here in the U.S. Now as you might expect, during Q3, we saw the initial impact of the Zyprexa patent expiration. Specifically, we saw some reduction in wholesaler purchases in anticipation of reduced future sales of branded Zyprexa.  In addition, we also made accruals to account for the potential future return of products that were sold to wholesalers during the third quarter. 
In European markets, we've already seen multiple generic companies enter the various markets, offering very large discounts. For example, in Germany, there are about 20 generic players, and the initial generic pricing came in at about a 75% discount to Zyprexa's pre-patent expiry price.  
Now here in the U.S., while we expect rapid and significant erosion of the branded Zyprexa sale, the competitive dynamic will be a bit different, as we will have a single generic company marketing each presentation of olanzapine for the first 6 months, post patent expiration.  Also, as part of our late life-cycle planning, we've entered into an authorized generic agreement here in the U.S. with Prasco to allow them to market a generic version of olanzapine. Now upon the expiration of the 6-month exclusivity period in late April of 2012, we would expect additional companies to market their own generic olanzapine, leading to further sales erosion of Zyprexa. 
In summary, on the revenue line, we expect to see a significant negative impact in Q4. This is reflected in the fact that our worldwide revenue has grown 8% September year-to-date, while our full year guidance for 2011 is for revenue growth in the mid-single digits. As you think about the impact of the Zyprexa patent expiration on other line items of our income statement, you should keep in mind a few items. We do not expect Zyprexa-related manufacturing expenses to decrease at the same rate as sales. While there will be some savings of variable production costs, other fixed costs that had been absorbed by the production of Zyprexa will remain.  As a result, the expected decline of Zyprexa sales will put downward pressure on our gross margin as a percent of revenue. This is why we forecast gross margin as a percent of revenue for the full year 2011 to be between 78% and 79%, despite the fact that it is at 79.5% for the first 9 months of the year. 
Now in terms of marketing and selling expenses, we currently have very little variable marketing spend behind Zyprexa during this late stage of its life cycle.  Consequently, there will be minimal marketing savings post patent expiration. The major spend behind Zyprexa has been the sales force. 
Now, you should not expect to see a significant reduction in sales force expense as a result of the Zyprexa patent expiration for 2 main reasons. First, beginning in late 2009, we restructured our U.S. and then our European neuroscience sales forces. Among other factors, this restructuring took into account the CNS sales footprint needed post Zyprexa patent expiration. Second, keep in mind that Cymbalta's sold by these same sales forces, and we remain committed to providing a competitive detailing effort behind this very important brand.
In a nutshell, our strategy for managing costs, leading up to the Zyprexa patent expiration, has been to act early and not wait until the event itself was upon us. Since 2004, we've been reducing headcount and driving productivity improvements across all areas of our business. And since 2009, we've upped the pace of rightsizing our organization for the post-Zyprexa period, significantly restructuring everything from our senior management layers to our back-office operation to our sales and marketing organization.  
As a result of these efforts, we fully expect to meet our goal of reducing our expenses by $1 billion by the end of this year. This will essentially complete our restructuring effort. While we will continue to drive incremental productivity, we have no plans for a major restructuring. Hopefully, this additional color commentary on the impact of the Zyprexa patent expiration is helpful as you update your models. 
Now let's review our updated 2011 financial guidance. At a high level, our updated guidance is very consistent with the guidance we issued on our July earnings call. It reflects continued strong underlying performance of our business. It also includes the discrete tax benefit and the additional charges recorded in Q3. In total, these changes result in an increase and narrowing of our EPS guidance. 
On a non-GAAP basis, we now expect 2011 EPS of between $4.30 and $4.35. Our 2011 reported EPS guidance range of $3.89 to $3.94 reflects the $0.23 IPR&D charge for the Boehringer Ingelheim alliance and $0.18 in restructuring recharges in the first 9 months of the year. 
Our guidance on individual line items is largely unchanged. Revenue is still expected to grow in the mid-single digits, and the gross margin as a percent of revenue it is still expected to decline by 2 to 3 percentage points when compared to the full year of 2010. SG&A growth is still expected to be in high-single digits, and R&D growth is still expected to be in the low-single digits. Our guidance for other income is now forecast to be a net loss in the range of $175 million to $225 million, reflecting the partial impairment of the acquired in-process R&D asset related to Amyvid. 
As a result of the discrete tax benefit recognized this quarter, we now expect our 2011 effective tax rate to be approximately 20% on a non-GAAP basis, and approximately 19.5% on a reported basis. And we now expect capital expenditures to be approximately $700 million. 
Now Slide 15 provides a reconciliation between reported and non-GAAP EPS for 2010, and the associated growth rates from these numbers to our revised 2011 guidance. In terms of key future events, highlights for the balance of 2011 include: potential FDA approval of ERBITUX for first-line head and neck cancer; the anticipated European Commission approval of ALIMTA as continuation maintenance therapy in non-squamous, non-small-cell lung cancer; expected Phase III starts for our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis. This would bring our Phase III portfolio to 12 new molecular entities, exceeding our goal of 10. 
We also expect to present key Phase II data on our CETP inhibitor at the American Heart Association meeting in November, as well as for our anti-IL-17 and RA at the ACR meeting, also in November.  And in psoriasis at the Jane D. Clinic [ph] meeting in London in December. 
Now in the interest of time, I will not recite the full list of potential events for 2012. But as you can see, we have made a significant number of -- we have a significant number of potential regulatory actions, Phase III trial completions and potential data disclosures.  We are clearly excited about the year ahead and are pleased with the progress we continue to make in advancing our pipeline. This will remain our #1 priority. 
Now as I mentioned on our July earnings call, 2011 is playing out largely as we had expected. We're delivering solid financial results, as we head into the Zyprexa patent expiration, and importantly, we are making progress in advancing our pipeline.  
As expected, in Q3 we saw the impact of known headwinds, including: patent expirations that are lowering sales of Gemzar outside of Japan, U.S. health care reform, which is exacting a higher cost in 2011 than it did in 2010, and near term dilution from expenses associated with our strategic diabetes alliance with Boehringer Ingelheim.  Now, while these headwinds negatively affected our Q3 results, we again deliver strong underlying growth in the rest of our business. Excluding these items, on a non-GAAP basis, we posted revenue growth of 15%, operating expense growth of 3% and mid-20s percent EPS growth. 
As you think about our future revenue, you'll clearly need to factor in the patent expiration of Zyprexa in the U.S. and Europe. But I also like to highlight that in Q3, our countercyclical growth engines of Japan, emerging markets and animal health collectively grew 19%. And we had a number of key brands that posted double-digit worldwide revenue growth, including: Cymbalta, Humalog, Strattera, Forteo, Cialis and ALIMTA. 
We've already achieved our goal of having 10 molecules in Phase III development by the end of the year. And we expect to begin Phase III testing of our innovative basal analog insulin and our anti-IL-17 monoclonal antibody in psoriasis before year end. We firmly believe that our current pipeline serves as the foundation for Lilly to return to growth post-Years YZ.
Moving forward, we will continue to focus on executing our 3-part strategy as we stated in June. Replenishing and advancing our pipeline, and for innovation-based biopharmaceutical company, this is our future. Second, investing to drive growth in our countercyclical growth engines and key currently marketed brands, particularly those that do not lose patent protection in the YZ period. And third, continue to drive productivity gains across our business that allow us to fund R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Now this concludes our prepared remarks, and we'll now open the call for the Q&A session. Operator, first caller please."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","[Operator Instructions]  First question's from the line of Steve Scala, Cowen.",11,"[Operator Instructions]  First question's from the line of Steve Scala, Cowen."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 2 questions, both of which are on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to, had the look occurred in the current quarter, when per",138,"I have 2 questions, both of which are on solanezumab. Does the delay in the futility look allow for a view of the data, reflecting a longer duration of treatment such as, say, 15 months as opposed to, had the look occurred in the current quarter, when perhaps it would've been more like 12 months, or regardless of when the look was taken is the duration of treatment the same? That's the first question. And then the second question is for Dr. Lechleiter. Do you view the final solanezumab Phase III result in the second quarter of 12 as just another Phase III readout? Or is this perhaps the most important data point for Lilly in years, and will dictate where you lead the business? And perhaps asked differently, is your current course viable, if solanezumab should fail?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that to January. So there is no particular change in the numbe",77,"I'll go ahead and take your first question, have John answer the second. The futility analysis had been originally scheduled for December and for purely logistical reasons, the DMC rescheduled that to January. So there is no particular change in the number of months, number of patients type data that they would be reviewing at that particular review. It was simply a logistical change that led to the movement from this year to next year. John?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other",149,"Steve, with respect to your second question, obviously, we're very interested in those results, and we're very interested, frankly, in anything we can do to advance the cause of developing new therapies to treat Alzheimer's. I will mention, we have other molecules as well in various stages of development in our portfolio, looking at the beta-amyloid and other mechanisms associated with Alzheimer's disease. While this is a very important readout for us next year, it's not something -- whether it's positive or negative is going to change our strategy or change the basic underlying assumptions that we're carrying forward as we go through YZ. Our future does not depend on any single molecule including solanezumab, there are soon to be 11 other molecules in Phase III. And we'll go where the data takes us and proceed accordingly, but we're really interested in prosecuting and moving forward that entire portfolio."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Steve, this is Phil. Before we go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is",142,"Steve, this is Phil. Before we go to the next caller, as you're thinking about solanezumab, also in relation to the financial projections that we had discussed in Derica's section of the Investment Community Meeting in June, we have said all along this is a high-risk program. It's very interesting science. We're very hopeful of the potential outcome, but we have recognized that it's high risk. Essentially, for the financial modeling, what that means is it's a sign of relatively low probability of actually hitting, if you will. So that means for our financial projections, if that low probability goes to 0, it really does not take them down very much. If on the other hand, it were to go ahead and go from that low probability to 1, it would have a substantial potential upside to those numbers. Hope that's helpful."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Seamus Fernandez, Leerink Swann.",11,"Next question is from the line of Seamus Fernandez, Leerink Swann."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little",115,"Another pipeline question. As we think about the prospects for the spend, as you move through and into some of these new trials, I do see that you have a potential move forward of the CETP inhibitor into Phase III. Maybe, John, can you just talk a little bit strategically about your interest in the CETP inhibitor? And perhaps even -- there are many, many CETP inhibitors in development across the industry, would there be any interest in basically saying, ""Okay, let's look across the different CETP inhibitors, take the data and perhaps partner with someone else who has this and share the development cost, given the risk profile associated with this still untested mechanism?"""
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time",148,"Seamus, I can't speak specifically to the CETP inhibitor, because we really need to wait and see the data as we share that in November. But I think as we look at our pipeline, obviously, we're making decisions and looking at different things all the time that say, ""Should we alone with this, or should we partner that one."" Obviously, we got a huge benefit, I think, from the deal we struck with BI earlier this year, where we, in essence got our 4 potential assets. One of which is now launched, Linagliptin, shared between the 2 companies on a global basis. And as we move new molecules into Phase III, other programs begin to wind down. So we're looking at this all the time, and obviously, we'll do what we think is in the best interest of the company and the shareholders, as we make these decisions."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question from the line of Marc Goodman, UBS.",9,"Next question from the line of Marc Goodman, UBS."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase II",73,"First, can you give us a little more color on the emerging markets, maybe just talk about why it slowed a little bit, maybe talk about a couple other countries. And then second of all, maybe you can talk about some of the products that moved into Phase III a little bit. Is there any color you can give us -- mechanism of action? And maybe just a little bit more color there."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, you want to handle the first question? Maybe Jan can have the second, please?",15,"Deric, you want to handle the first question? Maybe Jan can have the second, please?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in t",96,"Sure, Phil. Marc, this is Derica. We still are very pleased with our performance in the emerging markets. And as I stated, it's really playing out as we had expected. What we saw in the third quarter is the beginning effects of Zyprexa patent erosion in the emerging markets, and specifically, in Brazil. In markets like China, where we haven't seen that, that's why you saw the 22% volume growth there and the 31% growth overall. So the growth that you saw in the third quarter is according to the expectations that we had laid out."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Jan?",1,"Jan?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In relation to the new Phase III starts, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the",104,"In relation to the new Phase III starts, as you see on the pipelines slide, we have a new insulin glargine opportunity that we have moved into Phase III. This will fit very well into our diabetes portfolio overall and then help actually the choice for the physicians then to different patients. We believe we have a very good agent, and we are comparing this to Lantus statin in two Phase III trials, both then in type 1 and type 2 diabetes for non-inferiority. Furthermore, with our expertise and in manufacturing and advanced devices, we think we can be really competitive in this area."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI.",43,"Marc, anything that you will see are some new names for what was previously on the chart as mGlu2/3 and NERI. So you've got pomaglumotab methyanol [ph] which is mGlu2/3, so new name, but same molecule, and then edovoxotin [ph] which is NERI."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question's from the line of Chris Schott, JPMorgan.",10,"Next question's from the line of Chris Schott, JPMorgan."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 2013 shaping up from a pri",124,"First question was if you just elaborate a little bit more on the European pricing environment, and how it's trending relative to your expectations. I think most importantly, kind of as we go forward, how are you seeing 2012 and 2013 shaping up from a pricing perspective relative to 2011? Second question was on the insulin business. Can you talk about the competitive response you've seen in the market? You're obviously doing very well with volume trends here. Can you just talk about -- again, are you seeing any different competitive response as you've regained some share? And then finally, just color on Trajenta and how you see the EU opportunity for this product, given some of the challenges that you highlighted in Germany?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Deric, go handle your first question, I'll take a shot at the second too, Chris.",15,"Deric, go handle your first question, I'll take a shot at the second too, Chris."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 p",162,"Okay. Chris, regards to the current pricing situation in Europe, it's actually playing fairly consistent with what we've seen historically. If you look at our Q3 results, you can see price was down about 1%. Historically, we typically see about a 1 to 2 percentage point erosion on an annual basis, year-on-year, so very much aligned. Now, obviously, each government is acting at different points in time, but we continue to be able to manage our way through that. As I think about 2012 and 2013, at least in Europe, we still see things playing out more or less along those lines. Probably the biggest question from a pricing standpoint still remains in the U.S., and what emerges from the discussion around the super budget committee and if there's any change as it relates to healthcare reform and dual eligibiles or so forth -- increases in rebate. That's probably the biggest unknown from a pricing standpoint facing the industry at this stage."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Also, on European pricing, Chris, probably since our last call, the one thing that would've changed that would be the largest impact was in Spain, where they instituted a couple of new measures, one for those products that have been on the market for more",438,"Also, on European pricing, Chris, probably since our last call, the one thing that would've changed that would be the largest impact was in Spain, where they instituted a couple of new measures, one for those products that have been on the market for more than 10 years, and for which there is no generic reference pricing group, because there's no generic competition. They had asked for a 15% rebate essentially on those products, that compares to the 7.5% that they had been requesting prior. And then probably and more materially for us here, they went ahead and said that innovative formulations, even if they are protected by patent protection would still be subject to reference pricing. So specifically for us, Velatab [ph], the rapid dissolving form of Zyprexa, while it will not have generic competition in Spain, it probably has now been pegged to the reference pricing for the generic olanzapine group broadly. For the insulin competition, this is a sector that we've dedicated a lot more focus to over the last couple of years, in particular, I'd say, with the formation of our diabetes business in early 2010. And we intend to maintain that focus on that business. And we have said before, we are seeing -- it is more competitive, I think, Nolos [ph] is now seeing a more competitive Lilly. And as we would expect, they're going to react. And I would say though, while the insulin business is one that is extremely important, it's going to be a very large part of the overall diabetes treatment market, one that we intend to go ahead and be very competitive in. Our goal of regaining leadership over time in diabetes is not predicated solely on insulin. It really does encompass the GLP space as well as orals. So our focus on building that broad-based portfolio and leveraging that is intact, and we'll continue to execute that very diligently. Trajenta is really very early days. You may have been also referring to the decision made in Germany, where there were some very difficult comparables being applied to what the government was espousing it would like to reimburse the product at, that did not make it appropriate for Boehringer Ingelheim or Lilly to move forward at this time. We definitely do anticipate we'll be able to reach some agreement with the government that provides this product to patients and also recognizes innovation, the benefits that it brings and the appropriate  compensates Boehringer Ingelheim and Lilly. So we remain very optimistic about this class and about this product. Again, very early days in Europe on this particular front."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is from the line of Catherine Arnold, Crdit Suisse.",11,"Next question is from the line of Catherine Arnold, Crdit Suisse."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, from other innovators. Are you in a position that you can actually use",117,"I wanted to ask you guys about the insulin diabetes market. And first of all, more broadly, now that you have this broader portfolio, some assets homegrown, some assets are, obviously, from other innovators. Are you in a position that you can actually use that portfolio for contracting purposes either to government, particularly, outside the United States or from the standpoint of private payers? If you could just comment on what you're able to do as you approach the customer on payment. And then I wanted to ask you on your insulin glargine aspirations, have you considered doing a combination with BYETTA and would you need a separate contract with Amylin to move forward on that idea?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Catherine, I'll go ahead and take a shot at the first two, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- using different pr",232,"Okay. Catherine, I'll go ahead and take a shot at the first two, and if anyone wants to chime in feel free to. So I don't necessarily believe that we're able to go ahead and leverage this in terms of the bundling, if you will, or the -- using different products to go ahead and gain leverage with payers that way. I think that one of the main things that we have been focused on is the ability to approach the physician and talk about what their patients' needs are, and those patients do have different needs over the course of their disease. So this clearly positions us to offer products that go from earlier stages with the oral treatments into the injectable phases with GLP initially, and then, obviously, you've got people who eventually will progress to, and will need insulin therapy, and obviously, we have very strong offerings, which we hope to expand in the future with the 2 basals that we're developing. In terms of the combo, to my knowledge there have not been any active discussions. I'm not familiar, Catherine, enough with the contract. I would think if you introduced another molecule into that collaboration, we would need to probably have some discussions to figure out how that would work, as the current collaboration really is focused on the exenatide molecule whether that's BYETTA, Bydureon or subsequent formulation."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tim Anderson, Sanford Bernstein.",6,"Next question Tim Anderson, Sanford Bernstein."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","You talked about having already pulled much of the sales and marketing spend from Zyprexa. On the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these",180,"You talked about having already pulled much of the sales and marketing spend from Zyprexa. On the variable spending unrelated to the sales force, can you give us some idea of when you started to make these cuts in earnest? Can you quantify how much these spend savings annualize to compared to when you fully resourced the brand? And then looking forward to maybe the end of 2013 when Cymbalta looks like it's going to go away, that seems like it's going to have an impact on Lilly that's about the same as what Zyprexa's likely to have in the current year. Can you just confirm that the Cymbalta impact will be about the same as Zyprexa's a few years from now?:p id=""E05"" name=""Philip Johnson"" type=""E"" />
How about Dave comment on the Zyprexa dual marketing spend. And if you don't mind, maybe, Dave, talking about how you're thinking of -- not necessarily the comment on the sales decline, but just the management of sales operations, as we go off Cymbalta and we'll come to Derica for the financial piece."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Great. So with Zyprexa, this is a brand that for many years has had a very entrenched positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last",145,"Great. So with Zyprexa, this is a brand that for many years has had a very entrenched positioning in the minds of physicians. And we've been able to begin taking down expenses as early as 2007 in the U.S. on the variable side of the equation. In the last calendar year, we can just say that they were a fraction of that peak level already in 2010, in 2011 or even lower, per Derica's earlier comment. Cymbalta will see a very different picture in the U.S. This is a brand in a very competitive, highly genericized market, with less clinical differentiation in the minds of physicians. We do plan on having a robust sales and marketing effort, much closer to the loss of exclusivity, and therefore, as you think about modeling after LOE, there will be a more significant expense impact post LOE with Cymbalta."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab",133,"Tim, when you think about the financial impact of -- so how do the numbers play out. Some of that is still also going to be predicated on how our pipeline emerges. So remember in our late stage pipeline, we have 3 new key neuroscience assets, solanezumab for Alzheimer's disease, mGlu2/3 or -- still pronounce the new name, I won't try it, but for schizophrenia, as well as NERI stil for depression. So as those play out, we may see a re-purposing of some of those Cymbalta assets and resources to these new brands as we anticipate gearing up for their launches, assuming that we're successful in bringing those through the regulatory process. So this is how we're trying to manage our way through this period and seize the opportunities as they emerge."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question is David Risinger, Morgan Stanley.",7,"Next question is David Risinger, Morgan Stanley."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add",171,"I have 3 questions for Derica, and then one for Enrique if he's on the online. So with respect to animal health, Derica, can you comment on what the organic growth was in the quarter? And then second, I was just hoping that you could rephrase or maybe add a little bit more color on your comment about Zyprexa product returns and what investors should expect in terms of fourth quarter U.S. Zyprexa sales. And then third, with respect to SG&A, obviously, spending continues to rise as you build businesses, and that's clearly working to drive the top line. But maybe you can just comment on the outlook for SG&A spending growth in coming years should we expect SG&A to continue to rise post Zyprexa going generic? And then if Enrique's on the line, or maybe somebody else can comment, I'm just wondering if you can provide any more color on the diabetes formulary pressure going into 2012 and your ability to offset the loss of CVS Caremark as a partner."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipa",230,"Okay. Let me try the first 3. In regards to the animal health organic growth, it was about 18% in the quarter. As we think about Q4 and the U.S. Zyprexa sales, as you know, we do not provide product-level projections or forecast. But what you can anticipate, when we think about just return, we probably took about 1/3 of the impact -- anticipating impact in the third quarter. And we would anticipate about another 60% impact of returns in the fourth quarter, clearly, as you have -- we go through the brunt of the erosion -- the initial phase of the U.S. erosion curve. In regards to SG&A expenses, if you look at the third quarter, it was really driven by 3 elements, if you look at our total OpEx growth. FX was about 3 percentage points. The remaining 2 items was the pharma fixed fee, okay? And the third was the expenses both in SG&A, as well as R&D behind our BI collaboration. If you exclude those 3 items, our expense growth in the quarter was essentially flat, so 0. In fact, it was slightly negative in real terms. So when you think, projecting forward, we're not at a stage of putting out guidance beyond this period from a line item standpoint. But what you can expect is we're going to be managing our SG&A very tightly, okay?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","And just a little short commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the",197,"And just a little short commentary on that 7% non-FX OpEx growth. Derica mentioned these 2 factors, the BI, the Boehringer Ingelheim strategic diabetes alliance, as well as the pharmacy. You've got approximately 5% of total OpEx growth being driven by the Boehringer Ingelheim collaboration and about 1.5% or so is driven by the pharma fee. And then your last question, Dave, on the diabetes formularies access here in the U.S., each and every year, there are some contracts that are up, not all of them. And each and every year, we have seen a dynamic where we've maintained probably the majority -- vast majority of those we have had. We've gained some additional ones, and then we've lost a few. That dynamic we expect to continue. In terms of talking about specific contracts, often in agreement with the actual customers, we don't disclose the specific contracts that have been won or lost until they actually take effect. I can't provide specific commentary on ones that we may anticipate could come off in '12 or that we may be gaining in '12. We'll have that information probably for you in the January call with the Q4 results."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question Tony Butler, Barclays Capital.",6,"Next question Tony Butler, Barclays Capital."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And the",71,"Two brief questions. One is, Derica, the volume in Japan has been quite spectacular. Question is with price cuts assumed to come in the spring of next year, what do you currently anticipate those price cuts to be, that is, how are you modeling it? And then second, back to the Zyprexa returns, can you tell us what you're actually accruing for -- the amount that you're accruing for those returns?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to go very well. We're not in a position of providing our pricing projections for Japan for 2012. Clea",84,"Okay. Tony, in regards to Japan, we continue, once again, to be very pleased with our performance there and the launches of Cymbalta and Forteo continue to go very well. We're not in a position of providing our pricing projections for Japan for 2012. Clearly, on our call in January, we'll be in a position to provide overall guidance for our outlook for `12, which would include Japan and the potential pricing. So if we can, we can put that off until then. John?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, this is John. One comment I would make is, although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play o",139,"Tony, this is John. One comment I would make is, although this is still being implemented in Japan on a trial basis, in the last year or 2, pricing has been liberalized there to better recognize true innovation. Now, how's that going to continue to play out and how will other products that don't fall in that category be affected remains to be seen. But actually, in contrast to some other parts of the world, we actually see in the last 2 years and going forward a more favorable pricing environment in Japan as the government there recognizes the need to call out innovation and to value innovation, and also continues with its intent to ensure that more medicines that are approved in Europe and the U.S. are approved and made available to Japanese patients in a contemporaneous way."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter.",20,"Tony, to your last question, the returns was a little bit less than $50 million charge in the third quarter."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Next question John Boris, Citi.",5,"Next question John Boris, Citi."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? Sec",132,"First question is for Dave Ricks. Dave, can you maybe help frame or characterize the opportunity for Cialis in BPH? What percent of the business have you already shifted to the once-daily size of the market opportunity and reimbursement going forward? Second question for Derica. You'd mentioned on the sequential growth for the emerging markets that it was largely attributed to Zyprexa. Can you maybe give some color of the 500 basis points sequential decline? What percent of Zyprexa sales accounted for that in rest of world. And then third question, just for John, very quickly. In the environment in Washington, what do you find, John, that the industry is winning on going forward? And what do you think some of the challenges are in Washington that the industry continues to face?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave?",1,"Dave?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily",112,"In Cialis, we're excited about the recent approval of Cialis for use in men who suffer from BPH as well as men who suffer from both ED and BPH. We're now detailing to physicians and are looking forward to this launch. To your question about the once-daily formulation, which is specific to this indication, you need to take the medicine every day prior to the DPH launch. About 1 in 4 Cialis prescriptions in the U.S. were for the once-a-day form. We would anticipate with BPH uptake that to continue to grow, and we see the BPH opportunity as a nice growth driver over the main life of Cialis in the U.S."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay.",34,"John, in regards to emerging market sequential growth, I don't have the specific data with me at this stage, at this meeting. But we can follow up with you on that, if that's okay."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John?",1,"John?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal",364,"John, I think the Washington environment remains very fluid. I think when you couple the ongoing healthcare reform with the debts of reduction focus in terms of wins, patent reform is a huge win. It should in the medium- to long-term restore a great deal of confidence for investors that our patents can be -- can remain valid, can be enforced and can be the basis for investor confidence in addition to clearing this huge backlog. I think there is still strong support for maintaining 12.5 years of data protection, for biologics, which is part of the Affordable Care Act, and we -- it's the law, and we want to keep it that way. And I think there's a general recognition, appreciation to the fact that this industry employs directly and indirectly between 3 and 4 million people in this country. And is the only way we're going to attack diseases like Alzheimer's and cancer, which not only cause immense suffering, but help drive up a lot of the healthcare cost today and in the future. I think the area of concern for us right now is Part D. We're fighting, and we're quite adamant in our opposition to imposing government price controls in Part D. This is a program that's working. Premiums for seniors have remained low. The overall cost of the program is stunningly lower than any one forecast 5 or 6 years ago. And most seniors in Part D today have access to medicines. In terms of deficit reduction, Part D is making a difference there too. A recent study published in Jamma [ph] show that for every person enrolled in Part D, they have $1,200 a year less costs in other parts of the medical delivery system. That's more than $10 billion a year in savings that I think we have to attribute to that program as it's currently structured. So we're going to continue to make sure that, that message gets heard and understood, as we go forward. We'll continue as well to express concerns we have about IPAB, the Independent Payment Advisory Board, as well as the way the 340 B program is being expanded,  we believe, inappropriately."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Gregg Gilbert, Bank of America Merrill Lynch.",7,"Gregg Gilbert, Bank of America Merrill Lynch."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what will happen there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP produ",86,"First, I was hoping you could attempt to quantify your dual eligible's exposure. And maybe, John, you can handicap that specific item, what will happen there? Secondly, for Jan, as we head into AHA, can you frame your latest thinking on how your CTP product stacks up against others in the category based on info that's been made public over time? And third, perhaps for Derica, or Dave, on Axiron, was there any abnormally high discounting or couponing in the quarter that will abate over time?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to, to consider as you're trying to bracke",167,"This is Phil. I'll actually take your first question. So in terms of the exposure on the dual-eligible, low-income subsidy, today we've not provided a specific quantification. I guess, one thing I would point you to, to consider as you're trying to bracket how large this could be, for the original healthcare reform that was to have been a $80 billion cost to the industry over a 10-year period, we'd actually estimate, it's probably closer to $115 billion cost over that 10-year period of the industry. And as we talked about earlier, we've estimated that this year, you're probably talking about a $600 million to $700 million cost to Lilly in 2011 from healthcare reform. Numbers I've seen from the CBO, I guess,  who scored Medicare dual eligible low-income subsidy going to Medicaid pricing, I believe they scored this at around $105 billion, $110 billion over a 10-year period. So as far as order of magnitude, without getting into specific numbers, I'll have you consider that. Jan?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Co",53,"Right. Well, the main thing I can say is that listen to the presentation at the American Heart Association. And secondly, what I stated in June was that in the interim analysis of the current study, where we now have the final data, the Data Monitoring Committee said accelerate progression of this agent."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Dave for Axiron?",3,"Dave for Axiron?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Axiron in the U.S., as you know, we launched the drug in Q2, in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're",117,"Axiron in the U.S., as you know, we launched the drug in Q2, in June in primary care against the entrenched competitor. Like any launch in the U.S., your main mission in early days is to drive trial and a good use experience for patients. We believe we're doing that very successfully today in the U.S., about 1 in 4 of new starts in the testosterone class are going on to Axiron just 6 months into the launch. Obviously co-pay cards, vouchers, samples, our key partners ensuring that positive early use experience. But through time, those dissipate as you get more refills. So we're tracking right according to our plans and pleased with the early uptick."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","And that question is from Barbara Ryan, Deutsche Bank.",9,"And that question is from Barbara Ryan, Deutsche Bank."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Analysts","Question is really on China, where obviously, you've been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're",69,"Question is really on China, where obviously, you've been very successful in showing very strong sales growth, although we read about various government initiated programs, the reduced price, et cetera. And I wonder if you could share with us what you're seeing there, what your outlook is and maybe some split between what is actually part of the reimbursement list and what percentage of your business is private pay?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay, John?",2,"Okay, John?"
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary status at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines ar",178,"Okay. Barbara, I think that -- we think, for us to be successful in China in the long run, formulary status at the national level, the provincial level and the hospital level is going to be key to that. So we work very hard to ensure that our medicines are included in those formularies all the way down to the local level. I think that there are going to be, today and going forward, situations where we have price decrease in China. I think in some cases, there's a focus on classes that we don't participate in, and in some cases, they're likely to affect us. I think, as we look at our long-term model in China, we tried to account for that, obviously, not only as the delivery of healthcare changing China, but I think the way in which healthcare is managed by the government will continue to evolve. And under any circumstance, our enthusiasm for the opportunity we have there to reach more patients with our products and to grow our business profitably has not diminished."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting.",25,"Thank you very much. I'll go ahead, as we approach the top of the hour and turn it over to Derica to close the meeting."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Executives","Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position: diabetes, oncology and neuroscience, those are also 3 of",236,"Sure, thanks. Barbara, just to close out, one thing I would say to add to John's comment is if you think about the therapeutic areas in which we compete, where we have a strong competitive position: diabetes, oncology and neuroscience, those are also 3 of the fast-growing therapeutic areas in the China market. So today, this is a lot of what's driving the strong volume growth that you're seeing in that business, in spite of the pricing environment that's resonant there. 
Thanks for everyone spending your time with us here this morning. And I guess, in closing, I'd like to just maybe reiterate a few points. One, Q3 was another strong quarter of our underlying revenue growth and financial performance for Lilly. And it was punctuated by double-digit growth from our countercyclical growth engines from 6 of our key brands. As we head into the teeth of our patent expiration period, we have positioned the company to fund the R&D necessary to fuel our future growth, recapitalize our physical assets and maintain our dividend. 
Finally, we continue to make progress in advancing our pipeline, which is the foundation of our future growth. We look forward to keeping you informed as we execute our strategy. And we thank you for your interest in Eli Lilly & Co. Our team will be available to answer any additional questions you may have following this call. Have a great day."
285467,97242208,175144,"Eli Lilly & Co., Q3 2011 Earnings Call, Oct 20, 2011",2011-10-20,"Earnings Calls","Eli Lilly and Company","Operator","Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1(800) 475-6701 wi",81,"Thank you. ladies and gentlemen, this conference will also be available for replay, and that's starting today at 11 a.m. Eastern Time and will run through October 27, midnight. You may dial the AT&T Executive Playback Service by dialing 1(800) 475-6701 with the access code 218233. International callers may dial area code (320)365-3844, access code 218233. And that does conclude your conference. We do thank you for joining, while using AT&T Executive TeleConference. You may now disconnect. Have a good day."
